key: cord-0322988-cvqt35ao
authors: Quaglia, Alberto; Roberts, Eve A.; Torbenson, Michael
title: 3 Developmental and Inherited Liver Disease
date: 2018-12-31
journal: nan
DOI: 10.1016/b978-0-7020-6697-9.00003-0
sha: b6ae4d88a03ac0b1142577db37678d6d59080bf3
doc_id: 322988
cord_uid: cvqt35ao

Abstract A new section on the approach to diagnostic histological interpretation, is the overture to this chapter on inherited and developmental disorders. This initial section is split chronologically into the early neonatal and infantile period and later childhood and adulthood; with the intention of reflecting clinical practice as closely and succinctly as possible. Disorders of the biliary tree, bile formation and secretion, and hepatocyte metabolism are the core of this chapter, a merger of chapters 3 and 4 of the previous edition. Considerations on the pathogenetic and/or clinical overlap between developmental, genetic and metabolic disorders were the rationale behind this change. The complexity of hepatocyte metabolism is reflected into the miriad of related pathological conditions. Recent technological advances, particularly in genomics in the last five years, have resulted in a plethora of new entities and changes in terminology, challenging the authors to balance detail and application to clinical practice. Tables and figures from previous editions have been largely kept due to their quality and contemporary relevance, whilst new ones have been added to accommodate new advances (e.g. classification of mitochondrial disorders), a compromise to bridge between the two editions for the accustomed reader. Liver involvement in immunodeficiency and miscellaneous disorders precede the final section on anatomical anomalies. Vascular anomalies are now included in the chapters on vascular disorders.

Developmental and inherited disorders affecting the liver typically present in childhood but may affect individuals of any age. The effect of inherited metabolic disorders on the liver may be considered primary, caused by the accumulation of a metabolite resulting from an enzyme defect (e.g. sphingomyelin in Niemann-Pick disease), or secondary, when the major changes in the liver are the result of a primarily extrahepatic defect (e.g. steatosis of the liver secondary to pancreatic insufficiency in Shwachman syndrome). Likewise, as the list of identified inherited metabolic disorders continues to expand, many have significant but indirect relevance to the liver. For example, liver histology is usually normal in primary hyperoxaluria while the kidneys and other organs may be irreparably damaged; however, despite medical management, dialysis and repetitive kidney transplants, cure is only obtained with a liver transplant. 1 In other inherited disorders, the liver disease may remain asymptomatic until precipitous acute liver failure develops; the classic example is Wilson disease. 2 This similarly occurs with developmental disorders; choledochal cyst may be diagnosed by prenatal sonography, or it may not become evident until late in childhood. In many cases the clinical diagnosis of an inherited disorder is not clinically evident, and consequently, diagnosis becomes the responsibility of the histopathologist, who may save not only the life of the patient, but that of other family members as well. Advances in molecular genetics constantly improve our understanding of the biological basis of many metabolic diseases. Prenatal diagnosis is available for more families.

Many metabolic disorders manifest similar morphological findings despite having diverse aetiopathogenesis. Numerous diverse disorders are characterized neonatally by cholestasis and giant cell transformation of liver cells, such as α1-antitrypsin deficiency, Niemann-Pick disease type C and bile salt export pump (BSEP) deficiency, also known as progressive familial intrahepatic cholestasis type 2. Steatosis is one of the most frequent abnormalities, either alone (as in the urea cycle disorders, homocystinuria, lipoprotein disorders, the mitochondrial cytopathies and Shwachman syndrome) or in combination with other changes such as cholestasis, pseudogland formation and fibrosis (e.g. in galactosaemia, hereditary tyrosinaemia type 1 and hereditary fructose intolerance). Furthermore, neutral lipid may be stored in combination with other metabolites such as cholesterol (e.g. in Wolman disease or cholesterol ester storage disease) or glycogen (as found in glycogen storage disease types I and III). Many disorders of lipid metabolism are expressed morphologically by 'foam' cells (as in Niemann-Pick disease types A and B and the gangliosidoses). 3 The ultimate diagnosis depends on the clinical and laboratory data and identification of the specific enzyme defect. Histological changes may not lead to a specific diagnosis, but characteristic findings add to the phenotypic expression of individual disorders and guide selection of further investigations, in particular enzymatic assays and genomic studies. Accordingly, the following discussion includes the major clinical, laboratory and genetic features-the context in which histological changes should be evaluated.

The histopathologist has access to many special stains and techniques, both at the light microscopic and ultrastructural levels. The best all-round fixative for light microscopy remains 10% buffered formalin; however, some metabolic diseases (e.g. the mucopolysaccharidoses, cystinosis and the glycogen storage diseases) require special fixatives to prevent leaching of water-soluble metabolites. Special stains for lipid, cholesterol and sphingomyelin must be performed on frozen sections cut from formalin-fixed or fresh material since routine processing will extract the lipid material from the cells. The histopathologist must be familiar with the many special stains that can be used on formalin-fixed and routinely processed material: uroporphyrin, haemosiderin, copper, copper-binding protein, bile, lipofuscin, lipomelanin (the pigment in the Dubin-Johnson syndrome), carbohydrates, mucopolysaccharides and other substances. Immunohistochemical stains are useful in a number of diseases, such as for identifying catalase in patients with peroxisomal diseases or the presence of α1-antitrypsin, α1-antichymotrypsin or fibrinogen in eosinophilic globules in various storage diseases. The repertoire of specific antibodies working on paraffin sections is continuously broadening, including antibodies reacting with various bile canalicular transporters such as the BSEP and multidrug-resistance protein 3 (MDR3); such antibodies can be commercially sourced and are readily available in specialist centres. Special microscopy should be utilized whenever necessary. The porphyrins can be demonstrated by their autofluorescence in frozen sections made from unfixed hepatic biopsy or autopsy material. Polarizing microscopy is especially useful for the identification of various crystals such as cholesterol, cystine, calcium oxalate, uroporphyrin and protoporphyrin.

Transmission electron microscopy (TEM) is very important in the diagnosis of many inherited metabolic diseases. [4] [5] [6] [7] According to Phillips et al., 5 the findings are diagnostic in α1-antitrypsin deficiency, Farber disease, glycogen storage diseases types II and IV, hereditary fructose intolerance, Gaucher disease, metachromatic leucodystrophy, the gangliosidoses, Dubin-Johnson syndrome, erythropoietic protoporphyria, Wilson disease, Zellweger syndrome and infantile Refsum disease. In other disorders, electron microscopy (EM), although not diagnostic, can help to categorize the disease (e.g. as a glycogenosis, phospholipidosis or oligosaccharidosis) or to suggest the correct diagnosis, as in progressive familial intrahepatic cholestasis type 1 (PFIC1) disease, arteriohepatic dysplasia and cholesterol ester storage disease. The role of scanning electron microscopy (SEM) 3 is much more limited. Whether TEM will continue to serve a critical role in histological diagnosis of genetic/metabolic liver diseases, given the wide-ranging and cost-effective advances in immunohistochemical and molecular methods, is currently an area of debate.

In summary, histopathological studies contribute significantly to the diagnosis of metabolic disorders. Selection of appropriate pathological studies must be made before liver biopsy, to ensure appropriate fixation and handling of samples. Prebiopsy consultation with a histopathologist, and at times with laboratory staff of a centre dealing with highly specialized techniques, may preclude the loss of diagnostic information. In general, a portion of the biopsy core at least 5 mm in length should be snap-frozen using optimal cutting temperature (OCT) compound, which does not interfere with most enzyme assays and allows subsequent frozen sectioning for microscopy. Ideally, a few bits (1 mm 3 ) should be immersed in a fixative appropriate for EM. Tissue freezing and EM fixative, in addition to usual fixation and paraffin processing, should be applied to all biopsy specimens taken from children or older patients in whom a metabolic disorder is suspected.

Many different disorders manifest with conjugated hyperbilirubinaemia in neonates (Table 3 .1). Some are caused by direct hepatocellular injury, and others by defects in hepatocyte bile formation or physical obstruction to bile flow. The distinction between primarily hepatocellular versus primarily hepatobiliary injury is critical for clinical management. The primary histological differential diagnosis for infantile conjugated bilirubinemia disorders is therefore between obstructive and nonobstructive causes.

Obstructive causes include biliary atresia (BA), choledochal cysts, neonatal sclerosing cholangitis, spontaneous perforation of the common bile duct, the inspissated bile syndrome specifically associated with cystic fibrosis, and Langerhans cell histiocytosis. A survey at King's College Hospital of 1086 consecutive cases of neonatal conjugated hyperbilirubinaemia showed that BA constituted approximately one-third of all cases. 8, 9 Destruction and obliteration of the extrahepatic biliary tree of variable extent occurring early in embryonal development or perinatally is the cause of BA. Surgery is the only treatment option at present. Clinically, jaundice due to conjugated hyperbilirubinaemia, acholic stools, 'nondraining' hepatobiliary scan and ultrasonographic abnormalities of the biliary tree support a diagnosis of BA.

Portal expansion associated with oedema and fibroplasia, a variable mixed inflammatory cell infiltrate along with a ductular reaction, and cholangiolar bile plugs are the histological hallmarks of an obstructive pattern. In the lobule, giant cell transformation with multinucleation of hepatocytes and canalicular bile plugs are also present. These portal changes are typically seen at about 6 weeks of life in infants with BA. These may be very mild or absent in biopsies taken earlier than 6 weeks. Biopsies from neonates 2-4 days old have shown minimal portal changes, suggesting that the portal changes observed later are the result of the perinatal bile flow causing periductal leakage and consequent inflammation and fibrosis. 10 The typical obstructive pattern observed in BA can be simulated by other disorders, such as α1-antitrypsin deficiency (alpha-1AT), cystic fibrosis and MDR3 deficiency. Steatosis often accompanies the biliary changes in both α1-antrypsin deficiency and cystic fibrosis. Diastase-resistant periodic acid-Schiff (PAS)-positive globules are usually not evident in the first few months of life but may be demonstrated by immunohistochemistry (IHC) for α1-antitrypsin. If present, eosinophilic cholangiolar casts are a classic finding in liver biopsies from patients with cystic fibrosis. MDR3 deficiency is caused by a mutation of the ABCB4 gene, which encodes for the MDR3 protein, critical for the transport of phospholipids, and in particular phosphatidylcholine, into the bile. Without phosphatidylcholine, bile salts are not incorporated into micelles. The bile remains hydrophobic and damages the biliary epithelium, causing a cholangiopathy, without gross architectural changes to the bile ducts, which may nevertheless manifest histologically with an obstructive pattern. Conditions manifesting with an obstructive pattern simulating BA include total parenteral nutrition, sepsis and the so-called inspissated bile syndrome associated with ABO incompatibility.

Nonobstructive causes include diverse disorders causing hepatocellular injury. The portal changes previously described are not observed. The histological picture is dominated by the lobular changes, usually described with the term 'neonatal hepatitis' . These consist of a combination of hepatocellular changes such as swelling, multinucleation, apoptosis, cholestasis, lobular and portal inflammation, extramedullary haematopoiesis and fibrosis. These features are described in more detail in the section on neonatal hepatitis. Hepatocellular injury can be very severe in some patients, resulting in confluent hepatocellular loss and parenchymal micronodular transformation or even massive hepatic necrosis. The clinical scenario is that of neonatal acute liver failure. There may be clues in the clinical presentation, biochemistry and/or histology pointing to a metabolic aetiology or even to a specific metabolic disorder.

A defect of bile acid metabolism including inborn errors of bile acid synthesis, and certain defects in bile formation due to defective bile canalicular transporters, previously called 'progressive familial intrahepatic cholestasis' (PFIC), caused by mutations of ATP8B1 (FIC1) or ABCB11 (BSEP) are usually suspected when conjugated hyperbilirubinaemia is associated with normal or near-normal serum levels of γ-glutamyltransferase (GGT).

Inborn errors of bile acid synthesis and BSEP deficiency are associated with marked hepatocyte disarray, hepatocyte multinucleation and a tendency to progressive fibrosis.

Text continued on p. 118 Note: Acute-pattern neonatal liver failure denotes metabolic instability, coagulopathy and extremely elevated serum aminotransferases in a neonate; chronic-pattern neonatal liver failure denotes metabolic instability, coagulopathy, hypoalbuminaemia, near-normal serum aminotransferases in a neonate; conditions which require specific consideration vis-à-vis biliary atresia are denoted 'Differentiate from biliary atresia'. Table 3 .1 Classification of infantile conjugated bilirubinaemia disorders (neonatal hepatitis syndrome) with major histological and diagnostic investigations-cont'd of acute parenchymal injury or fibrosis, whose pattern, development and rate of progression may vary among different diseases, singledisease variants or individual patients. In some cases the lobular architecture can be entirely normal. For example, Wilson disease, hereditary tyrosinaemia type 1, α1-antitrypsin deficiency, mitochondrial disorders, inherited disorders associated with intrahepatic cholestasis and Niemann-Pick disease type C tend to progress more or less rapidly to advanced fibrosis. In cystic fibrosis and MDR3 deficiency the pattern of fibrosis is biliary, although these are highly disparate disorders. Type IV GSD progresses rapidly to cirrhosis, whereas certain other types of GSD do not. Bands of fibrous tissue associated with irregularly shaped parenchymal islands and containing bile ducts reminiscent of the ductal plate and scant portal vein branches are typical of congenital hepatic fibrosis.

Despite the presence of fibrosis, some metabolic disorders (e.g. Wilson disease, hereditary tyrosinaemia type 1) may present with fulminant liver failure. External factors such as infections or drugs may act as triggers. They manifest histologically with confluent parenchymal collapse, in some cases resulting in multiacinar loss or even massive hepatic necrosis, which may be superimposed to underlying fibrosis. Liver biopsy has a limited role in these cases because of its risks and proven limited contribution to diagnosis and clinical management. 13 Mitochondrial disorders may present with neonatal liver failure or severe liver dysfunction later in infancy. Liver biopsy may play a role in confirming the diagnosis, noteworthy because multisystemic mitochondriopathies are not an indication for liver transplantation.

Hepatocyte morphology is affected in many metabolic and inherited disorders. Changes can be evident on standard haematoxylin and eosin (H&E)-stained sections or manifest as cytoplasmic accumulations demonstrated by histochemical stains, IHC or EM. In some disorders, the hepatocyte morphology can be entirely normal.

Steatosis is a common change, caused by primary or secondary abnormalities of pathways for metabolism of sugars, fats and amino acids. Macrovesicular steatosis, defined as a single, large droplet displacing the hepatocyte nucleus, is seen in galactosaemia, fructosaemia, citrullinaemia type 2 (citrin deficiency), hypertriglyceridaemia, urea cycle defects and Wilson disease. Paediatric obesity and associated fatty liver disease may act as a confounding factor. Wilson disease should always be considered, even in obese children and in the absence of histochemically demonstrable copper or copper-binding protein. Poor nutrition (as in cystic fibrosis) or a metabolic crisis can contribute to its development, severity and distribution. Microvesicular steatosis, defined as fine cytoplasmic vacuolation around a centrally placed nucleus, is typically observed in fatty acid oxidation defects and other mitochondrial disorders. Histochemical techniques on frozen tissue or EM may be necessary to confirm that the changes noted are caused by accumulation of lipid. Micro-and macrovescicular macrovesicular steatosis can coexist and also can be associated with other hepatocyte changes, such as oncocytosis (mitochondriopathies), or clarification of the hepatocyte cytoplasm due to glycogen accumulation (GSD). Reye syndrome, first described in the 1960s and now very rare, was characterized clinically by encephalopathy and liver dysfunction after a viral illness and exposure to salicylates and histologically by microvesicular steatosis. Reye syndrome could be part of an idiosynchratic reaction to acute illness in individuals harbouring an underlying metabolic disorder.

Accumulation of glycogen in the hepatocyte cytoplasm results in a plant cell-like appearance. It is typically seen in the context of GSD. It simulates microvesicular steatosis, lysosomal storage and urea cycle disorders, and drug-induced expansion of the smooth FIC1 deficiency caused by ATP8B1 mutations manifests histologically more mildly with bland cholestasis, in the form of pale canalicular bile plugs not accompanied by hepatocellular disarray or giant cell transformation. Other forms of low-GGT cholestasis exist. Severe low-GGT cholestasis has been described in patients with mutations in the tight junction protein 2 gene (TJP2). 11 Steatosis associated with features of neonatal hepatitis is seen in galactosaemia, hereditary tyrosinaemia type 1, fructosaemia, mitochondrial disorders and citrullinaemia type 2 (citrin deficiency). Ground-glass inclusions are associated with the uncommon early manifestation of glycogen storage disease (GSD) type IV. Accumulation of lipidic substances in hepatocytes and portal or sinusoidal macrophages suggests a storage disorder such as Niemann-Pick disease type A or B, Wolman disease and Gaucher disease.

Histological features of neonatal and early infantile liver disease must be evaluated in the context of normal histological features at birth. These include two-cell-thick hepatic plates, extramedullary haemotopoiesis, and periportal siderosis and accumulation of copper and copper-binding protein. Portal tracts may be lacking interlobular bile ducts. Biliary development appears to progress from the hilum through to the periphery, and the biliary tree may not be fully developed at birth. Degree of hepatobiliary maturation needs to be taken into consideration in the differential diagnosis of cholestatic conditions.

The clinical and histological manifestations of inherited and metabolic liver disorders in older children and adults are heterogeneous. 12 They constitute a wide spectrum, which includes acute, subacute or chronic liver or multiorgan dysfunction, organomegaly, and systemic metabolic abnormalities such as hypoglycaemia, protein intolerance or metabolic acidosis. An external factor can exacerbate their course and make them manifest acutely. They can mimic other metabolic disorders, disorders of various other aetiologies or even the effect of medical treatment. Wilson disease is a typical example. Its histological picture ranges from steatosis resembling nonalcoholic fatty liver disease (NAFLD) to a chronic hepatitis similar to autoimmune hepatitis. The clarified appearance of hepatocytes in GSD is identical to that of poorly controlled diabetes in Mauriac syndrome.

Histological interpretation is usually required in patients with a known disorder (to confirm the diagnosis and estimate the extent of liver damage) or in patients in whom the clinical diagnosis is uncertain. A systematic approach ensures a comprehensive histological assessment. It can be divided into the following components: (1) assessment of structural changes caused by acute parenchymal injury or chronic disease and fibrosis; (2) changes affecting hepatocytes; (3) presence and pattern of cholestasis and (4) changes suggestive of reticuloendothelial storage. These four components are described in more detail next. Of note, in some metabolic inherited disorders, there may be minimal or no significant histological changes, sometimes in relation to metabolic fluctuations. With urea cycle defects, for example, the histological appearance of the liver parenchyma ranges from near-normal to steatosis or cytoplasmic clarification simulating GSD when ammonia levels are high. Liver tumours may be the first manifestation or may complicate the course of many metabolic and inherited disorders (e.g. α1-antitrypsin deficiency, GSD). Cystic transformation is a characteristic of some of the ductal plate malformation (ciliopathy) disorders.

Since metabolic and inherited disorders can present acutely, subacutely or chronically, their histological manifestations can be in the form chronic biliary process. Hepatocytes contain granules of copper and copper-binding protein and may be swollen with clarification of their cytoplasm. Cholestasis is not seen in uncomplicated congenital hepatic fibrosis, although septal ducts may contain bile. Histological changes are usually minimal in Gilbert syndrome and may consist simply of accumulation of lipofuscin. Dubin-Johnson syndrome is characterised by black Fontana-positive pigment in the hepatocyte cytoplasm, particularly in the perivenular region. Deficient expression of canalicular multispecific organic anion transporter (cMOAT, MRP2) is diagnostic.

Deficiency of enzymes (typically single-enzyme deficiency) involved in lipid or glycoprotein metabolism results in the accumulation of substances usually in the lysosomes of one or more cell types and one or more organs. These disorders are rare and often fatal in infancy, but some may remain undetected through adulthood.

The combination of cell type and organ involvement helps in identifying a specific disorder. For example, cholesterol ester storage disease affects the liver, Gaucher disease affects liver and reticuloendothelial organs, and mucopolysaccharidosis affects multiple organs including the central nervous system. The affected cell type in the liver is also an important clue to the underlying disorder. Both hepatocytes and reticuloendothelial cells, including Kupffer cells, portal macrophages and endothelial cells, are affected in acid lipase deficiency (Wolman disease and cholesterol ester storage disease).

In contrast, other disorders affect reticuloendothelial cells only and spare hepatocytes. In Niemann-Pick disease type C, accumulation of esterified cholesterol and other lipids affects very few Kupffer cells, often in a hepatitic fibrotic background. They can be easily overlooked as ceroid-laden macrophages in the context of a nonspecific hepatitic condition. In Gaucher disease, pale PAS-positive portal macrophages and Kupffer cells show a typical 'crinkled paper' appearance. In Fabry disease, Kupffer cells, portal macrophages and endothelial cells contain D-PAS+ globotriaosylceramide. Other lysosomal storage disorders associated with predominant accumulation in Kupffer cells include gangliosidoses, metachromatic leucodystrophy, Farber lipogranulomatosis and cystinosis. D-PAS and IHC for CD68 help in evaluating Kupffer cells. Again, portal or sinusoidal storage cells can easily be missed or interpreted as scavenging ceroidladen macrophages, particularly in disorders associated with hepatitis and fibrosis.

'Neonatal hepatitis' is a term that was coined for presumed viral infections of the liver in early infancy. It has become evident that disorders demonstrating neonatal hepatitis are by no means exclusively viral, or even infectious, in aetiology. Moreover, disease processes affecting mainly the infantile biliary tree can display parenchymal inflammation. In effect, neonatal hepatitis represents a clinical pattern of neonatal liver disease; thus the designation 'neonatal hepatitis syndrome' has merit despite the inherent vagueness of the term 'syndrome' . Other diseases, such as galactosaemia, hereditary fructose intolerance, cystic fibrosis and the conditions discussed in relation to biliary atresia and paucity of the intrahepatic bile ducts, may also present with pathological changes in the liver resembling an infectious process. Giant cell transformation, a frequent histological component of neonatal hepatitis, has been seen in all cholestatic conditions in infancy, including pure haemolytic anaemias and endotoxic injury. 15 Although clinical jaundice is not present in every case of neonatal endoplasmic reticulum. EM can help in the differential diagnosis. It is indistinguishable from the clarification of hepatocellular cytoplasm observed in patients with poorly controlled diabetes (Mauriac syndrome).

Ground-glass cytoplasmic inclusions are observed in a number of metabolic conditions, including GSD type IV myoclonic epilepsy (Lafora disease) and hypofibrinogenaemia, as well as in drug-induced hepatitis and chronic hepatitis B.

Diastase-resistant PAS-positive (D-PAS+) globules in periportal hepatocytes usually indicate α1-antitrypsin deficiency, and typically patients with the PI*Z allele, due to retention of the polymerized abnormal enzyme within the rough endoplasmic reticulum. These globules may represent an acute-phase phenomenon in patients with PI*M phenotype or when heterozygosity for a defective M variant has not been detected. They are seen in the liver of patients with PI*MZ but not with PI*S or PI*MS. Finer D-PAS+ inclusions have been described in association with α1-antichymotrypsin deficiency, and D-PAS-negative/α1-antitrypsin-negative globules may be found with antithrombin III deficiency.

Copper accumulation may be observed. Periportal copper and copper-binding protein deposits (rhodanine and orcein or analogue stains) and siderosis (Perls stain) are physiological up to approximately 4 months after birth. Accumulation of copper or copper-binding protein suggests a chronic cholestatic disorder, Wilson disease or copper toxicosis. In the early stage of Wilson disease, hepatocellular copper is intracytoplasmic rather than lysosomal and therefore not demonstrable histochemically.

Iron accumulation may be localized in hepatocytes or nonparenchymal cells. Siderosis of Kupffer and endothelial cells indicates secondary iron overload or ferroportin disease. Hepatocellular siderosis is a feature of genetic HFE haemochromatosis (see Chapter 4) . Children with genetic haemochromatosis are asymptomatic. Juvenile haemochromatosis usually presents clinically in the second decade of life, mainly as a cardiac disorder. Siderosis may be observed in children with peroxisome disorders (e.g. Zellweger syndrome).

Siderosis in residual hepatocytes, pancreas, heart and salivary glands (demonstrated with a lip biopsy)-rather than in reticuloendothelial cells-of infants with neonatal liver failure due to massive necrosis characterizes the syndrome of neonatal (or perinatal) haemochromatosis. It is currently regarded for most, but not all, cases as a form of alloimmune injury to the fetal liver (gestational alloimmune liver disease). A similar clinical presentation occurs with 'le foie vide', characterized by massive loss of hepatic plates, but not cirrhosis. 14 Its pathogenesis remains uncertain, apparently a failure of regenerative capacity.

Canalicular cholestasis in the absence of portal changes of large bile duct obstruction, cholate stasis or ductopenia is called 'bland cholestasis' . It may be the only histological change in children, adolescents or adults presenting with pruritus with or without jaundice and with or without an external trigger such as an infection or hormonal imbalance (e.g. oral contraceptives). These symptoms may be caused by mutations of the same genes that cause bile canalicular transport defects (ATP8B1 and ABCB11) in neonates, but in a milder form. IHC for canalicular enzymes, mutation analysis and exclusion of other causes (e.g. drugs, lymphoma) is part of the diagnostic workup. Lobular cholestasis accompanied by progressive bile duct loss and periportal deposits of copper and copper-binding protein is the histological picture of Alagille syndrome. A ductular reaction may be present at an early stage. A sclerosing cholangitis-type pattern is observed in MDR3 deficiency. 'Cholate stasis' refers to the changes affecting periportal hepatocytes, usually as a result of a idiopathic neonatal hepatitis is generally good, with mortality of 13-25%. 18, 29 In the study of Dick and Mowat, 16 2 of 29 patients with idiopathic neonatal hepatitis died, and only two others had signs of persisting liver disease. Overall, predictors of poor prognosis include persisting severe jaundice, acholic stools, prominent hepatomegaly, severe inflammation on liver biopsy and familial occurrence. Numerous inherited disorders causing the neonatal hepatitis syndrome have recently been described in terms of gene defect, such as the bile canalicular transporter disorders and bile acid synthesis disorders, and these had previously been classified as idiopathic neonatal hepatitis. Undoubtedly, other such disorders remain to be defined. A hereditary form with giant cell transformation and lymphoedema resulting from abnormal deep lymphatics has been reported, but the gene abnormality has not yet been determined. 30, 31 Another identified aetiology is adenosine deaminase deficiency, with recovery after enzyme replacement. 32 Citrullinaemia type 2 due to deficiency of citrin can cause neonatal hepatitis syndrome (then also known as NICCD, neonatal intrahepatic cholestasis caused by citrin deficiency [33] [34] [35] [36] ; it may occur in ethnicities other than East Asian. 'Le foie vide', of which multiple cases have been identified, describes a severe neonatal liver disorder characterized by failure of hepatocellular regeneration, also manifested as chronic-pattern neonatal liver failure. 14, 37, 38 Histopathological features Liver biopsy specimens are characterized by varying degrees of cholestasis (with or without pseudoglandular structures), giant cell transformation, ballooning, apoptotic bodies, extramedullary haemopoiesis, lobular and portal inflammation and progressive fibrosis in some cases. Unusually severe inflammation and hepatocellular damage may be found in α1-antitrypsin deficiency, hereditary tyrosinaemia type 1, Niemann-Pick disease type C, syncytial giant cell hepatitis, citrullinaemia type 2, primary disorders of bile acid synthesis (mainly δ 4 -3-oxosteroid-5β-reductase deficiency), BSEP deficiency (progressive familial intrahepatic cholestasis type 2) and idiopathic neonatal hepatitis. Associated macrovesicular steatosis favours a metabolic disorder. Confluent hepatocyte necrosis or loss with bridging collapse is seen in the rare patients presenting with acute-pattern neonatal liver failure or having a subacute clinical course associated with perinatal haemochromatosis, non-Wilsonian copper toxicosis or other metabolic disorders such as hereditary tyrosinaemia type 1. It may also occur occasionally with viral hepatitis, especially in infants born to mothers carrying the precore mutant of hepatitis B, and idiopathic neonatal hepatitis.

The pathological aspects of giant cell transformation, a frequent and often dominant finding in neonatal hepatitis, have been reviewed extensively. [39] [40] [41] The change is seen throughout the parenchyma but is often more marked in the perivenular areas. The giant cells contain four or more nuclei, sometimes as many as 40 per cell, have poorly defined outlines and may be detached from other cells in the hepatic plate (Figs 3.1 and 3.2). The cytoplasm of some giant cells may contain remnants of cell membranes. It is partially rarefied and often contains bile and/or haemosiderin. The cells may have more glycogen than normal hepatocytes and a greater activity of a variety of enzymes, such as glucose-6-phosphatase, acid phosphatase and succinic dehydrogenase. Death of the giant cells is associated with a neutrophilic inflammatory response (Fig. 3.3) . In severe forms, extensive bridging cell loss may divide the parenchyma into micronodules which are highlighted by a reticulin stain (Fig. 3.4 A and B ). The number of giant cells decreases as patients grow older and are rare after age 1 year. Formation of giant cells is considered to be a characteristic change resulting from mitotic inhibition of the young, growing liver tissue by a number of agents, such as viruses, drugs hepatitis syndrome, conjugated hyperbilirubinaemia is invariably present. Therefore the entire spectrum of these diseases might best be called 'infantile conjugated bilirubinaemia disorders', a term which avoids the inherent disadvantages of each of the component terms of 'neonatal hepatitis syndrome' . Table 3 .1 shows a classification of infantile conjugated bilirubinaemia disorders (neonatal hepatitis syndrome). In the past 20 years the proportion of cases with no known aetiology has fallen substantially, from 50-60% 16 to approximately 30% or less. Many of the disorders dissected out of the 'idiopathic' category are inherited metabolic diseases.

Nomenclature for neonatal liver disease is very problematic. The simplest term 'neonatal jaundice' may be confused with physiological jaundice in the newborn. The term 'neonatal cholestasis' is not precise because in the first 3-4 months of life, every infant has some degree of cholestasis physiologically. This physiological cholestasis occurs because mechanisms for uptake of bile acids and other organic anions by hepatocytes are immature and thus inefficient, leading to high concentrations of bile acids in blood. In addition, hepatocellular pathways for bile acid conjugation and biliary secretion are also immature, in part because bile canalicular transporters are also regulated developmentally. The circulating bile acid pool is contracted, and ileal uptake of bile acids is underdeveloped. The term 'neonatal hepatitis' is obviously imprecise because hepatic inflammation is not a feature of every condition. 'Neonatal hepatitis syndrome' emphasizes the uniformity of the clinical presentation and similarity of pathological findings, as well as the broad spectrum of causative disease processes. The term 'infantile conjugated bilirubinaemia disorders' (ICBRDs) not only identifies the definitional finding but conveys inclusion of a broad spectrum of infectious, metabolic, structural and other aetiologies. It suffers only from being linguistically unwieldy.

Numerous infections, usually congenital, are implicated in neonatal hepatitis syndrome, including cytomegalovirus (CMV), rubella virus, hepatitis B virus (HBV), herpes simplex virus (HSV), herpes zoster virus, coxsackievirus, echovirus, paramyxovirus, 17 Toxoplasma and Treponema pallidum. An unusually high incidence of CMV infection (49%) was reported in a series of 45 cases from Taiwan. 18 HSV, enteroviruses, adenovirus and HBV may cause neonatal liver failure characterised by an acute pattern of liver disease, with extremely elevated serum aminotransferases. In addition to genetic metabolic disorders, endocrine disorders may cause neonatal hepatitis syndrome. An association with hypopituitarism was reported in two infants by Herman et al., 19 and later Sheehan et al. 20 Immunological disorders may cause neonatal hepatitis syndrome; neonatal lupus erythematosus is most common. Most infants with the rare disorder known as 'neonatal (or perinatal) haemochromatosis' have an immunological disorder which results in neonatal liver failure with a chronic pattern (near-normal serum aminotransferases, profound coagulopathy, subnormal serum albumin), called 'gestational alloimmune liver disease' (GALD). 21 Rarely, a Coombs-positive haemolytic anaemia defines a severe form of giant cell hepatitis which rapidly progresses to cirrhosis or death. 22 Early and sustained immunosuppressive therapy may control the disease in some patients. 23 The liver lesion has been shown to recur in the allograft of the few cases transplanted. 24, 25 Infants with birth asphyxia may develop severe neonatal hepatitis syndrome. 26, 27 It may be caused by an ischaemic hepatitis. 28 Conjugated hyperbilirubinaemia typically occurs at 1 week of age, lasts 3-4 months, and the hepatomegaly and liver tests return to normal by 1 year of age. Various hepatobiliary structural abnormalities, most importantly biliary atresia, are associated with the neonatal hepatitis syndrome. Furthermore, certain chromosomal defects predispose to the syndrome.

In approximately 30% of infants with conjugated hyperbilirubinaemia, no aetiology is found. The prognosis for this so-called

Biliary atresia is one of the most important causes of severe neonatal liver disease. It is the major indication for liver transplantation in young children. Initially, the extrahepatic biliary tree is affected, evident as an obstructive picture both clinically and histopathologically; this is the defining lesion of this disorder. Biliary cirrhosis develops early in life. The children who survive infancy because of a successful Kasai portoenterostomy continue to have intrahepatic bile duct damage, which leads eventually to profound loss of small intrahepatic bile ducts and recurrent cholestasis due to bile duct paucity. Accordingly, this hepatobiliary disorder is now called simply biliary atresia, without specifying an extrahepatic (or intrahepatic) location. The term 'biliary atresia' (BA) is used in this section interchangeably with the former term 'extrahepatic biliary atresia' (EHBA). The term 'intrahepatic biliary atresia' to denote intrahepatic bile duct paucity has been obsolete for many years and should be abandoned. Additionally, biliary 'atresia' must be distinguished from biliary 'agenesis' .

Approximately 30% of infants presenting with conjugated hyperbilirubinaemia in the neonatal period have BA, the overall incidence being approximately 1 in 6000 to 1 in 19,000 live births. [45] [46] [47] [48] There is no clear-cut racial predilection, although some ethnicities appear to have a higher incidence: African-Americans 49 and Polynesians 50 compared with Caucasian infants. BA is more common in girls than boys. 47, 51 Seasonal variation in the occurrence of this disease has been suggested in North American studies, 49, 50 although this pattern has not been confirmed in Europe 45 or Japan. 52 Unquestionably, multiple disease mechanisms can produce BA because it may occur as an isolated lesion or in association with various types of congenital structural abnormalities or specific chromosomal abnormalities. It can be conceptually useful to classify BA in two general patterns: 'embryonic,' occurring early in development and accounting for 15-35% of cases, and 'perinatal/acquired', comprising 65-85% of cases. This aetiopathogenic heterogeneity of BA was first delineated by a study of 237 children by Silveira et al. 53 Forty-seven of the children (20%) had associated congenital anomalies (28 cardiovascular, 22 digestive and 19 splenic). The splenic malformations included 13 with polysplenia syndrome and two with asplenia. Karyotypic abnormalities were found in two of eight children studied. The and hereditary abnormalities, 42 or from dissolution of cell membranes, as suggested by Craig and Landing, 43 who first described this entity. Negative nuclear staining for cell proliferation markers and the demonstration of canalicular remnants using carcinoembryonic antigen (CEA) immunostaining support a fusion of rosette-forming hepatocytes as the likely mechanism of giant cell formation. 41 Phillips et al. 44 used the term 'syncytial giant cell hepatitis' to describe 10 patients (age range, 5 months to 41 years) with hepatitis characterized by giant multinucleated hepatocytes, usually containing up to 30 nuclei within a single large cell body. These large cells conformed to the reticular framework of the hepatic cords but in some cases crossed the sinusoids to form syncytial masses with adjacent cords. The authors concluded that these large cells were the product of fusion of hepatocytes (thus the term 'syncytial'), most likely caused by paramyxovirus infection. extrahepatic biliary atresia, and oesophageal and duodenal atresia was reported in one family; description of the findings suggests agenesis of the extra-and intrahepatic ducts. 70 Viral infection in combination with a genetic predisposition to a robust or disordered inflammatory response may play a role in the development of perinatal/acquired BA. Chance occurrence of a viral infection during a limited period of susceptibility would explain the rarity of BA. No consensus exists as to which viruses are pre-eminent in such an aetiopathogenesis. The proposed viruses form a heterogeneous group, including both DNA and RNA viruses. Some recent observations suggest that viral infection is a secondary phenomenon. 71 CMV infection is found in a high proportion of children with BA. Accordingly, a recent classification of BA specifies CMV association not only in the perinatal form, but also in the embryonic form and cystic variant. 72 Tarr et al. 73 found evidence for viral infection in 5 of 23 patients with BA. The diagnosis was based on histopathological evidence of CMV infection, serology (IgM antibodies) or culture. The detection of CMV infection by the polymerase chain reaction (PCR) is higher in neonatal hepatitis than in BA. 74 In a set of identical twins both infected with CMV, one twin had BA and the other had neonatal hepatitis. 75 Infants with BA and concurrent CMV infection may have a worse prognosis. 76 CMV may elicit immune responses, which interfere with the action of regulatory T (Treg) cells. 77 Reovirus 3 was suggested as a cause of BA and neonatal hepatitis on the basis of clinical and experimental studies, [78] [79] [80] [81] but this association was questioned by other investigators. 82, 83 Tyler et al. 84 provided more compelling evidence for an aetiological association between BA and reoviruses, detecting reovirus RNA from hepatobiliary tissues of 55% of patients with BA and 78% of patients with choledochal cysts. Riepenhoff-Talty et al. 85 suggested a possible relationship between group C rotavirus and BA. Subsequently, however, no evidence of group A, B or C rotaviruses was detected by PCR in BA. 86 Human papillomavirus (HPV) has been detected in neonatal hepatitis and BA by nested PCR for DNA, 87 but the role, if any, of HPV needs to be clarified.

Recent progress has focused on immune mechanisms in the pathogenesis of BA, especially perinatal/acquired BA. 88, 89 The envisioned disease mechanism is that during the perinatal period a viral infection occurs and targets the biliary epithelium and provokes an aberrant autoimmune injury to the bile ducts that persists long after the viral investigators divided BA into four distinct subgroups, three involving a congenital form that could arise through a malformation, a disruption or a chromosomal abnormality, with the fourth attributable to agents active in the perinatal period (the acquired form). 53 Most infants have this perinatal/acquired pattern; their apparently normal biliary system has been subjected to a fibrosing inflammatory process late in gestation or shortly after birth. Discordance for BA in HLA identical twins supports a postnatal event being of primary importance in the pathogenesis of perinatal/acquired BA. 54 By contrast, approximately 10-30% of infants with BA have extrahepatic congenital abnormalities such as polysplenia, left atrial isomerism, double-sided left lung, preduodenal portal vein, intestinal malrotation and/or congenital heart defects. 51, 55, 56 Preduodenal portal vein is the result of a variation in the normal developmental pattern of the embryonic precursors of the portal vein, i.e. the right and left vitelline veins and their three anastomotic channels. These congenital defects are sometimes grouped as a 'laterality complex' . Abnormalities of the spleen are not invariably present in infants who have other typical features of the laterality complex, and thus 'splenic disorder' does not define this association. 57 The best currently available term for this category of BA is 'biliary atresia with structural malformations' (BASM).

A further subset of infants with BA, comprising 6-10% of patients overall, have damage to the biliary tree which produces cystic dilation [58] [59] [60] ; these patients look as if they have a choledochal cyst. Exceptionally, the cystic change is confined to intrahepatic ducts. This type of BA, now termed 'cystic' BA (formerly called 'correctable' BA), may be identified on sonography of the fetus in approximately 40% of affected cases. 60 It may represent yet another disease mechanism for BA, distinct from those represented by embryonic and perinatal BA, although cystic BA has been identified in patients with embryonic BA. Notably, some infants with BA have specific chromosomal abnormalities such as trisomy [17] [18] 61 Turner syndrome 62 or cat-eye syndrome. 63 BA has been reported with the Kabuki make-up syndrome, 64 in one patient with Zimmermann-Laband syndrome and brachydactyly 65 and in Martinas-Frias syndrome. 66 Other genetic disorders may be associated with BA because familial occurrence has been reported, 67, 68 and in one case a woman who previously had BA gave birth to a daughter with BA. 69 A lethal autosomal recessive syndrome with intrauterine growth retardation, once called intra-and human disease. IFN-γ plays an important role in bile duct damage: knockout mice not expressing IFN-γ failed to incur severe duct damage after infection with RRV despite a brief hepatitis, whereas wild-type animals did; administration of recombinant IFN-γ abrogated the protective effect of not being able to produce IFN-γ. 113 Certain chemokines may also contribute to biliary damage 114 ; IL-12 seems to play a lesser role 115 ; TNFα appears not to be involved. 116 Recent observations implicate IL-17, which plays a role in various autoimmune disorders. 117 In this mouse model, primed neonatal CD8 T cells appear capable of initiating damage to bile ducts. 118 When T cells from RRVdisease mice were transferred into naive syngeneic severe combined immunodeficiency (SCID) mice, the recipients developed bile ductspecific inflammation without previous RRV infection. 119 Some autoantibodies have been detected in this model (directed to α-enolase or vimentin). 92 Thus the combination of observations in infants with BA and in this mouse model strongly suggests that a complex pattern of immune reactivity appears to be important in perinatal/acquire BA. Of interest, circulating markers of inflammation persist after surgical palliation with the Kasai portoenterostomy, although it is not clear why. 120 In embryonic BA, other genes may play a more direct role.

Other theories have been proposed for the pathogenesis of BA. Landing 121 first proposed that neonatal hepatitis, BA, infantile choledochal cyst and possibly some cases of 'intrahepatic biliary atresia' (meaning congenital duct paucity syndromes) are all manifestations of a single basic disease process that he named 'infantile obstructive cholangiopathy' . He considered BA (and choledochal cyst) to be the result of an inflammatory rather than a maldevelopmental process and postulated that the most probable cause was a viral infection. Since the aetiopathogenesis of an important congenital bile duct paucity syndrome, namely, Alagille syndrome, has since been elucidated as genetic, this theory clearly requires modification. Nevertheless, as previously discussed, the role of viral infection, at least in the pathogenesis of perinatal/acquired BA, is an important focus of current research. Certain chromosomal abnormalities may give rise to complex syndromes, including altered immune reactivity, and thus predispose to hepatobiliary disease mediated by viral infection. Microchimerism has recently been proposed as part of the mechanism of hepatobiliary damage in BA 122 ; it might initiate an immune response in the absence of viral infection. The various manifestations of infantile obstructive cholangiopathy may depend on the timing of the insult. Specifically, rats given the drug 1,4-phenylenediisothiocyanate during fetal life developed stenotic or atretic bile ducts caused by thickening and fibrosis, whereas those given the drug after birth had dilation of the ducts with inflammation. 123 It is difficult to generalize from this rat model to human infants. BA with features of the ductal plate malformation (DPM) might reflect a different disease mechanism. 124 Recent observations, however, have argued against the presence of DPM in BA as unique to patients with embryonic BA. 125 Whereas the pathogenesis of perinatal/acquired BA probably involves immunogenetic susceptibility and exposure to an instigating factor, such as viral infection, during a limited period of susceptibility, the aetiopathogenesis of embryonic BA appears to be much more diverse. An important subset has BASM (biliary atresia with structural malformations). Extrahepatic congenital abnormalities such as polysplenia, congenital heart defects and disturbed rotation of the intestines suggest an extensive and early developmental abnormality. Some infants with BASM show features of the ductal plate lesion on liver biopsy. 124, 126, 127 This abnormal configuration of small bile ducts is attributed to disorganization in the fetal development of the biliary tree; failure of remodelling of the ductal plate leads to residual embryonic bile duct structures in this rather striking configuration. Finding the ductal plate lesion in extrahepatic BA is consistent with a destructive hepatobiliary process beginning early in gestation. Abnormal cilia have been reported in children with the polysplenia infection is gone. This proposed mechanism entails an active, ongoing immune response, which can be documented empirically, and it accounts for the conflicting reports of viral infection in BA as well as the absence of detectable ongoing viral infection in liver or biliary tissue from BA patients. Currently, it is seen as involving macrophages and dendritic cells primed as a result of the infection, followed by activation of natural killer (NK) cells, which then actuate biliary epithelial damage. Amplification of the immune response by T cells and proinflammatory cytokines then takes place. 90, 91 Molecular mimicry may play a role. 92 This general disease mechanism is based on findings in human tissue from BA patients and also on disease models of BA. The hepatic inflammatory infiltrate in BA was found remarkable for evidence of lymphocyte activation. 93 Studies in liver tissue from infants with BA showed a T-helper cell type 1 (Th1) form of cytokine expression pattern with CD4+ and CD8+ lymphocytes, CD68+ macrophages in portal tracts and increased interleukin-2 (IL-2), IL-12, interferon-γ (IFN-γ) and tumour necrosis factor alpha (TNFα). 94 Determinants on the activated T cells are typical of an oligoclonal expansion, consistent with being evoked by a specific antigen. 95 The rarity of BA raises the possibility of genetic susceptibility in perinatal/acquired BA. Genomic studies of liver from infants with BA have shown upregulation of genes involved in regulating lymphocyte differentiation, mainly of those with Th1 commitment. 96 Upregulated expression of IFN-γ and osteopontin was notable. Subsequently, upregulation of osteopontin expression in intrahepatic biliary epithelium was found to correlate with portal fibrosis and ductular reaction. 97 A different genomic study, which included somewhat older patients, also found upregulation of genes involved in morphogenesis, cell signalling and regulation of gene transcription. 98 Further studies suggested that the pattern of regulatory gene expression in perinatal/acquired BA is not equivalent to that in embryonic BA; however, these data also failed to show a pattern of gene expression relating to laterality genes in embryonic BA. 99 Both forms of BA appear to induce a strong immunological response.

Genome-wide association studies have been used to identify possible susceptibility loci. In North American children, a locus at 2q37.3 was found to be GPC1, 100, 101 which encodes a regulator of Hedgehog signalling and inflammation. In Chinese children a locus at 10q24.2 was also identified as a possible susceptibility locus for BA; it proved to be ADD3, 102 and this finding was confirmed in a North American series. 103, 104 A further study in North American children found a locus at 14q21.3, and this was identified as encoding ADP ribosylation factor-6 (ARF6). 105 These three proteins have been investigated in the zebrafish, where they play a role in biliary morphogenesis. Of note, GPC1 mediates fibroblast growth factor signaling, and ARF mediates epidermal growth factor signaling. XPNPEP1, which is also found in the 10q24 region, is expressed as X-prolyl aminopeptidase P1 on biliary epithelial cells. 103, 106 XPNPEP1 is involved in metabolism of inflammatory mediators, but whether XPNPEP1 is a susceptibility locus remains uncertain.

Human leukocyte antigen (HLA) studies in BA might support a disease mechanism involving autoimmunity, but results to date are contradictory. One early study showed that infants with perinatal/ acquired BA have a high prevalence of the HLA-B12 determinant compared both to normal controls and to infants with BA plus congenital anomalies 107 ; haplotypes A9-B5 and A28-B35 were more common in infants with late-pattern (perinatal/acquired) BA. A subsequent study failed to confirm any characteristic HLA pattern in BA. 108 However, additional studies have shown an association with HLA-DR2 109 and with HLA-B8 and HLA-DR3. 110 Further insight into the possible mechanism of perinatal/acquired BA has come from recent work in the Rhesus rotavirus (RRV) murine model of BA. It can be simulated in Balb/c-mice which have been infected with rotavirus. 111, 112 This model shares many features with the of the radiolabelled substance into the intestinal tract over a 24-hour period. This is the 'nondraining hepatobiliary scan' . Although hepatobiliary scanning has high sensitivity, scanning may appear normal if performed very early in the disease process in late-pattern BA. 146, 147 Hepatobiliary scanning is informative if it shows that tracer, and thus bile, reaches the intestine; it is objective, recorded, and can be quantified. A negative or nondraining scan does not mean that the disorder is necessarily BA, because nondraining hepatobiliary scans may be found with severe idiopathic neonatal hepatitis, small duct paucity syndromes (e.g. Alagille syndrome), severe α1-antitrypsin deficiency or TPNassociated cholestasis. The role of endoscopic retrograde cholangiopancreatography (ERCP) remains controversial: ERCP is technically feasible in infants and may be useful in select cases. [148] [149] [150] Percutaneous liver biopsy is essential and has high diagnostic specificity in the range of 60-95%, depending on the timing of the biopsy, adequacy of the specimen and expertise of the pathologist. 151, 152 In our experience, the majority of nondiagnostic biopsy specimens are taken within the first few weeks of life. In fact, incidental liver biopsy specimens taken at laparotomy for duodenal stricture within the first week of life in three infants with BA showed only trivial liver abnormalities. 153 This may imply that although bile duct destruction is likely to have started in utero, the actual liver damage may not occur until the placenta no longer provides clearance of biliary products, in particular bile salts.

Portoenterostomy (Kasai procedure) was introduced in 1959 and remains the only potentially corrective procedure for BA, other than liver transplantation. 154 In this operation, the atretic biliary tree is resected, and bile drainage is re-established through a broad anastomosis at the end of an intestinal Roux-en-Y loop to the bare edge of the transected porta hepatis. The efficacy of the laparoscopic version of the Kasai portoenterostomy, introduced in the past 10 years, remains uncertain. Although meta-analysis has suggested that it is inferior to the traditional portoenterostomy, 155 other reports suggest favourable results, partly dependent on local expertise. 156, 157 Extensive retrospective studies have shown that the prognosis for a good long-term result from the conventional Kasai procedure depends primarily on operation before 60 days of age and the absence of cholangitis. 8, 47, [158] [159] [160] [161] [162] [163] The potential exists, however, for reasonable medium-term survival in about one-third of infants coming to primary corrective surgery at 100 days or older. Most centres continue to favour the Kasai procedure as the first therapeutic option, rather than subjecting patients to immediate liver transplantation simply on the basis of age. 164 The lack of significant fibrosis at operation may play a role in a good long-term outcome. 165 Computerized quantification of fibrosis on liver biopsy obtained at portoenterostomy may discriminate between negligible fibrosis and sufficient fibrosis to portend a poor prognosis. 166 One group suggested that histological features on the initial liver biopsy specimen can predict the success of portoenterostomy. 167 Another group reported that the extent of ductular reaction, based on keratin 7 (K7) immunostaining, found in the liver biopsy specimen obtained at the Kasai procedure was predictive of native liver survival over the following year. 168 Histological studies of the extrahepatic bile ducts removed at surgery have been performed by several groups of investigators. [169] [170] [171] [172] [173] In a study of 98 cases, Gautier and Eliot classified the biliary remnants into three types. In the first the duct is completely atretic, with few or no inflammatory cells in the surrounding connective tissue (Fig. 3.5 A) . In the second type the duct is present as a cleft-like lumen lined by occasional cuboidal or low columnar epithelium which is variably necrotic, hyperplastic or focally absent (Fig. 3 .5 B and C). The altered ducts are sometimes very numerous, usually having lumina of <50 µm; periluminal neutrophilic infiltration is syndrome and BA. 128, 129 Although the association with abnormal cilia is unclear, ciliary function appears to be important in left/right asymmetry. 130 There is a pathogenic role for multiple defects in the laterality sequence. 131 Early studies focused on the inversion (inv) gene, one of three genes that control left/right asymmetry in the mouse. 132 Beginning in early embryonic development, the liver is a predominant site for this gene expression. A transgenic mouse with recessive deletion of inv develops situs inversus and jaundice; the early fetal lesion is a complete obstruction with cystic change of the biliary tree. 133 Few of the various genes which have been found mutated in human laterality disorders (ZIC3, CFC1, LEFTYA, ACVR2B, NODAL) have been investigated in BA; however, mutations in CFC1 134 and ZIC3 135 have been found in infants with BA and major laterality defects. Three children were described with ultrastructural abnormalities of the canalicular microvilli and no expression of villin; phenotypically they had BA without laterality complex or DPM. 136 The extrahepatic biliary tree in BA may be totally atretic, or the atresia may involve only proximal or distal segments. The intrahepatic bile ducts are gradually destroyed with progression of the disease. Most infants with BA have conjugated hyperbilirubinaemia from an early age, 137 but clinical jaundice is not always apparent or appreciated. Indeed, in many infants, jaundice is initially physiological and merges with the jaundice of advancing liver disease. Infants typically have dark urine and pale stools, but the stools may retain enough colour to be falsely reassuring. The infants look well and generally gain weight adequately. At clinical presentation they have hepatomegaly and usually some degree of splenomegaly, unless polysplenia is present. The infant who presents with congenital heart disease and conjugated hyperbilirubinaemia requires intensive evaluation because the leading hepatic diagnoses will be BA or Alagille syndrome. Untreated BA rapidly progresses to hepatic fibrosis and cirrhosis with all the complications of portal hypertension, in addition to malnutrition and fat-soluble vitamin deficiency. The median age of death is 12 months if BA is not diagnosed and treated. 138 Early diagnosis and treatment may be promoted by the use of stool colour cards for all infants at discharge from the newborn nursery. 139, 140 Clinically, the differential diagnosis is the broad spectrum of disorders constituting the neonatal hepatitis syndrome 141 presenting with conjugated hyperbilirubinemia (see Table 3 .1). Congenital infection should be excluded, although CMV may be found along with BA. Systemic bacterial infection should be ruled out, including a silent urinary tract infection. Inherited metabolic diseases require specific attention, especially α1-antitrypsin deficiency, which can be associated with severe cholestasis and acholic stools and very rarely has been associated with BA. Cystic fibrosis can generate a duct lesion indistinguishable clinically from BA. These two conditions as well as galactosaemia may produce a histological picture closely resembling that of BA. Structural abnormalities of the extrahepatic biliary tree cause the clinical presentation similar to BA: choledocholithiasis, idiopathic perforation of the biliary tract, 142-144 true choledochal cyst and extrahepatic biliary hypoplasia or 'hair-like' bile duct syndrome. Some infants with Alagille syndrome show ductular reaction, rather than duct paucity, on liver biopsy taken early in the course of the disease. Whether some infants with perinatal/acquired BA have an unusually slow progression of liver disease, sometimes called 'BA in evolution', is disputed, but these patients pose a diagnostic challenge and require repeated assessment. 145 Preoperative diagnosis relies on demonstrating the presence or absence of bile secretion in the intestine. Hepatic sonography may reveal a dilated extrahepatic biliary tree, consistent with distal cystic atresia, but it is unusual to find dilated intrahepatic bile ducts. Hepatobiliary scanning, using a technetium 99m-labelled iminodiacetic acid derivative such as DISIDA or PIPIDA, fails to demonstrate passage of which effectiveness in bypassing the atretic duct is uncertain; anastomoses between ramified peribiliary glands are well demonstrated in normal adult livers using injection techniques (see Chapter 9) . Correlations between the size and number of residual ducts and establishment of bile flow after surgery have yielded conflicting results. Two groups of investigators believed that bile flow is most likely to occur when the diameter of the residual ducts exceeds 150 µm. 158, 169, 174 However, another study of the extrahepatic biliary remnants of 204 cases of BA showed that the patterns of bile duct obliteration are not indicative of prognosis. 173 Although the Kasai procedure is essentially a palliative operation, many children enjoy prolonged good health afterward, and approximately 20-25% of patients who undergo portoenterostomy will survive into adulthood without liver transplantation. Approximately 30-35% of patients drain bile but develop complications of cirrhosis and require liver transplantation before age 10 years. 175 For the remaining patients, characteristic; and cellular debris, and less often bile, may be found in the lumen. Epithelial necrosis is evident in ducts with a diameter exceeding 300 µm. The third type of biliary remnants consists of altered bile duct incompletely lined by columnar epithelium, in addition to numerous smaller epithelial structures (Fig. 3.5 D) . These histological types were evaluated by Gautier et al. 171 at three levels: porta hepatis, junction of the cystic and common hepatic ducts and an intermediate level; completely atretic duct becomes increasingly more common from the porta hepatis to the junction of the hepatic duct and cystic ducts. This classification, which may help pathologists describe the changes observed in the biliary remnants removed at portoenterostomy, is of limited clinical significance because in individual cases, serial sectioning often shows atretic ducts alternating randomly with variably destroyed ducts. In addition, the numerous smaller structures intermingled with variably altered ducts are likely to represent anastomosing channels recruited from peribiliary glands, Kasai procedure. Bisected specimen showing macronodular areas of re-expanded parenchyma (centre of the field) with more fibrotic micronodular areas particularly at the periphery. Note the large fibrotic and seemingly stretched portal areas which contain well-identifiable bile duct branches (yellow and light green).

bile flow is inadequate after portoenterostomy and cirrhosis rapidly develops. Survival in BA with a functioning Kasai portoenterostomy but without orthotopic liver transplantation is 10-20% by age 20 years. 176 In a recent survey of 271 patients, 23% were alive with their native liver 20 years after surgery, all but two having signs of cirrhosis; after age 20, two patients died of liver failure and 14 underwent, or were waiting for, a liver transplant. Women who are long-term survivors with BA and have not yet had a liver transplant may have a normal pregnancy, 177 but in general such pregnancies must be treated as high risk because of complications from portal hypertension or hepatic decompensation. 178 Liver transplantation has become the treatment of choice for infants and children in whom the Kasai portoenterostomy has failed. The safety and results of liver transplantation with the use of livers from living-related donors and cadaveric donors are excellent.

One-year survival is >90%, with better results obtained under elective conditions and in children who weigh more than 10 kg. 176, 179 Recent data indicate that the overall survival at 10 years for all surgical treatment is 75-80% 47, 180 ; general health 10 years after paediatric liver transplantation is good, although renal impairment and cardiovascular disease may develop. 181 The macroscopic appearance of the liver in BA varies according to the stage of the disease. At first the liver is enlarged and dark green in colour, becoming finely nodular as cirrhosis develops ( Fig. 3.6 ). In untreated cases, the cirrhosis may take between 1 and 6 months from birth to develop. Dilated bile ducts filled with inspissated bile may be seen in sections of large portal areas ( Fig. 3.7) . The cystically dilated bile ducts may resemble Caroli disease. 182 They only occur after age 3 months and are not amenable to surgical drainage procedures. There may be portal lymphadenopathy. The median maximum node dimension in six cases studied by Hübscher and Harrison 183 was 14 mm. These lymph nodes are brown in colour and full of pigment-laden macrophages. Livers removed at transplantation after an apparently successful Kasai procedure (loss of jaundice), but with subsequent development of cirrhosis and portal hypertension, are often coarsely nodular with areas of macronodular hypertrophy and broad intervening or peripherally located scars resembling the gross appearance of focal nodular hyperplasia ( Fig. 3.8 ).

The histological features of BA include cholestasis, portal tract expansion by oedematous fibroplasia and periportal ductular reaction with the presence of bile plugs in dilated lumens of cholangioles that are distorted and often form an irregularly anastomosing network at the portal periphery (Figs 3.9 and 3.10). Arterial branches are unusually prominent, and portal vein branches appear attenuated. Giant cell transformation of hepatocytes is seen in some cases ( Fig. 3.11 ) and may occasionally be prominent. Loose fibrosis is progressive and periportal/perilobular in location, with linkage of portal areas and eventual development of a secondary biliary cirrhosis ( Fig. 3.12) . In a study of the extracellular and cellular components of the connective tissue matrix in BA, de Freitas et al. 184 suggested that activation of a connective tissue cellular clone by the reactive ductules may be responsible for the portal fibroplasia. Ho et al. 185 reported an arteriopathy (hyperplasia and hypertrophy) of the common hepatic artery and its peripheral branches supplying the entire biliary tree in 11 cases of biliary atresia. Thickening of the medial layer of small hepatic arteries may be present. 186 Subsequent studies have indicated that the transcription factor HNF6 plays an important role in intrahepatic bile duct and arterial development. 187, 188 HNF6 and HNF1ß appear necessary for ductal plate formation. 187 Large perihilar bile ducts may show ulceration with loss of epithelial lining, bile impregnation of the wall and bile sludge formation in the lumen. In addition to the severe cholestasis, the cirrhotic stage of BA is characterized by marked pseudoxanthomatous transformation, the presence of bile lakes, Mallory-Denk bodies and variable accumulation of copper and copper-associated protein in liver cells (Figs 3.13 and 3.14). In one study, copper concentrations were increased in more than two-thirds of liver samples obtained during portoenterostomy and decreased in some patients after successful biliary drainage. 189 However, copper deposition in liver is elevated in the first 2 months of life, and periportal deposition of copper on liver biopsy specimens does not discriminate extrahepatic from intrahepatic causes of cholestasis in early infancy. Acute and chronic inflammation is noted in portal/periportal areas in BA in both precirrhotic and cirrhotic stages, and bile duct degeneration and inflammation may be evident (Fig. 3.15 ). The mononuclear infiltrate in portal and lobular areas of livers with end-stage BA is similar to normal adult liver and very different from that associated with autoimmune hepatitis or chronic HBV infection. It is particularly prominent in cases associated with CMV infection. 190 The growth of large, perihilar regenerative nodules, probably as a consequence of functioning intrahepatic ducts in this region, may be important for maintaining biliary drainage after Kasai procedure. 191 Bile lakes occur after age 3 months, by which time irreversible hepatic damage has occurred. 192 Interlobular bile ducts become few in number as early as the fourth or fifth month after birth (Fig. 3.16) , and advanced duct loss accompanies progressive fibrosis by age 8 or 9 months. 121 Activated hepatic stellate cells are responsible for increased collagen production. 193, 194 In addition to paucity of ducts, Raweily et al. 127 identified concentric tubular ductal structures in 21.6% of cases of BA; these bore some resemblance to those seen in ductal plate malformations ( Fig. 3.17) . Similar observations had been made earlier by Desmet and Callea, 195 who hypothesized that this subgroup has more severe and rapidly progressive liver damage. Interestingly, children in this subgroup reveal a histopathological picture resembling that of congenital hepatic fibrosis 4 or 5 years after portoenterostomy 195, 196 (Fig. 3.18 ; see also Fig. 3.17) . The interlobular bile ducts continue to disappear, and cirrhosis can develop despite satisfactory bile drainage after portoenterostomy. The bile duct loss has been attributed to persistent interference with bile flow, 197 recurrent cholangitis or continuation of the immune process causing the atresia. Detailed histopathological study of sequential liver specimens taken at Kasai operation, relaparotomy and/or transplantation has provided evidence that the bile duct loss is caused by an unpredictable and uneven obliteration of bile ducts in the porta hepatis during wound healing and scarring after portoenterostomy. 197 Ultrastructural degenerative changes affecting the intrahepatic bile ducts and ductules in BA have been described in detail by Ito et al., 198 who found that the degree of obstruction of the lumen of syndrome, 208 trisomy 17-18, trisomy 21 209 and prune-belly syndrome, 210 may have duct paucity. More importantly, the term nonsyndromic duct paucity may be used to refer to isolated, idiopathic paucity of interlobular bile ducts in infancy and childhood; this condition may be the same as idiopathic adulthood ductopenia. Finally, paucity of the intrahepatic ducts or ductopenia is frequently found as a late feature of certain chronic diseases, such as BA, primary sclerosing cholangitis, Langerhans cell histiocytosis and primary biliary cirrhosis (see Chapter 9).

Patients in the syndromic group have Alagille syndrome (ALGS), also known as arteriohepatic dysplasia. 211 Comprehensive descriptions have been reported by Alagille and colleagues 212, 213 and others. [214] [215] [216] Two distinct genetic mechanisms are known to be responsible for ALGS. Most cases (ALGS1) are caused by mutations in JAGGED1 (JAG1, encoding the ligand for the Notch 1 receptor) on chromosome 20p12, 217, 218 and may be associated with a macroscopic deletion of the short arm of chromosome 20 in some patients or microdeletions of 20p in others. The pattern of genetic transmission is autosomal dominant due to haploinsufficiency or dominant negative effect 218 ; gene penetrance is high, but expression is extremely variable. 219 The reported incidence of arteriohepatic dysplasia as 1 in 70,000 live births was an underestimate, and it is actually 1 in 30,000. 216 Approximately 50-70% of patients have new mutations, rather than genetic transmission within the family. Crosnier et al. 220 found mutations of the JAG1 gene in 69 of 109 patients (63%) with ALGS, and transmission analysis showed a high frequency of sporadic cases (70%). Numerous mutations have now been defined. 221 The common clinical findings in Alagille syndrome include cholestatic liver disease caused by paucity of the intrahepatic bile ducts (94%); congenital heart disease, usually peripheral pulmonary stenosis, although complex congenital heart disease, usually right sided, may occur (92%); a typical facies (91%); posterior embryotoxon in the eye (80-93%) and butterfly-shaped vertebral arch deficits (40-67%). 215 The facies of ALGS consists of an inverted triangle shape, slight hypertelorism, deep-set eyes, broad and rather prominent forehead, and beak-like nose. Although the specificity of the facies has been questioned, 222 it is accepted as a typical finding, 223 better appreciated in the actual clinical setting than in photographs. The facies is sometimes not evident in the first months of life, and in adults the facies is somewhat different from that described in children (longer face, rather coarse features, prominent forehead and comparatively small nose). Most patients have a systolic murmur related to stenosis of the pulmonary arterial system. More severe conditions include tetralogy of Fallot, pulmonary valve stenosis, aortic stenosis, ventricular septal defect, atrial septal defect, anomalous pulmonary venous return and complex problems involving a single right ventricle with pulmonary valve atresia. 224, 225 Up to 15% of patients may have life-threatening cardiac complications. 213 In addition to posterior embryotoxon or Axenfeld anomaly, abnormal retinal pigmentation may be found. 226 Strabismus, ectopic pupil, and hypotrophic optic discs have also been reported. Optic disc drusen, which are calcified deposits in the extracellular space of the optic nerve head, often occur in Alagille syndrome. These can be found by ocular ultrasound examination and may facilitate the diagnosis. 227 In addition to 'butterfly vertebrae' (vertebral sagittal cleft), other skeletal abnormalities include short distal phalanges and clinodactyly, and ALGS patients may be prone to bone fractures, beyond what might be attributed to chronic cholestatic liver disease. [228] [229] [230] [231] Systems other than those in the cardinal criteria for the syndrome may be affected. Renal abnormalities may be prominent; renal these ducts appears to be an important determinant of prognosis following corrective surgery.

Malignant epithelial tumours of hepatobiliary origin rarely complicate biliary cirrhosis associated with biliary atresia, but both hepatocellular carcinoma [199] [200] [201] and cholangiocarcinoma 202 have been reported. Focal nodular hyperplasia after portoenterostomy has been reported in a few children with BA. 203, 204 Macroregenerative nodules may also develop. 205 

Paucity of the intrahepatic bile ducts has been reported in many conditions, either congenital or acquired, affecting all age groups, especially infants and children. The relevant finding is a reduction in the number of interlobular bile ducts, that is, in the small bile ducts within portal tracts. The normal ratio of small bile ducts per portal tract in full-term infants, children and adults is 0.9-1.8 ducts per tract. In duct paucity syndromes, this ratio is <0.5, given an adequate number of portal tracts (at least 10) examined on biopsy. Herman et al. 206 have proposed the use of IHC for K7 and EMA to help calculate the ratio between interlobular bile ducts and neocholangioles, with a low ratio indicating bile duct paucity. Premature infants have a reduced number of small bile ducts per portal tract, and if they have duct paucity with cholestasis, it may be physiological. In addition, early biopsy specimens in a few cases of clinically undisputed paucity of the intrahepatic bile ducts have shown not only identifiable ducts, but significant ductular reaction as well.

Liver disorders with paucity of the intrahepatic bile ducts are generally divided into two groups: 'syndromic', which refers to Alagille syndrome, and 'nonsyndromic', which refers to all the rest of these diseases. The nonsyndromic duct paucity conditions include numerous diseases in which portal small duct paucity is associated with another identifiable disease. These include infection (congenital rubella or CMV infection), immune abnormality (graft-versus-host disease, liver allograft chronic rejection) and hepatotoxicity (from carbamazepine or amoxicillin-clavulanic acid), 207 the latter two groups being generally referred to as ductopenia, formerly 'vanishing bile duct syndromes' (see Chapters 9 and 14) . Various inherited metabolic diseases such as Zellweger syndrome, α1-antitrypsin deficiency and inborn errors of bile acid metabolism may display paucity of the intrahepatic ducts. Chromosomal defects, such as 45,XO Turner Catch-up growth after LT is variable. 256, 257 Long-term complications of Alagille syndrome not requiring LT have included renal failure and intracranial bleeding or stroke. 215, 247, 249 Hepatocellular carcinoma has been reported in children and adults with ALGS. [258] [259] [260] [261] Although rare, hepatic malignancy may occur in ALGS infants.

Histopathological aspects of Alagille syndrome are described in various reports and reviews. 212, 213, 245, [262] [263] [264] [265] [266] [267] [268] The major finding is absence of bile ducts from portal areas (Figs 3.19 and 3.20) . The ratio of interlobular bile ducts to the number of portal areas is between 0.0 and 0.4, compared with 0.9-1.8 in normal children. A reduced number of portal areas has been noted. 262 The loss of bile ducts is progressive from early infancy to childhood. 215, 245, [267] [268] [269] Cholangiodestructive lesions have been observed in infants between 3 and 6 months of age. 245, 268 The degree of cholestasis is variable in intensity and is especially prominent in the first 12 months of life. Immunohistochemical staining for endopeptidase (CD10) is typically absent from the canalicular surface in ALGS children. 270 Endopeptidase, however, is not expressed physiologically until about 7 years of age, 270 as well as during fibrosis progression in various liver disorders. 271 Giant cell transformation of hepatocytes may be seen in early infancy. 245, 267, 268 There is usually patchy pseudoxanthomatous change and accumulation of stainable copper and copper-associated protein dysplasia with or without cysts is most common. 232 Renal tubular acidosis may be found, 216 and vesicoureteral reflux is also a frequent finding. Renovascular hypertension may develop. Single horseshoe kidney has been reported. The most frequent histological finding is mesangiolipidosis, 233 and other findings include tubulointerstitial nephropathy and membranous nephropathy. Nephrolithiasis may occur. Two children with ALGS and nephroblastoma were reported. 234 Renal impairment in ALGS detected before liver transplantation does not improve spontaneously after liver transplant and mandates consideration of 'renal-sparing' immunosuppression. Systemic vascular disease appears to be more prevalent than originally appreciated. Several cases of moyamoya disease in association with ALGS have been reported. [235] [236] [237] The propensity to intracranial bleeding found in the first few years of life in ALGS may be caused by abnormal intracranial vessels. [238] [239] [240] Abnormalities in the large intraabdominal vessels have been found, and these abnormalities may complicate liver transplantation. 237, 241 Skin changes relate mainly to formation of xanthomas, which regress after successful liver transplantation. 242 Abnormalities of the biliary tract include hypoplasia of the extrahepatic bile ducts, [243] [244] [245] [246] [247] hypoplasia of the gallbladder 229 and cholelithiasis. 242 ERCP has demonstrated narrowing of the intrahepatic ducts, reduced arborization and focal areas of dilation, as well as narrowing of the extrahepatic ducts. [243] [244] [245] Portal venous disease may also be present, specifically hypoplasia of the portal vein. 248 Many patients develop growth retardation before adolescence, 249,250 especially if they have persisting clinical jaundice. Short stature is found in some affected children whose nutrition is normal. Although some display a degree of mental retardation, in general children with ALGS show a broad range of cognitive and intellectual ability. Almost all patients have pruritus, although it may be mild. They have elevated serum bile acids; cholic acid levels are greater than chenodeoxycholic acid levels. Variable hyperlipidaemia (sometimes severe, with xanthomas) is common. Treatments for the pruritus include cholestyramine, rifampicin or surgical diversion of bile flow. 216, 251 In general, the prognosis is good for children whose jaundice resolves; however, approximately 25% of patients succumb in childhood to severe cardiac disease or progressive liver disease. The outcome in 92 patients in the series of Emerick et al. 215 was as follows: the 20-year predicted life expectancy was 75% for all patients, 80% for those not requiring liver transplantation (LT) and 60% for those who required LT. LT has been reserved for patients with chronic liver failure, intolerable pruritus unresponsive to medical treatment and severe growth failure. LT for hepatic decompensation was necessary in 19 of 92 cases (21%), with 79% alive 1 year after transplantation; mortality was 17%. In the Bicêtre series of 163 patients followed over 40 years, 102 of 132 patients presenting with cholestatic jaundice in infancy remained jaundiced at the study endpoint, and one-third required LT; cirrhosis was found in some children with ALGS, but no neonatal hepatitis syndrome, and none underwent LT (two succumbing to end-stage liver disease before the advent of LT). 249 Overall survival in this series was 62% at 20 years and seemed unaffected by availability of LT. 249 Mortality is higher among patients who have more severe cardiac disease or intracranial bleeding, or who had previously undergone portoenterostomy. 252, 253 A retrospective study suggested that affected preschool-aged children with total serum bilirubin >111 µmol/L, serum conjugated bilirubin >77 µmol/L and serum cholesterol >13.5 mmol/L were likely to have a severe outcome, irrespective of actual JAG1 mutation. 254 LT is an option for those in end-stage liver failure, or with severe chronic cholestasis or intractable pruritus; however, severity of cardiac and renal involvement, as well as intra-abdominal vascular abnormalities, must be evaluated as contributing to increased surgical risk. 255 to human ALGS; zebrafish with knockdowns of jagged ± notch genes have biliary, pancreatic, cardiac, renal and craniofacial developmental abnormalities; these studies suggest that Notch may promote biliary epithelial cell evolution from a bipotential precursor cells. 280 In humans, mutations in JAG1 result in truncated and inactive proteins; since residual gene expression cannot compensate, there is haploinsufficiency. 221 Dose of Notch ligands is critical and may contribute to the clinical diversity of ALGS. No clear relationship between genotype and phenotype has been found, but the Delta/ Serrate/Lag-2 (DSL) domain in the JAG1 protein may influence the severity of liver disease. [281] [282] [283] A second genetic basis for Alagille syndrome (ALGS2) has been reported. 284 It accounts for a very small proportion of cases. 285 Children with mutations in the gene encoding Notch 2 (found on chromosome 1p13) have a clinical disorder similar to conventional Alagille syndrome, notably with intrahepatic duct paucity leading to cholestatic liver disease; however, the typical facies and skeletal abnormalities were much less common. Frequency of renal involvement is similar to that in ALGS1. Notch 2 appears to have an important role in bile duct development. 286, 287 

In contrast to patients with Alagille syndrome, those with nonsyndromic bile duct paucity do not have a constellation of extrahepatic features. Children with nonsyndromic bile duct paucity are supposed to have a less favourable outlook than children with ALGS. They present with persistent cholestasis and severe pruritus. Growth retardation is common. No associated aetiological agent, defined genetic factors or congenital anomalies have been found in this group, except for one study of 10 patients with a high rate of consanguinity. 288 A chronic cholestatic disease with duct paucity, called 'idiopathic adulthood ductopenia, ' has been described in adults. [289] [290] [291] Most of these patients are young adults, although patients over age 60 have been reported. 292 Nonsyndromatic paucity of bile ducts in infancy and idiopathic adulthood ductopenia may be related diseases. The outlook for younger patients with idiopathic adulthood ductopenia is poor; approximately 50% succumb to progressive liver disease or require transplantation. Hepatocellular carcinoma has been reported in a woman with intrahepatic biliary hypoplasia, apparently distinct from ALGS. 293 A histopathological study of 17 children with nonsyndromic paucity of bile ducts was reported by Kahn et al. 294 Before 90 days of age there was paucity of ducts and periportal fibrosis as well as nonspecific parenchymal changes (cholestasis, giant cell transformation, perisinusoidal fibrosis and haematopoiesis). After 90 days the duct paucity and fibrosis persisted but cholestasis was mild or no longer apparent. Kahn et al. 294 suggested that the paucity in nonsyndromic cases may result from a primary ductal insult with destruction and disappearance of the ducts. The differential diagnosis of paucity of the intrahepatic bile ducts in children and adults has been reviewed by West and Chatila. 295 Bile duct anomalies, congenital dilations and ductal plate malformation disorders in periportal hepatocytes. 245, 267, 268 Copper accumulation has been demonstrated by quantitative methods in both syndromic and nonsyndromic types of paucity of the intrahepatic bile ducts. 263 Periportal fibrosis is mild, and it may remain unchanged long-term, 212 possibly due to the absence of ductular reaction, known to play a role in periportal fibrogenesis. Nonetheless, although progression to cirrhosis is rare, some patients do develop extensive fibrosis or cirrhosis ( Fig. 3.21 ). Portal inflammation and periportal ductular reaction, when present, are seen mainly in early infancy and can suggest the presence of distal duct obstruction. 245, 268, 272 Ultrastructural studies of the intrahepatic bile ducts in Alagille syndrome have been reported. 265, 267, 268, 273 Bile canalicular changes are controversial. In one study of 12 biopsies from 10 patients, distinctive ultrastructural changes were noted. 265 Bile pigment retention was found in the cytoplasm of liver cells, especially in lysosomes and in vesicles of the cis-Golgi, but only rarely in bile canaliculi or the immediate pericanalicular region. It was suggested that the basic defect in ALGS involves the bile secretory apparatus. 265 The aetiopathogenesis of the cholangiodestructive lesions described histopathologically and ultrastructurally remains to be elucidated, but the possibility of 'disuse atrophy' has been raised by two groups of investigators. 265, 268 Recent studies suggest defective branching of intrahepatic bile ducts in the postnatal period. 274 Alagille syndrome is the first childhood disorder identified with a mutation in a ligand for a Notch protein. JAG1 encodes a ligand of Notch 1, one of a family of transmembrane proteins with epidermal growth factor (EGF)-like motifs. Notch proteins are highly conserved and have a role in determining cell fate during differentiation, especially in tissues where epithelial-mesenchymal interactions are important. 275 Jagged/Notch interactions are known to be critical for determination of cell fates in early development. Notch 4 expression during embryogenesis is seen in endothelial cells of vessels forming the dorsal aorta, intersegmental vessels, cephalic vessels and the heart. The expression of Notch 1 and its ligand includes many of the organs potentially abnormal in ALGS. 276 JAG1 plays an important role in embryogenesis of the heart, kidneys and blood vessels; in embryonic and fetal liver it is expressed in portal vascular tissue. Recent studies in mice indicate that Notch signalling regulates the remodelling of the ductal plate and bile duct morphogenesis, and that Jagged 1 plays an important role in this complex process. 277 Jagged 1 on ductal plate and Notch 3 on portal tract mesenchyme and hepatic arterial endothelium interact for ductal plate remodelling and development of intrahepatic bile ducts. 278, 279 Mice with defects in murine Jagged 1 and Notch 2 expression have abnormalities similar Maljunction of the pancreaticobiliary ductal system (common channel) remains the most plausible aetiopathogenic mechanism for choledochal cysts, which is supported by experimental studies. 325 The lesion is defined as a junction of the pancreatic and bile ducts located outside the duodenal wall, usually forming an extremely long common channel. The anomaly allows pancreatobiliary regurgitation because hydrostatic pressure within the pancreatic duct is usually higher than that in the CBD. As a result, high pancreatic enzyme levels are found in the bile. Common channels may occur without bile duct dilation and lead to primarily gallbladder rather than biliary complications, including malignancy. In this situation, prophylactic cholecystectomy might be sufficient, whereas biliary complications and the risk of cholangiocarcinoma underpin the need for radical surgical resection in cases associated with choledochal cysts. 322 Reovirus-3 RNA sequences have been recovered from resected choledochal cysts, 84 but the implication of reovirus infection in the aetiology of choledochal cyst is unclear. A single report of choledochal cysts in association with familial adenomatous polyposis raises the possibility of a genetic basis for the cysts. 326 Treatment is by complete cyst resection, cholecystectomy and Roux-en-Y hepaticojejunostomy as a preventive measure against the subsequent development of carcinoma. 327, 328 Laparoscopic repair has been successful in two recent series. 329, 330 Dilemmas may arise when the cysts involve the intrahepatic or intrapancreatic segments, requiring more extensive surgery, given the small risk of malignancy developing in cystic remnants at the anastomotic site or in the dilated intrahepatic bile duct of type IV or V cysts. 301, 331 In a report of 48 Japanese patients treated by total or subtotal excision, no malignant change occurred after a mean follow-up of 9.1 years. 332 Similar excellent results were reported from Finland with median follow-up of 4.8 years (range, 1.3-13.2). 299 Choledochal cysts vary greatly in size, with some larger lesions containing 5-10 litres of bile (Figs 3.22 and 3.23). Histopathologically, the wall is usually thickened by inflammation and fibrosis and is bile stained. Smooth muscle fibres may be identified in the lower portion of the cyst but not in the narrow (intrapancreatic) portion. 333 There is generally no epithelial lining, but islets of cylindrical or columnar epithelium may be preserved ( Fig. 3. 24 ). Intestinal metaplasia with mucous gland proliferation has been reported, as well as the presence of goblet and Paneth cells and neuroendocrine differentiation. 334 Types I and IV account for the majority of reported cases, although types IV and V may prevail in the Far East, where the disease occurs more frequently. Type IV cysts are more frequent in adults than in children. 297 Although this classification remains in common use, its value has been questioned by Visser et al., 298 who consider the distinction between types I and IV arbitrary; they suggest that the term 'choledochal cyst' should be reserved for congenital dilation of the extrahepatic and intrahepatic bile ducts, with other forms referred to by their name, e.g. choledochocoele and bile duct diverticulum. Caroli disease, assimilated to type IV in Hadad classification, is not clearly related to 'choledochal cyst', given its common association with both congenital hepatic fibrosis and fibrocystic lesions in the kidney and its distinct morphological features (see next). Hukkinen et al. 299 have observed a considerable increase in the incidence of cholechal malformation in Finland.

The classic clinical triad of pain, a mass in the right upper quadrant and jaundice occurs in less than a third of patients with a choledochal cyst. 300, 301 In children, jaundice is the most common presentation, while in adults the signs and symptoms are those of ascending cholangitis. 302 In the early years of life, cholestasis is usually associated with cystic dilation of the common bile duct (CBD) and accounts for 2% of infants presenting with cholestasis. Up to 60% of choledochal cysts are diagnosed before age 10 years, but diagnosis can be made at any age, and some cases may present for the first time at as late as the eighth decade. 303 Several cases have been diagnosed antenatally. 304, 305 About 80% of the patients are female. Differences in presentation between children and adults with choledochal cysts have been emphasized in two large series. [306] [307] [308] The preoperative diagnosis can be made in the majority of patients by cholangiographic studies, ultrasonography (US) and isotope scanning. 309 Dynamic magnetic resonance cholangiopancreatography (MRCP), including secretin stimulation, contributes to the understanding of the pathophysiology. 310 Complications include perforation, liver abscesses, stone formation, secondary biliary cirrhosis, pancreatitis, amyloidosis and carcinoma of the biliary tree. 300, [311] [312] [313] [314] [315] Regression of biliary cirrhosis following drainage of a choledochal cyst has been reported. 316 One patient presented with anaemia secondary to bleeding from erosions of the duodenal mucosa between the ampullary sphincter and the sphincters of the CBD and pancreatic duct. 317 Biliary tract anomalies reported in association with a choledochal cyst include double CBD, double gallbladder, absent gallbladder, annular pancreas, biliary atresia or stenosis; 318 stenoses of the intrahepatic bile ducts 319 and most frequently, anomalies of the pancreaticobiliary junction. [320] [321] [322] In a series of 104 choledochal cysts from Japan, 25% of patients were found to have coexisting biliary anomalies. 323 Differences between (1) isolated choledochal cysts and (2) choledochal cysts associated with biliary atresia have been noted by US. In the former the cysts are larger, intrahepatic ducts are dilated and the gallbladder is not atretic as compared to those with choledochal cysts and biliary atresia. 324 In general, the apparent choledochal cyst associated with BA is actually proximal duct dilation associated with focal atresia of the distal CBD, so-called correctable or cystic atresia. with an increased risk of biliary tree malignancy irrespective of the presence of cysts. 346

The term fibropolycystic diseases of the liver-not to be confused with cystic fibrosis-is used to describe a heterogeneous group of genetic disorders in which segmental dilations of the intrahepatic bile ducts and associated fibrosis can be interpreted as sequelae of persistence and aberrant remodelling of the embryonal ductal plate (see Chapter 1). They represent a spectrum of microscopic and macroscopic cystic lesions often associated with fibrocystic anomalies in the kidneys. The severity of the renal lesions may overshadow the liver disease, as in the early presentation of autosomal recessive polycystic kidney disease. Conversely, portal hypertension with a preserved liver function may dominate the picture later in life, as exemplified by congenital hepatic fibrosis. Cholangitis may develop, especially when the cysts communicate with the biliary system. These abnormalities are classified as ductal plate malformation, 347,348 a term that refers to the histological changes of circumferentially disposed and variably ectatic bile ducts and ductules, often directly abutting the hepatocytic plates, which resemble an exuberant embryonal ductal plate. The main disorders, in particular autosomal recessive polycystic kidney disease (ARPKD), the closely associated congenital hepatic fibrosis and Caroli disease, and autosomal dominant polycystic kidney disease (ADPKD), are discussed in detail, whereas the rarer associated syndromes, which have been comprehensively reviewed by Knisely, 349 are briefly mentioned. Over the past decade, genes and encoded proteins for several of these disorders have been identified (Table 3 .2). The recognition that the 'cystoproteins', the mutation of which causes polycystic disease, have been localized in the primary cilia or basal bodies of tubular epithelial cells has led to a renewed interest in these forgotten structures. The clinicopathological discussion of specific disorders is therefore preceded by a short account on cilia and cystogenesis; more details and comprehensive references can be found in reviews. 350, 351 Primary disorders of cilia development or cystogenesis

Most studies on mechanisms of cyst development in hereditary polycystic disease have been conducted in the kidney, but there are The majority of tumours arising in congenital cystic dilations of the bile ducts are adenocarcinomas, but some anaplastic and several squamous carcinomas have been reported, [337] [338] [339] and one report mentioned sarcomatous changes. 340 The overall incidence of carcinoma arising in all cystic dilations of the bile ducts is about 3%. 338 The risk is age related, increasing from 0.7% in the first decade to 6.8% in the second decade to 14.3% in later decades. 339 This finding has been confirmed in a recent series of 36 choledochal cysts describing a high rate of biliary intraepithelial neoplasia in approximately a third of cases and adenocarcinoma in about 15%. 341 The complication is thus usually seen in adults; only three patients reviewed by Iwai et al. 342 were under 18 years of age. An 11-year-old boy is the youngest reported to date. 343 Reveille et al. 344 found that stasis of bile in the choledochal cyst contributes to bacterial overgrowth and the generation of unconjugated secondary bile acids, a possible cause of biliary metaplasia and carcinoma. Interestingly, bile from congenital choledochal cyst patients is shown to promote the proliferation of human cholangiocarcinoma QBC939 cells. 345 Certain bile acid fractions together with reflux of pancreatic enzymes may play a primary role, because pancreaticobiliary maljunction is associated mouse cpk mutation is the most extensively characterized murine model, closely resembling human ARPKD, with the exception that the B6-cpk/cpk homozygotes do not express the lesion of ductal plate malformation (DPM). However, homozygous mutants from outcrosses to some other strains express the DPM. Genetic analysis supports a loss-of-function model (two-hit model) for biliary cysts developing in an age-dependent fashion. There is no correlation between the severity of the DPM and the renal cystic disease. Expression of the biliary lesion is modulated by genetic background, and the specific biliary phenotype (DPM predominant or cyst predominant) is determined by whether loss of function of the cpk gene occurs as a germline or a somatic event. 368 In the mouse model generated by targeted mutation of Pkdh1, the animals develop severe malformation of their intrahepatic bile ducts, but develop normal kidneys. 369 The cholangiocytes maintain a proliferative state secreting transforming growth factor β1 (TGFβ1) that continuously stimulates mesenchymal cells to synthesize and put down extracellular matrix, resulting in fibrosis. The findings suggest that fibrocystin/polyductin, already expressed in the embryonic ductal plate stage, 370 acts as a matrix sensor and signal receptor during intrahepatic bile duct development, and that its mutation results in a congenital hepatic fibrosis-like picture. 371 Its role in liver and kidney appears to be functionally divergent, because protein domains essential for bile duct development do not affect nephrogenesis in this model. 369 Hepatic features of autosomal recessive polycystic kidney disease

This PKD is inherited in an autosomal recessive manner. The prevalence is estimated to be between 1:10,000 and 1:60,000 live births. 372 The gene for this disorder, PKHD1 (polycystic kidney and hepatic disease 1), was mapped to chromosome 6p 21.2-p12 373, 374 ; both the severe and the mild form of ARPKD mapped to the same locus. 375, 376 The gene encodes a 4074-amino acid protein, called fibrocystin 377 or polyductin 378 ; this large transmembrane polypeptide, also known to localize to the cilia, 357 may be a receptor that acts in the differentiation of renal collecting duct and bile duct. An animal model is widely used. 368 In humans, there is an equal sex incidence. Depending on the age at presentation and the degree of renal involvement, Blyth and Ockenden 379 divided ARPKD into four types: perinatal, neonatal, infantile and juvenile. They proposed that four different mutant alleles are responsible, and that there may be a fifth group in which the onset of symptoms is later than juvenile. ARPKD has been reviewed by a number of authors. 124, 380, 381 The perinatal type is the most severe form; 50% of patients are diagnosed perinatally and die shortly after birth. 375 In the series of Blyth and Ockenden, 379 no infant survived beyond 6 weeks of age. The majority of patients were admitted with signs of respiratory distress and had marked abdominal distension due to huge symmetrical renal masses. Liver function test (LFT) abnormalities were uncommon. Surviving patients with the neonatal type of the disease develop gradually increasing renal insufficiency and systemic hypertension. Pyelonephritis is common. Portal fibrosis and cystic dilation of bile ducts are severe, and cholangitis is a frequent complication. In the infantile group the clinical picture is either of chronic renal failure or of increasing portal hypertension. Portal fibrosis is moderate. The juvenile group of Blyth and Ockenden 379 typically includes children (1-5 years old) who present with portal hypertension. Liver histopathological changes are marked. It is likely that this group represents cases of congenital hepatic fibrosis, as suggested by Landing et al. 382 Gang and Herrin 383 have found that ARPKD has a spectrum of phenotype expression with prognostic implications, but suggest that not all cases fit into the sharply defined subgroups of Blyth and strong suggestions that a number of pathways are common to the conversion of tubes into cysts in general, especially in the kidney tubules and hepatic bile ducts. Primary (or solitary) cilia arise from centrioles and form a finger-like extension of the cytoplasm covered with the cell membrane. In their axis, primary cilia contain a system of nine pairs of longitudinal microtubules arranged in a circle (the axoneme); in contrast, motile cilia (e.g. those in ciliated respiratory epithelium) contain a set of two centrally located microtubules within the circle of the nine pairs of longitudinal microtubules ('9+2 pattern'). The pattern typical of, and defining, primary ciliary is the '9+0 pattern' . 352 The microtubules secure the circulation of non-membrane bound macromolecules, intraflagellar transport, which is essential for the assembly and maintenance of cilia and also acts as a sensory process, in that the particles and associated peptides are changed in the cilium and carry a message back to the cell body. The solitary cilium is at present considered to represent a sensory antenna, functioning through the polycystin complex as a mechanotransducer. Loss of function of the complex results in perturbation of normal intracellular calcium ion (Ca 2+ ) concentration which underlies a multitude of pathological reactions. 353 Severe alterations in structure and function of tubular or ductal cells will follow involving cell-cell contact, actin cytoskeleton organization, cell-extracellular matrix interactions, cell proliferation and apoptosis. 354 An enticing finding of recent years has been the demonstration that most proteins mutated in experimental polycystic liver disease (PCLD) have been localized in the primary cilia or basal bodies of tubular epithelial cells. 355 They include those responsible for human disease, in particular polycystin 1 and polycystin 2 356 and fibrocystin/ polyductin, 357 but not the cystoproteins of isolated PCLD: hepatocystin and SEC63. 358 Mutational analysis best studied in ADPKD suggests that both germline and somatic mutations may be involved in a two-hit model, as either a prerequisite initiating event or a later somatic event needed for cyst expansion and progression. 355 Although the ciliary model is most attractive, it may represent only one of several parallel pathways that control essential cellular functions, such as proliferation, apoptosis, adhesion and differentiation. 359 Cyst epithelial lining cells show profound pathological alterations. An increased proliferation has been observed in ADPKD, comprising formation of papillary projections and overexpression of Ki-67 and PCNA (proliferating cell nuclear antigen), a loss of their 'planar or tissue polarity' (the ability to sense their position and orientation relative to the overall orientation of the epithelial sheet) and a switch from an absorptive to a secretory cell type, resulting in fluid secretion that is responsible (together with epithelial proliferation) for further cyst expansion. 360 Although studies of cyst development have been mainly performed in kidney, primary cilia have been explored in cholangiocytes, 361 and evidence showed that, at least to some extent, cystogenesis in bile ducts and ductules may be similar to that in the kidney. In ADPKD, PKD1 and PKD2 are co-localized in bile duct epithelial cells 362 and the two-hit model of germ-line plus somatic mutations of PKD1 in focal liver cyst development appears applicable, as in the kidney cysts. 363 As with kidney cyst, biliary cyst expansion occurs by secretion (as well as proliferation) of the cyst lining epithelial cells. Autocrine and paracrine factors, including IL-8, epithelial neutrophil attractant 78, IL-6 and vascular endothelial growth factor (VEGF), secreted into the cystic lumen modulate the rate of errant hepatic cyst growth. 364 In ARPKD, findings suggestive of similarity with renal cystogenesis include the localization of PKHD1 in the cilia of cholangiocytes in the PCK rat, 361 which is a model for Caroli syndrome, 365 and that hepatocyte nuclear factor 1β (HNF1β) localized in bile duct epithelium regulates expression of PKHD1, 366 together with other 'cystoproteins' that co-localize into the cilium. 367 Differences in cystogenetic pathways between liver and kidney in ARPKD are indicated in animal models of the disease. 350 The Ockenden. In their study of 11 patients, four had 90% or more renal cystic change; these patients did not survive beyond 20 days of birth. In contrast, five of the seven less severely affected patients with a 20-75% range of cystic changes in the kidneys were all alive at 6-21 years of age. 383 The liver in ARPKD does not appear abnormal macroscopically, although it may be enlarged and firm. About 70% of patients have enlargement of the left lobe on imaging. 384 Histologically, the changes range from a persistent, circular ductal plate ( Fig. 3 .25) to a striking increase in the number of biliary channels which arise in portal areas and extend irregularly and deeply into the parenchyma (Fig. 3 .26 A). They appear to branch or 'anastomose' and often show polypoid projections ( Fig. 3.26 B) . Normal interlobular ducts with corresponding arteries are not seen. According to Witzleben, 380 the biliary channels are in continuity with the rest of the biliary system, similar to the cystic spaces of Caroli disease ('communicating' cystic disease), in contrast to the noncommunicating ADPKD. The supporting connective tissue is very scanty and, in the intralobular extensions, the basement membrane of the epithelium appears to be in direct contact with the liver cell plates. The epithelial lining consists of a single layer of low columnar to cuboidal cells. Cyst formation is uncommon. The dilated channels may contain a small quantity of a pink or orange-coloured material or rarely pus. Reconstruction studies by Adams et al. 385 have shown irregularly dilated ducts running longitudinally at the periphery of the portal tract and anastomosing so extensively that they formed a single annular channel; no main interlobular duct could be identified in that portal tract or in several others from the same liver. A stereological study of 10 cases by Jörgensen 386 showed ductal structures that could be divided into two groups: one consisted of irregular tubular structures shaped like circular cylinders, and the other of elliptical cylinders (the 'ductal plates'). These were dilated but cysts were rare. In patients who survive for months or years, there is marked fibrosis in the liver as well as kidney lesions which appear to have been progressive lesions.

Congenital hepatic fibrosis (CHF) is considered a variant of ARPKD affecting predominantly children and adolescents, some cases being identical to the 'juvenile' form. The inheritance pattern is not a simple autosomal recessive one. PKHD1 missense mutation has been identified in CHF patients with minimal kidney involvement. 387 It may be associated with dilation of the intra-or extrahepatic bile ducts, 388,389 so-called Caroli syndrome (see next section), the intrahepatic cysts being detectable by US or magnetic resonance cholangiography (MRC). 390 Infants present with abdominal distension from enlarged organs, respiratory distress and systemic hypertension. Older patients come to medical attention because of hepatosplenomegaly or bleeding from oesophageal varices, 391 but asymptomatic cases have been reported. 392 Cholangitis as a manifestation of CHF has been emphasized by Fauvert and Benhamou, 392 who recognized four clinical forms: portal hypertensive, cholangitic, mixed portal hypertensive-cholangitic and latent. The pure cholangitic form is rare. In the mixed form, patients have recurrent bouts of cholangitis, with or without jaundice, in addition to the manifestations of portal hypertension.

In one series of 42 children with ARPKD from 20 sibships, 12 patients presented in the perinatal period, nine in the neonatal period, 13 in the infantile period, and eight in the juvenile period; the presentation and course of the disease was disparate in over 50% of patients. 393 The organ predominantly affected may vary within the same family. Routine liver enzymes are usually normal, although alkaline phosphatase (ALP) levels may be increased.

When present, the usual renal disease in CHF is medullary tubular ectasia, a fusiform or cystic dilation of tubules (particularly the collecting ducts). Occasionally, patients have cystic kidneys typical of adult-type polycystic disease (ADPKD), an autosomal dominant disease, and others may have nephronophthisis. [394] [395] [396] [397] The prognosis in patients surviving beyond the neonatal period is generally good and depends on the extent of hepatic and renal disease. Death related to renal failure or uncontrollable variceal bleed is now the exception. 398 The combination of a patent portal vein and well-preserved liver function makes patients with CHF ideal candidates for standard portosystemic shunt surgery. Follow-up examination of 16 patients who underwent portosystemic shunt surgery 399 revealed no impairment of liver function or hepatic encephalopathy. Development of cholangiocarcinoma may have been a chance occurrence in an adult case not associated with Caroli disease. 400, 401 Pathological descriptions of CHF have been published by many authors. 380, 392, 402 Grossly, the liver is enlarged, has a firm to hard consistency, and shows a fine reticular pattern of fibrosis; no cysts are visible to the naked eye. Although the entire liver is usually involved, occasional lobar cases of CHF are described. 399 Microscopically, there is diffuse periportal fibrosis, the bands of fibrous tissue varying in thickness. Irregularly shaped islands of hepatic tissue, some incorporating several lobules, may be seen ( Fig. 3.27 ). When the bands of fibrous tissue are thick, hepatic venules may be encroached on and become incorporated within the fibrous tissue; thus portal hypertension in this condition may not always be presinusoidal. The fibrous bands may encircle single or groups of lobules; occasionally, a small islet of hepatic tissue becomes separated from an acinus and encircled by fibrous tissue. Numerous uniform and generally small bile ducts are scattered in the fibrous tissue ( Fig. 3.28 ). An interrupted circular arrangement of the ducts (DPM) is often recognizable (Fig. 3.29 ). The ducts are lined by cuboidal to low columnar epithelium and may contain bile or traces of mucin. They may be slightly dilated and irregular in outline. Cholestasis is not a feature of the uncomplicated case of CHF. Reduction in the number of portal vein branches is often apparent, the likely cause of the portal hypertension. There is generally minimal inflammation in CHF except in cases associated with cholangitis, when numerous neutrophils infiltrate ducts, ductules and surrounding connective tissue (Fig. 3 .30); rupture of the ducts can result in microabscess formation. Histopathologically, the latter cases may be difficult to differentiate from extrahepatic biliary obstruction with reported, 401, 428 with an incidence of 7%. 429 Hepatocellular carcinoma occurs rarely. 430 Medical treatment consists of symptomatic or prophylactic treatment of cholangitis and promotion of bile flow with ursodiol. Surgical treatment includes internal or external drainage procedures. 420 Transhepatic decompression has been advocated. 431 Segmental or lobar forms of Caroli disease can be treated by partial hepatectomy. 420, 432 Extracorporeal shock wave lithotripsy has been used for disintegration of intrahepatic stones. 433 Liver or combined liver and kidney transplantation has been successfully performed in patients with mono-and multilobar disease with portal hypertension, with 96 and 8 receiving liver or combined liver and kidney grafts, respectively, from 1987 to 2006 in the United States 434 ; the authors propose an algorithm for evaluation and treatment of Caroli disease.

Macroscopically, the intrahepatic cystic dilations are round or lanceolate, 1.0-4.5 cm in diameter, and may be separated by stretches of essentially normal duct (Fig. 3.31 ). 417 Transluminal fibrovascular bridges are reminiscent of the periportal location of the cysts (ductal plate) and explain in part the central dot sign observed on CT. 425 Inspissated bile or soft and friable bilirubin calculi may be found in the lumen. Microscopically, the dilated ducts usually show severe chronic inflammation, with or without superimposed acute inflammation, and varying degrees of fibrosis ( Fig. 3 .32). The epithelium ascending infection, particularly since there may be an associated tissue cholestasis. The correct diagnosis must be based on the history, clinical findings and the results of imaging studies. Cholestasis is particularly prominent in those cases associated with microscopic dilation of the intrahepatic bile ducts, too subtle to be seen on imaging ('microscopical Caroli'). Recurrent cholangitis may lead to progressive fibrosis with functional impairment similar to cirrhosis.

A number of malformation syndromes, characterized by hepatic morphological changes that resemble those of CHF (DPM), can be differentiated by the associated findings. Some of these are recognized as being 'ciliopathies' in that the defective protein is part of the ciliary apparatus. 403 They include:

• Medullary cystic kidney disease 1 (MCKD1), 404 which has an autosomal dominant inheritance, has been mapped to chromosome 1q21. • Medullary cystic kidney disease 2, via uromodulin (UMOD2), 405 also autosomal dominant, mapped to chromosome 16p12. • Nephronophthisis-congenital hepatic fibrosis, 406 a recessive disorder whose gene NPHP1 has been mapped to chromosome 16p12. • Meckel syndrome, 407 with encephalocoele, polydactyly and cystic kidneys. • Renal-hepatic-pancreatic dysplasia, 408 with polycystic kidney disease, DPM in liver and pancreatic dysplasia, incompatible with postnatal survival; candidate genetic locus on chromosome 3. • Asplenia with cystic liver, kidney and pancreas, which represents Ivemark syndrome with variants, 409 possibly in the same spectrum as renal-hepatic-pancreatic dysplasia. • Ellis-van Creveld syndrome or chondroectodermal dysplasia, 410 with polydactyly, short limbs, short ribs, postaxial polydactyly and dysplastic nails and feet; mapped to chromosome 4p16. • Sensenbrenner syndrome (cranioectodermal dysplasia), 411 with dwarfism and progressive tubulointerstitial nephritis. • Asphyxiating thoracic dystrophy (Jeune syndrome), 412 

Caroli disease generally involves the entire liver, but it may be segmental or lobar. [417] [418] [419] The inheritance is autosomal recessive. By 1982, some 99 cases had been reported; they were evaluated together with 10 personally studied cases by Mercadier et al. 420 Since then, many other case reports, as well as small series, have been reported. 421, 422 Clinically, patients suffer from bouts of recurrent fever and pain. Jaundice occurs only when sludge or stones block the common bile duct. Liver enzymes are generally normal except during episodes of biliary obstruction. The diagnosis is established by a variety of imaging modalities (e.g. ERCP, US, computed tomography (CT) and MRCP). [423] [424] [425] [426] The complications of Caroli disease resemble those of choledochal cyst and include recurrent cholangitis, abscess formation, septicaemia, intrahepatic lithiasis and amyloidosis. Spontaneous rupture of a bile duct was reported by Chalasani et al. 427 Adenocarcinomas, including some arising in cases with a lobar distribution, have also been 

Mutations mainly in two different genes, PKD1 and PKD2, can lead to ADPKD, one of the most common genetic disorders worldwide. The PKD1 gene lies on the short arm of chromosome 16 (16p 13.3), immediately adjacent to the TSC2, a gene responsible for approximately 50% of tuberous sclerosis. 355, 439 The incidence of ADPKD due to mutations in PKD1 is 1 in 1000 live births, comprising 90% of cases. The PKD1 gene encodes a protein called 'polycystin' . 440 It is present in plasma membranes of renal tubular cells, bile ductules, pancreatic ducts, 441 hepatocytes and cells of large bile ducts. In the kidney, localization at the contact points (only between neighbouring cells) indicates that its main function is cell-to-cell interaction, such that loss of function contributes to cyst formation. 442 The PKD2 gene is located on chromosome 4 (4q 21-23) and encodes a 100-kilodalton (kD) protein, polycystin 2, with sequence homology to α-subunits of voltage-activated calcium channels. 443 As mentioned earlier, localization of polycystin 1 and polycystin 2 to primary cilia in cultured renal epithelial cells 371 and demonstration that the proteins function as a ciliary flow-sensitive mechanosensors 444 implicate defects in ciliary structure and function as an important mechanism of cyst formation. 367 There is at least one unmapped focus, which accounts for 5% of the disease population. 445 Although PKD2 is clinically milder than PKD1, it does have a deleterious impact on overall life expectancy and cannot be regarded as a benign disorder. 446 The mean age to death or end-stage renal disease is 53 years in PKD1-associated disease, 69 years in PKD2-associated disease and 78 years in controls. PKD2 patients are less likely to have systemic hypertension, urinary tract infections and haematuria. 446 Cerebral aneurysms are found in 10-15% of patients with PKD1 and represent a significant risk of subarachnoidal haemorrhage causing death and disability. Familial clustering of bleeding from intracranial aneurysms is recorded. 447 In an earlier mutational analysis of 58 ADPKD families with vascular complications, 51 were PKD1 (88%) and seven PKD2 (12%). The authors found that the position of the mutation in PKD1 is predictive for development of intracranial aneurysms (59 mutations are more commonly associated with vascular disease) and is therefore of prognostic importance. 448 ADPKD is a multisystem disease with cysts and connective tissue abnormalities involving multiple organs. 449 Associated conditions include colonic diverticula (70%), cardiac valve complications (25%), ovarian cysts (40%), inguinal hernia (15%) and intracranial aneurysms (10%), suggesting a diffusely abnormal matrix. 450 Mitral valve prolapse was found in 12% of affected children. 451 ADPKD is the cause of end-stage renal disease in 8-10% of adults; the number of cysts is age related. 452 The renal disease can be present at birth, but hepatic manifestations are rare before 16 years of age. 453 The typical hepatic disorder in ADPKD is polycystic liver disease. The average age at first admission for liver-related problems was 52.8 years, with an average duration of symptoms of 3 years. 454 The symptoms included a gradually enlarging abdominal mass, upper abdominal pain or discomfort and rare episodes of severe pain with or without nausea, vomiting and occasionally fever. The most frequent physical finding is hepatomegaly, which can be massive. 455 Liver tests are often normal. Jaundice is unusual. 456, 457 Portal hypertension is rare 458 but may occur from hepatic outflow obstruction. 459, 460 There is an increased risk of gallstones in patients with hepatic cysts. 461 Rarely is treatment needed by excision 462 or a combination of excision and fenestration. 463 Additionally, it has become evident that CHF may occur with ADPKD; it becomes clinically evident in childhood or adolescence and may lead to portal hypertension. 464 Liver or combined liver and renal transplantation has been performed successfully in patients with ADPKD. 465 may appear normal (cuboidal to tall columnar), partly or completely ulcerated, or focally hyperplastic; all these changes can be found in different ducts in the same liver ( Fig. 3.33 ). Mucous glands (sometimes in abundance) may be present in the fibrotic and inflamed wall. Areas of severe epithelial dysplasia are seen rarely. 435 The lumen contains admixtures of inspissated mucin and bile, calcareous material or frank pus during bouts of acute cholangitis (Fig. 3.34 ). Caroli disease is frequently associated with congenital hepatic fibrosis (in which case it is termed Caroli syndrome), rarely with infantile polycystic disease (ARPKD) 436 and even adult polycystic disease (ADPKD). 437 According to Desmet, 347 the pathogenesis of Caroli disease seems to involve total or partial arrest of remodelling of the ductal plate of the larger intrahepatic bile ducts. In Caroli syndrome the hereditary factor causing the arrest of remodelling seems to exert its influence not only during the early period of bile duct embryogenesis, but also later on during development of the more peripheral biliary ramifications (the interlobular bile ducts).

There is a single case described of 'Marfan syndrome with diffuse ectasia of the biliary tree' . 438 The authors suggested that the defect of connective tissue in that disease could have led to weakness of the wall of the bile ducts with resultant ectasia.

One liver reported by Kwok and Lewin 455 weighed 7.7 kg. Occasionally, only one lobe, usually the left, is affected. Diffuse dilation of the intra-and extrahepatic bile ducts has been reported in some cases. 475 The cysts contain a clear, colourless or yellow fluid. Analysis of cyst fluid in one case disclosed similarities to the 'bile salt-independent' fraction of human bile, suggesting that such cysts are lined by a functioning secretory bile duct epithelium. 476 Microscopically, the cysts are lined by columnar or cuboidal epithelium, but the larger cysts have a flat epithelium (Fig. 3.36 ). Collapsed cysts resemble corpora atretica of the ovary (Fig. 3.37 ). The supporting connective tissue is scanty except in relation to von Meyenburg complexes (see Fig. 3 .36), a frequently associated lesion, where it may be dense and hyalinized. A small number of inflammatory cells, usually lymphocytes, may infiltrate the supporting stroma. Infected cysts contain pus and may rupture ( Fig. 3.38 ). Calcification of the wall of hepatic (and renal) cysts in ADPKD has been reported. 477 Von Meyenburg complexes are considered part of the spectrum of adult polycystic disease, and Melnick believed that polycystic disease of the liver develops progressively over years by gradual cystic dilation of these complexes. 478 This view is supported by a histomorphometric The incidence of liver involvement and its complications has been reviewed in a large series of 132 patients receiving and 120 patients not receiving haemodialysis. 465 Liver cysts were found by noninvasive imaging procedures in 85 of 124 patients on dialysis; gender distribution was equal. In contrast, the nondialysed population demonstrated a 75% incidence of liver cysts in females and 44% incidence in males, the peak incidence occurring 10 years earlier in females. The cysts were larger and greater in number in the nondialysed females, and there was a correlation with the number of pregnancies. Nineteen autopsies were reported in which five deaths were liver related. Risk factors for the development of hepatic cysts in ADPKD were also examined in 39 patients and 189 unaffected family members by Gabow. 466 The hepatic expression of the disease was found to be modulated by age, female gender, pregnancy and severity of the renal lesion and functional impairment. Oestrogen treatment of postmenopausal women with ADPKD is associated with selective liver enlargement and abdominal symptoms. 467 Although the leading complication in ADPKD is infection of the liver cysts, cholangiocarcinoma is the second most common complication. A study examining hepatic cyst infection suggested that the incidence increases from 1% to 3% during end-stage renal failure. 468 Enterobacteriaceae were cultured from the infected cysts in 9 of 12 patients. In the case of Ikei et al., 469 Pseudomonas aeruginosa was cultured from the infected cysts. Positron emission tomography (PET) scan will probably make the diagnosis of cyst infections easier and more accurate. This may allow early treatment with appropriately selected antibiotics, often including a fluoroquinolone; the timely drainage of large infected cysts remains an option. 470 Hepatic cysts are rarely detected before puberty and increase with age (ultimately to 75%) in individuals over 70. 471 However, cysts have been found in early childhood and even in the first year of life. 472, 473 Before the availability of a genetic probe, the criteria for identification of this disorder in children included a positive paternal history, cysts in any portion of the renal tubule or Bowman space, macroscopic cysts in the liver and cerebral aneurysms. Molecular diagnosis is useful in individuals in whom the diagnosis of ADPKD is uncertain due to lack of family history or equivocal imaging results and in younger at-risk individuals who are being evaluated as livingrelated kidney donors. 474 Grossly, the liver in ADPKD is enlarged and diffusely cystic, the cysts varying from <1 mm to 12 cm or more in diameter ( Fig. 3 .35). substrate 80K-H gene (PRKCSH), a known gene encoding for a previously described human protein, 'noncatalytic β-subunit of glucosidase II' (GIIβ), have been associated with ADPKD. This protein, now renamed hepatocystin, seems to segregate in families with PCLD. 490, 491 The protein is widely distributed in tissues and predicted to be an endoplasmic reticulum luminal protein that recycles from the Golgi complex. The mutations found in PCLD are all predicted to cause premature chain termination, rendering loss-of-function changes most likely. The two-hit hypothesis for cyst formation in ADPKD appears applicable to PCLD. Glucosidase II plays a major role in regulation of proper folding and maturation of glycoproteins. Polycystin 1, polycystin 2 and fibrocystin/polyductin are all glycoproteins. Mutations could compromise the processing of the N-linked oligosaccharide chains of the newly synthesized glycoproteins. 491 Improper association and trafficking of the polycystins due to defective glycosylation by mutant GIIβ may link PCLD to the ADPKD pathway. This would be consistent with the marked similarity in clinical liver disease in both conditions. 490 The second gene involved in PCLD, SEC63, encodes a protein that is part of the multicomponent translocon of the endoplasmic reticulum (Sec63p) which is required in both the post-translational and the co-translational (or signal recognition particle-dependent) targeting pathway and may explain a functional link between the two genes known to be associated with PCLD. Respective lack of expression of hepatocystin and Sep63p in PCLD cyst lining appears to correlate with mutational results. 492 Immunohistochemical analysis of cyst lining suggests that the disease involves overexpression of growth factor receptors and loss of adhesion, but proliferation or deregulated apoptosis do not seem to be implicated in PLCD. Differential findings for PRKCSH-and SEC63-PCLD suggest a divergent mechanism for cystogenesis in the two groups. 493 A recent study has identified mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) gene in patients with polycystic liver disease. 494

Solitary bile duct cyst is defined as a unilocular cyst lined by a single layer of columnar or low cuboidal epithelium resting on a basement membrane and a layer of fibrous tissue. The cysts occur at all ages, although the majority present in the fourth to sixth decade. They are rare in the paediatric age group; in the Boston Children's Hospital series, 31 solitary nonparasitic cysts (26 unilocular, 5 multilocular) were diagnosed in 63 years. 495 The female/male ratio is 4:1. 496 Cysts and clinicopathological study of 28 cases of ADPKD reported by Ramos et al. 479 Kida et al. 480 have suggested that cystic dilation of peribiliary glands also may lead to formation of the cysts in ADPKD. Von Meyenburg complexes are small (<0.5 cm in diameter), greyish white or green, and are usually scattered in both lobes. 481 They have an abnormal vascular pattern in angiographic studies and are occasionally associated with cavernous haemangiomas. Microscopically, the lesions are discrete, round to irregular in shape and typically periportal in location. The constituent ducts or ductules are embedded in a collagenous stroma, are round or irregular in shape and have a slightly dilated lumen ( Fig. 3 .39) (see Chapter 13) . They are lined by low columnar or cuboidal epithelium and contain pink amorphous material that may be bile stained or actual bile ( Fig. 3.40 ). Congenital hepatic fibrosis has been found in some cases. 397, 464 Cholangiocarcinomas have been reported in association with von Meyenburg complexes, 482, 483 as well as with multiple hepatic cysts considered part of the spectrum of ADPKD. 484, 485 Intraductal papillary-mucinous neoplasm of the pancreas has been reported. 486 Polycystic liver disease without kidney abnormalities Isolated polycystic liver disease (PCLD), not linked to PKD1 or PKD2, has been reported. [487] [488] [489] Germline mutations in protein kinase C In the past, the treatment of choice of solitary cysts was excision. 507 This has been supplanted by aspiration and sclerotherapy, 508, 509 however, or laparoscopic fenestration. 510, 511 Cystic fibrosis Cystic fibrosis (CF), the most common autosomal recessive disorder, with an estimated incidence of approximately 1 in 2500 live births among Caucasians, has a worldwide distribution. CF was first recognized as a pancreatic disease distinct from coeliac disease in 1938. 512 Originally known as 'cystic fibrosis of the pancreas' (mucoviscidosis), the disease was soon labelled simply 'cystic fibrosis', with the recognition that not only the exocrine pancreas, but also the bronchial glands (obstructive bronchopulmonary disease), the intestinal glands (meconium ileus), the sweat glands (high sweat electrolytes) and the biliary tree (focal biliary cirrhosis) may be affected by the disease.

The gene was localized at chromosome 7q31.2 in 1989. 513-515 It encodes a large protein named cystic fibrosis transmembrane regulator (CFTR), whose key role is in maintaining the fluid balance across epithelial cells. CFTR belongs to the ABC family of adenosine triphosphate (ATP)-dependent channels and transporters. It functions mainly as a cyclic adenosine monophosphate (cAMP)-dependent chloride channel in the apical membrane of secretory epithelial cells of many tissues, where it promotes transmembrane efflux of chloride ions. [516] [517] [518] [519] The protein is abundantly present in the branching ducts of the pancreas, intestinal epithelium and testes, and to a lesser degree in respiratory tissue. 520 CFTR is expressed at the apical membranes of the epithelium of branching hepatic bile ducts and the gallbladder, but not on cells of the common hepatic bile duct or hepatocytes. 521, 522 The CF secretory defect results in inability to maintain the luminal hydration of ducts, leading to physicochemical abnormalities of secretions and duct obstruction. 523 More than 1000 different disease-causing mutations have been identified. They are distinguished in terms of severity on the basis of the residual activity of the codified protein. 524, 525 The most common mutation is ΔF508, a three-base pair (bp) deletion in CFTR, resulting in loss of phenylalanine from the protein with subsequent retention in the endoplasmic reticulum. 526 Since liver disease in CF is often subclinical, its prevalence is uncertain and to some extent depends on definition, type of screening and age. As overall life expectancy has improved, liver disease has become the third most frequent cause of death in CF patients. 527, 528 The availability of new therapies targeting the function of CFTR that could prevent or reverse CF liver disease constitutes an additional rationale for identifying CF patients at risk of developing liver impairment. 529 Based on prospective studies, significant clinical liver disease is seen in 4-6% of CF patients, 530-532 but biochemical evidence of liver involvement without clinical symptoms occurs in 20-50%. 533 Autopsy series in the 1950s found an incidence of multifocal biliary fibrosis (or 'cirrhosis') of 22-25%. 534, 535 The liver disease usually becomes apparent in the first decade, with sharp decline in incidence thereafter. 530, 533 The mode of presentation of the liver disease is variable. There may be transient neonatal conjugated hyperbilirubinaemia. In one series the majority of such cholestatic infants had meconium ileus, 28% had mucus plugs and 11% had focal biliary fibrosis. 536 Paucity of the intrahepatic bile ducts has been reported in one patient who presented with neonatal conjugated hyperbilirubinaemia. 537 Obstruction by pancreatic fibrosis has been reported but is much more common beyond infancy. 538 Bile duct obstruction due to a rubbery concretion of abnormal bile has been reported in a few infants. 539 In late childhood, intermittent elevation of serum aminotransferases and ALP, asymptomatic hepatomegaly, hepatosplenomegaly, hypersplenism or variceal haemorrhage might be the first indications of liver involvement. The unique liver lesion, termed smaller than 8-10 cm rarely cause symptoms. When present, symptoms include fullness or an upper abdominal mass, nausea and occasional vomiting. Rapid enlargement has been reported in infancy. 497 Jaundice occurs infrequently. 498 An acute abdominal crisis may result from torsion, strangulation, haemorrhage into the cyst or rupture. 499 Diagnosis is usually established by US, CT or other imaging modalities. Solitary bile duct cysts involve the right lobe twice as often as the left. Rarely, they can arise in the falciform ligament. 500 They are usually round and rarely are pedunculated; the lining is typically smooth (Fig. 3.41 ). The larger ones may contain one to several litres of fluid which is usually clear, but may be mucoid, purulent (if the cyst is infected), haemorrhagic or rarely bile stained.

Microscopically, the cyst lining usually consists of a single layer of columnar, cuboidal or flat epithelium ( Fig. 3.42 ). The epithelium rests on a basement membrane that in turn is supported by a layer of fibrous tissue. Adenocarcinomas may arise in the cyst. 501 Other malignancies reported to arise in solitary cysts include squamous cell carcinoma, 502 carcinosarcoma 503 and carcinoid tumour. 504 The pathogenesis of solitary bile duct cyst is unknown. A congenital origin is supported by the occurrence of the cysts in fetuses and newborns, 497 by a case presenting as a congenital diaphragmatic hernia 505 and the association of another case with the Peutz-Jeghers syndrome. 506 A transjugular intrahepatic portosystemic shunt (TIPS) procedure is only rarely used in patients with CF liver disease because sclerotherapy or, preferably, band ligation therapy has been reasonably successful for treating bleeding esophageal varices. 574, 575 Because of rebleeds, some surgeons still advocate portosystemic shunts for patients with a good synthetic function. 575 Liver transplantation has been successful, 576,577 with long-term survival comparable with that of LT for other causes. 578 Postoperative death has resulted mainly from lung complications. A few combined liver-heart-lung, liverpancreas and liver-intestine transplants have been reported. [578] [579] [580] Pathological studies of the liver have been described in a number of reports. 512, 545, [581] [582] [583] The changes include steatosis, periportal fibrosis with ductular reaction and dilation (with or without inspissation of secretions) ( Fig. 3 .43), focal biliary fibrosis ('cirrhosis') and multinodular biliary fibrosis ('cirrhosis'). Steatosis is probably the most frequent lesion, present in 121 of 198 cases (61%) reported by Craig et al. 545 (Fig. 3 .43). The fat was located most frequently in periportal hepatocytes but was unevenly distributed throughout when severe. No positive correlations could be made between the presence of fat in the liver and the patient's general nutritional status. An incidental finding in infant livers is the deposition of haemosiderin in periportal hepatocytes. 584 This finding is presumably related to the increased iron transport from the gut in pancreatic insufficiency. 585 The characteristic, if not pathognomonic, lesion is focal biliary fibrosis, found in 22-33% of patients in three early series. 545, 581, 586 An increasing frequency with duration of survival was noted. 584 Thus it was found at postmortem examination in 10.6% of infants younger than 3 months, in 15.6% of infants from 3 to 12 months and in 26.9% of children older than 1 year.

Macroscopically, the liver with focal biliary fibrosis shows multiple, depressed, greyish white scars that are triangular or stellate in shape. 545, 586 As already noted, there is variable ductular reaction and periportal fibrosis. The ductules are generally dilated and show varying degrees of atrophy of the lining cells. The lumen contains the pathognomonic pink to light-orange, rounded masses (concretions) or amorphous material (Figs 3.44 and 3.45), first described by Farber in 1944. 587 The inspissated secretions in the cholangioles stain intensely with PAS and resist diastase digestion; they do not stain positively with mucicarmine or Alcian blue, but there may be some mucin in the interlobular bile ducts. Some greatly dilated ductules eventually rupture with extrusion of their contents and induction of an acute inflammatory response. 586 The cholangitis is thus 'chemical' 'focal biliary fibrosis' (or 'cirrhosis'), is found in over 70% of adults who die after 24 years of age. 540 A prospective study of 183 CF patients followed for a mean of 10 years revealed an incidence of liver disease of 17%. 541 Clinically relevant disease suggests an incidence of 1.4-2.7%, with a peak in adolescence. 540 Rare and unusual manifestations of liver disease in CF include common bile duct involvement proximal to the pancreas, 542 obstruction by pancreatic fibrosis and nodular regenerative hyperplasia of the liver in CFassociated colitis with fibrosing colonopathy. 543 At times, ERCP and liver biopsy findings may mimic those of primary sclerosing cholangitis. 544 Irrespective of relatively rare chronic progressive liver disease, steatosis (macrovesicular) is the most common pathological finding in the liver and is present in more than 50% of autopsy cases. 545 The cause of the steatosis is not entirely evident, although it has been attributed to malnutrition 546 and essential fatty acid deficiency. 547 Death from liver disease occurs in 3.4% of patients, 548 whereas lung disease accounts for 78% of CF-related deaths.

Factors that contribute to the variability in incidence and severity of liver disease are unknown. Some studies have found significant association with meconium ileus, 532,549 male gender, meconium ileus and severe genotype, 530 or meconium ileus and pancreatic insufficiency, 533 but such risk factors were not identified in a Swedish cohort. 531 There is no close correlation between particular CFTR mutations and liver disease. 526, 550 Kinnman et al. 522 examined the expression of CFTR and its relationship to histopathological changes in CF. They found impaired processing of ΔF508 CFTR protein in intrahepatic biliary epithelium. However, intercellular adhesion molecule 1 (ICAM1) expression on biliary epithelial cells and inflammatory infiltrates were rare findings, indicating that immunological mechanisms are unlikely to be involved in initiation of CF-associated liver disease. Generally, there is discordance for liver disease within sibships, 551,552 but not always. 526 These observations have intensified the search for modifier genes which may in part explain the lack of genotypic/phenotypic correlations. 553, 554 The mannose-binding lectin gene, 555 a relation with HLA-DQ6 in males, 556 and the PI*Z allele of α1-antitrypsin have already been proposed as potential candidates. Among these, the PI*Z allele has been shown to increase the risk of developing severe liver disease in CF patients. 557 The development of the sweat chloride test 558 followed the observations of salt depletion through sweat during summer heat waves. 535 Values >60 mmol/L are diagnostic of CF. There are unusual CF patients with sweat chloride values between 40 and 60 mmol/L or even in the normal range. 559, 560 In such patients, abnormal bioelectric potential or immunoreactive trypsinogen screen can confirm the diagnosis. 561, 562 Extensive CFTR gene sequencing has been proposed to detect rare mutations and to establish a definite diagnosis in symptomatic patients with previously negative results. 563 An elevated serum collagen type VI has been suggested as a screening test for detection of liver disease. 564 Newborn screening using elevated serum trypsin (trypsinogen) by radioimmunoassay at 3-5 days of age or mutational analysis on Guthrie spots is followed by substantial and prolonged health gain when compared with children clinically diagnosed at a later stage. 565 Most investigations have shown improved liver enzymes, lipid profiles and vitamin A levels with ursodeoxycholic acid therapy. 547, [566] [567] [568] [569] One report documents normalization of liver function tests (LFTs) and improvement in the portal tract inflammation on pathological examination. 570 The same authors also noted improvement in ultrastructural abnormalities of bile ducts. Importantly, in CF patients, ursodeoxycholic acid is not effective for gallstone disease, 571 the incidence of which may be 12% in older patients. 572 Although the stones are often radiolucent, they contain calcium bilirubinate instead of increased cholesterol. 573 and encirclement of groups of hepatic lobules. 586 This type of lesion, referred to as 'multilobular biliary cirrhosis with concretions' or 'multilobular cirrhosis', occurs in 6% of patients older than 1 year. 582 Large irregular nodules are produced, and the deep clefts between the nodules may resemble hepar lobatum. 586 A recent study using dual-pass needle biopsy 588 emphasizes the role of liver biopsy in predicting an individual's risk of liver fibrosis or development of portal hypertension. A significant number of noncirrhotic portal hypertension in CF children is confirmed by others. 589 In addition to the presence of excessive mucus in extrahepatic bile ducts in occasional patients, there may be excessive mucus accumulation in intrahepatic bile ducts, particularly those adjacent to the porta hepatis. 582 This change occurs in 23.4% of infants under 3 months of age and in 12.5% of patients from 3 to 12 months. In two-thirds of the patients less than 3 months of age with mucus in their ducts, histological cholestasis is seen, and a history of jaundice is noted. The gallbladder in up to 30% of patients is hypoplastic and contains mucoid material and a small amount of viscid bile. Mucous cysts are seen in the wall, and stones may be present in the lumen. Liver biopsy material from 11 patients with CF was examined ultrastructurally by Arends et al. 590 A finding unique to this disease was the presence of filamentous material, with an average diameter of 15 nm, in the lumen of bile ductules and ducts. Bile granules were scattered between the filaments. A reaction product of carbohydrates was found in the filaments by histochemical techniques. It was suggested that the typical mucus deposits in bile ducts are built up from these filaments. Similar ultrastructural findings were noted by others. 5,591 Bradford et al. 591 studied the ultrastructure of liver cells in detail and described the presence of membrane-bound deposits of electron-lucent material containing electron-dense cores resembling mucus. Bile duct cells with irregular shapes protruding into the lumen and the presence of necrotic cells have been observed. 592 An increase in the number of hepatic stellate cells (HSCs) around portal areas, with deposition of collagen around bile ducts and ductules, has been noted, 592, 593 and bile duct destruction, rather than cholestasis, is suggested as the inducer of collagen deposition in CF-associated fibrosis and cirrhosis. 592 A definitive role for hepatic stellate cells has been shown and TGFβ1, produced by bile duct epithelial cells, demonstrated as an inducer of stellate cell collagen gene expression. 594 Hereditary disorders of bile acid synthesis and bilirubin metabolism

Patients with bile acid synthetic defects present clinically with conjugated hyperbilirubinaemia within the spectrum of the neonatal hepatitis syndrome. There are no distinguishing features among routine liver tests other than age-related normal levels of γ-glutamyltransferase (GGT). In contrast to infants with other low-GGT cholestatic disorders, those with congenital bile acid synthetic defects typically are not pruritic. Patients presenting with infantile conjugated hyperbilirubinaemia and normal GGT for age can be screened for elevated cholenoic bile acids in the urine by a colour reaction with the Lifshütz reagent. (This reagent is prepared by mixing 10 mL glacial acetic acid and 1 mL concentrated H 2 SO 4 ; when 200 µL of reagent are added to 25 mL of dried urine extract, a purple colour is produced when cholenoic acids are present.) Total serum bile acids can also be measured by a 3β-hydroxysteroid dehydrogenase assay: these are absent or else found at very low concentrations, clearly disproportionately low to the degree of jaundice. (An exception but may be complicated by bacterial infection. Chronic inflammatory cells may also be present in the fibrous tissue. It is important to emphasize that periportal fibrosis may occur in the absence of ductular reaction and inspissation of secretion 545, 582 ; this nonspecific change has been found only in infants less than 3 months of age.

Over time the focal biliary lesions may coalesce, with extension of fibrosis, atrophy of the intervening parenchyma and entrapment not detected. Concentration of the natural substrate, unesterified 7α-hydroxy-cholesterol, were elevated in the serum. Fibroblasts from this patient demonstrated complete absence of the enzyme; the parents' fibroblasts demonstrated reduced 3βHSD activity. 598 The patient responded to chenodeoxycholic acid, including relief from pruritus. 599 The presentation during infancy/childhood may be quite variable. 600 Five patients aged 4-46 months had hepatomegaly, four of whom had jaundice and two with fatty stools; none was pruritic. Microcysts were found in the kidney in two patients. All patients responded to ursodeoxycholic acid. 600 The challenge here is to distinguish 3βHSD (and 5α-reductase) deficiency from bile canalicular transporter disorders, especially when presence or absence of pruritus does not provide a clinical distinction. In both these bile acid synthetic disorders, the abnormal bile acids that are formed inhibit the canalicular ATP-dependent bile acid transporter. 601 In another consanguineous family, manifestations of 3βHSD deficiency were extremely variable: the proband died from end-stage liver disease at age 24 years, but one sister was asymptomatic at age 32 despite homozygosity for a null allele of the HSDRB7 gene encoding for 3βHSD. 602 Hepatic histopathological changes in 3βHSD deficiency depend on the age of the patient and rate of progression of the liver disease. Two of the three patients reported by Clayton et al. 597 who were biopsied at 6 weeks and 18 months of age had giant cell hepatitis and giant cell hepatitis with bridging fibrosis, respectively. Similarly, Jacquemin et al. 600 found giant cell hepatitis in young patients (4 and 6 months of age) and portal and perilobular fibrosis in older patients (36-46 months) . Three patients studied by Bove et al. 603 had portal and intralobular fibrosis with 'pseudoductular metaplasia' and cholangiolar proliferation (ductular reaction); there was no paucity of interlobular bile ducts. An adult with cirrhosis of undetermined etiology has been described as having 3βHSD deficiency. 602

The responsible enzyme is found only in the liver 604, 605 and not in fibroblasts. It is the enzymatic step in the primary pathway from cholesterol to cholic and chenodeoxycholic acid, involved in the saturation of the steroid ring. A deficiency would result in the decreased formation of these primary bile acids with an elevation of cholenoic bile acids. Δ 4 -3-Oxosteroid-5β-reductase was not detectable in the original patients presenting with neonatal hepatitis who is when there is amidation defect present. 595 ) Definitive diagnosis is by determining which bile acids are present in urine or bile using electrospray-ionization tandem mass spectrometry (ESI-MS/MS). Analysis can also be performed by fast-atom-bombardment mass spectrometry (FAB-MS) or gas-liquid chromatography (GLC). Determination of urinary cholanoids by ESI-MS/MS-MS is probably most practical, and accumulating experience argues for this investigation in any infant with neonatal hepatitis syndrome. 596 Most of the entities in this rapidly developing sector of genetic liver disease are rare, having been identified in only a few patients, but they may be more common than this. Affected enzymes may be microsomal, cytoplasmic or peroxisomal. Importantly, infants with severe liver disease may acquire defects in bile acid synthesis, usually Δ 4 -3-oxosteroid-5β-reductase, and they must be distinguished from those with an inherited disorder of bile acid synthesis, since treatment may be different. Gene sequencing may be required to confirm or disconfirm the diagnosis in some cases. Clinical experience shows that patients with genetic disorders of bile acid synthesis often respond well to oral bile acid supplementation. Table 3 .3 shows currently identified primary disorders of bile acid synthesis. The discussion here focuses on defects in (1) 3β-hydroxy-Δ 5 -C 27 -steroid dehydrogenase/isomerase (3βHSD), (2) Δ 4 -3-oxosteroid-5β-reductase, (3) oxysterol 7α-hydroxylase and (4) sterol 27-hydroxylase (CTX). Some rare defects causing infantile conjugated hyperbilirubinaemia are also discussed, as well as amidation disorders that may present with transient, apparently idiopathic, neonatal hepatitis syndrome or later in childhood with growth failure and fat-soluble vitamin deficiency. Bile acid physiology, synthesis, conjugation and transport are discussed in Chapter 9.

3β-Hydroxy-Δ 5 -C 27 -steroid dehydrogenase/ isomerase deficiency This enzyme, 3βHSD, is the second step in the pathway for synthesizing bile acids. It is involved in the conversion of 7α-hydroxy-cholesterol to 7α-hydroxy-4-cholesten-3-one and then into the pathways producing the primary bile acids. 597 Specifically, it can proceed directly into the pathway for synthesizing chenodeoxycholic acid, or it can be 12-hydroxylated and enter the pathway for producing cholic acid. Among the primary bile acid synthetic defects, 3βHSD deficiency is most common. The first patient reported was a 3-month-old infant with cholestasis. Early biopsies of the liver in the patient and siblings demonstrated giant cell hepatitis. Primary bile acids were 

Since bile acid metabolism represents a complex pathway, it seems reasonable to expect other rare defects in bile acid metabolism. Alternate pathways may be more prominent in the fetus and newborn. The effects of developmental changes in the intestinal microbiome may be relevant. Rare defects in bile acid synthesis may account for what has been regarded as 'idiopathic neonatal hepatitis.' For instance, a 25-hydroxylation pathway exists which may normally contribute in a limited fashion to cholic acid production. 618 A deficiency in this hydroxylase was reported in a family where one child died at age 13 months after lifelong jaundice, and another was stillborn. The third child developed conjugated hyperbilirubinaemia with hepatomegaly at 7 days old 619 ; his serum GGT was normal, and his liver biopsy showed giant cell hepatitis. On treatment with chenodeoxycholic acid, he later developed pruritus, which gradually improved when cholic acid was added to the treatment regimen and chenodeoxycholic acid was stopped. Although clinically well, including improvement in pruritus, normal LFTs, and physical examination, this patient developed cirrhosis, which appeared to stabilize.

Amidation defects cause failure to conjugate a bile acid with glycine or taurine. This is the last step in bile acid synthesis. The mechanism is somewhat complicated: a coenzyme A (CoA) thioester of the bile acid is formed by the enzyme bile acid-CoA ligase (BACL, encoded by SLC27A5), and glycine or taurine is conjugated by bile acid-CoA:amino acid N-acyltransferase (BAAT, encode by BAAT). Some patients with defective amidation present in early infancy with conjugated hyperbilirubinaemia, occasionally severe enough to resemble biliary atresia. Liver biopsies in those patients showed lobular cholestasis, giant cell transformation of hepatocytes and mild to severe ductular reaction with bridging fibrosis but no ductular bile plugs. 620 Other patients are never noted to be jaundiced but have growth retardation and severe deficiency of fat-soluble vitamins resulting in rickets or coagulation abnormalities. 620 Infants who do manifest jaundice also have prominent clinical features of fat-soluble vitamin deficiency. Based on limited observations, this seems to be a low-GGT disorder. Detailed analysis of serum bile acids shows striking lack of conjugated bile acids, but total bile acid concentrations may be elevated. Histological analysis may show a giant cell hepatitis or ductopenia. Immunostaining for BAAT is depleted or absent. Similar clinical disease appears to occur with BACL mutations. In one reported case where the amidation defect was associated with BACL deficiency, 621 the infant was homozygous for a missense mutation in ABCB11 (thus compromising BSEP); however, other cases exclusively with BACL defects have been identified. These infants may be at greater risk for neonatal hepatitis syndrome if born premature and requiring total parenteral nutrition (TPN).

Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive metabolic disease caused by deficiency of mitochondrial C 27 -steroid-26-hydroxylase on the inner mitochondrial membrane, which can be demonstrated in liver and cultured fibroblasts, [622] [623] [624] leading to tissue accumulation of cholestanol, a minor component in the human body. The defective gene, for sterol 27-hydroxylase, localized to chromosome 2q33, has been cloned, and mutations associated with the disease have been described. 625, 626 The symptoms of this disease often begin with chronic diarrhoea in infancy. Neonatal hepatitis has been recorded in a few patients. [627] [628] [629] Juvenile cataracts develop during childhood, 630 as do tuberous xanthomas (particularly over the Achilles tendons). The neurological were evaluated in follow-up after bile acid therapy. [606] [607] [608] Enzyme analysis of the liver in a subsequent patient did not verify that this is a specific genetic defect, i.e. no mutation was present. 609 Notably, this enzyme is somewhat fragile and can cease to function in the presence of severe liver disease.

A tentative diagnosis of 5α-reductase deficiency is presently based on >70% of the urinary bile acids being of the 3-oxo-Δ 4 type and significant detection of allo-(5α-hydroxy) bile acids. 608, 610 The gene encoding Δ 4 -3-oxosteroid-5β-reductase is AKR1D1 (also known as SRD5B1); mutation analysis can confirm the diagnosis. Elevation of primary bile acids should raise doubts concerning a diagnosis of a bile acid synthetic defect, and other aetiologies should be sought. Why these patients might respond to ursodeoxycholic acid is unclear other than by a decrease in the levels of the offending bile acids. If clinical response is insufficient, improvement subsequently can be observed with chenodeoxycholic acid and cholic acid therapy. 611 More recent experience indicates that response to supplementation with chenodeoxycholic plus cholic acid is better in patients whose disease is not advanced. 612 Light microscopic and ultrastructural findings in 5β-reductase deficiency (and other bile acid synthetic defects) are discussed in detail by Bove et al. 603 Light microscopic changes in most reported cases resemble nonspecific neonatal hepatitis, with prominent cholestasis, giant cell transformation and erythropoiesis. Interlobular bile ducts are consistently normal. Ultrastructurally, injury patterns common to other forms of cholestasis are seen, as well as features that may be specific for the defect. Thus there is a nonuniform mosaic of normal and abnormal canaliculi, often in adjacent clusters of hepatocytes, but there is no canalicular dilation. However, some canaliculi show diverticula, and junctional complexes are extraordinarily convoluted, often enclosing pockets of dense granular material presumed to be bile residue.

Deficiency of oxysterol 7α-hydroxylase, the third enzyme in the 'acidic' pathway that can generate chenodeoxycholic acid, can produce severe infantile liver disease. The deficiency results in the accumulation of 3β-hydrocholenoic and 3β-hydroxy-5-cholestenoic acids. One infant has been described who presented with conjugated hyperbilirubinemia and low GGT and whose liver disease had already advanced to cirrhosis. 613 Serum levels of 27-hydroxy cholesterol were greater than 4500 times normal. Histopathologically, the liver showed giant cell transformation, ductular reaction, and canalicular and bile duct plugging; no specific ultrastructural changes were noted. 613 Both parents had an exon 5 premature terminated codon (R388X) as a heterozygous defect. There was no response to either ursodeoxycholic acid or cholic acid, either by clinical indicators or alterations in the measured bile acids. This patient underwent a liver transplant but died of complications relating to disseminated post-transplant lymphoproliferative disease. A second patient also succumbed to severe cholestatic liver disease in the first year of life. Two patients have been reported subsequently: one died at age 11 months before LT, 614 and the other had successful living-related donor transplant from an obligate heterozygote. 615 Both patents had cirrhosis with multinucleated giant cells on liver biopsy. A single case of successful treatment with chenodeoxycholic acids has been reported. 616 Patients with oxysterol 7α-hydroxylase have normal serum GGT and, in general, rapidly progressive liver disease. Diagnosis based on finding elevated serum and urine 3β-monohydroxy-Δ 5 -C 24 bile acids may generate a false-positive diagnosis of oxysterol 7α-hydroxylase deficiency. Such an infant was found to have 3βHSD deficiency, 617 not entirely surprising because 3βHSD serves as the next enzyme in that same 'acidic' pathway, as well as early in the 'neutral' pathway.

helpful: diseases manifesting normal (or low) levels of serum GGT and those with elevated levels. Two low-GGT forms of PFIC are now termed 'FIC1 deficiency' 644 and 'BSEP deficiency' . 645 The predominant form with a high GGT is termed 'MDR3 deficiency' . 646 All three are autosomal recessive disorders and involve different genes. The neonatal presentations of these three conditions are the best described. In fact, there are less severe and later-presenting forms of all three of these bile canalicular transporter defects, including but not limited to 'benign recurrent intrahepatic cholestasis' (BRIC). Later-onset disease may not be recognized as such, unless features indicating similarity to neonatal disease are noted. This applies particularly to the histological features.

Previously known as 'progressive' familial intrahepatic cholestasis type 1' (PFIC1), FIC1 deficiency is caused by mutations in ATP8B1. 644, 647 Most recognized patients present in the first 6 months of life with conjugated hyperbilirubinaemia, normal serum GGT, and itching. In FIC1 deficiency, extrahepatic manifestations of disease are clinically important. 648 Chronic diarrhoea may develop; growth failure due to maldigestion as well as fat-soluble vitamin deficiency is a major complication. Sensorineural deafness requiring hearing aids develops in 30% of patients. Recurrent respiratory infections may occur. There is a slow progression to cirrhosis.

Liver biopsy shows a bland cholestasis ( Fig. 3 .46), without significant giant cell transformation or cellular infiltrate. 648, 649 Canaliculi filled with pale-appearing bile may be identified. In 1972, Linarelli et al. 650 suggested that the ultrastructure of canalicular bile was coarsely granular in PFIC and called it 'Byler's bile' (Fig. 3.47 ). Subsequently, this type of bile was found to be characteristic of FIC1 deficiency, from which members of the Amish Byler family suffer. 644, 649 The function of the FIC1 protein, a P-type ATPase, has been unclear. 651, 652 Groen et al. 653 have proposed a model by which the concerted action of FIC1 and MDR3, encoded by ABCB4, is critical in maintaining the asymmetrical lipid composition of the hepatocyte plasma membrane outer leaflet (facing the canalicular lumen) and the inner leaflet (facing the cytoplasm). FIC1 is a flippase, and MDR3 is a floppase. FIC1, along with an accessory protein CDC50A, flips phosphatidylserine from the outer to inner leaflet to complement the action of MDR3, which 'flops' phosphatidylcholine from the inner to the outer leaflet so that it can be associated manifestations vary from mental retardation developing during adolescence to normal intelligence throughout adult life. 631, 632 Spasticity and ataxia are usually detected in the second and third decades. Progression results in dementia, spinal cord paresis and peripheral neuropathy. Less frequent findings include seizures, gallstones and osteoporosis. Death in the fourth to sixth decade is usually related to neurological deterioration; however, some patients develop early heart disease and/or atheroma. 633 The 5α-dihydro derivative of cholesterol, cholestanol (but not cholesterol), is elevated in serum. There is excessive deposit of cholestanol and cholesterol in tissues. Bile acid concentrations are low in bile, with high bile alcohol levels in bile and urine. 634 Heterozygotes can be detected by measurement of urinary bile alcohol levels after administration of a bile salt-binding agent, cholestyramine. 635 Liver specimens from two patients revealed intracellular inclusions that appeared either as amorphous pigment or in crystalloid form. 636 The pigment is usually found in association with the smooth endoplasmic reticulum but occasionally lies free in the cytosol. An ultrastructural study of four cases revealed perisinusoidal fibrosis, bile canalicular changes (dilation, distortion and loss of microvilli, increase in microfilaments), fatty change, proliferation of smooth endoplasmic reticulum, accumulation of lipofuscin, focal cytoplasmic degeneration, proliferation of microbodies and prominent mitochondrial changes. 637 One patient had crystalloid cores in microbodies that disappeared after therapy. 637 The accumulated material may indicate the presence of unmetabolizable bile alcohols resulting from a defect of bile acid synthesis. 636 

In general, treatment is by bile acid supplementation to bypass or offset the synthetic defect. Ursodeoxycholic acid may serve as initial treatment, but this may not be curative. It is preferable to treat patients with primary bile acids: cholic acid or chenodeoxycholic acid, separately or in combination. However, these bile acids are not widely available commercially. Chronic oral cholic acid treatment for patients with 3βHSD or 5β-reductase deficiency appears to be safe and effective. With a median follow-up of 12 years, Gonzales et al. 638 found that serum aminotransferases normalized and liver histology improved, including some with apparent regression of cirrhosis.

For CTX, a combination of chenodeoxycholic acid and pravastatin (an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A, HMG-CoA reductase) 639 has reduced serum cholestanol and prevented an increase of total cholesterol. The therapy has stopped disease progression, but has not reversed clinical manifestations. Low-density lipoprotein (LDL) apheresis has been added to the regimen in a few patients. 640 Liver transplantation has been performed for oxysterol 7α-hydroxylase deficiency and occasionally for other of the bile acid synthesis disorders when liver disease is far advanced and unresponsive to medical treatment.

A comprehensive review of diseases of bile acid synthesis is recommended for further reading. 641

Progressive familial intrahepatic cholestasis (PFIC) was originally described in 1965 in a Pennsylvanian Amish kindred named Byler, thus called Byler disease/syndrome. Now PFIC is recognized as occurring worldwide. [641] [642] [643] Although widely referred to as PFIC types 1, 2 and 3, these terms are confusing and should be avoided. The disorders have been reclassified according to the molecular basis, with designation based on the protein that is deficient. Since genetic testing is not always immediately available, a clinical subdivision is 662 and eventually cirrhosis. There is usually marked intracellular retention of biliary pigment and considerable hepatocyte disarray. Byler bile is not seen; instead the bile is amorphous or finely filamentous, and microvilli are lost. 662 Mallory-Denk bodies may be present. 649, 663, 664 Individual mutations do not correlate with specific histological patterns. 662 Milder forms of BSEP deficiency do not seem to constitute as large a proportion of later-onset disease as seen with FIC1 deficiency; however, there is also clearly a spectrum of disease, 665 which may be considerably underestimated due to difficulties in clinical diagnosis. A missense mutation in a sibling pair manifested in childhood with a BRIC phenotype but later progressed to advanced fibrosis. BSEP function was impaired, although its canalicular with bile salts to form micelles. This asymmetry would make the membrane outer leaflet resistant to the detergent effect of bile salts, which are at high concentration in the bile duct lumen. The precise mechanism by which a defect in this flippase function leads to cholestasis and extrahepatic manifestations is still not clear. 651, 652 The reduction in ectoenzymes seen in the canalicular membrane of patients probably reflects the bile acid-dependent extraction seen in mice. 651 This finding has been proposed as an indirect feature of PFIC1, although in the absence thus far of a specific antibody available for formalin-fixed paraffin-embedded (FFPE) tissue. In PFIC1 patients, expression of GGT and neutral endopeptidase (CD10) is lost on the canalicular membrane but not on the cholangiocyte apical surface. In contrast, canalicular expression of integral membrane proteins encoded by ABCB11 and ABCB4 (BSEP and MDR3, respectively) is preserved. 651 Other rare cholestatic disorders have been identified as FIC1 deficiency. A form of cholestatic syndrome was reported as being specific to the inhabitants of Greenland. 654 Jaundice, bleeding, pruritus, malnutrition, steatorrhoea, osteodystrophy and dwarfism were typical clinical features. Eight of the children died between ages 6 weeks and 3 years from bleeding or infections. Hyperbilirubinaemia, profound hypoprothrombinaemia, thrombocytosis and elevated ALP values were evident. 'Greenland familial cholestasis' has now been shown to be FIC1 deficiency, with all affected individuals carrying two copies of the same missense mutation. 655 Ornvold et al. 656 studied the liver biopsies from the 16 children and characterized the changes as early, intermediate and late. Early changes (up to 5 months of age) were restricted to the perivenular zone and consisted of cholestasis with rosette formation. Intermediate-stage changes (5-14 months) included perivenular and then periportal fibrosis in addition to persistent cholestasis. Changes in the late stage (17-60 months) included progressive cholestasis and portoportal and portocentral fibrosis in seven patients, and cirrhosis in two of the patients. Inflammation and paucity of bile ducts were not seen. Although poorly documented and now largely disappeared, it is likely that the 'Welsh cholestasis' was also a form of FIC1 deficiency. 657 Bile salt export pump deficiency Also known as 'progressive familial intrahepatic cholestasis type 2' (PFIC2), 658 BSEP deficiency is caused by mutations in ABCB11, which by this toxic bile, in particular the damage it causes to the biliary epithelium resulting in a cholangiopathy. In severe cases the features seen include portal inflammation, bile ductular reaction and subsequent fibrosis 646 (Fig. 3.51 A) . In the neonatal setting, conjugated hyperbilirubinaemia in the presence of elevated serum GGT values differs dramatically from the normal GGT levels usually observed in patients with FIC1 and BSEP disease. The histological differential diagnosis on liver biopsy specimens is with biliary atresia or other disorders manifesting in a biliary pattern. Copper and copper-binding protein accumulate considerably, and in excess of the levels usually observed with other cholangiopathies, potentially simulating Wilson disease. 679 In the somewhat older child, the cardinal diagnostic finding is that cholangiography discloses normal biliary architecture despite the appearance of bile duct obstruction.

The result of partial loss of function of MDR3 may have more widespread clinical importance than the neonatal disease. 680 De Giorgio et al. 681 have shown that a substantial proportion of adults expression was normal, as demonstrated with immunofluorescence. 666 Two cases of hepatocellular carcinoma in the cirrhotic liver of patients with PFIC 667,668 were reported before the characterization of the various subtypes; however, BSEP deficiency appears to be the main risk factor. 669 Mutations predicted to cause a complete loss of this protein seem to be particularly associated with malignancy. 661 HCC complicating BSEP deficiency may reflect the effect of multiple gene mutations. 670 Cholangiocarcinoma has been observed in two patients with BSEP deficiency. 671 The histological features of BSEP deficiency are not specific. 648 In an attempt to improve this, immunohistochemistry methodology, using a number of anti-BSEP antibodies, has been developed ( Fig. 3 .50). IHC may reveal no canalicular expression or focal, patchy and faint canalicular staining. 661 Redistribution of BSEP expression from cytoplasmic to canalicular (retargeting) or de novo expression has been described in children treated with ursodeoxycholic acid and biliary diversion. 672 Genetic liver diseases in which the gene is only expressed in the liver have generally been thought to be ideal candidates for liver transplantation. BSEP deficiency has recently highlighted a problem, which may have wider significance. Patients have been noted to occasionally have 'recurrent disease' . [673] [674] [675] [676] It is only recently that the mechanism has been determined to be caused by the presence of antibodies against the BSEP protein of the liver graft. 674 It appears that the antibodies are capable of inhibiting the function of the protein. Various strategies have been employed to overcome the problem, but several patients have been retransplanted before the mechanism of apparently recurrent disease was understood.

This entity, previously termed 'type 3 PFIC', has been shown to be caused by a deficiency in the multidrug-resistance protein 3 (MDR3), a floppase, caused by mutations in the encoding gene ABCB4. 646, 677 This protein is essential for the entry of the main phospholipid, phosphatidylcholine, into bile. In the absence of phospholipids, bile acids cannot form mixed micelles, and the bile is extremely hydrophobic. 678 Much or all of the phenotype is probably induced inflammation, resembling the changes in the mouse model. One diagnostic test is the detection of low bile phospholipid levels. When compared to the control bile samples of cholestatic children with sclerosing cholangitis (mean phospholipid, bile acid and cholesterol concentration of 29.1 mmol/L, 116.5 mmol/L and 3.4 mmol/L, respectively), the bile of patients with a PFIC3 phenotype had much lower phospholipid concentration (mean phospholipid, bile acid and cholesterol concentration of 1.4 mmol/L, 25.7 mmol/L and 0.74 mmol/L, respectively). 684 In patients with MDR3 deficiency, the biliary bile salt/phospholipid and cholesterol/phospholipid ratios are approximately five times higher than control bile. Biliary phospholipids in MDR3 deficiency patients are 1-15% of total biliary lipids (normal range, 19-24%). The residual percentage relates to the severity of the mutation (<2% associated with nonsense frameshift mutations). 689 Mutations in ABCB4 may also manifest as lowphospholipid-associated cholelithiasis syndrome, characterized by biliary symptoms before 40 years of age, intrahepatic microlithiasis and recurrence of biliary symptoms after cholecystectomy. 690

As with PFIC, benign recurrent intrahepatic cholestasis (BRIC) was also described in 1965. 691 Although the name and the original description suggest a distinct condition, it is now understood that BRIC is really a form of PFIC. When associated with ATP8B1 mutations, it is called BRIC1, and when associated with ABCB11 mutations, BRIC2; its association with as yet undetermined transporter defects is still possible. The clinical definition of BRIC involves specific criteria: at least two episodes of jaundice separated by a symptom-free interval lasting several months to years; laboratory values consistent with intrahepatic cholestasis, notably elevated serum GGT and total serum bile acids; severe pruritus and normal intra-and extrahepatic bile ducts confirmed by cholangiography. 692 The clinical presentation is usually jaundice with pruritus, but there is much interindividual variation in terms of severity, frequency and duration of episodes. Symptoms can be triggered by factors such as pregnancy, oral contraceptives, drugs or infection. There is an association with gallstones. Severe cholestasis in a young adult with polymorphism in ABCB11 and ATP8B1 preceded the diagnosis of Hodgkin lymphoma with cholestasis liver disease including primary sclerosing cholangitis have ABCB4 mutations. Progressive cholestatic liver failure in the adult members of a Transylvanian family was characterized histologically by a small duct cholangiopathy with ductopenia and associated with ABCB4 mutation. 682 Heterozygosity for ABCB4 mutations have been observed in children with cholestatic liver disease. 683 Furthermore, a reduction in biliary phospholipid not only results in parenchymal damage but also reduces the amount of cholesterol that may be maintained in solution. [684] [685] [686] As with BSEP, anti-MDR3 antibodies have been raised. Although this may be a useful method of establishing a complete loss of protein (Fig. 3.51 B) , it is less clear-cut in milder cases, as also evident in cell lines. 677 Partial loss of MDR3 function may lead to a more slowly progressive disease (Figs 3.52-3.54), but may still require liver transplantation. Lipid clefts may be identified in the lumen of bile ducts. 687 Cholestasis during pregnancy has also been reported in individuals heterozygous for mutations in ABCB4 (MDR3 deficiency). 646, 688 Histopathological findings include bile ductular reaction with model of microfilament dysfunction-induced cholestasis. The disease locus was mapped to chromosome 16q22. 712 A single mutation was identified in all affected individuals in a gene labelled CIRH1A. 713 The encoded protein (cirhin) has proved to be a nucleolar protein. 714 It remains controversial. 715, 716 A zebrafish model suggests a role in biliary development. 717 Cirhin also interacts with the nucleolar protein NOL11, which has a role in production of ribosomes. 718 The common mutation found in patients with North American Indian childhood cirrhosis (NAIC) disrupts that interaction.

In familial hypercholanaemia, clinical jaundice is classically uncommon in affected infants, who usually present clinically with nutritional sequelae of chronic cholestasis, such as failure to thrive, fat-soluble vitamin deficiency, rickets and bleeding tendency. Pruritus may be severe. Serum GGT is normal or low, but serum bile acids are elevated.

The genetic defect in familial hypercholanaemia is complex. Most cases exhibit oligogenic inheritance. The genes involved are the tight junction protein 2 gene (TJP2, previously known as ZO2) and BAAT. 719 Some patients are homozygous for a disease-causing mutation in TJP2 and have normal BAAT; others have mutated TJP2 plus they are heterozygous for a mutation in BAAT; still others are homozygous for a mutation in BAAT and have normal TJP2. Some children are homozygous for the TJP2 mutation, with normal BAAT, and they are entirely asymptomatic. TJP2 encodes a tight junction protein (TJP2, formerly ZO-2) and BAAT encodes the protein bile acid CoA:amino acid N-acyltransferase, which plays an important role in amidation, the process by which bile acids are conjugated to taurine or glycine (see earlier). The postulated mechanism is that bile acids do not enter the bile because of BAAT mutation or leak back into plasma because of faulty tight junctions caused by TJP2 mutation. Other genes have not been excluded. Mutations in the microsomal epoxide hydrolase gene (EPHX1) have also been reported.

Recent observations indicate that truncating mutations in TJP2 can produce a much more severe clinical phenotype. Affected children presenting in the first 3 months of life with severe cholestatic liver disease and low serum GGT (without mutations in ATP8B1 and ABCB11) were found to have homozygous mutations TJP2 11 in the absence of BAAT mutations. In these patients, claudin 1 is normally expressed in the cytoplasm but cannot co-localize at tight junctions without TJP2. These children have unfavourable outcomes, and the majority have required liver transplantation. Likewise, BAAT mutations may be associated with more severe liver disease, classified as an amidation disorder of bile acid synthesis.

This disorder, which is caused by an abnormal mitochondrial protein (citrin, a mitochondrial aspartate-glutamate carrier; see urea cycle disorders later), encoded by the gene SLC25A13 on chromosome 7q21, has different clinical presentations dependent on age. Infants with citrullinaemia type II typically present with infantile conjugated hyperbilirubinaemia. The features are distinctive enough to be called 'neonatal intrahepatic cholestasis with citrin deficiency' (NICCD). This name is misleading, however, in that the degree of hepatic inflammation can be very severe. Moreover, the infant can have various metabolic defects affecting glucose metabolism (resulting in hypoglycaemia), urea synthesis and fatty acid synthesis. The infant may appear to have galactosaemia due to decreased UDP-galactose epimerase activity, but in citrullinaemia type II, measurement of serum amino acids shows elevated plasma levels of citrulline and methionine. 36, 720 Liver biopsy may display steatosis in addition to inflammatory changes. by 7 months. 693 In one series, early onset of the first attack was associated with a more severe course, in terms of frequency and duration of attacks; some patients developed kidney stones, pancreatitis and diabetes. 694 The authors proposed dropping the adjective 'benign' because of the profoundly detrimental effect that the disease has on the long-term quality of life of affected patients. The suggestion that BRIC is in fact not benign is supported by the finding that some cases do progress, if slowly. 695, 696 There is a spectrum of severity, with some degree of genotype to phenotype correlation. 647 Histopathological observations of biopsy specimens from 22 patients at the milder end of the BRIC spectrum were detailed by Brenard et al. 697 During attacks of jaundice, cholestasis (hepatocellular and canalicular) occurred in all patients, and infiltration of portal areas with mononuclear cells in seven patients. Other findings included focal mononuclear cell infiltration with or without focal necrosis, infiltration of portal areas with many eosinophils, ductular reaction (one patient) and periportal fibrosis (one patient).

The primary medical therapies used in PFIC include ursodeoxycholic acid, phenobarbital and rifampicin (the latter two as treatment for pruritus); response to medical therapy occurs but is unusual. Some investigators have found ursodeoxycholic acid to be more beneficial in PFIC. 698, 699 Some patients with FIC1 deficiency respond poorly to ursodeoxycholic acid treatment. It may be of particular benefit in MDR3 deficiency, where bile salt hydrophobicity is thought to be particularly important in the disease pathogenesis; certainly, findings in the mouse model for MDR3 deficiency support this concept. 700 Partial bile diversion by a cholecystojejunal cutaneous conduit and/or ileal diversion produces complete resolution of the liver disease, but the results are variable from one institution to another. The surgery must be performed before significant fibrosis has developed. [701] [702] [703] [704] [705] [706] New treatment modalities are in development. The possibility of chemical chaperones for certain mutations is being explored. Specifically, 4-phenylbutyrate has been proposed as treatment for BSEP deficiency. 658 A wealth of data, mainly unpublished, regarding liver transplantation in PFIC exists. It appears to show generally good results in both BSEP deficiency and MDR3 deficiency. The results in FIC1 deficiency are less clear, in keeping with the widespread expression of the gene. In one series, hepatic transplantation was performed in 14 children with 'Byler's disease' . 707 One patient died postoperatively from arterial thrombosis. In the remaining 13 patients, graft function, growth and quality of life were good after an average follow-up of 17 months, without evidence of disease recurrence. Steatosis and steatohepatitis affect the liver allograft of patients transplanted for PFIC1. 708, 709 Other diseases causing intrahepatic cholestasis North American Indian childhood cirrhosis Weber et al. 710 studied 14 children, all from the Cree and Ojibwa-Cree tribes, with a severe familial cholestasis. Jaundice occurred neonatally in nine children but disappeared before the end of the first year. Subsequent reports clarified that this was a high-GGT cholestatic disorder. 711 On light microscopy, there was giant cell transformation and bilirubinostasis. Progressive liver damage was documented by persistently high levels of ALP, moderate elevation of aminotransferases severe pruritus and morphologically by fibrosis and cirrhosis. Early portal hypertension and variceal bleeding necessitated portosystemic shunts in seven children. Ultrastructural and immunohistochemical studies suggested that this group of children might represent a human α-lipoprotein level was found in affected individuals. The inheritance is believed to be autosomal recessive. A defect in prekeratin-keratin metabolism is postulated to account for the lesions in liver and other tissues.

This syndrome is characterized by café au lait spots, polyostotic fibrous dysplasia and sexual precocity. Silva et al. 734 reported two patients with McCune-Albright syndrome (MAS) who presented with neonatal cholestasis. Despite the severity of presentation, which can resemble biliary atresia on a nondraining hepatobiliary scan, both patients cleared their jaundice in 6 months but continued to have mild LFT abnormalities. The patients have been shown to carry an activating mutation in the gene encoding the α-subunit of the G protein. 734, 735 The protein stimulates adenylcyclase in liver tissue, suggesting that this metabolic defect could be responsible for their cholestatic syndrome. 736 Serum GGT is elevated in MAS. A variety of hepatobiliary and pancreatic neoplasms have been observed in MAS patients, in particular inflammatory hepatocellular adenomas. 737 

Also known as lymphoedema cholestasis syndrome type 1 (LCS1), Aegenaes syndrome is a rare disorder with limb oedema and cholestasis, originally reported in Norwegian kindreds. 30, 738, 739 Infants present clinically with conjugated hyperbilirubinaemia and elevated serum GGT along with a lymphatic disorder, typically lower-limb oedema, although a generalized oedema or lymphangiomas may occur. The intrahepatic cholestasis may be severe, with fat-soluble vitamin deficiencies and pruritus. The neonatal hepatitis syndrome may predate the lymphatic disorder and resolve before the lymphatic component is evident. The typical course is relapsing with intermittent bouts of cholestasis. Progression to end-stage liver disease is uncommon; however, a few young children have required liver transplantation. Hepatocellular carcinoma was reported in a teenager who was thought to have LCS1. 740 In adulthood the lymphatic disorder predominates. 741 The disease mechanism is unknown; the gene has been localized to chromosome 15q, but there may be genetic heterogeneity. 31 

Some patients with microvillus inclusion disease (MVID), associated with mutations in the MYO5B gene, develop intrahepatic cholestasis with jaundice, severe pruritus, normal serum GGT and increased serum bile acid concentrations. The genetic basis is not known; no mutations in ATP8B1 or ABCB11 were found. 742 The degree of cholestasis may worsen after intestinal transplantation.

Patients present with asymptomatic jaundice from elevated serum unconjugated bilirubin (Crigler-Najjar syndrome I and II, Gilbert syndrome) or conjugated bilirubin (Dubin-Johnson syndrome, Rotor syndrome). Bilirubin metabolism is discussed in Chapter 9; see also reviews by Bosma 743 and Erlinger et al. 744 Crigler-Najjar syndrome type I Crigler-Najjar syndrome is characterized by severe nonhaemolytic unconjugated hyperbilirubinaemia beginning in the newborn period.

Although primary sclerosing cholangitis can present clinically in infancy, it is extremely rare for it to present in the first 6 months of life. By contrast, some infants with neonatal conjugated hyperbilirubinaemia clear the jaundice and experience a period of apparent recovery. Later, cholestasis recurs, and imaging of the biliary tree reveals an appearance similar to that of primary sclerosing cholangitis. These infants are said to have 'neonatal sclerosing cholangitis' (NSC). It was first described in 1987, with subsequent reports. 721, 722 Serum GGT is elevated. The disease mechanism is likely multiple, and it has not been determined for every case. Affected infants should not undergo a Kasai portoenterostomy; medical management is that of childhood chronic cholestatic liver disease; with the development of end-stage biliary cirrhosis, liver transplantation is the required intervention.

Neonatal ichthyosis-schlerosing cholangitis (NISCH) is one form of NSC where the genetic basis is known. [723] [724] [725] Affected infants have prominent cutaneous features (scanty scalp hair, scarring alopecia, ichthyosis) as well as hepatic findings of NSC. It involves mutations in the gene encoding claudin-1, a tight junction protein, CLDN1 (found on chromosome 3q27-q28). Biliary damage may be caused by disturbed regulation of hepatic paracellular permeability. 726 The severity of the neonatal liver disorder may resemble biliary atresia. Serum GGT level is increased. Liver biopsy shows features of duct obstruction.

The full-blown arthrogryposis, renal dysfunction and cholestasis (ARC) syndrome involves skeletal changes, renal tubular dysfunction and cholestasis, and some infants also have severe ichthyosis, central nervous system (CNS) deformity (lissencephaly) and prominent growth failure. Approximately 10% have cardiac defects. 727 However, ARC syndrome is frequently incomplete, lacking the skeletal changes. Infants with incomplete ARC may present with conjugated hyperbilirubinaemia plus renal tubular dysfunction. This appears to be a disorder characterized by normal serum GGT. The genetic abnormality is twofold. Some patients have germline mutations in the gene VPS33B on chromosome 15q26, encoding a protein that regulates vesicular membrane fusion by interacting with SNARE proteins. 728 Others have mutations in VIPAS39, which encodes the VIPAR protein 729 Mutations in VPS33B are approximately twice as frequent as those in VIPAS39.

The histological pattern in the liver includes giant cell transformation of hepatocytes, lobular cholestasis and paucity of bile ducts. 730, 731 However, liver biopsy can be hazardous in ARC syndrome because of intrinsic platelet dysfunction severe enough to lead to haemorrhage after liver biopsy 732 ; consequently, mutation analysis is the diagnostic test of choice. Prognosis for patients with ARC syndrome is generally poor, with limited survival beyond infancy. Cirrhosis may develop.

Three of four adult siblings in a family studied for three generations had clinical and/or laboratory evidence of slowly progressive intrahepatic cholestasis. 733 Slight hyperpigmentation, facial hypertrichosis and hypothyroidism were seen in affected individuals, who also had prolonged increases in serum aminotransferases GGT and ALP levels. A biopsy of one patient who was jaundiced showed cholestasis and other changes indistinguishable from those of extrahepatic obstruction. Asymptomatic intervals were characterized by abnormal BSP retention, reduced N-demethylation capacity, elevated fasting total bile acid levels and normal light microscopic findings. A high serum intercurrent illness, serum bilirubin levels may rise to 40 mg/dL and cause kernicterus.

Crigler-Najjar syndrome type II is inherited as an autosomal recessive disease, although occasional patients with autosomal dominant inheritance have been reported. [759] [760] [761] [762] Type II patients also have significantly reduced levels of bilirubin UDP-glucuronosyltransferase 1. Analysis of bile before administration of phenobarbital demonstrates the presence of significant quantities of bilirubin monoglucuronide, which are not seen in type I disease. Patients with Crigler-Najjar II and significant bilirubin elevations can be distinguished from type I patients by the response to phenobarbital: in type II patients, the drug lowers the serum bilirubin by 30%.

Gilbert syndrome is a mild, and usually intermittent, form of unconjugated hyperbilirubinaemia. Patients often present at puberty, when jaundice is first noticed. Bilirubin levels increase following starvation or other stress. 763 In newborns it can exacerbate neonatal jaundice in the first 2 days and can contribute to higher bilirubin levels in patients with concomitant glucose-6-phosphate dehydrogenase (G6PD) deficiency. 764 Mild haemolysis and hepatocyte bilirubin uptake defects have been found. 765, 766 Liver enzymes are in the normal range.

Gilbert syndrome is the most common genetic bilirubin defect in Caucasians. 767, 768 The incidence is 3-16% of the population; inheritance is autosomal recessive. Hepatic bilirubin UDP-glucuronosyltransferase-1 activity may be 25% of normal. Mutations have been found in both the promoter and coding regions of the UDP-glucuronosyltransferase-1 gene in patients with Gilbert syndrome, resulting in reduced enzyme expression. [769] [770] [771] As with Crigler-Najjar syndrome type II, analysis of bile before administration of phenobarbital demonstrates the presence of significant quantities of bilirubin monoglucuronide. Diagnosis of Gilbert syndrome is clinical. Liver biopsy, even if direct measurement of bilirubin UDP-glucuronosyltranserfase can be performed, is not justified.

No therapy is necessary for Gilbert syndrome. Prolonged fasting should be avoided. A primate animal model has been reported. 772 Increased lipofuscin pigment accumulation in liver cells has been described in Gilbert syndrome. 773 The pigment granules do not exhibit the coarse granularity of those of the Dubin-Johnson syndrome. Ultrastructurally, hepatocytes reveal hypertrophy of the smooth endoplasmic reticulum. 774 

Dubin-Johnson syndrome was first described in 1954 by Dubin and Johnson 775 and Sprinz and Nelson. 776 Dubin 777 subsequently reviewed in detail 50 cases reported up to 1958. Patients typically present with asymptomatic conjugated hyperbilirubinaemia, but they have normal liver enzymes and no other evidence of hepatic dysfunction. Some patients have hepatomegaly and abdominal pain. Cholecystitis associated with minute bilirubinate stones may develop.

Elevations of predominantly conjugated bilirubin range from 2 to 5 mg/dL. Sulphobromophthalein is retained in these patients, with levels increased at 60-90 min over those at 45 min after intravenous administration. 778 In urine the total coproporphyrin level is normal, but isomer I is >80%, which is characteristic of the syndrome.

Age of onset may be as late as the sixth decade. Dubin-Johnson syndrome is rare in infancy, 779,780 except in an inbred population of Iranian Jews, where the incidence is as high as 1 in 1300. 778 Inheritance is autosomal recessive, with reduced penetrance in females. 781 The It was named after the physicians who provided the first description in 1952. 745 Patients with Crigler-Najjar syndrome type I can develop kernicterus at any age. The diagnosis should be entertained in the first 3 days of life. Levels of unconjugated bilirubin are usually over 20 mg/dL and may be as high as 50 mg/dL before therapy. Routine LFTs are in the normal range.

Crigler-Najjar syndrome type I is rare, with an incidence of about 1 per 1 million. Inheritance is autosomal recessive. Patients lack the enzyme uridine diphosphate (UDP)-glucuronosyltransferase completely and consequently are unable to conjugate bilirubin. 746 Mutations in exons 2-5 of the UGT1A gene affect all isoforms influencing glucuronidation of bilirubin and other substrates (type Ia). Mutations of exon 1 affect bilirubin glucuronidation only (type Ib). 744 Therapy is difficult and limited. Patients do not respond to phenobarbital. Phototherapy has been used long-term with plasmapheresis for acute bilirubin elevations and, if initiated promptly, such therapy can reverse early bilirubin encephalopathy. 747, 748 Therapeutic effectiveness decreases during adolescence. 749, 750 Currently, light-generating blankets or mattresses have proved effective. 751 Liver transplantation results in a cure. 749, 750, 752 This can also be achieved by an orthotopic auxiliary transplant. Experimental hepatocyte transplantation has decreased the hours needed for phototherapy. 753 Gene therapy is under investigation. The Gunn rat has been a valuable animal model. 754 The histopathology of the liver in Crigler-Najjar syndrome type I is characterized by intrahepatic cholestasis (Fig. 3.55) , 5,755-757 but the liver may be normal. 5 Crigler-Najjar syndrome type II Crigler-Najjar syndrome type II appears to be a milder variant of type I. It is also characterized by unconjugated hyperbilirubinaemia. The deficiency of bilirubin UDP-glucuronosyltransferase is less severe, but the mechanism of this difference is not entirely clear. 744 Arias et al. 758 described Crigler-Najjar syndrome type II in 1969. Patients present with neonatal jaundice, but the jaundice is less severe than in patients with type I. Bilirubin levels fluctuate between 7 and 20 mg/dL. These patients generally do not develop the severe intellectual compromise of type I patients, although during an Figure 3 . 55 Crigler-Najjar syndrome type I. Liver removed at transplantation is normal except for bile pigment seen in some canaliculi and in Kupffer cells.

in being pleomorphic and having a more variegated appearance and less lipid. 5, 791 An electron spin resonance spectroscopy study suggested that the pigment is not melanin but rather is a stable free radical with unusual properties. 792 Phillips et al. 5 consider the lysosomes distinctive in having very dense areas as well as moderately electrondense, finely stippled areas.

A form of conjugated hyperbilirubinaemia, Rotor syndrome was reported in 1948. 793 Although clinically similar to the Dubin-Johnson syndrome, there is no abnormal liver pigmentation. 794 Total coproporphyrin excretion in the urine is increased, and isomer I is elevated but is less than 80% of the total. Inheritance is autosomal recessive, but the genetic defect is unknown. 795 Hepatobiliary scanning reveals no minimal visualization. 796 There is no pigment storage or other morphologic change in Rotor syndrome. A number of ultrastructural changes were described by Phillips et al., 5 including distinctive 'two-tone' lysosomes.

The porphyrias are a group of eight disorders of the biosynthesis of porphyrins and haem that lead to the excessive accumulation and excretion of porphyrins and porphyrin precursors. Caused by a defect underlying defect is complete absence of the canalicular multispecific organic anion transporter (cMOAT). The ABCC2 gene is localized to chromosome 10q24. 782 It was cloned in humans in 1996. 783 Human multidrug-resistance protein 2 (MDR2) is the same gene with 32 exons. 784 Multiple gene mutations have been documented and can be detected in fibroblasts. 785 The most common mutation is R1066X, which leads to a premature termination of cMOAT. 786 On liver biopsy, IHC for cMOAT (MDR2) reveals a complete absence of staining (Fig. 3.56 C) . Animal models include the Corriedale sheep 787 and the transport-deficient (TR) rat. 788 Pigment accumulation resembling that of the Dubin-Johnson syndrome has been described in the howler monkey. 789 Accumulation of a coarsely granular brown pigment, called lipomelanin, in liver cells is characteristic of the Dubin-Johnson syndrome 775, 777 (Fig. 3.56 A) . Lobular distribution is diffuse, although more heavily concentrated in the perivenular zone. The accumulation of the pigment in hepatocytes gives the liver a grey to black colour grossly, although this feature may be less prominent in younger patients. Thus the gross (black) colour of the liver biopsy core may be diagnostic. The pigment shares some of its physicochemical properties with lipofuscin and melanin in that it is Oil Red O-positive (in frozen sections), stains black with the Fontana stain ( Fig. 3.56 B) , is variably PAS positive and is autofluorescent when examined by ultraviolet microscopy. 790 Ultrastructurally, the Dubin-Johnson pigment is lysosomal and thought to differ from lipofuscin C B A Histopathological findings in the liver in PCT include the accumulation of uroporphyrin in the cytoplasm of hepatocytes. Needleshaped cytoplasmic inclusions have been identified in hepatocytes by light, fluorescent and electron microscopy in biopsy specimens; the crystals are also birefringent under polarizing light. 825, 826 According to Cortes et al., 825 the inclusions are best seen by light microscopy in unstained paraffin sections. The crystals can be specifically stained in paraffin sections by the ferric ferricyanide reduction test ( Fig. 3 .57). 827 They are often found close to ferritin-like deposits. 826 Morphometric studies have shown significantly greater amounts of uroporphyrin crystals in familial than sporadic PCT. 826 The crystals have been induced experimentally in mice by iron overload. 828 Ultrastructurally, they reveal alternating areas of differing electron density. The crystals appear to be a mixture of porphyrinogens and porphyrins surrounding uroporphyrin crystals. 828 Other changes in liver biopsy specimens from patients with PCT have been described in several series. 825, 829, 830 They include steatosis, variable haemosiderosis in periportal hepatocytes and fibrosis. Cortes et al. 825 found periductal lymphoid aggregates in 43% of their cases. The incidence of cirrhosis in two series was 33% and 34%. 825, 830 It should be emphasized that tests for chronic viral hepatitis, particularly chronic HCV infection, were not performed in these series.

Hepatocellular carcinoma (HCC) has been reported in association with PCT 825, 826, [831] [832] [833] and also in patients with acute intermittent porphyria, variegate porphyria and hereditary coproporphyria. [834] [835] [836] [837] [838] [839] [840] The risk in patients with acute hepatic porphyria is high particularly after 50 years of age. 798 Factors related to an increased risk of HCC in PCT are a long symptomatic period before start of therapy, chronic hepatitis (particularly HCV), iron overload and advanced fibrosis or cirrhosis. In one series, there was a direct relationship between increasing age and extent of liver damage, with fibrosis present at a mean of 48 years, cirrhosis at 57 years and HCC at 66 years. 825 A somatic second-hit mutation has been proposed as the critical mechanism for the development of HCC in acute porphyrias. 841 in one of the eight enzymes involved in haem synthesis, porphyrias are classified into hepatic or erythropoietic depending on where overproduction of the haem precursors takes place. Porphyrias manifest with cutaneous sensitivity, acute neurovisceral symptoms or both. 797 Acute hepatic porphyrias are associated with primary liver cancer and in particular hepatocellular carcinoma. 798 Only two of the porphyrias importantly affect the liver: porphyria cutanea tarda and the erythrocytic protoporphyrias. Severe liver injury is increasingly recognized in association with X-linked protoporphyria, 799 the variability of its manifestations probably depending on random X chromosome inactivation. 800 Liver transplantation is used to treat the liver disease complicating porphyria or to correct the genetic defect causing intractable neurovisceral involvement.

The classification, clinical aspects and therapy of porphyria cutanea tarda (PCT) and other porphyrias are covered in several comprehensive reviews. 797, [801] [802] [803] [804] [805] PCT is classified as sporadic or familial. Most patients with PCT have the sporadic form (type I). Decreased activity of uroporphyrinogen decarboxylase is restricted to the liver, and the family history is negative. Familial (type II) PCT, accounting for approximately 20% of cases of PCT, is inherited as an autosomal dominant trait. The gene (UROD, encoding enzyme hepatic uroporphyrinogen decarboxylase) is located on chromosome 1p34. 806 The enzyme defect (50% reduction of activity) is present in all tissues. Clinical penetrance is low, with less than 10% of affected persons developing symptoms. Of note, some familial PCT occurs with mutations in gene(s) other than UROD; this is classified as PCT type III. Familial (type II) PCT has an earlier onset than sporadic (type I) PCT, with some cases presenting in childhood.

Sporadic (type I) PCT occurs typically in male patients between 40 and 50 years of age. Precipitating factors in the sporadic form include toxins (e.g. hexachlorobenzene), oestrogens, alcohol, mutations in the HFE gene and viral infection. 807, 808 An isolated case of PCT has followed interferon-alfa therapy of hepatic metastases. 809 The interaction of the HFE mutation and susceptibility to sporadic PCT has been discussed in several studies. [810] [811] [812] [813] Mild to moderate iron overload is found in 60-70% of patients with PCT; 10% have increases in the range of hereditary haemochromatosis. 814 In almost all studies, a high prevalence of HFE gene mutations has been detected, with differences between patients of northern European ancestry and those of Mediterranean origin. 815 In a U.S. study, 19% of the PCT patients tested were homozygous for the C282Y mutation, and 7% were compound heterozygous (0.5% and 1.0%, respectively, in the general population). 810 Viral infections may trigger PCT. Initial reports documented a high incidence (40%, 57% and 70.7% in three series) of hepatitis B serological markers in PCT [816] [817] [818] and anecdotal cases of HIV infection. 819 The strong association between hepatitis C virus (HCV) and PCT is most important. 816, [820] [821] [822] In the series reviewed by Elder, 803 the prevalence of antibodies to HCV in PCT has ranged from 9% to 79%. This is broadly related to the level of endemicity of HCV infection in the general population in various countries. A subsequent meta-analysis allowed Gisbert et al. 821 to conclude that the mean prevalence of HCV infection, detected by polymerase chain reaction (PCR) in PCT patients, is approximately 50%, much higher than that reported in the general population. Prevalence similarly varied depending on the country and the type of PCT (57% in sporadic, 25% in familial). It must be noted that HCV infection in itself is unlikely to derange the haem synthesis pathway; only a small proportion of HCV patients show an increase in urinary porphyrins, and prevalence of PCT among HCV patients is 1-5%. 820, 823 Treating PCT patients with chloroquine apparently does not affect the course of the underlying liver disease. 824 by mononuclear cells. Cholelithiasis occurs in some patients with EPP, and the calculi contain protoporphyrin. 870 Crystals isolated from the liver in one EPP patient had the same fluorescence spectrum as protoporphyrin. 870 The deposits in canaliculi, bile ducts and Kupffer cells display bright-red birefringence with a centrally located, dark Maltese cross ( Fig. 3.59 ). 871 Some of the larger deposits and most of the smaller ones in the cytoplasm of hepatocytes and Kupffer cells appear as clusters of brilliantly illuminated granules on polarizing microscopy.

Transmission EM studies have demonstrated that the deposits of protoporphyrin in EPP consist of numerous, slender, electron-dense crystals arranged singly in sheaves or in a 'star-burst' pattern 5,871-877 ( Fig. 3.60 ). The crystals are straight or slightly curved and are 43-646 nm in length and 6.1-22.0 nm in width. The crystalline accumulations in the cytoplasm of liver cells are not surrounded by a membrane, but in Kupffer cells they are intralysosomal. Nonmembrane-bound crystals have also been demonstrated in the cytoplasm of bile duct cells. 875 The protoporphyrin casts in canaliculi are readily visualized by scanning EM (Fig. 3.61) .

As already noted, the liver disease in EPP may progress to cirrhosis, although the overall incidence of significant hepatic disease is probably small. 851, [878] [879] [880] [881] Hepatic failure may be precipitated by viral infection (e.g. Epstein-Barr virus) or by alcohol. 815, 882 A direct toxic effect of protoporphyrin in the pathogenesis of liver disease is suggested by the changes observed in protoporphyrin-perfused rat livers. 883 The occurrence of cirrhosis in two sisters with EPP also raises the possibility of a genetic predisposition for hepatic disease. 884 A unique association of two rare diseases, Langerhans cell histiocytosis and EPP, has been reported. 885 A separate disorder closely resembling erythropoetic protoporphyria is X-linked dominant protoporphyria (XLP). 886 It is caused by gain-of-function mutations in ALAS2, the 5-aminolaevulinate synthase gene on Xp11.2. 887 The mutation is typically a deletion of two or four bases in exon 11. The increased activity of the mutated enzyme

Erythropoietic protoporphyria (EPP) was first reported in 1926, 842 with further definition of the dermatological manifestations in 1961, 843 and liver disease reported in 1965. 844 Clinical presentation begins with photosensitivity, usually before 6 years of age; patients have an extreme burning sensation with erythema and swelling. Onset of liver disease is usually later; most cases are diagnosed after 30 years of age, although liver disease can become evident in adolescence. Males are affected twice as often as females. Patients with EPP often present with right upper quadrant pain radiating to the back. Cirrhosis develops in only 1-10% of patients. 845, 846 There is no evidence of biliary obstruction. 847 Death occurs within 3-5 months (range, 1 month to 2 years) following the development of jaundice. A few patients with EPP have exhibited haemolysis and neurological dysfunction.

Ferrochelatase, the defective enzyme, catalyses the insertion of iron into protoporphyrin as the final step in haem synthesis. 848 Functional enzyme levels are usually less than 50%. Diagnosis of EPP is by measurement of elevated plasma, erythrocyte, and faecal protoporphyrin. Cord blood analysis is not a reliable prognostic tool. 849 The bone marrow contributes 80% of the protoporphyrins and the liver up to 20%. 850 Protoporphyrin is poorly water soluble and is secreted by hepatocytes only into bile. When this hepatobiliary transport is overwhelmed, insoluble aggregates of protoporphyrin form crystals in hepatocytes, canaliculi and proximal bile ducts, resulting in 'black liver disease' . 851 Autosomal dominant inheritance is found in most families, but autosomal recessive inheritance has been documented. 852 The incidence of EPP is 1 in 75,000 to 1 in 200,000 live births worldwide.

Approximately 90 different mutations have been identified in the ferrochelatase gene, localized on chromosome 18, including point mutations, nucleotide deletions and a partial chromosome deletion. 805, [853] [854] [855] [856] The ferrochelatase gene is composed of 11 exons and 10 introns with a size of approximately 4.5 kilobases (kb), and the enzyme is localized to the matrix side of the inner mitochondrial membrane. Patients with EPP who develop liver disease usually have a mutation in one ferrochelatase allele that alters enzyme function, together with a polymorphism in the nonmutant allele that causes low gene expression. This results in significant increase in the hepatobiliary excretion of protoporphyrin, which can damage the liver through both cholestatic injury and oxidative stress. 857 Haematin has been the most successful medical therapy. 858,859 Liver transplantation is appropriate for patients with liver failure or end-stage cirrhosis. 860, 861 However, recurrence of protoporphyric liver disease has been reported. [861] [862] [863] Bone marrow transplantation (BMT) is needed after LT to prevent disease recurrence in younger patients. 864 A mouse model is available for future evaluation of therapy. [865] [866] [867] The hepatobiliary alterations in this murine model have been reversed by BMT. 868 It has thus been suggested that BMT may be an option for EPP patients at risk of developing hepatic complications. 868 A recent study has confirmed that bone marrow-derived cells play a significant role in restoring and regenerating hepatic tissue in this mouse model. 869 Macroscopically, the liver affected by EPP is generally black. The first description of the characteristic, if not pathognomonic, changes was published by Cripps and Scheuer. 844 Sections from percutaneous hepatic biopsy specimens from five patients showed focal accumulations of a dense, dark-brown pigment in canaliculi, interlobular bile ducts, connective tissue and Kupffer cells (Fig. 3.58) . The pigment had an intense red autofluorescence in frozen sections examined by fluorescence microscopy with an iodinetungsten-quartz light source. Two of the patients had portal and periportal fibrosis, and in one case, the portal areas were infiltrated 

Liver disease is significant with glycogen storage disease (GSD) types I, III, IV, VI and IX. Strictly speaking, GSD type IV is an amylopectin storage disorder. GSD type II may be associated with hepatomegaly (Table 3 .4).

Type I GSD is caused by a deficiency of glucose-6-phosphatase, an enzyme that converts glucose-6-phosphate (G6P) to glucose, resulting in decreased hepatic production of glucose and accumulation of glycogen in the liver, kidney and intestine. Von Gierke 889 described type Ia GSD in 1929. The incidence of the disease is 1 in 100,000. Inheritance is autosomal recessive. The G6PC gene is mutated in type Ia GSD and is located on chromosome 17q21, 890 while the SLC37A4 gene is mutated in type Ib and is located on chromosome 11q23. 891 At least 84 mutations have been reported in type Ia and 80 mutations in type Ib GSD. 892, 893 Overall, type Ia is more common, accounting for approximately 80% of GSD type I cases. 894 Of note, previous classification of 'types Ic and Id' GSD was based on the belief that additional genes were involved, but subsequent studies have shown that these cases have type Ib SLC37A4 mutations. 895 In 1952, Cori and Cori 896 reported that G6P activity was virtually absent in the livers of individuals with type I GSD. This enzyme is necessary for gluconeogenesis and glycogenolysis, providing 80% of the normal hepatic glucose production. In addition to the liver, glucose-6-phosphatase also is present in the kidney, pancreas and intestinal epithelium, but not in white blood cells (WBCs). 897 In type Ia GSD, glucose-6-phosphatase protein expression is absent generates high levels of protoporphyrin in erythrocytes, found either as free protoporphyrin or as zinc chelated. These patients may be at higher risk for hepatic complications. Phenotypic variation is considerable. Prevalence in a North American series was greater than that in European series, accounting for 10% of patients with a disorder appearing to be EPP. 888 due to G6PC gene mutations, while in type Ib GSD, a transmembrane transport protein is defective (glucose-6-phosphatase translocase, encoded by SLC37A4). 898 This transporter is present in many organs, as well as being active in neutrophils and monocytes. In fact, the loss of glucose-6-phosphatase translocase activity in WBCs leads to neutrophil dysfunction through enhanced endoplasmic reticulum stress, oxidative stress and apoptosis, all leading to neutropenia. 893 In the first year of life, type I GSD usually presents with hypoglycaemia in the presence of a greatly enlarged liver. Additional features associated with type Ib GSD include neutropenia, recurrent infections and inflammatory bowel disease, which may resemble Crohn's disease. Affected individuals also can have oral, perioral and perianal ulcers, infections, abscesses and fistulas. [899] [900] [901] [902] Effective medical management permits survival into adulthood, if death does not occur in the first year of life. However, in adulthood, type I GSD is a multisystemic disorder. All adults with GSD type Ia have hepatomegaly. 903 Other common findings include short stature in 90%; hepatocellular adenomas in 75%, usually multiple; iron deficiency in 81%; proteinuria from focal glomerulosclerosis in 67%; renal calcification in 65%; and osteopenia and fractures in 27% of patients. Hypertriglyceridaemia occurs in all patients, hypercholesterolaemia in 76%, and hyperuricaemia in 89%. Less common complications include pancreatitis (thought to be secondary to high lipid levels) and myocardial infarction (from coronary artery disease). Pericardial effusion with valvular disease has been reported. 903 In children, epistaxis and bleeding during invasive procedures is associated with long bleeding times. Studies indicate a decrease in platelet adhesion, aggregation and ATP release associated with hypoglycaemia, which can improve after normalization of blood glucose levels. 904, 905 Von Willebrand factor may be deficient. Correction has been documented with intravenous 1-deamino-8-D-arginine vasopressin (DDAVP). 906 Two serious complications of this GSD type I may develop by adulthood. Chronic renal disease is caused by focal segmental glomerulosclerosis without immune deposits and uric acid nephropathy. 907 Hyperfiltration occurs throughout childhood. 908 The second major complication is the hepatocellular adenomas. [909] [910] [911] The male/female ratio is at least 2:1 for individuals who develop adenomas. Adenomas are seen as early as 3 years of age and as late as 40 years, the vast majority developing in the second decade. The development of adenomas appears to be independent of dietetic treatment, compliance to treatment or biochemical parameters related to metabolic balance. 912 On IHC subclassification, most of the hepatic adenomas are inflammatory adenomas or unclassified adenomas. For example, one large study found 26 of 33 hepatic adenomas were inflammatory adenomas, while the remaining five were unclassified. 913 There is a well-documented risk of malignant transformation in the hepatic adenomas, although it is not clear if the risk is the same for inflammatory adenomas versus unclassified adenomas. In one study, mean patient age was 23 years, and adenomas were followed between 2 and 7 years before malignant transformation. 909 Of note, serum alpha-fetoprotein (AFP) levels are often not elevated; thus the diagnosis of malignant transformation of a hepatic adenoma depends on the presence of careful liver imaging and/or liver biopsy. HCCs can develop even if successful dietary management leads to adenoma regression. 914, 915 The goal of therapy for GSD type I in infancy and childhood is to keep the glucose level at 70 mg/dL. This can be achieved by nocturnal gastric infusions of glucose-containing solutions, or by the administration of uncooked cornstarch around the clock, or by a combination of both. 916, 917 Infections and inflammatory bowel disease in type GSD type Ib can be improved by granulocyte colony-stimulating factor (G-CSF), 918 which seems to ameliorate neutrophil membrane function, 919 but does not reduce the number of apoptotic neutrophils in the circulation. 920 In one study of 17 patients with long-term follow-up, near-normal growth was achieved; however, puberty was delayed in five patients. Five patients also received allopurinol for hyperuricaemia, while two were treated for hypertriglyceridaemia. Some 35% of the patients were anaemic. Hepatocellular adenomas developed in 29%.

in up to 25% of patients. 951 Type IIIb is characterized by liver involvement alone, whereas type IIIa involves muscle as well as liver; type IIIb is specifically associated with mutations in AGL exon 3. 952, 953 Adults may develop adenomas, cirrhosis and, rarely, HCC. 954 Portal hypertension can be present despite normal liver enzymes. 955 Some children have mild splenomegaly at initial clinical presentation. Muscle involvement, including cardiac, can become an increasing problem in adulthood. 956 Treatment consists of a high-protein diet and uncooked cornstarch. 957, 958 Prenatal diagnosis is available. 959 Liver transplantation is sometimes required.

Type IV glycogen storage disease (branching enzyme deficiency; amylopectinosis; Andersen disease) Type IV GSD is a rare autosomal recessive disorder caused by a deficiency of glycogen branching enzyme, leading to the accumulation of amylopectin-like polysaccharides in affected tissues. The deficient enzyme can be measured in the liver, WBCs or cultured fibroblasts, and prenatal diagnosis is available. The GBE1 gene is located on chromosome 3p12; multiple defects have been described, 960, 961 which may correlate with clinical heterogeneity. 962 The prenatal course may be complicated by polyhydramnios, decreased fetal movement and dilated cardiomyopathy. 963 A rare infantile variant exists with early perinatal death. [964] [965] [966] Infantile presentation includes hepatosplenomegaly and failure to thrive. Some patients may have arthrogryposis of the lower limbs. 961 Hypoglycaemia is rare except as a feature of liver failure. Occasionally, patients may not have progression of the liver disease. 967 Later presentation includes congestive cardiac failure, skeletal muscle weakness and nerve involvement. 968, 969 In adults, progressive involvement of the upper and lower motor neurons, sensory loss, early neurogenic bladder and, in some patients, late dementia may be presenting features. 962 Adult cases are sometimes referred to as 'adult polyglucosan body disease' . 970, 971 Liver transplantation is an effective treatment for patients who develop liver failure. [972] [973] [974] In a study of 14 patients, death from cardiac failure occurred in a single case, 975 while nine of the survivors did not have neurological, muscular or cardiac complications up to 13.5 years after LT. 947 A reduction in myocardial amylopectin storage was reported by one group 974 but was not found by others. 973 Types VI and IX glycogen storage disease and related subtypes (phosphorylase system deficiency)

Defects in the phosphorylase system are caused by either deficient phosphorylase enzymes or deficiencies in the phosphorylase kinases, which activate the phosphorylase enzymes. The phosphorylase systems are enzymatically distinct in the liver and skeletal muscle. Muscle phosphorylase deficiency (GSD V) does not involve the liver and is not discussed further. Of the liver phosphorylase system defects, phosphorylase kinase defects (GSD IX) 976 are much more common than liver phosphorylase deficiency (GSD VI). 977 Enzyme activity is measured most accurately in liver tissue. Blood cells may or may not demonstrate these deficiencies.

Mutations in the PYGL gene lead to deficient activity of liver phosphorylase in type VI GSD (Hers disease), leading to glycogen accumulation because of a decreased ability to degrade glycogen by cleavage of the α1, 4-glycosidic bonds. The disease is inherited in an autosomal recessive manner and appears to be more common in the Mennonite population. 978 Signs and symptoms can be very mild in children, whereas other children can present with hepatomegaly and growth retardation. Hypoglycaemia can also be induced by limited dietary intake, e.g. during an illness. However, almost all All but one patient had glomerular hyperfiltration, with protein loss in two patients. 917 Liver transplantation has been successful in curing GSD type Ia but does not alter the course of the renal disease. [921] [922] [923] Combined liver-kidney transplantation has been successful. 924, 925 Management of hepatocellular adenomas includes resection or, preferably for multiple adenomas, hepatic transplantation, because the potential trophic effect on residual adenomas of resecting an adenoma is not known. 910, [926] [927] [928] [929] Despite the persistence of neutropenia after LT, 930 dramatic catch-up growth and reduced infections have been observed. 931 LT in four patients with GSD type Ib was followed by stabilization of glucose intolerance, decreased hospital admission and normalized neutrophil counts, but long-term observation is needed to confirm a sustained benefit. 932 Type II glycogen storage disease (acid maltase deficiency, Pompe disease) Type II GSD, first described by Pompe, 933 is caused by a deficiency of the lysosomal enzyme acid α-glucosidase (also called acid maltase), encoded by GAA. The prevalence of type II GSD is 1 in 100,000 live births (infantile form), 1 in 720,000 (juvenile form) and 1 in 53,000 (adult form). 934 The defect in acid maltase can be demonstrated in all cells, including fibroblasts, lymphocytes, amniotic cells and chorionic villi. The milder forms have more enzyme activity.

The gene is localized to chromosome 17q25. 935 There are more than 40 mutations, 936 which influence the clinical phenotypes. 937 However, there is tremendous phenotypic variation, even for individuals with the same mutation. 938 Type II GSD can present as a generalized infantile type, 939 as a milder form that presents during childhood (juvenile) or in adulthood. 940, 941 In one study, the median age at presentation was 33 years. 938 The fatal infantile disease presents as a 'floppy baby' with massive cardiomegaly, macroglossia, and progressive muscle weakness leading to death at a median age of 6-8 months. 942 Hepatomegaly is mild, there is no liver synthetic dysfunction, and hypoglycaemia is absent.

The milder forms have a later onset and present with exercise intolerance, myalgia, weakness with or without rhabdomyolysis and myoglobinuria; contractures develop eventually. 940 The juvenile form also involves respiratory muscles, and death may result from respiratory failure. 940, 941, 943 The adult form presents from the second to sixth decade without cardiac involvement. Creatinine phosphokinase is usually elevated. There is no abnormality in glucose metabolism. Vacuolated lymphocytes are found in the peripheral blood and bone marrow; the percentage of PAS-stained lymphocytes on blood smears is of diagnostic value. 944 Many organs show vacuolated cells due to enlarged lysosomes containing glycogen. For example, skeletal, cardiac and smooth muscle fibres contain glycogen-filled vacuoles. Vacuolated cells are particularly prominent in autopsy material as a result of the disappearance of extralysosomal glycogen. In the kidneys, glycogen accumulation is primarily in the loops of Henle and collecting tubules, a location that distinguishes this variety from GSD type I. 945, 946 Type III glycogen storage diseases (Forbes disease, limit dextrinosis)

The autosomal recessive GSD type III is caused by a deficiency in amylo-1,6-glucosidase, 4α-glucanotransferase (AGL or glycogen debranching enzyme), whose gene is located on chromosome 1p21. 947, 948 Multiple mutations have been identified, which mirror the biochemical and clinical heterogeneity of the disease. 949, 950 Clinical presentation may be similar to type I GSD, with hypoglycaemia, hepatomegaly and hyperlipidaemia. Growth failure is less severe, with better resolution at puberty. Hepatocellular adenomas occur appearance, with myriad tiny nodules that occasionally aggregate into larger nodules. 991 A reticular pattern of fibrosis or rarely a micronodular or mixed type of cirrhosis may be seen in some types of GSD, such as types III and IV. Tumour nodules of varied size (representing either adenomas or carcinoma) may be visible macroscopically.

The diagnosis of a specific type of GSD requires biochemical determination of the enzyme defect or gene sequencing. Although subtle histological differences have been described, 945 the pathological features are distinctive in only a few of the glycogenoses, such as the light microscopic appearance of the liver in type IV and the ultrastructural features of types II and IV.

In the majority of the glycogenoses, hepatocytes are swollen and rarefied, with wisps of pinkish material in an otherwise empty cytoplasm (Fig. 3.62) . Cell membranes appear thickened due to peripheral displacement of organelles by the stored glycogen. The overall appearance of hepatocytes has been likened to that of plant cells. Nuclei of liver cells also may be glycogenated. The excess cytoplasmic glycogen can be stained with periodic acid-Schiff (PAS) and readily digested by diastase (Fig. 3.63) . However, the haematoxlyin and eosin (H&E) findings are a better clue to the diagnosis than PAS staining, because even the normal liver can have abundant patients with type VI GSD improve with age to the point that as adults, they are generally asymptomatic.

In contrast to phosphorylase deficiency seen in GSD type VI, phosphorylase kinase deficiency, GSD IX, is clinically and genetically more complex, since the enzyme consists of four tissue-specific subunits encoded on different genes (including chromosome X) and differentially expressed in different tissues. The phosphorylase kinase liver α-subunit genes PHKA1 and PHKA2 are on chromosome X, the β-subunit gene PHKB is on 16q12-13, and the γ-subunit PHKG2 is on 16p11.2.

Phosphorylase kinase activates phosphorylase and is itself activated by a cAMP-dependent protein that can be stimulated by glucagon or adrenaline. 979 The αand β-subunits modulate the γ-subunit, which contains the catalytic portion of the enzymes.

The most common phosphorylase kinase deficiency is GSD IXa (~75% of cases), which manifests between ages 1 and 5 years with hepatomegaly (92%), growth retardation (68%), hypercholesterolemia (76%), hypertriglyceridemia (70%) and mild elevation in serum aminotransferases (56%), while hypoglycemia and metabolic acidosis are rare. 980 Hepatomegaly and growth retardation usually resolve at puberty. Autosomal recessive forms of phosphorylase kinase deficiency (GSD IXb, c) present with more severe liver disease, which may progress to cirrhosis. [981] [982] [983] Renal tubular acidosis and neurological complications are seen, including peripheral sensory neuropathy. 984 Therapy is usually not necessary in types VI and IX GSD; in some patients, uncooked cornstarch may be helpful.

This rare form of GSD is characterized by hepatorenal glycogen accumulation, fasting hypoglycaemia, hypergalactosaemia and renal tubular acidosis. GSD type XI results from defective function of GLUT2, 985 which is the most important glucose transporter in hepatocytes, pancreatic β-cells, enterocytes and renal tubular cells. 986 The SLC2A2 gene encoding GLUT2 is on chromosome 3q26.1-q26.3, and 34 different mutations have been reported. 987 Deficiency results in impaired import and export of glucose and galactose in affected tissues. Renal glycogen accumulation leads to impaired tubular function, Fanconi nephropathy and rickets. Patients may be picked up by the galactosaemia screen test because galactose, as well as glucose, is transported by GLUT2. 987 Untreated, the disease can be compatible with survival into adulthood, but patients continue to be symptomatic even after hepatomegaly recedes. 985 Glycogen synthase deficiency (glycogen storage disease type 0) Glycogen synthase deficiency is a rare inborn error of metabolism leading to fasting hypoglycaemia in infancy or early childhood that is accompanied by high blood ketone levels and low alanine and lactate concentrations. 988 The liver glycogen synthase gene (GYS2) is on chromosome 12p12.2. 989 Glycogen synthase deficiency can present with nonspecific symptoms after overnight fasting, as an incidental finding or because of a positive family history. The diagnosis is based on the characteristic biochemical profile and the demonstration of absent glycogen synthase activity and slightly reduced glycogen content in liver tissue, which is frequently steatotic. 990 Gross, light microscopic and ultrastructural features of glycogenoses Grossly, the liver in the glycogenoses tends to be enlarged, smooth and paler than normal. GSD type IV livers have a tan and waxy with colloidal iron (green), Best carmine (red) and Lugol iodine (mahogany brown). 996 Globular, PAS-positive inclusions with a Maltese cross birefringence have been reported in the liver, skeletal muscle and CNS in several congenital cases. 966 Fibrosis, which can progress to cirrhosis, is a frequent finding in glycogenosis type IV but can also occur in types III 954 and IXb, c 981,982 (Fig. 3.66) . As already noted, patients with glycogenosis type I may develop hepatocellular adenomas or HCC. The hepatocellular adenomas are often multiple, and most are subtyped either as inflammatory adenomas or unclassified adenomas. 913, 997 Unusual histological features in some adenomas have been described, including a steatohepatitic morphology with marked steatosis, Mallory-Denk bodies and fibrosis. 998, 999 Amyloid deposition has also been described in a small subset of GSD-related adenomas. 998 Focal nodular hyperplasia can also develop in livers with GSD, including types I and VI. 997, 1000 The ultrastructural features of the glycogenoses are quite comparable, with the exception of types II and IV. In the cytoplasm of the hepatocytes, large pools of glycogen rosettes displace organelles, such as mitochondria and the endoplasmic reticulum (ER), to the periphery of the cell. The glycogen may be associated with vesicles of smooth ER, or it may assume a starry-sky pattern, as observed in glycogenosis types III, VI and IX. 5 Morphometric analysis in glycogenosis type I has shown an increased volume of glycogen per unit volume of the hepatocyte cytoplasm. 1001 Additionally, there is marked reduction (by 50%) of the rough ER per unit volume of liver tissue. Double-contoured vesicles in the ER are characteristic of type I GSD. 1001 Lipid droplets of varied size are seen in most of the glycogenoses, but appear to be more prominent in types I, II and VI. 5 Nuclear glycogenation is minimal or absent in type Ib GSD, in comparison to type Ia. 1002 Increased collagen deposition in the space of Disse is observed in the GSD types I, III, IV, VI and XI. 5 Glycogenosis type II differs from the other types in the accumulation of monoparticulate glycogen (versus rosettes) in lysosomes that vary from 1 to 8 µm in diameter (Fig. 3.67 ). 1003 However, increased accumulation of glycogen rosettes may also be noted in the cytoplasm. 5 glycogen. Thus strong PAS staining plus diastase digestion is not strongly suggestive of anything per se, in the absence of typical H&E findings. The presence of sharply defined vacuoles in the cytoplasm, particularly in GSD types I and III, indicates the simultaneous accumulation of fat. Perivenular Mallory-Denk bodies have been reported in glycogenosis type Ia. 992 The histopathology of the liver in glycogenosis type IV is extremely different from that of the other glycogenoses. [993] [994] [995] The changes closely resemble those of Lafora disease, 996 but in Lafora disease, progression to cirrhosis does not occur. Typically, hepatocytes in type IV GSD are enlarged and contain colourless or lightly eosinophilic ground-glass inclusions that are round, oval or bean shaped (Fig. 3.64 ). An artefactual space may surround the inclusions. They are most heavily concentrated in the periportal zone but can be found in other zones. Both the inclusions and the rest of the hepatocyte cytoplasm in type IV glycogenosis are stained deeply with PAS (Fig. 3.65) ; diastase treatment removes the normal glycogen but not the abnormal amylopectin-like material in the inclusions. The latter can, however, be digested by pectinase (Fig. 3.65) , and αor β-amylase. 993, 996 The inclusions can be nonspecifically stained GSDs, despite their variable findings at presentation, present with low or normal blood glucose levels.

Urea cycle defects also can show variable and sometimes marked glycogen accumulation in hepatocytes. 1005 As with glycogenic hepatopathy, the clinical setting is distinct because urea cycle defects present most often in the neonatal period with hyperammonaemia, lethargy, hypotonia and seizures. The elevated ammonia levels are a critical clue to the diagnosis, which can be further supported by quantitative amino acid level analysis of the serum. Children with milder forms of urea cycle defects who present later in life can have a history of avoiding meat and other high-protein foods. The H&E findings can closely mimic a GSD, and correlation with clinical and laboratory findings is typically needed to secure the proper diagnosis. Ultrastructural differences can exist between urea cycle defects and glycogenoses. One study found that the intracytoplasmic organelles in urea cycle defects are not displaced to the cell periphery by the abundant glycogen, in contrast to glycogen storage diseases. 1005

Lafora disease is an autosomal recessive and fatal form of epilepsy with onset in late childhood or adolescence. One of the characteristic features of the disease is the presence of PAS-positive inclusion bodies in hepatocytes that are morphologically and immunohistochemically similar to those of glycogenosis type IV. Two genes can be mutated in Lafora disease: EPM2A on chromosome 6q24 and NHLRC1 (EPM2B) on chromosome 6p22.3. 1006, 1007 The EPM2A gene produces a protein, tyrosine phosphatase, called laforin, whereas NHLRC1 encodes a protein named malin. At least 43 different variations in EPM2A and 23 in NHLRC1 are known. 1008 Laforin, through its phosphorylase activity, and malin, possibly through inactivation of glycogen synthase, seem to have an inhibitory activity to polyglucosan accumulation. Their deficiency leads to an accumulation of insufficiently branched, and hence insoluble, glycogen molecules, which are deposited in the form of polyglucosan or Lafora bodies. 1009 The disease begins in adolescence with epileptic seizures (grand mal attacks being the most common) followed by myoclonus (beginning in the face and extremities, but progressively involving other muscles) and dementia. Atypical cases without myoclonus or epilepsy have been reported. Axillary skin biopsy is the simplest, least invasive diagnostic procedure, with characteristic inclusion bodies reliably found in duct cells of eccrine sweat glands. Most patients die between ages 16 and 24. However, a late-onset slowly progressive form, possibly related to a distinctive mutation, has been reported. 1010 The histological hallmark of Lafora disease is the presence of distinctive intraneuronal inclusions (Lafora bodies) most frequently found in the substantia nigra, globus pallidum, dentate nucleus, parts of the reticular system and cerebral cortex. The Lafora bodies vary in size from dot-like to as large as 35 µm. They stain positively with PAS, Best carmine, Lugol iodine (dark brown), colloidal iron and methenamine silver nitrate. 1011-1015 Three types have been described. 1016 With the PAS stain, type I bodies (the most common) are granular and red, type II bodies have a densely stained peripheral zone, and type III bodies (the least common) are homogeneously bright red. 1016 The bodies are digested by α-amylase, amylopectidase and pectinase. On the basis of histochemical studies, Yokoi et al. 1015 concluded that Lafora bodies are composed predominantly of an unusual branched polyglucosan. Ultrastructurally, they are not membrane bound and are composed of varying proportions of fibrillar and granular material. The core is usually granular while the fibrils, which measure from 6 to 13 nm, radiate outward and branch repeatedly. 994, 1011, 1013, 1016, 1017 Extraneural deposits of abnormal material are frequently present. The histochemical and ultrastructural characteristics of these deposits

The ultrastructural features of glycogenosis type IV are pathognomonic. 5 The inclusions noted by light microscopy consist of undulating, randomly oriented, delicate fibrils that measure up to 5 nm in diameter; these accumulations are not membrane bound (Fig. 3.68 ).

The differential diagnosis for the light microscopic findings in the glycogenoses includes primarily glycogenic hepatopathy and mutations leading to urea cycle defects. Individuals with glycogenic hepatopathy present with enlarged livers and elevated liver enzymes. The hepatocytes in glycogenic hepatopathy are diffusely swollen with glycogen, and the H&E findings can be essentially indistinguishable from a GSD. 1004 However, the clinical settings are distinct: glycogenic hepatopathy occurs in the setting of elevated and poorly controlled blood sugar levels (typically type 1 diabetes mellitus), often in children and teenagers, and responds dramatically to diabetic control, whereas chemotherapy, particularly in the liver of leukaemic children treated with 6-thioguanine 1025 and other drugs, 1026 especially cyanamide (see Chapter 12) . Cirrhosis has not been reported in myoclonus epilepsy, but there may be slight portal fibrosis. 1021

Galactosaemia is an autosomal recessive disorder caused by a deficiency of galactose 1-phosphate uridyltransferase and first described by von Ruess in 1908. 1027 The deficient enzyme was identified by Isselbacher et al. in 1956 Isselbacher et al. in . 1028 The incidence is 1 in 45,000 births. The GALT gene is located on chromosome 9q13, and several allelic variants have been reported, resulting in varying degrees of residual enzyme activity. 1029 Missense mutations are associated with low to undetectable enzyme activity, resulting in the most profound symptoms. The 'Duarte' variant produces some active enzyme, and patients with this allele have a better prognosis. 1030 Compound heterozygotes (e.g. a classic allele with a Duarte allele) can be affected, although less severely than homozygotes. 1031 Much more rarely, a defect in the epimerase enzyme (encoded by GALE) produces the same neonatal symptoms. [1032] [1033] [1034] Common symptoms in early infancy are conjugated hyperbilirubinaemia, failure to thrive, vomiting and diarrhoea after galactose ingestion. 1035 Oil-drop cataracts may be noted. Newborns are predisposed to overwhelming sepsis, most often from Escherichia coli. 1036 Haemolytic anaemia may occur early. 1035 Increased intracranial pressure and cerebral oedema may be presenting features. 1037 Neonatal liver failure with acute or chronic pattern may occur, without predisposing sepsis; clinical features include lethargy, with severe cases manifesting oedema, ascites and bleeding. 1038, 1039 Long-term complications such as mental disability, speech defects, ataxia [1040] [1041] [1042] and ovarian failure 1043 may occur despite dietary restriction. 1044 The diagnosis is classically suggested by the detection of urinary reducing substances (nonglucose), which is neither sensitive nor specific, and may be positive with any liver failure. Erythrocyte galactose 1-phosphate uridyltransferase activity can be measured, but the test must be done before the infant receives a blood transfusion. Erythrocyte galactose 1-phosphate levels can be assayed in Guthrie spots. 1045, 1046 Testing for the main genetic mutation or measurement of parental-erythrocyte galactose 1-phosphate uridyltransferase may be confirmatory. Since routine clinical management of an infant with conjugated hyperbilirubinaemia involves withholding lactose-containing feed until galactosaemia has been excluded as the diagnosis, speedy diagnosis is important. Prenatal diagnosis is performed by assaying chorionic villus biopsies or amniotic cells for the enzyme deficiency. 1047 Complete dietary restriction of galactose is the only available therapy. The liver disease undergoes remarkable recovery, 1048 but neurodevelopmental complications are not necessarily avoided by dietary therapy. Dietary therapy is difficult, since fruits and vegetables contain significant amounts of soluble galactose. 1049 In addition, there is an endogenous synthesis of galactose. 1050 Longterm follow-up should be considered in peripheral epimerase deficiency. Dietary restriction is recommended during an affected pregnancy; but it is unknown whether this will prevent or reduce neurological damage.

Of the histopathological changes, those in the liver are the most distinctive, although they are not pathognomonic. 1051, 1052 The earliest change, which may appear within 10 or 11 days of birth, is marked steatosis and a bile ductular reaction; the cholangioles usually contain bile plugs and may be surrounded and infiltrated by neutrophils. Fibrosis can already be present at this early stage (Fig. 3.71 A  and B) . The next change, which begins as early as 2 weeks and is fully developed by 4-6 weeks, is a striking pseudoglandular in skeletal and smooth muscle, myocardium, liver and other organs resemble those of Lafora bodies in the brain, with minor differences. Hepatic involvement has been reported by a number of investigators. [1018] [1019] [1020] [1021] [1022] [1023] In H&E preparations, liver cells contain round, oval or kidney-shaped inclusions that are sharply circumscribed, homogeneous or finely granular and lightly eosinophilic; they may be surrounded by a 'halo' that is probably artifactual 1021 (Fig. 3.69) . The nuclei of hepatocytes are frequently displaced to the periphery.

Affected hepatocytes in Lafora disease are predominantly periportal in location. They resemble those seen in type IV glycogenosis and show identical staining reactions, with the exception of the colloidal iron stain; the cytoplasm in Lafora disease is homogeneous (Fig. 3.70) , whereas the stored material in type IV glycogenosis is coarse and clumped. Hepatocytes not harbouring Lafora bodies contain a large quantity of glycogen. The inclusions also bear a resemblance to ground-glass hepatocytes of hepatitis B antigen carriers (but do not stain HBsAg), as well as to liver cells injured by cyanamide, a drug used in alcohol aversion therapy. Lafora body-like inclusions have also been reported in patients who did not have myoclonus or epilepsy. 1024 These inclusions have been observed after vomiting and failure to thrive. 1056, 1057 Other findings may include hepatomegaly, pallor, haemorrhage, trembling and jerkiness, shock, jaundice, oedema, tachypnoea, ascites, splenomegaly, fever and rickets. Patients who survive beyond infancy develop an aversion to sweet foods and characteristically have caries-free teeth. Some present later with cirrhosis.

Laboratory tests may reveal fructosaemia and fructosuria after recent fructose ingestion, together with hypophosphataemia, metabolic acidosis and abnormal LFTs. Uric acid levels may be elevated. A generalized amino aciduria with excretion of organic acids, as well as elevated serum levels of tyrosine and methionine, can simulate the findings in tyrosinaemia. None of these findings is diagnostic. 1056 An unequivocal diagnosis is made by mutational analysis of the aldolase B gene, located on chromosome 9q22. 1058 More than 30 mutations have been identified. 1059, 1060 The A150P (65%), A175D (11%) and N335K (8%) were the most common mutated alleles in a large series from Europe, where the disease occurs in an estimated 1 in 26,000 births. 1061 Analysis of liver or intestinal tissue for aldolase B enzyme activity can also confirm the diagnosis. 1062 Administration of fructose as a diagnostic test (so-called fructose tolerance test) is potentially dangerous; this obsolete test should be avoided.

(pseudoacinar) transformation of the hepatic plates. The hepatocytes surround dilated canaliculi that are either empty or contain bile or some pink or orange-coloured material. During this and the preceding phase, extramedullary haemopoiesis and haemosiderosis may at times be prominent (Fig. 3.71 C) . Fibrosis can be significant by age 6 weeks and culminate in cirrhosis at 3-6 months, typically with a micronodular pattern. A galactose-free diet can lead to regression of liver damage. 1048 One patient who survived to age 52 years with established cirrhosis has been reported. 1053 Occasional findings in the liver in galactosaemia include giant cell transformation. 1054 Hepatic adenomas have also been reported, 1054 but in current terminology, the 'adenomas' would be called macrogenerative nodules (or dysplastic nodules), since they occurred in a cirrhotic liver.

Hereditary fructose intolerance is caused by a deficiency of aldolase B, resulting in the inability to convert fructose 1-phosphate into dihydroxyacetone and glyceraldehyde. This may result in acute liver failure or in cirrhosis. The disorder was first described by Hers and Joassin in 1961. 1055 The clinical presentation is quite variable. Typically, liver disease appears in infants on introduction of fructose into the diet at weaning. The predominant symptoms are poor feeding, 

These diseases involve systemic disorders resulting from deficient activity of enzymes mediating the catabolism of glycosaminoglycans (mucopolysaccharidoses) or the synthesis or degradation of glycoproteins and glycolipids (aspartylglycosaminuria, α-mannosidosis, fucosidosis, mucolipidoses and congenital disorders of glycosylation).

In the mucopolysaccharidoses, excessive amounts of mucopolysaccharides accumulate in somatic and visceral tissues, and their partial degradation products are excreted in the urine; in addition, there may be accumulation of gangliosides. These extremely rare disorders are distinguished by their clinical manifestations and by twodimensional (2D) electrophoresis of glycosaminoglycans (GAGs) and specific enzyme assay. Enzyme analysis is performed in WBCs and fibroblasts, and the use of dried blood spots appears promising. 1074 The selective measurement of GAG-derived oligosaccharides in urine provides a sensitive method for the early identification of individuals with mucopolysaccharidosis (MPS) and allows the determination of oligosaccharide profiles that not only characterize subtype but also can be used for the biochemical monitoring of therapies. 1075 The role of genetic testing has been reviewed recently, 1076 particularly in terms of identifying carriers or undiagnosed family members. Except for type II, which is X-linked, all mucopolysaccharidoses are inherited as autosomal recessive traits. Six mucopolysaccharidoses (Hurler syndrome, Hunter syndrome, Sanfilippo syndrome, Morquio syndrome, Maroteaux-Lamy syndrome and type VII β-glucuronidase deficiency) are associated with variable degree of enlargement of the liver and spleen.

Mucopolysaccharidosis type I: Hurler, Scheie and Hurler-Scheie subtypes MPS type I is caused by a deficiency of the degradative lysosomal enzyme α-L-iduronidase. It results in clinical symptoms ranging from mild somatic complications and a normal lifespan to severe CNS involvement and a significantly shortened lifespan. A particularly high incidence of 1 in 26,206 births, with a carrier frequency of 1 in 81 (1 in 10 in 'travellers'), has been reported from the Irish Republic. 1077 The leucocytes of obligate heterozygotes have about half the mean specific enzyme activity of normal controls. 1078 The gene is located on chromosome 4q16 1079 ; multiple mutations have been characterized, with disease severity linked to the specific mutation. 1080, 1081 Patients with the most severe phenotype (Hurler [MPS IH] subtype) manifest developmental delay by 12-14 months of age. Features include corneal clouding, dysostosis multiplex, organomegaly, macroglossia, a prominent forehead and stiff joints. Death occurs by 10 years of age, usually from obstructive airway disease, respiratory infections or cardiac complications. Scheie (MPS IS; formerly MPS type V) and Hurler-Scheie (MPS IH/S) subtypes are associated with less severe clinical disease. 1082 Prenatal diagnosis by amniocentesis is now routine, and in utero therapy has been attempted. BMT is very effective if performed before significant loss of cognitive function, usually at under 2 years of age. [1083] [1084] [1085] [1086] [1087] Cord blood 1088 or haematopoietic stem cell transplantation (HSCT) 1089, 1090 can achieve a favourable outcome in Hurler syndrome, with improved cognitive function, but with a limited effect on corneas and skeleton. 1091 Enzyme replacement with intravenous laronidase therapy is well tolerated and effective for patients who do not have Dietary treatment with restriction of fructose, sorbitol and sucrose may lead to full restoration of normal health, growth and development, provided liver and renal diseases are not advanced at initiation of treatment. 1057 Patients need to be aware of high-fructose corn syrup and honey in the diet. Life-threatening acute liver failure may develop on the reintroduction of fructose, sucrose or sorbitol. Since there is endogenous production of fructose, some worsening of liver disease may occur despite meticulous avoidance of fructose.

Histopathological findings in hereditary fructose intolerance include neonatal hepatitis with giant cell transformation, 1063 steatosis, 1057,1064,1065 fibrosis and cirrhosis. 1057, 1064, [1066] [1067] [1068] [1069] The resemblance of the lesions to those of galactosaemia has been noted. 1064, 1070 As noted by Hardwick and Dimmick, 1071 most descriptions of the histopathology of the liver in hereditary fructose intolerance refer to changes consistent with the early phases of cirrhosis rather than with an established cirrhosis. Hepatocellular carcinoma has been reported in a 49-year-old man suspected of having hereditary fructose intolerance. 1072 Ultrastructural changes include concentric and irregularly disposed membranous arrays that are present in the glycogen areas of most hepatocytes and are associated with marked rarefaction of the cytoplasm ('fructose holes') 5,1073 (Fig. 3.72) . Many of the membranous formations resemble cytolysosomes. It has been suggested that these changes are related to the intracellular accumulation of substrates. Similar ultrastructural changes have been reproduced in rats whose livers were infused with fructose through the portal vein. 1073 Survival of injured cells is thought to depend on the sequestration of damaged areas (cytolysosome formation), as might occur with minimal or mild exposure to fructose. Larger quantities of fructose, particularly if repeated, may lead to more severe liver injury with necrosis and ultimately to cirrhosis. neuronal pathology. [1092] [1093] [1094] It may safely be combined with subsequent HSCT. 1095 Mucopolysaccharidosis type II: Hunter syndrome MPS type II is caused by a deficiency of iduronate-2-sulphatase and is the only X-linked MPS. The gene has been localized to Xq27.3-28. Affected children have coarse facies, deafness, cognitive deterioration, growth failure, joint contractures, severe hepatosplenomegaly and chronic diarrhoea. Death usually occurs before age 15 years, with mean age at death before and after 1985 being 11.3 and 14.1 years, respectively, which may reflect improvements in patient identification, care and management. 1096 A milder form of this disease exists with complications that include hearing impairment, and papilloedema resulting from local infiltration in the eye. Death is usually from airway obstruction or cardiac failure. BMT does not prevent the severe cognitive deterioration and is not currently recommended. 1097, 1098 Enzyme replacement therapy with idursulfase has the potential to benefit many patients with MPS II, especially if started early in the disease course. 1099 Mucopolysaccharidosis type III: Sanfilippo disease MPS type III comprises four phenotypically identical subtypes with different enzyme defects. All forms are characterized by coarse features, hepatomegaly, variable splenomegaly and mental retardation, but there is no corneal clouding. Type A results from deficiency of heparan-N-sulphatase; type B from deficiency of N-acetylα-D-glucosidase; type C from deficiency of acetyl CoA:α-glucosaminide acetyltransferase; type D from deficiency of N-acetylglucosamine 6-sulphatase. 1100 The gene for type A has been cloned, and several mutations associated with Sanfilippo disease have been described. 1101 A locus for type C has been mapped to the pericentromeric region of chromosome 8. 1102 The gene for type D has been cloned and localized to chromosome 16q24. Prenatal diagnosis is available. 1103, 1104 There is no known therapy for MPS III.

MPS type IV is caused by deficiency in N-acetylglucosamine 6-sulphate sulphatase (type A) or β-galactosidase (type B). Both types are phenotypically similar, with severe skeletal deformities and growth retardation, cervical myelopathy, a potentially fatal hazard, mild corneal clouding and hepatomegaly, but no mental retardation. Late onset has characterized type B MPS IV. 1105 Mucopolysaccharidosis type VI: Maroteaux-Lamy syndrome Deficiency of N-acetylgalactosamine 4-sulphatase (arylsulphatase B) is the cause of MPS type VI, which has three clinical subtypesinfantile, intermediate and adult-that vary in severity. The infantile form is characterized by growth retardation, dysostosis multiplex, coarse facial features, restricted movement, hepatosplenomegaly and corneal clouding. Clinical presentation with neonatal conjugated hyperbilirubinaemia has been reported. 1106 Death in the second and third decades is the result of cardiac failure. Intellect is not compromised in any form of the disease. The gene has been localized to chromosome 5q13-14; several mutations in the arylsulphatase gene have been found, but clear mutational-phenotype correlations are not yet possible. 1100, 1107 Sensitive immune assays to detect 4-sulfatase activity may allow an early detection of MPS VI on blood spots. 1108 BMT has been helpful in this disorder. 1109 Recent studies have concentrated on recombinant enzyme therapy, 1110 which is well tolerated and reduces lysosomal storage, as evidenced by reduction in urinary GAG, with clinical responses in all patients; the largest gains occur in patients with advanced disease receiving high-dose recombinant enzyme. 1111 Long-term enzyme therapy resulted in significant improvement in pulmonary function. 1112 Mucopolysaccharidosis type VII: Sly syndrome MPS type VII is caused by a deficiency of β-glucuronidase. This rare disorder is characterized by dysostosis multiplex, hepatosplenomegaly, mental retardation and frequent pulmonary infections. MPS VII is one of the storage disorders that can present with hydrops fetalis. One patient had isolated neonatal ascites as the first manifestation. 1113 Another infant presented with conjugated hyperbilirubinaemia with hepatosplenomegaly. 1114 The gene has been localized to chromosome 7q21.1-22; it appears that more than one mutation can result in MSP VII. 1100 Prenatal diagnosis is possible using amniotic fluid. 1115 In one case, BMT resulted in improved motor function and fewer infections. 1116 

Macroscopically, the liver in the mucopolysaccharidoses is enlarged, firm or hard and has a pale, slightly yellowish or greyish colour. 1117 There may be extensive fibrosis or cirrhosis. Microscopically, both hepatocytes and Kupffer cells are swollen and have an empty or faintly vacuolated cytoplasm (Fig. 3.73 ). Since much of the stored acid mucopolysaccharide is leached out by aqueous fixatives, other methods of fixation, such as Lindsay dioxane picrate solution, 1118 are preferable. Alternatively, addition of a 10% solution of acetyl trimethylammonium bromide to the formalin fixative is said to preserve acid mucopolysaccharide in the cells. 1119 The stored acid mucopolysaccharide is best demonstrated by a colloidal iron stain, and most of it can be digested with hyaluronidase ( Fig. 3.74 ). It is weakly positive with PAS stain but cannot be digested by diastase. Acid mucopolysaccharide is metachromatic when stained with toluidine blue. Little or no neutral lipid can be demonstrated in frozen sections of the liver stained with the sudanophilic dyes.

When fibrosis is present in the mucopolysaccharidoses, it is diffuse, with heavy deposition of collagen bundles in the space of Disse and gradual microdissection of the parenchyma into nodules (Fig. 3.75 ). Periportal bridging fibrosis has been emphasized by Parfrey and Hutchins. 1120 The type of cirrhosis associated with the 

The deficient enzyme, aspartylglycosaminidase, is normally present in the liver and brain as well as other tissues. Several different mutations in the gene, located on chromosome 4q32-33, can result in clinical disease. [1131] [1132] [1133] [1134] Peripheral blood and bone marrow examinations show vacuolated lymphocytes that do not stain with Best carmine or PAS. The urine contains increased quantities of 2-acetamido-1 (B-L-aspartamido)-1,2-dideoxy B-D-glucose. 1135 The diagnosis of aspartylglucosaminuria should be considered in children who present with a mucopolysaccharide-like disorder but with negative urinary screens. 1136 Clinical signs include coarse facial features (which increase with age), a protuberant abdomen with an umbilical defect, hepatosplenomegaly (which regresses with age) and the heart murmur of mitral insufficiency. Other features may include acne, macroglossia causing tooth malocclusion, hoarseness and short stature. Oral complications include dental cavities, gingivitis, candidiasis, extensive gingival overgrowth, benign odontogenic tumours or tumour-like lesions and reduced maxillary sinuses. 1137 Appearing normal at birth, patients have accelerated growth through early puberty but end up short in stature. Mental development may be normal except for delayed speech until 5 years of age. Deterioration is noted between 6 and 15 years of age with development of clumsiness and hyperkinesia. Rapid mental and somatic deterioration occurs in adulthood; adults usually have an IQ under 40, along with uncontrollable behaviour and seizures. 1138 Patients seldom reach age 45. The neurological abnormalities are related to significant changes in the grey matter; the white matter is characterized by delayed myelination. 1139 The incidence of aspartylglucosaminuria is highest in Finland, 1140 where the frequency of carriers is 1 in 36, 1141 and DNA testing is available. 1132 Prenatal diagnosis is achieved by enzyme assay in amniotic cells.

BMT may be beneficial. No loss of capabilities and an improvement in biochemical markers and white-matter signals on magnetic resonance imaging (MRI) were observed in two siblings followed for 5 years after BMT. 1142 Histopathologically, liver cells contain large and small vacuoles that stain variably with PAS. 1136 Kupffer cell vacuoles do not react with PAS. There is no increase in fibrous tissue. Ultrastructurally, enlarged lysosomes are present in hepatocytes and Kupffer cells. 1143, 1144 The fine matrix background is similar to that of the mucopolysaccharidoses. Membranous structures are found in these large lysosomes, as well as electron-lucent lipid droplets. Round, electron-dense structures and, less frequently, single membranous structures of varied sizes are also present.

α-Mannosidosis is a rare autosomal recessive disease caused by a deficiency in acidic α-mannosidase A and B in various tissues and in leukocytes, which leads to the tissue accumulation and abnormally high urinary excretion of mannose-rich oligosaccharides. Diagnosis is established by analysing urinary oligosaccharides by thin-layer chromatography (TLC) to demonstrate increased mannose enrichment or by assaying α-mannosidase activity level in leukocytes. Prenatal diagnosis is made by measurement of α-mannosidase in chorionic villi or trophoblast biopsy. 1145 The gene for acidic α-mannosidase has been localized to chromosome 19p13.2-q12, 1140 and several mutations have been identified. 1146 mucopolysaccharidoses may be macronodular or micronodular. 1121 When cirrhosis supervenes, it generally does so in older children and adults. [1121] [1122] [1123] Ultrastructural studies of the liver in MPS I, MPS II and MPS III have demonstrated the presence of vacuoles of varied size in both hepatocytes and Kupffer cells; these are bounded by a single membrane and contain some electron-dense, poorly structured material. 5, 1117, 1124, 1125 It is now generally accepted that the clear vacuoles represent lysosomes filled with acid mucopolysaccharide. Cytoplasmic vacuoles may form by mitochondrial 'budding' in the hepatocytes of patients with MPS I and MPS III. 1126 A peculiar crystalloid structure has been described in mitochondria of hepatocytes in MPS III. 1127 In MPS IV, Kupffer cells but not hepatocytes contain clear vacuoles. 1128 The ultrastructural changes in MPS IS (Scheie syndrome; formerly MPS V) are similar to those of MPS I and MPS II. 1129 In MPS VI there is moderate storage of electron-lucent material in lysosomes of hepatocytes, but Kupffer cells and hepatic fibroblasts contain as much acid mucopolysaccharide as in MPS I. 1128 Noncirrhotic portal hypertension and nodular regenerative hyperplasia of the liver have been reported in dogs with MPS I. 1130 The nodular regenerative hyperplasia is associated with a venopathy Mucolipidoses are lysosomal storage diseases with evidence of multiple primary defects of mucopolysaccharide, lipid and glycoprotein metabolism in various combinations. 1140, [1161] [1162] [1163] 

Mucolipidosis I is a rare syndrome caused by a deficiency in lysosomal sialidase (neuraminidase) resulting in defective intralysosomal catabolism of sialylated glycoconjugates and sialic acid transport out of the lysosomes. Mutations in the sialidase gene NEU1, located on chromosome 6p21.3, result in the progressive lysosomal storage of sialylated glycopeptides and oligosaccharides. 1164 Two major forms are recognized. Sialidosis type I (Salla disease) is a milder, late-onset, nondysmorphic form of the disorder; patients develop visual defects, myoclonus syndrome, cherry-red macular spots, ataxia, hyperreflexia and seizures. Type II, the severe infantile form, is characterized by gargoyle-like facial dysmorphism, and dysostosis is apparent by 4 or 5 years of age. Peripheral neuropathy develops, with muscular weakness and difficulties in coordination. Findings include corneal opacities, impaired hearing and hepatosplenomegaly. Vacuolated lymphocytes are found in all cases. An increased amount of bound sialic acid is excreted in the urine, a finding that can be used as a simple screening test. 1162, 1165 Definitive diagnosis is established by demonstration of a deficiency of sialidase in peripheral leukocytes or cultured fibroblasts of both type I and type II patients. Some patients with similar features appear deficient in both sialidase and β-galactosidase, a disease termed galactosialidosis (gene map locus 20q13). 1166 Sialidase can also be measured in cells from amniotic fluid, but special fresh preparations are necessary. 1167 A mouse model of sialidosis is currently used to evaluate enzyme replacement therapy. 1168 Light microscopy of the liver reveals marked enlargement of portal macrophages and Kupffer cells, both of which have a foamy cytoplasm. 5, 1163, 1169 Ultrastructurally, hepatocytes contain membrane-bound vacuoles that are electron-lucent. The vacuoles frequently contain numerous osmiophilic droplets as well as a reticulogranular or flocculent material. Riches and Smuckler 1169 also described multilamellar bodies and fragments of membrane-like material in the vacuoles. Similar vacuoles are found in Kupffer cells and to a lesser extent in endothelial cells, stellate cells and biliary epithelial cells. 5 

Mucolipidosis II and III (MLII and MLIII) are biochemically related diseases with different clinical manifestations. These disorders of lysosomal enzyme targeting are caused by a defective N-acetylglucosamine 1-phosphotransferase (termed phosphotransferase) activity in Golgi compartments of the cells and lead to the impaired formation of mannose 6-phosphate recognition markers in soluble lysosomal enzymes, followed by their defective transport to lysosomes and increased excretion into the serum. 1170, 1171 The diseases are autosomal recessive and linked to chromosome 4q21-23. 1172 MLII presents in the first year of life, with severe psychomotor retardation, early growth retardation, facial dysmorphism with characteristic gingival hyperplasia, equivocal or absent corneal clouding, hepatomegaly, skeletal dysplasia and severe dysostosis multiplex, [1173] [1174] [1175] which may resemble Pacman dysplasia. 1176 MLIII has similar symptoms, but these are milder and present later in life. Patients may survive into adulthood with the milder form of the disease.

Fibroblasts cultured from patients with MLII contain numerous dense inclusions (thus the term 'I cell') which are best seen on Patients present with psychomotor retardation. They have a distinctive coarse facies, corneal and lenticular opacities, hearing loss, hepatosplenomegaly (usually early in the disease course) and symptoms and signs of recurrent infection. 1148 Dysostosis multiplex is demonstrated by skeletal radiology in the majority of patients. Vacuolated lymphocytes are seen in the peripheral blood. About half the patients have decreased levels of serum immunoglobulin G (IgG). The susceptibility to infection may be a direct consequence of impaired leukocyte membrane recognition processes, which result from defective catabolism of substrates with α-D-mannose residues. 1148 The disorder may contribute to the onset of systemic lupus erythematosus (SLE) in predisposed patients. 1149 Two types of α-mannosidosis are recognized. Type I is the more severe infantile type, with death between 3 and 10 years of age. Type II is a milder disease with a juvenile or adult onset. There is no known treatment, but despite recurrent infections, some patients may survive into adulthood. 1150 Allogeneic haematopoietic stem cell or T-cell-depleted peripheral blood stem cell transplantation may halt the progressive cognitive loss and reverse the pattern of urinary oligosaccharides. 1151, 1152 Hepatocytes in mannosidosis contain PAS-negative vacuoles in the cytoplasm. Ultrastructurally, the vacuoles are bounded by a single membrane and contain amorphous and occasionally membranous and filamentous material. 1145, 1153 Vacuoles may also be present in sinusoidal lining cells. 1153 Light microscopic changes, which are nonspecific, include vacuolization of liver cells, steatosis and perisinusoidal fibrosis. 1153

Fucosidosis is caused by a profound deficiency of tissue α1-fucosidases resulting in storage of fucose-containing glycolipids, glycoproteins and polysaccharides or oligosaccharides. There seems to be no biochemical difference in α1-fucosidase between the phenotypically different type I and II disease. 1154 The gene has been localized to chromosome 1q34. The disease results from several different mutations in one subunit of the α-fucosidase gene. 1155 Type I fucosidosis is rapidly progressive and fatal between 4 and 6 years of age. Type II pursues a much slower course, with survival into adolescence and beyond. Common to both variants are psychomotor retardation, neurological deficits and skeletal abnormalities, Hurler syndrome-like features, hepatosplenomegaly, thickness of the skin, tendency to hernias and cardiomegaly. Almost all patients experience repeated bouts of respiratory infection. 1156, 1157 The patients with the slower evolution are characterized by angiokeratoma corporis diffusum. 1158 Diagnosis is made by TLC of urine. Prenatal diagnosis has been made by both DNA analysis and enzyme analysis but requires an experienced laboratory. 1155 BMT in one patient has been followed by progressive rise of enzymatic levels and some improvement in psychomotor development. 1159 The gross and light microscopic changes are similar to those of Hurler disease. 1140, 1155 Both hepatocytes and Kupffer cells are vacuolated. Ultrastructurally, hepatocytes show membrane-bound vacuoles representing lysosomes that contain granular or reticulogranular material suggesting polysaccharide, as well as lamellar bodies which indicate the accumulation of complex lipids. 1117 

The mucolipidoses are a group of diseases with features overlapping those of the mucopolysaccharidoses and sphingolipidoses.

A congenital disorder of glycosylation (CDG; previously called 'carbohydrate-deficient glycoprotein syndrome') refers to any of a heterogeneous group of metabolic defects in glycosylation pathways. Most recently discovered CDGs are caused by defects in three of the currently eight recognized major glycosylation pathways (N-glycosylation, GPI anchor synthesis and O-mannose-based glycosylation). 1191 The list is rapidly expanding, with eight new disorders described in 2013 alone. 1192, 1193 They are divided into type 1 (defective assembly of dolichol lipid-linked oligosaccharide [LLO] chain) and type 2 (defective trimming and processing of the protein-bound glycan). In the common form of this disease (CDG type Ia), patients present with neurodevelopmental delay, hypotonia, diarrhoea leading to poor weight gain and dysmorphism (esotropia, inverted nipples, peculiar distribution of fat). Cerebellar hypoplasia is seen on computed tomography (CT). Patients have deficiencies in many serum proteins and elevated hepatocellular enzymes. The illness may progress to death in infancy, usually from infections, stroke and/or inanition. 1194 If patients survive early childhood without diagnosis, many of the characteristic dysmorphisms become less apparent, and it becomes more difficult to recognize older patients with this disease. Older patients are characterized by nonprogressive neurodevelopmental delay with or without seizures, a stooped posture and a high risk of thrombosis. Ataxia is present in most patients. Some patients have progressive retinitis pigmentosa. 1195 Puberty is delayed in females, but not in males. 1196 Impaired linear growth is common. 1197 The characteristic serological findings are the result of deficiencies in a wide spectrum of serum proteins, all of which are normally glycosylated. Glycosylated residues on secretory proteins perform several essential functions: they assist in achieving proper threedimensional (3D) conformation, facilitate secretion of mature protein, protect the polypeptide from degradation and serve as recognition sites for some receptors. 1198, 1199 In all congenital disorders of glycosylation, the failure of normal glycosylation leads to deficiencies in the glycoproteins essential for coagulation and inhibition of coagulation (e.g. factor XI, antithrombin III, proteins C and S, heparin cofactor II). [1200] [1201] [1202] These defects contribute to the significant potential for strokes and transient stroke-like episodes. Defective synthesis of hormonal binding proteins or receptors cause the abnormal endocrine findings. 1194, 1203, 1204 There is no specific screening test for CDGs. The disease should be suspected in a patient with the characteristic clinical findings or an unexplained deficiency of more than one glycosylated serum protein, particularly albumin, transferrin, antithrombin III and α1-antitrypsin. Studies for several different diseases which depend on the absence of a glycosylated protein may be abnormal, suggesting several different unrelated diseases.

Diagnosis is made by isoelectric focusing of serum transferrin, with quantification of the glycosylation variants. The absence of sialic acid residues in transferrin from patients with CDGs results in a more cathodal migration of serum transferrin. The test is simple, easily available and relatively inexpensive. Patterns of transferrin isoelectric focusing are used to determine the type of CDG, in combination with the clinical presentation. 1205, 1206 False-positive results in the transferrin assay are not common: hypoglycosylation of serum proteins can occur in chronic alcoholism, in classic galactosaemia or in hereditary fructose intolerance. In these cases, treatment of the primary disease and clearance of the abnormal metabolic by-products results in resolution of the glycosylation phase-contrast microscopy. 1128 Vacuolated lymphocytes of B-cell lineage in lymph nodes, spleen and kidney have been found to contain large amounts of hexosamine. 1177 Cytoplasmic vacuoles were also noted in Kupffer cells, fibroblasts in the myocardium, renal podocytes and acinar cells of the pancreas. The vacuolated cells stain positively with Hale colloidal iron method.

Diagnosis is made by measurement of the activity of the phosphotransferase in patient's fibroblasts or by demonstration of elevated levels of serum lysosomal enzymes (as a result of hypersecretion rather than targeting into the lysosomes). Prenatal diagnosis is possible by measurement of lysosomal enzymes or phosphotransferase activity on cultured amnion cells. There is no definitive treatment, although BMT in one MLII patient has been followed by neurodevelopmental gains and prevention of cardiopulmonary complications. 1178 Light microscopy may show no changes in hepatocytes, but there is enlargement of Kupffer cells and portal macrophages that have a foamy cytoplasm, and granulomas composed of finely vacuolated epithelioid cells may be seen in portal areas. 1179 The vacuoles are limited by single membranes and contain fibrillogranular material, membranous lamellae or lipid globules. 1179 Hepatocytes are generally only slightly affected but may contain different types of dense polymorphic inclusions. 1128, 1174, 1180 Vacuoles in hepatocytes correspond to triglyceride droplets and membranous inclusions, as well as enlarged lysosomes containing granular material on EM. Kupffer cells contain electron-dense membranous lamellae.

Vacuolated cells (leukocytes and, in MLIII, bone marrow cells) similar to those of mucolipidosis I are present. Cultured fibroblasts show inclusions resembling those of the I cells of MLII. Ultrastructural findings in the liver include slightly enlarged secondary lysosomes without storage of any abnormal material, while Kupffer cells are relatively rich in unstructured osmiophilic material. 1128 

The rare disease of sialolipidosis is postulated to result from a defect in intracellular packaging or transport of lysosomal enzymes. 1181 Chromosome assignment is to 19p13.2-13.3. 1182, 1183 Most often seen among Ashkenazi Jews, mucolipidosis IV is characterized by an early onset of corneal opacification and psychomotor retardation; a small head circumference is common. Gargoyle-like facies, skeletal deformities and organomegaly are absent. 1184, 1185 Diagnosis is made by demonstration of characteristic inclusions in epithelial cells and conjunctival biopsies. Biochemically, mucolipidosis IV is characterized by the accumulation of gangliosides, phospholipids and acidic mucopolysaccharides in skin fibroblasts. 1186 The heterogeneity of the stored material accounts for cell vacuoles being variably stained with PAS, Sudan Black and Luxol fast blue. 1181 Prenatal diagnosis of mucolipidosis IV is performed by TEM to demonstrate lamellar bodies in endothelial cells of chorionic villi. 1187, 1188 Ultrastructural studies of conjunctival biopsies from four patients have shown two types of abnormal inclusion bodies, both in stromal fibroblasts and in epithelial cells: (1) single-membrane-limited cytoplasmic vacuoles containing both fibrillogranular material and membranous lamellae and (2) lamellar and concentric bodies similar to those found in Tay-Sachs disease. 1185 In liver biopsy material, Berman et al. 1189 have shown that hepatocytes contain inclusions composed predominantly of concentric lamellae, whereas vacuoles in Kupffer cells have clear contents. The prenatal diagnosis of mucolipidosis IV was reported by Kohn et al. 1187 A partial ganglioside sialidase deficiency has been found in cultured fibroblasts, but it is doubtful that this is the primary enzyme defect. 1190 complexing with α1-AT rather than with its substrate elastin. 1227, 1228 The major factors controlling serum levels of α1-AT are inflammatory stimuli, although some liver diseases, oestrogenic hormones and androgenic hormones can also alter serum levels. [1228] [1229] [1230] The association of panlobular emphysema with α1-AT deficiency was recognized by Laurell and Eriksson in 1963. 1231 Subsequently, Sharp et al. 1230 reported cirrhosis in 10 children from six different kindreds with α1-AT deficiency. Liver disease was subsequently shown to be most frequently associated with the α1-AT variant Z. 1232-1234 α1-AT deficiency was one of the first specific disorders to be dissected from the 'idiopathic neonatal hepatitis' category.

The diagnosis of α1-AT deficiency should be considered in all patients with undefined liver disease by measuring the serum level of α1-AT. In homozygotes, low levels of serum α1-AT (normal, >1.0 g/L) suggest the diagnosis of deficiency. However, α1-AT is an acute-phase reactant, and serum levels may increase as a result of hepatic inflammation, leading to normal values in heterozygotes. The diagnosis can be confirmed by protease inhibitor (PI) typing of the patient. PI typing is based on amino acid variations, which produce variably charged proteins that can be detected by isoelectric focusing in polyacrylamide gels. At least 90 allelic variants of α1-AT have been described by isoelectric focusing or DNA sequencing. 1235 By PI typing, the three most common alleles are M (normal) and the deficiency alleles S (plasma levels about 60% of normal) and Z (plasma levels about 15% of normal). Liver disease is predominantly seen in individuals carrying the Z allele, of whom only a relatively small proportion ever develops liver disease.

The PI*Z allele is found in approximately 1-2% of Caucasians of northern European ancestry, being highest in Scandinavian populations. It is virtually absent in black and Asian populations, but a review of epidemiologic surveys shows that it can affect individuals in all racial subgroups worldwide. 1236 In the West, α1-AT deficiency is estimated to affect about 1 in 2000-5000 individuals. 1237 The phenotypic expression of α1-AT deficiency depends on the protein production of both alleles: inheritance is codominant. Most allelic variants are the result of an amino acid substitution in the polypeptide chain. In the Z allele, the substitution of Lys342 for Glu342 directly inhibits secretion of α1-AT, which then accumulates in the ER. 1238 The marked variation in phenotypic expression of the liver disease results from genetic modifiers and environmental factors that influence the intracellular disposal of the mutant glycoprotein. [1239] [1240] [1241] Neonates and children Clinically, neonates who develop liver disease present with conjugated hyperbilirubinaemia. Severe cholestasis may be associated with acholic stools and must be differentiated from extrahepatic biliary atresia. Cholestasis usually resolves by 6 months of age without therapy, 1242 but a proportion of infants develop chronic liver disease. Up to 10% of neonates may have paucity of the intrahepatic bile ducts, with persistence of cholestasis and development of pruritus. A very small proportion of children with α1-AT deficiency never develop neonatal hepatitis syndrome but present clinically in the preschool age bracket, usually as toddlers, with hepatosplenomegaly caused by cirrhosis.

In prospective studies on the incidence of liver disease in PI*Z individuals, 1243 127 homozygous PI*Z children and 54 PI*SZ children were followed into adolescence by physical examinations and routine LFTs. Initially, symptomatic liver disease was found in only 11% of infants. In addition, 75% of all the infants with a PI*Z phenotype had elevated serum alanine aminotransferase (ALT) levels. By age 12 years, only 33% of the infants who presented with liver disease had ALT elevation, although 14% of patients who had had no liver disease in infancy now had an elevated ALT. Thus overall, evidence abnormalities. [1207] [1208] [1209] [1210] All patients with positive transferrin assays should have galactose 1-phosphate uridyltransferase testing and diagnostic testing for hereditary fructose intolerance.

In a patient with abnormal glycosylation of transferrin, the exact enzyme defect must be determined, if possible. The specific CDG syndrome is typed by a combination of the clinical presentation and the pattern of glycosylation present in isoelectric focused transferrin. CDG IIx, as well as phosphoglucomutase 1 deficiency, can resemble Wilson disease clinically; serum ceruloplasmin is low, hepatic copper concentration moderately elevated, but basal urinary copper excretion is normal. 1211 The incidence of CDGs has been difficult to determine; estimates have ranged from 1 in 50,000 to 1 in 80,000 live births, 1212, 1213 although these may be low. 1214 Cases of CDG have been described worldwide.

Gene localization for the CDGs varies according to types. Phosphomannomutase (type Ia, PMM2 gene) has been localized to chromosome 16p13, phosphomannose isomerase (type Ib) to 15q22-qter, and N-acetyl glucosaminyltransferase II (type II) to chromosome 14q21. Further gene loci are expected as identification of mutant genes continues.

There is no reliable method for prenatal diagnosis in CDGs; a combination of enzymology and genetic linkage analysis may allow prenatal diagnosis. [1215] [1216] [1217] Therapy in CDGs is symptomatic. Oral mannose supplementation has been successful in treating several cases of CDG Ib. 1218, 1219 Histopathological features in the liver in CDGS appear to be nonspecific. Conradi et al. 1220 studied liver biopsies from seven children and found slight to moderate fibrosis and steatosis. Similar findings have been reported recently by Socha et al. 1211 In the case report by Jaeken et al., 1221 a biopsy at the age of 5.5 months showed microvesicular steatosis and periportal fibrosis. A second biopsy at age 1 year revealed more pronounced fibrosis and ductular reaction, a picture resembling congenital hepatic fibrosis. Postmortem findings in twins with the deficiency included diffuse steatosis (particularly in periportal areas) and fibrosis in one twin and cirrhosis in the other. 1222 Ultrastructural findings in the cases of Conradi et al. 1220 included lysosomal vacuoles with concentric electron-dense membranes, and variable electron-lucent and electron-dense material in liver cells.

The term 'endoplasmic reticulum storage disease' was first used by Callea et al. 1223 to emphasize that a group of inborn errors of metabolism have as a common denominator the ER as the site of protein retention. The disorders affect secretory proteins: many of them, in particular α1-antitrypsin, α1-antichymotrypsin and C1 inhibitor, 1224 belong to the serine proteinase inhibitors (serpins), a superfamily of proteins whose gene cluster is located on chromosome 14q32.1. 1225, 1226 These storage diseases result from molecular abnormalities leading to protein misfolding and polymer formation, which prevents protein secretion. The resulting protein aggregates accumulate in the hepatocyte ER, with consequent low levels of the corresponding protein in the plasma.

α1-Antitrypsin (α1-AT) is a plasma glycoprotein of approximately 52 kD which is synthesized almost exclusively by hepatocytes. 1227 It is encoded by SERPINA1 on chromosome 14. α1-AT is a competitive inhibitor of leukocyte elastase with reaction kinetics favouring elastase As one example, in a series of 317 consecutive cancers, cholangiocarcinomas or combined HCC and cholangiocarcinoma were seen significantly more frequently in PI*Z-associated carcinomas (57.9%) than in non-PI*Z-associated carcinoma (27.2%). Interestingly, cirrhosis was found in only 3 of the 19 PI*Z-associated carcinomas. Other studies also report that cholangiocarcinomas in noncirrhotic livers can be associated with α1-AT deficiency. 1258 

Overall, rare variants causing α1-AT deficiency are seen in about 1% of cases. 1260, 1261 Interestingly, many of these rare variants are initially misclassified on PI* typing. 1262, 1263 In some cases that were initially misclassified, unexpectedly low serum α1-AT levels for the initial PI* type suggested the need for further study. 1262, 1263 Overall, the most common of the rare variants is PI*M malton . PI*M malton is most likely to cause clinical lung and/or liver disease when individuals are PI*M malton homozygous or have a PI*M malton /Z phenotype. 1264 However, rare cases of severe liver disease have been reported in individuals heterozygous for Pi*M malton . 1265 PI*S iiyama is molecularly similar to Pi*M malton and is also capable of retention in hepatocytes. 1266 

Morphologically, the hallmark of Z-type α1-AT is PAS-positive, diastase-resistant globules in periportal hepatocytes (Figs 3.76 and 3.77). Overall, the morphology of the globules is essentially identical for Z and other α1-AT deficiency alleles. The globules represent the retention of polymers of the abnormal protein within the rough ER (Figs 3.78 and 3.79). The globules are located in zone 1 hepatocytes in the noncirrhotic liver but may show a more diffuse distribution when a liver becomes cirrhotic. The globules may show a patchy distribution in both noncirrhotic and cirrhotic livers, so the entire biopsy should be examined on D-PAS stain. Histological data are sparse, but rare phenotypes such as PI*M malton and PI*M duarte and S iiyama also produce globules similar to those with Z alleles. 1264, 1267 Likewise, histological descriptions are sparse for individuals with the PI*QO (null) phenotype. Individuals producing no α1-AT would have no globules, 1268 whereas those producing truncated but unsecreted forms of α1-AT (e.g. PI*QO hongkong ) might have globules if the rate of protein degradation in the ER were sufficiently slow. 1269 The S-deficiency allele polymerizes at a rate much lower than that of hepatocyte injury decreased as the children approached the teenage years. Chronic liver disease led to death in only 2.5% of PI*Z individuals by age 12 years. 1234, 1243 In PI*SZ children, elevated ALT levels were not seen when serum α1-AT levels were at least 40% of normal. 1244 In another study of 85 children with neonatal hepatitis and α1-AT deficiency, poor outcomes were associated with ALT >260 U/L, prothrombin time >16 s and α1-AT concentration <0.25 g/L. 1232 On follow-up, persisting total serum bilirubin elevations and abnormal coagulation tests associated with abnormal factor V levels predicted death within 1 year and served as criteria for liver transplant evaluation. 1232, 1245 In a survey of children with α1-AT liver disease in the United Kingdom, clinical outcomes fell into four categories. Approximately 25% of the individuals gradually improved and appeared normal at ages ranging from 3-10 years. In contrast, 25% had persistently abnormal serum aminotransferases levels but were otherwise well; 25% had raised aminotransferase levels with enlarged liver and spleens; and 25% died of cirrhosis or required transplantation at ages ranging from 6 months to 17 years. 1246 PI*MZ and PI*SZ are not associated with significant chronic liver disease in children; however, some may have elevated serum aminotransferases, which typically normalize by age 10 years. 1247 Adults Homozygosity α1-AT-deficient individuals who escape severe liver disease in childhood generally are free of clinical liver disease until late in life. 1248 From ages 20-40 years, the incidence of liver disease in the α1-AT-deficient population is approximately 2%. From 41-50 years, the incidence increases to approximately 5%, with a 2:1 male predominance. Between 51 and 60 years of age, the reported incidence is 15% in males and 0% in females. In an autopsy series of 246 Swedish PI*Z patients, the incidence of cirrhosis was 12%, but this increased to 19% in individuals over age 50. 1248 Registry data show that emphysema and cirrhosis are the most common underlying causes of death (72% and 10%, respectively), with malignancy and diverticulitis accounting for 3% of deaths each. 1249 Death usually occurs within 2 years of the clinical diagnosis of cirrhosis.

Swedish investigators have documented an increased incidence of malignancy, with or without cirrhosis, in adult homozygous PI*ZZ patients. In this study, the odds ratio in α1-AT deficiency for cirrhosis was 7.8 and for hepatocellular carcinoma (HCC) was 20. 1250 Although the mechanisms of carcinogenesis are not clear, recent studies suggest that hepatocytes with marked accumulation of α1-AT globules engender a cancer-prone state, by surviving with intrinsic damage and by chronically stimulating in 'trans' adjacent, relatively undamaged hepatocytes that have a selective proliferative advantage. 1239 Heterozygosity Prospective, non-disease-oriented population surveys do not demonstrate a risk in heterozygotes (PI*MZ) for either liver or lung disease. 1251 However, liver disease population studies in England, Sweden and Norway have shown an increased frequency of the PI*MZ phenotype in patients with cryptogenic cirrhosis. [1252] [1253] [1254] It is not entirely clear to what extent the heterozygous state of α1-AT deficiency contributes to liver disease in the setting of another chronic liver disease, but in one large study, α1-AT heterozygosity was associated with an increased risk of liver decompensation in individuals with hepatitis C or fatty liver disease. 1255 Overall, PI heterozygosity does not appear to be a major independent risk factor for HCC. [1256] [1257] [1258] In contrast, several studies found an association between PI*Z heterozygosity and cholangiocarcinoma. 1258 of Z or M malton , and therefore it does not ordinarily accumulate in the liver. 1266 However, typical globules were reported in a PI*SS individual who also had alcoholic liver disease. 1270 Several early studies reported the accumulation of α1-AT globules in hepatocytes, despite PI*M phenotypes, in individuals with chronic inflammatory conditions. 1271,1272 However, these reports are rather exceptional, and most individuals with significant liver inflammation and systemic illnesses do not develop α1-AT globules in the absence of an abnormal α1-AT genotype. Zone 3 eosinophilic globules have also been reported in congestive hepatopathy. 1273, 1274 In some cases the globules were either weakly positive on immunostaining for α1-AT or were positive for both α1-AT and fibrinogen, suggesting the globules represent a more generalized protein metabolism problem. Also of note, in congestive hepatopathy, the globules are located in zone 3 and not zone 1.

The eosinophilic globules of α1-AT can be subtle on H&E staining. In particular, they can be absent or very difficult to detect in infants less than 12 weeks of age, and the diagnosis in the first few months of life rests on PI phenotyping. Immunoperoxidase staining for α1-AT can occasionally help in ambiguous cases, 1275 but the stains can be challenging to interpret, because there can be background staining in inflamed, reactive hepatocytes without α1-AT deficiency. Inclusions can be found in bile duct epithelium. 1276 The histological features of α1-AT deficiency in cholestatic infants can mimic neonatal hepatitis or extrahepatic biliary atresia, since the most common findings are lobular cholestasis, bile ductular proliferation and varying degrees of fibrosis (Figs 3.80 and 3.81 ). This emphasizes the need for screening for α1-AT deficiency by PI typing before a patient is treated by a Kasai portoenterostomy. The distinction between these two entities is made more difficult by the be present as in idiopathic neonatal giant cell hepatitis. 1277 Also of note, up to 10% of biopsies in the setting of α1-AT deficiency may have paucity of the intrahepatic bile ducts (see Fig. 3 .80) and chronic cholestasis (Fig. 3.83) , mimicking 'paucity of intrahepatic bile duct' disorders. In fact, a patent but narrow extrahepatic biliary tree is often found at liver transplantation for α1-AT deficiency, and a Roux-en-Y procedure may be necessary rather than a duct-to-duct anastomosis. Risk factors for rapidly progressive liver disease include a prominent ductular reaction, bridging fibrosis or cirrhosis on the initial biopsy specimen. 1278 The cirrhosis is typically mixed macro-and micronodular in type (Figs 3.84-3.86).

Other than the characteristic globules, the histopathological findings are nonspecific in adults with both homozygous and heterozygous α1-AT deficiency. There can be minimal to mild portal inflammation with a predominance of lymphocytes. Fibrosis varies from none to cirrhosis. A ductular reaction is only obvious when cirrhosis is present. Mild fat accumulation is often seen in the periportal hepatocytes, but ballooning, cholestasis and iron accumulation are all uncommon. However, cirrhotic livers with α1-AT deficiency and moderate to severe iron accumulation (3-4+ on a scale of 4) can be associated with HFE mutations. 1279 The α1-AT globules are generally less prominent in heterozygous livers. In many cases, additional independent disease processes may be present, such as fatty liver disease or chronic viral hepatitis, and the histological findings of these diseases can dominate the histological changes.

Occasionally, individuals undergoing cadaveric LT can receive grafts heterozygous for the Z α1-AT deficiency allele. One study identified a frequency of 0.8% for the Z α1-AT allele in presumed healthy donor cadaveric livers. 1280 However, the globules may not be evident for up to several years after transplant, with no globules in earlier biopsies. 1281 Data are insufficient at this point to indicate clearly whether there is significant impact on the post-transplant course.

Medical therapy is mainly supportive, with attention to malabsorption associated with severe cholestasis. Ursodeoxycholic acid (UDCA) may significantly improve clinical status and liver test results in some children, but no beneficial effect was shown in children with the most severe liver disease. The drug 4-phenylbutyrate has been proposed often small size of the extrahepatic biliary tree in patients with α1-AT deficiency, likely because of disuse atrophy secondary to cholestasis. Inexperienced surgeons may misinterpret operative cholangiograms from these patients as showing biliary atresia and perform an unnecessary Kasai portoenterostomy.

In α1-AT deficiency, inflammation is rarely a prominent feature. However, residual extramedullary haemotopoiesis may be present, depending on the age of the neonate, and can be confused with inflammation. Hepatocyte necrosis, if present, is minimal. Interestingly, mild zone 1 steatosis is also a common feature (Fig. 3.82) .

Cholestasis can be seen in hepatocytes, canaliculi and even bile ductules. Hepatocytes vary in size, with some tendency for pseudoacinar formation. Giant cell transformation of hepatocytes can as a pharmacologic protein chaperone. 1282 More recently, drugs which specifically enhance autophagy have been shown to improve liver disease and are currently in clinical trial. 1283, 1284 These drugs include rifamycin and carbamazepine. Infusions of recombinant α1-AT are neither indicated for nor effective in treating the liver disease.

Liver transplantation corrects the genetic defect and cures the patient. 1245,1278 α1-AT deficiency is the second most frequent indication for LT in children and the most common inherited disease for which LT is performed. 1278, 1285 Although α1-AT deficiency does not recur in the allograft, globules can develop over time in allograft livers obtained from living-related donors or deceased donors with deficiency alleles, even if no globules are evident on liver graft biopsies at LT.

α1-Antichymotrypsin (α1-ACT) deficiency is familial, with a gene frequency of up to 0.003. Deficient individuals described thus far are heterozygotes; homozygosity may be incompatible with life. 1250 Diagnosis is by quantification of serum α1-ACT levels, with demonstration of a level of approximately 64% of normal. 1250 The inheritance is autosomal codominant. The α1-ACT gene maps to chromosome 14q31-32, which is the same site as the α1-antitrypsin locus. 1286, 1287 Treatment at present is supportive.

In adults, low levels of α1-ACT can be associated with cryptogenic chronic hepatitis. 1288 In addition, there is an increased incidence of cryptogenic liver and lung disease among relatives with the α1-ACT deficiency. 1288 In a U.S. study, a strong association was found between α1-ACT deficiency and cirrhosis, particularly HCV-related cirrhosis. 1289 Thus 34% of patients with HCV-related cirrhosis were α1-ACT deficient, compared with 11% of patients with cirrhosis of other aetiologies. Combined heterozygosity for both PI*SZ α1-AT and α1-ACT deficiencies may enhance the risk of developing liver disease. 1290 On liver biopsy, the zone 1 hepatocytes can have globular inclusions. In most cases the inclusions are smaller than those of α1-AT deficiency, and they are usually not visible on H&E stains. On D-PAS stain the globules are weakly positive. 1289 Immunohistochemical staining can highlight granular inclusions in liver cells, particularly those adjacent to portal areas and fibrous bands. 1289, 1291 A fluffy material has been noted in dilated cisterns of the ER ultrastructurally. 526

Afibrinogenaemia and hypofibrinogenaemia are very rare diseases affecting approximately 1-2 individuals per 1 million population; consanguinity is common. Plasma fibrinogen levels are low or absent and can also be functionally impaired. The inheritance of afibrinogenaemia is likely to be autosomal recessive, but hypofibrinogenaemia may be either autosomal recessive or autosomal dominant. 1292 The fibrinogen gene cluster is located on chromosome 4q28-31 and consists of three related fibrinogen genes: α (FGA); β (FGB) or γ (FGG). 1293 Mutations in the α-fibrinogen gene (FGA) account for the majority of cases of congenital afibrinogenaemia, although mutations in all three fibrinogen genes, FGG, FGA and FGB, can cause congenital afibrinogenaemia. [1294] [1295] [1296] In afibrinogenaemia, where there is complete absence of fibrinogen, individuals often present with umbilical bleeding. Other complications can include intracranial haemorrhage following mild trauma, severe epistaxis, gingival and gastrointestinal bleeding, ecchymoses and spontaneous splenic rupture. Affected females may experience menorrhagia, recurrent abortions and postpartum haemorrhage. 1297, 1298 Other findings include greatly prolonged prothrombin time (PT), partial thromboplastin time (PTT) and thrombin time (TT). The erythrocyte sedimentation rate (ESR) is also very low, since fibrinogen is the primary factor affecting this test. Mild thrombocytopenia is present in about 25% of patients. 1292 The differentiation of primary from secondary hypofibrinogenaemia (e.g. drug induced) is important.

In hypofibrinogenaemia, fibrinogen levels are low, yet variable, which accounts for the differences in symptomatology. The majority of patients are asymptomatic, and elevated serum aminotransferase levels may be the only manifestation of liver disease. Perhaps counterintuitively, some individuals have an increased risk for thrombosis due to additional mutations, such as factor V Leiden mutations, 1299 or because the fibrinogen mutations lead to fibrinolysisresistant fibrin polymers. 1300 Although histological data are sparse, the inclusions in hypofibrinogenaemia can vary in size, shape and color, presumably reflecting differences in underlying mutations. The inclusions can be eosinophilic, small and round, 1301 or can manifest as somewhat larger eosinophilic globules 1302 similar in size to those of α1-AT deficiency [1303] [1304] [1305] (Figs 3.87-3.89) . In other cases, the globules are large and pale 1306 and resemble that of ground-glass inclusions seen in chronic HBV infection, or the pseudo-ground-glass change seen in drug reactions. 1026 The globules are negative or weakly positive on D-PAS. They are also positive with the phosphotungstic acidhaematoxylin stain. Immunoreactivity to fibrinogen antibody can be demonstrated (see Fig. 3.89) . Ultrastructurally, the cisterns of the rough endoplasmic reticulum (RER) are filled with densely packed, curved tubular structures arranged in a fingerprint-like pattern 1303, 1304, 1307 (Fig. 3.90) . Rarely, inclusions of hypofibrinogenaemia may be found incidentally in patients without clinical evidence of hypofibrinogenaemia and in whom mutational analysis has not been found or investigated. [1308] [1309] [1310] [1311] Conversely, an afibrinogenic patient with proven mutation has shown no evidence of storage in liver. 1312 The inclusions are the main finding in hypofibrinogenaemia and afibrinogenaemia, and the biopsies typically do show significant inflammation or other findings, unless there is an additional superimposed disease process. Some patients progress to cirrhosis, although in afibrinogenaemia the bleeding diathesis is the more common cause of death. 1313 severe coagulopathy, as well as urinary findings compatible with the renal tubular changes of Fanconi syndrome.

Liver crisis, often precipitated by an infection, typically presents in the first 2 years of life and is characterized by increased severity of hepatic dysfunction. Coagulation tests (PT, PTT) worsen and are not responsive to vitamin K; jaundice heralds the terminal event. 1325, 1327 Neurological crisis may also be precipitated by infection. Children become irritable and less active and develop severe pain, often localized to the legs. Paraesthesias, hypertension, tachycardia and paralysis may develop. The paralysis may progress to complete flaccid quadriplegia, including paralysis of the diaphragm, and may require mechanical ventilation. Cerebrospinal fluid analysis is unremarkable. This complication may account for 10% of deaths, but the incidence varies greatly. 1324, 1328, 1329 Nerve toxicity due to δ-aminolaevulinic acid retention is thought to be responsible (Fig. 3.91) .

More than 80% of HT1 patients have renal tubular defects. Histologically, 25% have some degree of glomerulosclerosis, and 50% have mild to moderate interstitial nephritis and fibrosis. Nephrocalcinosis can be detected by ultrasound in one-third of patients; 50% may have an abnormal glomerular filtration rate. 1330 Hypertrophic cardiomyopathy has been documented. 1331, 1332 Hepatocellular carcinoma occurs in 10-37% or more of HT1 patients, 991, 1333, 1334 based on observations obtained before the routine use of the drug nitisinone, and may rarely be the presenting feature. 1335 HCC is associated with cirrhosis and may occur as early as the first year of life or in adulthood. Serum alpha-fetoprotein (AFP) screening may be helpful, but the complication has been seen with normal AFP levels. 1336 HT1 occurs worldwide, although it is particularly common in individuals of French-Canadian descent and is most common in the Lac St.Jean-Chicoutimi region of the Canadian province of Quebec. A variety of mutations in the FAH gene have been described; 100% of patients in the province of Quebec and 28% elsewhere carry a splice mutation in intron 12 of the FAH gene. 1337, 1338 The gene is found on chromosome 15q 23-25. 1339 Prenatal diagnosis is available. 1340, 1341 Early diagnosis by screening of Guthrie spots is 

This uncommon disorder has an autosomal dominant inheritance with complete penetrance. The gene for antithrombin III is located at chromosome 1q 23-25. 1315 There is a propensity for venous thromboembolism, ranging from superficial thrombophlebitis to pulmonary embolism. 1316, 1317 The deficiency may be complicated by the Budd-Chiari syndrome. 1318, 1319 The deficiency does not lead to excess mortality, according to Rosendaal et al., 1320 who do not recommend prophylactic anticoagulation. Antithrombin concentrates are used in high-risk clinical settings. 1321 An 8-month-old infant with antithrombin III deficiency developed multiple large venous and arterial thromboses and E. coli sepsis. 1322 He had a micronodular cirrhosis, and liver cells contained multiple, eosinophilic, PAS-positive globules resembling those of α1-antitrypsin deficiency.

Hereditary tyrosinaemia type 1 (HT1) is caused by a deficiency of fumarylacetoacetate hydrolase (FAH), the last enzyme in the tyrosine degradation pathway (Fig. 3.91) . 1323 This leads to accumulation of highly reactive intermediate metabolites such as maleyl-and fumarylacetoacetate, which are toxic and mutagenic within the liver. The secondary metabolite succinylacetone is excreted in the urine; a high urinary level is a diagnostic feature. 1324 Succinylacetone also has an inhibitory effect on porphobilinogen synthase, accounting for episodes similar to acute hepatic porphyria, with neurological crises and excretion of 5-aminolaevulinic acid in the urine (Fig. 3.91) .

Clinical presentation of HT1 is heterogeneous, even within the same family. Progressive liver damage is often not reflected in routine liver tests. 1325 The earlier the presentation, the worse is the prognosis. 1326 available 1342 ; it permits immediate introduction of treatment so that most of the severe liver disease can be abrogated. Interestingly, many patients with HT1 have a mosaic pattern of FAH expression in liver tissue. This phenomenon has been explained by a spontaneous reversion of the mutation in one allele to a normal genotype. 1343 There seems to be no evidence that it could be of maternal origin due to transplacental cell trafficking and subsequent fusion. 1344 In one study, the extent of mutation reversion of the FAH gene in the liver correlated inversely with the clinical severity of the disease, suggesting that the corrected hepatocytes play a substantial protective role in liver function. 1345 NTBC (2-(2-nitro-4-trifluoromethyl-benzoyl)-1, 3-cyclohexanedione), or nitisinone, inhibits 4-hydroxyphenylpyruvate, the enzyme deficient in tyrosinaemia type 2, and prevents the accumulation of toxic metabolites (see Fig. 3 .91). Since the first clinical trial of NTBC therapy in 1991, more than 220 HT1 patients have been treated with the drug 1346, 1347 and shown initial good response, including normalization of liver function and metabolic parameters in most patients. Recent experience in Quebec indicates that commencing nitisinone treatment before the patient is 1 month old eliminates acute complications of the disorder. 1348 Long-term studies are still necessary to determine whether NTBC may prevent or only delay long-term complications, and to examine the possible risks of the drug. 1349 Of the patients who started receiving NTBC early in life, two (1%) developed HCC during the first year of treatment, but no further cases occurred among these patients followed for up to 9 years. 1350 In one patient, liver tumour with lung metastases developing at age 15 months was reclassified as hepatoblastoma after a good response to chemotherapy and partial hepatectomy, which resulted in a 12-year disease-free period. 1351 However, with late onset of treatment, the risk of malignancy remains despite NTBC therapy, and lifelong surveillance is required. 1352 Besides an increase in AFP, a slow AFP decrease and never-normalizing levels of AFP are important predictors of liver cancer development in later life. 1353 Dietary therapy must be maintained despite NTBC therapy. Corneal lesions reported in 13% of treated patients can be controlled by using a low-tyrosine, low-phenylalanine diet. The unique renal tubular dysfunction of HT1 resulting in hypophosphataemic rickets is usually responsive to dietary therapy, 1354 but it is completely reversed by NTBC therapy. 1355 However, the marked coagulopathy, 1356 neurological complications simulating porphyria 1329 and development of HCC 1333 are not responsive to dietary therapy alone. Liver transplantation remains the treatment of choice for medical treatment failures. 1349 Renal disease does not progress after LT 1357 ; however, renal impairment associated with HT1 may be greater than appreciated. 1347 Pathological aspects of HT1 have been described in several reports. [1358] [1359] [1360] [1361] [1362] [1363] [1364] The liver, at autopsy or removed at transplantation, is slightly to moderately enlarged, yellow, firm and nodular (Fig. 3.92) . The microscopic features include fatty change, cholestasis, pseudoacinar transformation of hepatic plates, pericellular and periportal fibrosis, variable haemosiderosis, extramedullary haematopoiesis and varyingsized foci of nodular regeneration, some qualifying as macroregenerative nodules (Figs 3.93-3.95) . The regenerating nodules, which appear as high-attenuation foci on CT scans, are difficult to differentiate from multifocal HCC. 1365 The nodules often show more fat accumulation than the adjacent liver (Fig. 3.93) , and some may exhibit dysplastic changes (Fig. 3.94) . Periportal ductular reaction, although present, is usually not striking. Cirrhosis may be micronodular, macronodular or mixed. 1362,1366 Jaffe 991 has noted the prominence and variegated colours of the macronodules (yellow, tan, green) (see Fig. 3.92) . Transition from a micronodular to a macronodular cirrhosis has been documented. 1359 Liver cell dysplasia, both the large and small cell varieties, is frequently observed, and the distinction between dysplastic nodules and HCC may be difficult, if not impossible. 991 cycle disorders. These disorders are autosomal recessive except for ornithine transcarbamylase (OTC) deficiency, which is X-linked.

The urea cycle disorders have been comprehensively reviewed. 1374, 1377, 1378 Among the classic urea cycle disorders, the only one with significant liver disease is argininosuccinic aciduria (ASA). 1379 The urea cycle enzyme that is deficient in this disorder, argininosuccinic lyase, is located on chromosome 7. 1380 Several mutations within this gene may result in argininosuccinate lyase deficiency. 1381 The enzyme protein may be absent in the liver 1382 ; it can also be measured in red blood cells, fibroblasts and amnion cells, with substrate accumulation occurring in the fluid of cultured cells. Liver disease is manifested clinically by hepatomegaly and by serum ALT elevation and severe fibrosis on liver biopsy. 1379 Marked macrovesicular steatosis or clarification of hepatocyte cytoplasm 1383 has been noted. 1384 Ultrastructural changes include dilation of the RER or smooth endoplasmic reticulum (SER) 1379, 1384, 1385 and the presence of megamitochondria in zones affected by steatosis. 1384 Despite the structural changes, survival in ASA patients and in those with argininosuccinate synthetase deficiency (ASS, also known as 'citrullinaemia type 1') is much better than in those with OTC and carbamyl phosphate synthetase (CPS) deficiencies. Nonspecific changes, including steatosis and cholestasis, have been observed in patients with CPS1 and ASS deficiency, respectively. 1383 Pathological studies of the liver in males with OTC deficiency have generally been normal. Occasional case reports suggest some mitochondrial and peroxisomal changes. 1386 Acquired abnormalities, more likely to be seen over time, are documented in females who have varying degrees of deficiency. At the light microscopic level, the mild changes include fat accumulation, inflammation, interface hepatitis and mild periportal fibrosis. 1386, 1387 Organelles in the hepatocytes usually are normal. Intracytoplasmic D-PAS+ inclusions were identified at autopsy of a neonate affected by a chromosomal microdeletion including the OTC gene. 1388 Of note, OTC deficiency manifested clinically in both recipient and donor after living-related transplantation. 1389 In the neonatal period, management of hyperammonaemia in the intensive care setting is often necessary. Long-term treatment consists of a combination of dietary restriction of protein, bypassing the defect by administering arginine and, on occasion, the use of ammonia scavengers. 1377, 1390 Liver transplantation is the definitive treatment for patients with severe variants, progressive liver disease, and for some patients whose disease manifestations have proved very difficult to control with conventional therapy. 1391, 1392 Citrullinaemia type 2 is caused by deficiency of citrin, a transporter involved in the urea cycle (Fig. 3.96 ). Clinical features depend on age. In the infant it may present clinically as a conjugated hyperbilirubinaemia disorder, also called 'neonatal intrahepatic cholestasis with citrin deficiency' (NICCD). In older children it may present as failure to thrive and dyslipidaemia (FTTDCD). In adults it causes hyperammonemia and neuropsychiatric symptoms. 36

Cystinosis is a rare autosomal recessive disease (1 in 100,000-200,000 live births). 1393 It is characterized by the accumulation of L-cystine crystals in lysosomes from a defective carrier-mediated transport system for cystine. The cystine accumulates in the eye, reticuloendothelial system, kidney and other internal organs. The gene responsible for cystinosis, located on chromosome 17p13, is called CTNS; it encodes a lysosomal membrane protein named cystinosin, whose cysteine transport activity is hydrogen ion (H + ) driven. 1394 Several mutations of CTNS are associated with cystinosis. 1395, 1396 Massive hepatomegaly has been reported in this disorder, with the incidence of detectable Cytogenetic studies on skin fibroblasts from a patient with HT1 and HCC have demonstrated chromosome breakages in 71% of cells. 1367 DNA ploidy abnormalities detected in three patients 1364 may be a useful marker for early malignant transformation. Ultrastructural studies have confirmed the presence of fat in hepatocytes and the cholestasis, as well as a number of nonspecific changes. 5, 1362 In the case studied by Jevtic et al., 1368 hepatocytes surrounded a central canaliculus forming tubules; the cells were joined by many desmosomes. The basal portions of the cells were not covered by microvilli or a space of Disse, and basement membrane-like material was present. Hepatocellular mitochondria can be greatly increased in number in HT1 and may show mild to moderate pleomorphism with randomly oriented cristae. Peroxisomes are frequently enlarged and may contain nucleoids or small lipid droplets. 5 In the pancreas, about 50% of HT1 patients have hyperplasia of the islets of Langerhans. 1369 Renal changes include interstitial oedema, tubular dilation with vacuolar and granular degeneration, loss of glomeruli and hypertrophy and hyperplasia of the juxtaglomerular complex. 1368 Mouse models of HT1 are used to study mechanism of injury and potential therapy. [1370] [1371] [1372] 

Defects in any of the enzymes of the urea cycle (Fig. 3.96 ) may lead to hyperammonaemia and encephalopathy at any age, 1373 although presentation is typically in the neonatal period. 1374, 1375 Such patients are normal at birth but by 24 hours of age develop irritability, poor feeding, vomiting, lethargy and respiratory distress. This is quickly followed by hypotonia, seizures, coma and respiratory arrest. If treatment is not instituted early, neurological function may be irreversibly compromised. 1376 Patients may be misdiagnosed as having respiratory distress syndrome, sepsis or intraventricular haemorrhage in the newborn period, or Reye-like syndrome when presentation is delayed. Thus the evaluation of an acutely ill newborn should include the possibility of a hyperammonaemia syndrome, more so in families who have already lost children to one of the more common urea Diagnosis in all forms is made by identification of crystals in polymorphonuclear leukocytes or by slit-lamp examination to identify corneal crystals. The latter procedure may give false-negative results in infants. Prenatal diagnosis is available by measurement of cystine in amniotic cells or chorionic villi. 1403, 1404 The diagnosis of cystinosis is established by visualization of the rectangular and hexagonal crystals in bone marrow aspirates, in conjunctival, rectal or renal biopsy tissue, or by ophthalmological examination. Phase-contrast and polarizing microscopy are especially useful in searching for the crystals in biopsy material. Because of the solubility of the crystals in water, all tissues should be fixed in alcohol, and aqueous stains should be avoided. 1405 The crystals are therefore best seen in unstained frozen sections or in sections made from alcohol-fixed tissue, and examined by phase or polarizing microscopy. Electron microscopy is a useful method of diagnosis if light microscopic examination of biopsy tissue fails to reveal the crystals. 1406 The diagnosis has been made before birth by light and electron microscopic examination of fetal tissues. 1407, 1408 Other methods of diagnosis include the determination of the amount of cystine in white blood cells or in cultured skin fibroblasts. A noninvasive method of diagnosis is based on infrared spectroscopy of hair. 1409 Fluorescence in situ hybridization (FISH) may provide a rapid detection of the 57-kb deletion in CTNS. 1410 The cystine crystals accumulate within lysosomes. 1411, 1412 The most severely affected organ is the kidney. 1405, 1413 Most of the cells containing the crystals are of reticuloendothelial origin. Crystals in many organs, such as the cornea, conjunctiva, bone marrow, spleen and liver, excite little or no reaction. In the liver, markedly hypertrophied Kupffer cells packed with cystine are located mainly in perivenular zones (Fig. 3.97 ). They have a brilliant silvery birefringence when viewed in polarized light (Fig. 3.98 ). The spaces made by the crystals in Kupffer cells can be seen on EM 1414, 1415 (Fig. 3.99) , and the crystals have a characteristic appearance on SEM (Fig. 3.100) .

Hepatic fibrosis in cystinosis was reported in one case. 1416 The patient, who died at the age of 24 years after multiple renal transplants, hepatomegaly as high as 42% in patients over 10 years of age. Most patients do not have significant liver dysfunction.

The most severe clinical form is nephrogenic (infantile) cystinosis. Patients are normal at birth, but symptoms of renal tubular dysfunction (Fanconi syndrome) develop by 6-12 months and progress to renal failure by 10 years of age. This tubular defect accounts for the presenting symptoms of polyuria, polydipsia and failure to thrive. Affected children are often hospitalized because of dehydration, acidosis resulting from potassium and bicarbonate urinary loss, vomiting and electrolyte imbalance. Renal phosphate loss causes the subsequent development of vitamin D-resistant rickets. Mental development is normal. 1393 Patients develop photophobia from accumulation of cystine crystals in the cornea and conjunctiva. The crystals can be detected by slit-lamp examination and are diagnostic of the disease. 1397 Hot weather accentuates symptoms because of a decreased ability to sweat. Crystal accumulation in the thyroid may lead to hypothyroidism. 1398 Dialysis or renal transplantation is usually undertaken between 6 and 12 years of age. Although cystinosis does not recur in the donor kidney, storage continues in other organs, resulting in blindness, corneal erosions, diabetes and neurological deterioration between 13 and 30 years of age. 1399 Medical therapy consists of fluid and electrolyte replacement for the renal tubular defects and carnitine to replace urinary losses. Cysteamine has been given both systemically and topically (in the eyes). Although significant toxicity is involved in using this drug, large-scale trials have shown that it delays loss of renal function, particularly in patients treated very early in their disease course. 1400 Drug-induced lupus and antiphospholipid syndromes have been ascribed to cysteamine therapy in a paediatric patient. 1401 There are adolescents and adults with more benign forms of cystinosis. A late form, not associated with symptoms before the fifth year of life, is compatible with survival well into the second decade. Clinical manifestations include retinal depigmentation, rickets, mild renal failure and accumulation of cystine crystals in the conjunctiva and bone marrow. In benign cystinosis, patients are asymptomatic and have a normal life expectancy, presumably because substantially less cystine accumulates within cells than in the had presented with portal hypertension. In addition to massive crystal accumulation, the liver showed extensive fibrosis without cirrhosis, and numerous hepatic stellate cells were seen in association with the fibrous tissue. The authors suggested that the stellate cells were activated by injured cystine-laden Kupffer cells but could not dismiss a possible role of the multiple renal transplants in the fibrosis. A patient with cystinosis treated with oral cysteamine developed venoocclusive disease that eventually required LT. 1417 The hepatectomy specimen disclosed many cystine crystals in the fibrous scars around terminal hepatic venules. 991 Ten years later, after a kidney transplant that failed because of disease recurrence, the patient presented with hepatic dysfunction, once again with veno-occlusive disease and crystal reaccumulation. 991 Additional cases of noncirrhotic portal hypertension have been ascribed to cystine accumulation in Kupffer cells. 1418, 1419 In two patients, long-term infantile nephropathic cystinosis was associated with a form of sclerosing cholangitis, which responded to therapy with UDCA. 1420 Liver biopsy specimens showed severe accumulation of cystine, predominantly localized in Kupffer cells, together with morphological features of sclerosing cholangitis. One patient showed changes compatible with sclerosing cholangitis on MRI.

Patients present with ectopia lentis, osteoporosis, genu valgum, pes cavus, kyphoscoliosis and progressive mental retardation. 1421 In addition, arterial thrombosis is common; however, most patients with homocystinuria and strokes have a concurrent factor V Leiden or glycosylation of the apolipoprotein, but rather some aspect of lipoprotein assembly or secretion.

Histological studies of the liver in several cases of abetalipoproteinaemia have shown variable steatosis. 1439, 1447, 1448 The patient studied by Partin et al. 1448 underwent liver biopsy before and after 2, 14 and 20 months of therapy with medium-chain triglycerides. Before treatment, hepatocytes contained large fat droplets that had ruptured to form perivenular 'fatty lakes' . Ultrastructurally, the Golgi apparatus was almost completely deficient in trans-Golgi vacuole formation. Endogenous triglyceride particles could not be found, and the circum-Golgi SER was absent. During the 14 months of dietary treatment, the fat droplets in hepatocytes became smaller and less numerous, but there was progression of initially mild hepatic fibrosis to a micronodular cirrhosis. Mallory-Denk bodies were identified in hepatocytes of the cirrhotic liver by EM. Clinically, the patient had substantial hepatomegaly and a persistent increase of serum aminotransferase activity. Whether the hepatic lesions were part of the natural course of the disease or related to therapy remains undetermined. The ultrastructural findings of one reported case included fatty change, a normal Golgi apparatus and ER, acanthocytes in sinusoids and phagocytosis of deformed erythrocytes by Kupffer cells 1447 (Fig. 3.102 ). An ultrastructural study of another case by Collins et al. 1449 demonstrated striking changes in hepatocellular peroxisomes. They included pleomorphism and a broadened range of size, often larger than normal with marginal bars in some. Whether the changes were those of a peroxisomal disorder or a reflection of the disturbed lipid metabolism remains uncertain.

Familial hypobetalipoproteinaemia (FHBL) is characterized by reduced serum levels of β-lipoprotein and apo B-containing lipoprotein. 1450, 1451 Taruji et al. 1452 reported a mutation of the apo B gene leading to synthesis of a truncated form of apo B (apo B-38.95). Many other truncations of apo B have been identified and are reviewed by Kane mutation. 1422 Hepatomegaly with normal liver enzymes is common. Screening is by detection of high levels of methionine and homocystine in urine. Diagnosis includes evaluation for other causes of homocystinuria, including vitamin B 12 or an abnormality in its processing. Cystathionine β-synthase (CBS) can be measured in cultured fibroblasts. 1423 Homocystinuria has an estimated worldwide frequency of 1 in 344,000, but the frequency is higher in Ireland (1 in 65,000) . 1424 The cystathionase gene is found on chromosome 21q-22.3 1425 ; it has been cloned. 1426 Several different defects have been found to be associated with homocystinuria. 1427, 1428 Prenatal diagnosis can be performed. Treatment is with supplementation with folic acid and betaine. 1429, 1430 Light microscopic studies of the liver in homocystinuria have shown steatosis, more prominent in the perivenular regions. [1431] [1432] [1433] Mild to moderate portal fibrosis and thickened arterioles with intimal hyperplasia or fibrosis have been observed in some patients. 1432 Ultrastructural studies have demonstrated mitochondria with unusual shapes, increased SER and numerous pericanalicular lysosomes. 1434, 1435 Hyperhomocystinaemia in liver of CBS-deficient mice has been shown to promote oxidative stress, leading to fibrosis and steatosis. 1436 

The disease was first described by Bassen and Kornzweig. 1437 Patients with abetalipoproteinaemia have malabsorption of fat, acanthocytosis, retinitis pigmentosa and ataxic neuropathic disease. Symptoms usually begin in infancy with steatorrhoea and failure to thrive. Acanthocytes are evident by 12 months of age. Neurological abnormalities causing an unsteady gait develop between 2 and 17 years. Degenerative changes affect the posterior and lateral columns of the spinal cord, spinocerebellar pathways and peripheral nerves. 1437, 1438 The diagnosis is suspected on the basis of the clinical features, a serum cholesterol level <1.3 mmol/L (50 mg/dL) and an extremely low serum triglyceride level. Patients tend to be lean. 1439 The diagnosis is confirmed by determination of the β-lipoprotein concentration using lipoprotein electrophoresis, ultracentrifugation or immunochemical methods. Small bowel biopsies reveal fat droplets in the epithelium (Fig. 3.101) .

The inheritance is autosomal recessive. The defective gene (MTTP) codes for the microsomal triglyceride transfer protein. This protein is essential for the transport of triglyceride, cholesteryl ester and phospholipid from phospholipid surfaces. It is synthesized as a heterodimer; in abetalipoproteinaemia the large subunit of the protein is absent. 1440 Mutations in MTTP were demonstrated in two patients with abetalipoproteinaemia. 1441, 1442 Treatment consists of a low-fat diet and replacement of vitamins A and E. 1443 Late manifestations include essential fatty acid deficiency and peripheral vascular disease. Supplementation with medium-chain triglycerides for calories was a common recommendation in the past; this therapy has been implicated as the cause of cirrhosis in some patients and is no longer recommended. 1444 Liver transplantation cures the liver disease and corrects the serum lipid profile, but it does not cure the steatorrhoea, as the mutated MTTP gene is also expressed in the intestine. 1445 LT in a 20-year-old woman with untreated abetalipoproteinaemia who had developed cirrhosis 1446 was followed by a dramatic rise in serum cholesterol and triglycerides, as well as an increase in apolipoprotein B from barely measurable (<1 mg/dL to 76 mg/dL). Study of apo B and apo B mRNA in cultured liver and intestinal cells suggested that the defect in abetalipoproteinemia did not involve the apolipoprotein B gene or the synthesis Patients with classic familial HDL deficiency present with a striking tonsillar enlargement with orange discolouration, lymphadenopathy, hepatosplenomegaly and peripheral neuropathy. Thrombocytopenia, corneal opacities and xanthomas are less common. Some patients have hyperbilirubinaemia. 1471, 1472 Others present an atypical clinical picture with hepatosplenomegaly, low serum cholesterol and HDL cholesterol concentrations, early-onset coronary artery disease and corneal opacities, but no orange tonsils; the hepatosplenomegaly and corneal opacities may also be absent. 1473 The pathological aspects of Tangier disease have been comprehensively discussed. 1470, 1472 Deposition of cholesterol esters is widespread, with involvement of tonsillar and adenoidal tissue, liver, spleen, lymph nodes, bone marrow, thymus, intestinal mucosa, skin and cornea. The foam cells contain birefringent, needle-shaped cholesterol crystals, are sudanophilic and PAS negative, and stain positively with the Schultz modification of the Lieberman-Burchard reaction. Involvement of the liver by clusters of cholesterol-containing cells has been noted by several investigators. 1470, 1474, 1475 The differential diagnosis from other cholesterol storage diseases is discussed by Bale et al. 1470 

Patients with familial hypercholesterolaemia have elevated serum cholesterol, which is deposited in tendons and skin (xanthoma), cornea (arcus senilis) and arteries (atheroma). The severity of disease is related to the gene dosage; this is an autosomal dominant trait with homozygotes affected more severely than heterozygotes. 1476 Heterozygotes have a twofold elevation of serum cholesterol from birth, with onset of tendon xanthomas and coronary atherosclerosis after age 20 years. Homozygotes have severe hypercholesterolaemia with complications developing in the first decade of life; xanthomas may be present at birth. Coronary heart disease begins in childhood and frequently leads to death before age 20 years. Most patients have mutations in the gene for low-density lipoprotein receptor (LDLR), although two other sets of mutations contribute to the phenotype. However, similar phenotypes are described in association with mutations of APOB and PCSK9. 1477 Patients have elevated concentrations of low-density lipoprotein, the major cholesterol transport lipoprotein in plasma. The incidence of heterozygotes is about 1 in 500 and of homozygotes about 1 per 1 million live births. The defect is an abnormal LDLR gene. 1478 Several different mutations have been described. 1479 The gene is on chromosome 19p. 1480, 1481 Therapy is directed at lowering plasma cholesterol to control complications. 1482, 1483 Homozygotes have been managed by combined liver-heart transplantation. 1484 Reported pathological findings in homozygous familial hypercholesterolaemia have been reviewed by Buja et al. 1485 In addition to atherosclerosis of the aorta and coronary vessels, there is neutral lipid accumulation in extravascular sites that include the skin, tendons, spleen, thymus and other organs. In the liver, there is accumulation of lipid in hepatocytes and Kupffer cells. Ultrastructurally, accumulation of both neutral lipid and cholesterol has been observed in hepatocytes. 5 

Wolman disease and cholesteryl ester storage disease (also called 'cholesterol' ester storage disease in older literature) are two disorders caused, respectively, by absent or by reduced (3-8%) activity of the enzyme lysosomal acid lipase. 1486, 1487 The enzyme is essential for the intralysosomal metabolism of cholesterol esters and triglycerides, namely, their uptake by receptor-mediated endocytosis into lipoprotein and Havel. 1450 Sporadic cases of FHBL with an apparently recessive transmission may be caused by de novo mutations of apo B gene. 1453 Mutations in the gene encoding for the angiopoietin-like protein 3 (ANGPTL3) are also a cause of some forms of FHBL. [1454] [1455] [1456] Welty 1456 recently reviewed the different forms of FHBL.

In homozygous hypobetalipoproteinaemia, apo B and low-density lipoprotein (LDL) cholesterol levels are very low or undetectable. 1450, 1451 When β-lipoproteins are absent, the clinical phenotype is indistinguishable from that of abetalipoproteinaemia with fat malabsorption, acanthocytosis, retinitis pigmentosa and neuromuscular degeneration. Liver biopsies also reveal marked steatosis. 1457, 1458 Perisinusoidal fibrosis in one case was attributed to hypervitaminosis A. 1457 A mouse model should provide new insights into apo B metabolism. 1458 Treatment is similar to that of abetalipoproteinaemia: restriction of dietary fat and intensive vitamin E supplementation.

Patients with heterozygous hypobetalipoproteinaemia are usually asymptomatic and have low plasma levels of total cholesterol (45-150 mg/dL) and low to normal levels of triglycerides (11-140 mg/ dL). 1451 Mild to moderate increases in the levels of the serum aminotransferases have been reported. 1452 Ultrasound examination discloses a hyperechoic liver. Liver biopsies have revealed mild to moderate steatosis without necroinflammatory changes or fibrosis. 1452, [1459] [1460] [1461] [1462] [1463] The long-term prognosis is excellent; patients may actually be protected from developing coronary atherosclerotic disease. 1451

This rare autosomal recessive disease is caused by a mutation in the ATP-binding cassette transporter 1 (ABCA1) gene 1464-1466 on chromosome 9q31. 1467 The ATP-binding cassette transporter 1 protein is also called the 'cholesterol efflux regulatory protein' . 1465, 1468 In the absence of this regulatory protein, apolipoprotein-mediated cholesterol removal from cells is blocked, leading to the characteristic accumulation of cholesterol esters in reticuloendothelial cells 1469 and low or absent plasma high-density lipoprotein (HDL) and low plasma cholesterol levels. 1470 the years. 1512 In another patient, successful long-term engraftment was followed by continued normalization of acid lipase enzyme activity in peripheral leukocytes, weight gain, and normal cholesterol, triglyceride and liver enzyme levels at 4 years of age. 1513 Previous attempts had been unsuccessful, presumably because of advanced liver or systemic disease at BMT.

In CESD, a favourable clinical response with a stage I American Heart Association diet and large doses of cholestyramine has been reported from the University of Minnesota. Medical therapy with an HMG-CoA-reductase inhibitor has had reasonable success, although its effect on lipid levels and liver tests has been variable. 1498, [1514] [1515] [1516] [1517] One patient had a favourable response in terms of cholesterolaemia to lovastatin plus ezetimibe, 1518 an inhibitor of Niemann-Pick C1-like 1 (NPC1L1) protein. Enzyme replacement therapy is being developed. 1519 Success with liver transplantation has been reported. 1520, 1521 End-stage renal disease has developed in one LT patient. 1522 Rat [1523] [1524] [1525] and mouse 1526 models are available to study experimental therapies of acid lipase deficiency. In vitro correction of fibroblasts in the two human diseases was successful. [1526] [1527] [1528] [1529] The adrenal glands in Wolman disease are grossly enlarged, hard and bright yellow. They cut with a gritty sensation and have a yellow cortex and an inner calcified zone. The surface of the small intestine, particularly the duodenum and ileum, has a yellow velvety appearance.

In Wolman disease, all affected organs, particularly the liver, spleen, adrenals, haemopoietic system and the intestines, are infiltrated by numerous foamy macrophages that contain cholesterol and/or cholesterol esters. 1490 Stains for lipid (Oil Red O, Sudan Black) are positive, as is the Schultz modification of the Lieberman-Burchard reaction for cholesterol [1530] [1531] [1532] [1533] ; these stains must be performed on frozen sections, either of fresh or formalin-fixed tissue. Frozen sections examined by polarizing microscopy reveal numerous anisotropic acicular crystals in the foamy histiocytes. In the liver, cholesterol and cholesterol ester are mainly stored in Kupffer cells and portal macrophages, while hepatocytes contain increased neutral lipid. Reticuloendothelial cells may also contain free fatty acids. 1534 There may be marked pericellular fibrosis and varying degrees of periportal cholangiolar proliferation and fibrosis. 1534 Ultrastructurally, the enlarged Kupffer cells contain peripheral vacuoles, sometimes within lysosomes, and large central crystal clefts of cholesterol ester. 1535 Lake and Patrick 1534 observed that the crystals are membrane bound. Hepatocytes contain many lipid droplets but only occasional crystal clefts. 1534 It has been suggested that the cholesterol esters are discharged from the hepatic parenchymal cells in an insoluble form and then are taken up by the Kupffer cells, where crystallization occurs. 1535 The liver in CESD is enlarged, yellow-orange and greasy (Fig. 3.103) . The light microscopic and ultrastructural changes in the liver of patients with CESD are similar to those of Wolman disease. 1495, 1501, 1514 A highly characteristic feature of CESD is the presence of greatly hypertrophied Kupffer cells and portal macrophages with a foamy, tan-coloured cytoplasm that stains strongly with PAS ( Fig. 3.104 A and B) . 1514 The birefringent cholesterol crystals are shown in Fig. 3 .104 C. Periportal fibrosis of varied degree is present in most cases. 1497, 1501, 1514 A recent literature review by Bernstein et al. 1506 has shown advanced-stage fibrosis in about one-third of patients. Immunohistochemistry for lysosomal proteins, including cathepsin D, lysosomal-associated membrane protein 1 (LAMP1), LAMP2 and lysosomal integral membrane protein 2 (LIMP2), has been proposed for the diagnosis of CESD on paraffin sections. 1536 Ultrastructurally, triglyceride droplets are noted in abundance in hepatic and reticuloendothelial cells; most are surrounded by a single membrane. Many of the lysosomal lipid droplets have a 'moth-eaten' appearance caused by the inclusion of cholesterol within them (Fig. 3.105) . 1514 Cholesterol crystals are also seen lying free in the cytoplasm, as particles. 1486 The enzyme is trafficked to the lysosome by the mannose-6-phosphate receptor systems. 1487, 1488 The gene encoding the lipase is LIPA on chromosome 10q23.31 and contains 10 exons spread over 36 kb. 1489 Wolman disease was first described in 1956. 1490 Patients may present with hydrops fetalis or congenital ascites 1491 ; clinical presentation with conjugated hyperbilirubinaemia is uncommon. The usual presentation is failure to thrive with vomiting, frequently with severe diarrhoea accompanied by steatorrhoea. Physical findings include severe malnutrition, hepatosplenomegaly, ascites, pallor and mild lymphadenopathy. 1492 Neurological development is abnormal. Radiological studies reveal large adrenals with calcification, a critical finding for clinical diagnosis. Examination of the peripheral blood smear reveals vacuolated lymphocytes, while bone marrow examination discloses foam cells which stain positively for cholesterol and neutral fat or triglyceride. Serum lipid levels are usually low or normal, but in rare instances they are elevated. Adrenal responses become depressed with time. Death usually occurs in the first year of life despite aggressive nutritional support. 1492 The relatively milder form of the disease, cholesteryl ester storage disease (CESD), presents at any age with hepatomegaly, usually caused by lipid retention in hepatocytes and Kupffer cells, and variable splenomegaly caused by portal hypertension. 1486, [1493] [1494] [1495] In children, diarrhoea may occur because of lipid retention in enterocytes; resulting malnutrition may lead to short stature. 1496 Recurrent abdominal pain may be a feature. The typical natural history of CESD includes premature atherosclerosis [1497] [1498] [1499] and progressive liver disease resulting in cirrhosis. There have been reports of pulmonary vascular obstruction 1500 and mesenteric lipodystrophy. 1501 An asymptomatic 51-year-old man with CESD and accelerated atherosclerosis developed cholangiocarcinoma and died of liver failure as a result of extensive tumour infiltration. 1502 Cholangiocarcinoma had similarly developed in a 51-year-old woman with CESD (unpublished observation by authors). Laboratory abnormalities in CESD include elevated serum levels of aminotransferases cholesterol and its esters, LDL, triglycerides and bile acids. Sea-blue histiocytes have been noted in the liver, small bowel and bone marrow. 1503 Jaundice suggests the development of cirrhosis, which may be followed by liver failure. Prenatal diagnosis is available. 1491, 1504 Wolman disease can result from a number of mutations in the lysosomal acid lipase gene LIPA, all resulting in absence of enzyme activity. 1505 CESD appears to have a somewhat different array of mutations associated with it. 1506 CESD seems distinct from Wolman in that at least one mutant allele has the potential to produce enough residual enzymatic function to ameliorate the phenotype. 1507 The most common mutation in CESD is caused by aberrant splicing of an allele due to a point mutation, resulting in the production of a shortened lysosomal acid lipase mRNA lacking 72 nucleotides, and in the synthesis of an enzyme missing 24 amino acids. 1508 Compound heterozygosity for a mutation causing Wolman disease is common among CESD patients. 1509 CESD is probably underdiagnosed, and the incidence, estimated at 1 in 40,000, is not really known. 1506 Since these patients typically present with a clinical picture of liver enlargement and dyslipidaemia, misdiagnosis as nonalcoholic fatty liver disease (NAFLD), including normal-body-weight NAFLD, is possible. Liver biopsy showing typical findings of CESD may contribute to sorting out these two divergent diagnoses.

Therapy in Wolman disease, nutritional or otherwise, is difficult. Wolman 1510 suggests avoidance of lipid esters despite the presence of an essential fatty acid deficiency. The role of antioxidant therapy remains unclear, although vitamin E has been routinely used. Bone marrow transplantation corrects the enzyme defect. 1511 BMT performed early in the disease course preserved the life of one patient with Wolman disease; growth and mental development improved over demonstrated in a case of Wolman disease (Fig. 3.106) . A recent study of both liver and intestinal biopsy specimens in Wolman and CESD diseases is re-emphasizing the diagnostic role of morphological findings. 1537

Gangliosides are glycolipids found mainly in the neuronal membrane. Gangliosidoses are caused by defects in ganglioside catabolic pathways and abnormal accumulation of gangliosides (GM1, GM2) resulting in progressive neurodegenerative disorders. The degree of accumulation of gangliosides in visceral organs, including the liver, is variable and depends on the disease subtype. 1538 Disorders related to defect of ganglioside synthesis are very rare. 1539

Three subtypes of GM1 gangliosidosis are recognized, depending on age at clinical presentation. and upper lip and downy hirsutism of the forehead and neck. The gums are hypertrophied, and there is mild to moderate macroglossia. The corneas are clear. Cherry-red spots are present in the macula in half the patients, 1540, 1541 and dermal melanosis may be prominent. 1542 Gangliosides accumulate in neurons, liver, spleen and in histiocytes in other tissues, as well as in the epithelial cells of the kidney. 1543 This is a result of a deficiency in all three isoenzymes of lysosomal β-galactosidase-1 (A, B and C), located on chromosome 3p21. 1544 The mutations in the infantile form of GM1 gangliosidosis interfere with phosphorylation of precursor β-galactosidase, resulting in its secretion instead of its further processing in the lysosomes. 1545 Foam cells are seen in bone marrow preparations. Lymphocytes are vacuolated. Mild radiological abnormalities consist of inferior beaking of the lumbar vertebrae and proximal pointing of the metacarpal bones. Neurons are ballooned and contain cytoplasmic membranous inclusions similar to those of Tay-Sachs disease. Lipidladen histiocytes are found throughout the reticuloendothelial system. Renal glomerular epithelial cells, hepatocytes and Kupffer cells are finely vacuolated. Ultrastructurally, the vacuoles in affected cells in GM1 gangliosidosis are empty or contain fibrillar or granular material. 1543 Kupffer cells may also contain membrane-bound fibrillary structures 1546 (Fig. 3.107 ). Most affected systemic cells, including hepatocytes and phagocytic cells, bind WGA lectin, and to a lesser extent other lectins such as ConA, S-WGA, DSA and BS-1. 1543 Enzyme analysis indicates almost complete absence of β-galactosidase A, B and C in skin fibroblasts and leukocytes. Membrane-bound inclusions are also seen in cholangiocytes. 1547 

Type II, the juvenile form of GM1 gangliosidosis, presents at about 1 year of age. Clinical findings are primarily neurological and include seizures, spasticity, ataxia and mental retardation. Radiological changes are minimal. Facial abnormalities, visceromegaly and macular cherryred spots are absent. Death occurs between 3 and 8 years of age. 1548 This disease is also caused by a mutation in the β-galactosidase-1 gene, but only isoenzymes B and C are deficient. 1541 Successful bone marrow engraftment in a presymptomatic patient with type II GM1 normalized white cell β-galactosidase levels, but did not influence

Type I, the infantile form of GM1 gangliosidosis, manifests during the first 6 months of life. Patients present with progressive psychomotor retardation, seizures, hepatosplenomegaly, oedema of the extremities and failure to thrive. The appetite is poor and sucking is weak, in part because of the infant's hypotonia. By the first year of life, patients are blind, deaf and in decerebrate rigidity. Death, usually from bronchopneumonia, occurs within 2 years of age.

Facial abnormalities include frontal bossing, a depressed nasal bridge, large low-set ears, an increased distance between the nose Kupffer cells and hepatocytes. 1550 Two canine models of GM1 gangliosidosis have been described. 1551 

Type III, the adult form of GM1 gangliosidosis, is much less severe than the other two forms and is associated with little or no visceromegaly. Mutations in the β-galactosidase-1 gene are described, but the cause of the phenotypic differences from types I and II is as yet undetermined. 1552, 1553 

The GM2 gangliosidoses have primarily neurological manifestations. These disorders result from defects in the lysosomal enzyme hexosaminidase, leading to the accumulation of glycolipids, particularly GM2 gangliosidase. Hexosaminidase consists of two major isoenzymes, hexosaminidase A, composed of an αand a β-subunit, and hexosaminidase B, composed of two β-subunits. The α-subunit has been localized to chromosome 15 and the β-subunit to chromosome 5. A lysosomal enzyme, GM2 activator protein, also localized to chromosome 5, complexes with the lipid substrate for presentation to hexosaminidase for cleavage hydrolysis. Inheritance of all the variants is autosomal recessive. Prenatal diagnosis is available for all types.

These patients present at 3-6 months of age with motor weakness, apathy and feeding problems. The most common initial sign is the startle response to sound, characterized by upper-and lower-extremity extension, often associated with a myoclonic jerk. Progressive weakness and hypotonia develop, with definite neurological regression by 10-12 months of age. The mental and motor deterioration continue, with death from bronchopneumonia, usually by 4 years of age. The typical, but not specific, cherry-red spot is observed in the macula during the early stages of the disease. Degeneration of the optic nerve is common and results in blindness. Megalocephaly may develop during the second year of life.

Tay-Sachs disease has a carrier frequency of 1 in 30 for Ashkenazi Jews and 1 in 300 for non-Jewish persons. 1554 The diagnosis is based long-term clinical outcome. 1549 In common with type I, there is neuronal storage and foamy histiocytes are present in various organs (Fig. 3.108) . Hepatocytes are only slightly vacuolated, and Kupffer cells stain intensely with the PAS reagent (Fig. 3.109) . Ultrastructurally, the Kupffer cells contain a distinctive granulofibrillar material 1546 (Fig. 3.110) , or membrane-bound inclusions may be seen in both deposits to a diameter equal to that of the liver cell nucleus 1562,1565 (Fig. 3.111 ). The extent, size and variation of the membranous deposits within lysosomes are characteristic but not pathognomonic of Sandhoff disease. Kupffer cells are also involved and stain positively with the PAS reagent. Periportal fibrosis has been reported. 1566 The acinar cells of the pancreas are also deeply involved. EM reveals membranous and 'zebra body' hybrids.

Fabry disease is an X-linked disorder of glycosphingolipid metabolism. Hemizygous males are variably affected, whereas heterozygous females are often asymptomatic but may develop significant clinical features with advancing age. 1567, 1568 Fabry disease is caused by a defect in the lysosomal hydrolase α-galactosidase A (α-GLA), 1569 which results in accumulation of globotriaosylceramide in tissue lysosomes throughout the body. Complete absence or reduced activity of α-GLA results in more severe or milder forms. 1570 The gene localizes to chromosome Xq22. 1571 The α-galactosidase gene has been cloned, and several mutations are associated with Fabry disease. 1572 The prevalence of Fabry disease is 1 in 40,000, although it may occur more frequently in geographically isolated communities. Clinical disease usually begins during childhood or adolescence with pain and paraesthesias in the extremities secondary to vascular substrate accumulation that affects peripheral nerves. Nausea, vomiting and diarrhoea are common. 1573 Hypohidrosis results from vascular lesions in the autonomic nervous system. Skin signs of the disease are angiokeratomas. 1574, 1575 Renal lipid deposition leads to proteinuria, isosthenuria and gradual deterioration of renal function. Hypertension, left ventricular hypertrophy, myocardial ischaemia or infarction and cerebrovascular disease may develop. Some patients have lymphoedema and mild anaemia. Death is usually from renal or cardiovascular complications. Atypical variants affecting predominantly the heart 1576 or the kidneys 1577,1578 are well recognized. The diagnosis may be suspected by the combined findings of corneal dystrophy, lipid-laden and PAS-positive macrophages in the bone marrow, and birefringent Maltese crosses in the urinary sediment. Measurement of α-GLA enzyme activity in blood leukocytes is confirmatory. Examination of urinary sediment can be used as a noninvasive method for early diagnosis and monitoring the effect of therapy. 1579, 1580 on the absence or near-absence of hexosaminidase A in serum or fibroblast cell cultures. The deficiency allows massive accumulation of GM2 ganglioside and asialo-GM2 in enlarged cerebral neurons, retinal ganglion cells and autonomic ganglia. 1554 EM shows concentrically laminated inclusions or membranous cytoplasmic bodies in affected neurons, and somewhat more pleomorphic inclusions in the glia. Although hepatocytes appear normal by light microscopy, they may contain similar bodies by EM examination. 1550 More than 70 mutations in the hexosaminidase A gene (located on chromosome 15) have been described. 1555 Prenatal diagnosis is performed in most centres.

This disorder presents with motor ataxia between 2 and 6 years of age, followed by progressive dementia. Optic atrophy and retinitis pigmentosa occur late in the disease course without cherry-red spots. Decerebrate rigidity is present by 10-12 years of age, and death from infection occurs between 10 and 15 years of age. Patients have a form of hexosaminidase A which cannot be activated. 1556 Hexosaminidase β-subunit deficiency or defect (Sandhoff disease; infantile Sandhoff disease) Previously, infants with Sandhoff disease were misdiagnosed as having Tay-Sachs disease because the clinical features and course are similar.

In the first few months of life, subtle signs of delayed motor development are noted. Cardiovascular symptoms may be observed early in the course of the disease along with minimal hepatosplenomegaly. During the second half of the first year, little if any progress is made in motor or mental development. Cherry-red spots and early optic atrophy are evident by ophthalmoscopic examination. By 12 months of age the patients no longer use pincer grasp; they develop bilateral pyramidal tract abnormalities, including increased deep tendon reflexes, spasticity and positive Hoffman and Babinski signs. In addition, there is regression in sitting, smiling and laughing appropriately. The psychomotor deterioration is progressive, with death resulting from aspiration pneumonia, usually between 22 and 36 months of age. 1557 A juvenile form of this disease exists, but it lacks hepatic involvement. 1558 There are mild skeletal abnormalities in Sandhoff disease, and electrocardiogram (ECG) changes range from mild left ventricular hypertrophy to severe abnormalities compatible with endocardial fibroelastosis. Vacuolated lymphocytes may be present in the peripheral blood. Greatly increased levels of globoside in the urinary sediment and plasma differentiate Sandhoff from Tay-Sachs disease.

Sandhoff disease results from the deficient activity of both hexosaminidase A and B. 1559 Decreased activities of both enzymes are found in biopsy specimens, peripheral leukocytes, platelets, cerebrospinal fluid, cultured skin fibroblasts and plasma. There is neural and visceral deposition of GM2 ganglioside, its asialo derivative, and tetrahexosyl ceramide in affected infants. 1557 The gene is found on chromosome 5q11. 1560 Only the hexosaminidase B gene may be defective in the disease; the requirement for shared subunits between A and B may result in the complete absence of hexosaminidase activity. 1561 Heterozygosity in parents is more reliably established by examination of tissue specimens than of serum. 1562 Sandhoff disease shows no ethnic predilection. 1563 The diagnosis can be made in utero by demonstration of deficient hexosaminidase levels in amniotic fluid. 1564 Patients with Sandhoff disease were previously missed at autopsy because routine formalin fixation obscured the visceral lipid accumulation. However, 1-mm sections of Epon-embedded material reveal the lipid deposition when studied by light microscopy. Lysosomal lipid accumulation in the liver progresses with age; the lysosomes are twice the normal size at 3 months, and by 1 year, many are distended by membranous lipid lectin binding is more specific than any other histochemical method. Lectin histochemistry with enzyme digestion enabled Kanda et al. 1585 to detect α-galactosyl, β-galactosyl and glucosyl sugar residues in the lysosomal deposits at the ultrastructural level in Fabry disease. This technique has potential for the investigation of other glycolipid and glycoprotein storage diseases. The stored material is demonstrable by light and electron microscopy using a mouse monoclonal anti-GL-3 antibody. 1586

Metachromatic leucodystrophy (MLD) is a lysosomal lipid storage disorder caused by mutations in the gene for arylsulphatase A (ASA), an enzyme involved in the degradation of the sphingolipid Phenytoin or carbamazepine may be administered for the symptomatic relief of the neurological problems. Kidney failure may necessitate renal transplantation. 1562 Two recombinant enzymes, agalsidase-β and agalsidase-α, have been used clinically with significant long-term benefit, particularly when started before permanent tissue damage has occurred. 1573, 1576, 1580, 1581 The substance that accumulates in the blood vessels, myocardium, kidney, liver, spleen and other organs is globotriaosylceramide (GL-3). Pathological findings in Fabry disease have been reviewed in detail. 1582 In the liver there is accumulation of GL-3 and cholesterol in Kupffer cells, portal macrophages and the endothelial cells of blood vessels. The cells are swollen and light tan in H&E preparations (Fig. 3.112) . They contain birefringent crystals in frozen sections, and the Schultz modification of the Lieberman-Burchard reaction is moderately positive. The stored material is intensely PAS positive and resists diastase digestion (Fig. 3.113) . Ultrastructurally, the stored material in Fabry disease consists of concentrically laminated lysosomal inclusions with a periodicity of 5-6 nm (Figs 3.114 and 3.115). Lipid accumulations consisting of amorphous material as well as stacks of lamellar leaflets may be seen in hepatocytes, Kupffer cells and portal tract macrophages. 1583 Two peroxidase-labelled lectins are found to be strongly reactive with the storage material of Fabry disease. 1584 This observation has diagnostic implications because 3-O-sulphogalactosylceramide (sulphatide). Sphingolipid storage results in progressive demyelination and severe neurological symptoms. The ASA gene, localized to chromosome 22q13, has been cloned, 1587 and multiple mutations which cause MLD have been described. 1588 Clinically, MLD is a group of disorders, differentiated by the time of onset of the symptoms. 1589 Symptoms are worse the younger the presentation. Late infantile MLD presents between 1 and 2 years of age with developmental delay. Signs of neurological deterioration include progressive mental retardation, optic atrophy, loss of speech, hypertonic quadriplegia, ataxia and absent tendon reflexes. Pain in the extremities and unexplained fever are common. In the terminal stages of the disease the patient loses sensory contact with the surroundings. Death results from infection or hyperpyrexia.

Early and late juvenile MLD present between 4 and 6 and 6 and 12 years, respectively. The neurological progression previously described proceeds at a slower pace. 1590 The adult form of MLD presents after age 16 years (average, 29 years). Mean duration of the disease is 15 years. 1591 Most patients present with psychological problems, dementia or paralysis. Progressive neurological abnormalities develop during the course of the disease and include incoordination, ataxia, spastic paresis, visual disorders, tremors, skeletal muscle rigidity, athetotic movements and spastic dysuria. Hydrocephalus has been reported. Death occurs from cachexia or pneumonia. 1591 BMT has produced minor, if any clinical improvement, in selected patients. [1592] [1593] [1594] Diagnosis is made by detection of sulphatide in peripheral nerves and urinary sediment. Deficiency of ASA can be demonstrated in leukocytes, cultured skin fibroblasts and amniotic cells. ASA deficiency was used as the basis for prenatal diagnosis, but the presence of a pseudodeficiency allele of ASA made diagnosis difficult by this method. 1595, 1596 Histologically, sulphatide accumulation has been demonstrated in the CNS, liver, gallbladder, pancreas, kidneys, adrenals and other organs. [1597] [1598] [1599] The gallbladder is small and fibrotic and may show multiple polyps or papillomas and contain calculi. 1598, [1600] [1601] [1602] [1603] [1604] [1605] [1606] Microscopic examination reveals large, foamy macrophages in the gallbladder tunica propria (Fig. 3.116 ) that stain positively with cresyl violet, toluidine blue, PAS reagent and Hirsch-Pfeiffer stain 1607 (Fig. 3.117) . In frozen section these contain sudanophilic material hepatosplenomegaly progressing to death by 6 months of age. 1612 Type V presents with psychomotor deterioration before 3 years of age with sparing of the viscera; findings include subcutaneous nodules, joint disease and macular cherry-red spots. 1613 No therapy is available.

The diagnosis depends on demonstration of deficiency of acid ceramidase (<8% of normal) in cultured skin fibroblasts, WBCs, or amniocytes. 1614 Excess gangliosides are found in the granulomatous lesions and neurons of the cerebral cortex, whereas lymph nodes, liver, kidney and lung (as well as the subcutaneous nodules) contain very high levels of free ceramide. 1611 Histological studies have shown granulomatous infiltrates in the subcutaneous nodules, periarticular and synovial tissue, lymph nodes, and to a lesser extent in the lungs, liver, spleen and other viscera. 1611, 1615 These consist of lymphocytes, histiocytes and foam cells that contain PAS-positive material. Necrosis and dense fibrosis may develop in older lesions. 1615 In one case, a liver biopsy revealed numerous atypical histiocytes with cytoplasmic vacuolization which filled the sinusoids and distorted the liver architecture. Postmortem examination revealed massive histiocytic infiltration of the liver, spleen, lymph nodes, thymus and lungs. 1616 The granulomatous lesions of Farber disease have been reproduced experimentally by injection of ceramide from a patient and by commercial ceramide. 1614 In patients, neurons of the central and autonomic nervous systems are distended with PAS-positive cytoplasmic material, 1617 considered to be a mucopolysaccharidepolypeptide complex to which lipid was later added. 1615 Ultrastructurally, the histiocytes contain rectilinear and curvilinear structures in the cytoplasm, inclusions that are sometimes referred to as 'Farber bodies' . [1618] [1619] [1620] Cross sections strongly suggest a tubular disposition of the stored material, the diameter being 20-23 nm. The Farber bodies have also been reproduced experimentally in mice by injection of ceramides and related sphingolipids. 1621 Hepatocytic dense bodies and clear vacuoles have been described on EM. 1620 The former were generally round, osmiophilic deposits that surrounded that is anisotropic and can also be stained with the Schultz modification of the Lieberman-Burchard reaction due to simultaneous accumulation of cholesterol. 1602 Metachromatic granules can be demonstrated in epithelial cells of the gallbladder and to a lesser extent in those of the intrahepatic bile ducts. 1598 In the liver, metachromatic granules may be seen in some portal macrophages and less often in Kupffer cells and hepatocytes 1599 (Fig. 3.118) . Ultrastructurally, prismatic lysosomes are found in epithelial cells of the gallbladder and are composed of periodic leaflets which appear tubular in cross section. 5

This disease is caused by a deficit in acid ceramidase (AC), the lysosomal enzyme that degrades ceramide into sphingosine and fatty acid. The mode of inheritance is autosomal recessive. The acid ceramidase gene has been mapped to the chromosomal region 8p21.3-p22, and mutations responsible for Farber disease have been described. [1608] [1609] [1610] In the most common and classic form of the disease, type I, patients present between 2 weeks and 4 months of age. A triad of symptoms, including joint disease, erythematous subcutaneous nodules (particularly at the wrists) and a hoarse cry, has been described. Aphonia may result from swelling and granuloma formation in the epiglottis and larynx. Other symptoms include poor feeding and difficulty breathing, which result in poor weight gain, fever and pneumonia. 1611 Patients with severe involvement have generalized lymphadenopathy, an enlarged tongue, cardiac valve granulomas and hepatomegaly. Nerve involvement is common particularly in the lower motor neurons, and cerebrospinal fluid protein may be elevated.

Milder forms of the disease, types II and III, have been described with no significant liver, lung or brain involvement. Type IV ceramidase deficiency resembles a histiocytic disorder, with neonatal 

Type II Gaucher disease presents during the first 3 months of life with hepatosplenomegaly, cough and neurological signs. Patients may present with hydrops fetalis, ichthyosis or collodion skin. [1640] [1641] [1642] [1643] [1644] Rarely, the presentation is neonatal hepatitis syndrome with conjugated hyperbilirubinaemia. 1645 Late manifestations include laryngeal stridor and pulmonary infiltrates. Physical findings include hepatosplenomegaly, lymphadenopathy, opisthotonic posturing, spasticity and cranial nerve involvement. Death usually occurs by 3 years of age. Type II is rarely encountered in the Jewish Ashkenazi population, which led Aviner et al. 1646 to hypothesize that homozygosity for certain Ashkenazi alleles might be lethal, leading to a lower-than-expected frequency of type II Gaucher disease.

Type III Gaucher disease presents with hepatosplenomegaly followed by gradual mental deterioration any time after the first year of life. Initial evidence of neurological involvement may not present until adulthood with supranuclear oculomotor deficits. 1647 Death occurs in the second to fourth decade. Three subtypes are now described. Type IIIa is primarily a neurological disorder in adolescence with mild visceral involvement. Death is from slowly progressive neurologic degeneration. Myoclonic seizures are common. Type IIIb has the severe visceral involvement with massive hepatomegaly, oesophageal varices, and severe skeletal involvement. Horizontal supranuclear gaze paresis is the major neurological finding. 1648 Death is from hepatic or pulmonary complications. Hepatocytes rarely accumulate glucocerebroside because of biliary excretion. 1649 Disease is accelerated by splenectomy. Type IIIc is an unusual variant with calcification of the left-sided heart valves and corneal opacifications. 1650 Other visceral involvement is mild. In type III, typical complications of portal hypertension occur if cirrhosis develops. 1651 Hepatic calcification is rare. 1652 Pulmonary arteriovenous shunts causing hypoxia and cyanosis occur mainly in patients with liver disease. 1632 There is also infiltration of the lungs by storage cells. The pulmonary shunts as well as the cirrhosis respond to LT.

Based on the clinical presentation along with the detected genotypic heterogeneity, 1653 neuronopathic Gaucher disease appears more likely to be a continuum of phenotypes from type II with severe perinatal presentation to mild type III with oculomotor problems.

The gene for acid β-glucosidase is on chromosome 1q21. 1654 ,1655 Almost 200 mutations in this gene have been described. 1656 Although there is a trend for the N370S allele to be associated with milder electron-lucent material in a dense granular matrix. The clear vacuoles, which were also noted in cells lining intrahepatic bile ducts, resembled those seen in the mucopolysaccharidoses. Banana-like bodies have been seen in Schwann cells ultrastructurally. 1622 They resemble miniature bananas and seem to arise from needle-like, membranebound inclusions. On average, they are about 1.6 µm long and have a diameter of 0.23 µm.

Gaucher disease, the most common lysosomal disorder, is caused by deficiency in acid β-glucosidase (glucocerebrosidase) resulting in lysosomal accumulation of glucosylceramide (glucocerebroside), mainly in macrophages. 1623, 1624 Three major phenotypes of Gaucher disease have been recognized (Table 3 .5), 1625 although it is currently held that the disease manifests more as a continuum of phenotypes within a broad spectrum of clinical presentation. 1626, 1627 Type I (chronic non-neuronopathic) Type I Gaucher disease can be detected at any age, including in the ninth decade. The usual presentation is hepatosplenomegaly in late childhood or adolescence. More than 50% of patients have mild haemorrhagic phenomena associated with thrombocytopenia. 1628 Variable skin pigmentation is recorded. 1629 Adolescent patients may have aseptic necrosis of the metaphyseal areas, and 10% of patients have skeletal symptoms that include bone pain, spontaneous fractures, degenerative hip disease or pseudo-osteomyelitis. About 60% of patients have abnormal skeletal radiographs, including the classic 'Erlenmeyer flask' deformity. 1630 Bone symptoms and radiographic anomalies seem more likely to occur in splenectomized patients. 1631 The lungs are rarely infiltrated by storage cells. 1632 Hepatomegaly is common, often without significant clinical consequences. However, massive hepatic fibrosis with portal hypertension does occur and has required liver transplantation (LT) in a 15-year-old girl, despite 6 years of enzyme replacement therapy. 1633 One patient presented with neonatal conjugated hyperbilirubinaemia. 1634 Partial or complete splenectomy is often performed for pancytopenia. 1635, 1636 Splenic infarctions may cause severe left upper quadrant pain. 1637 Renal failure is rare. According to data from the International Gaucher Registry, Gaucher patients have an increased risk of developing multiple myeloma, but no other tumours. 1638 However, a recent study describes two or three different types of cancer either consecutively or simultaneously in 9 of 403 patients, with an apparent association with splenectomy. 1639 Relative frequency 94% <1% 5%

and non-neuronopathic disease and the L444P allele to be strongly associated with neuronopathic forms, genotype-phenotype correlations are poor, 1657 implying that other factors, besides mutation in the glucocerebrosidase gene, play an important role in the manifestation of the disease. Glucocerebrosidase is synthesized on endoplasmic reticulum (ER)-bound polyribosomes and translocated into the ER. After N-linked glycosylations, it is transported to the Golgi apparatus, from where it is trafficked to the lysosomes. The degree of ER retention and proteasomal degradation and impaired trafficking of the mutants are likely factors that determine disease severity. 1658, 1659 Diagnosis of Gaucher disease is made by assay of acid β-glucosidase enzyme in WBCs or cultured fibroblasts. Prenatal diagnosis is by assay of enzyme activity in amniocytes or chorionic villi; PCR can be performed when the genetic mutation is known in both parents. 1625 A rare variant of Gaucher disease is caused by deficiency in a small acidic protein activator, saposin C, which is required for optimal hydrolysis of sphingolipids. Mutation in the saposin gene localized to chromosome 10 leads to a variant with a normal acid β-glucosidase enzyme activity which will not be influenced by enzyme therapy. 1660, 1661 Biallelic mutations in the gene encoding for acid β-glucosidase can be identified except in those cases related to saposin C deficiency. Targeted mutation analysis can be performed in Ashkenazi Jews. 1627 Therapy for type I Gaucher disease is intravenous (IV) recombinant enzyme replacement therapy (ERT) designed to be taken up by the mannose receptor on macrophages. 1662, 1663 It results in rapid reversal of liver, splenic and bone marrow pathology with clinical improvement, but skeletal disease responds more slowly or may be resistant. 1663, 1664 The poorest responses have been in splenectomized patients or patients with advanced liver, splenic and bone marrow disease. Splenectomy increases the risk of avascular necrosis, which is reduced by starting ERT less than 2 years after diagnosis. 1665 As an alternative to ERT, substrate reduction using oral miglustat, an inhibitor of glucosylceramide synthase, a key enzyme in glycosphingolipid synthesis, has been shown to produce slower and less robust responses than those obtained with ERT. 1666 It is an effective therapy for the long-term maintenance of patients previously stabilized with ERT. 1667 Neurological disease does not respond because the enzyme does not cross the blood-brain barrier. Although stabilization or some improvement may be achieved with IV treatment in very high doses in type III disease, 1668 this does not eliminate the neurological problems that these patients ultimately experience. 1669 BMT has been successful but with significant morbidity. LT is rarely indicated and must be accompanied by other therapy to obtain a cure. 1670 Chimerism after hepatic transplantation will not reliably produce a cure. 1671 Gene therapy is being pursued vigorously. A knockout mouse model is available to assist in these studies. 1672 Histiocytes containing glycocerebroside (Gaucher cells) are dispersed throughout the reticuloendothelial system. A full surface marker study of the splenic storage cells in a case of Gaucher disease has largely substantiated the monocyte/histiocyte nature of Gaucher cells. 1673 SEM reveals microvilli, ruffles, ridges and blebs of varying number and shape on their surface. 1674 In the liver, Kupffer cells and portal macrophages are primarily affected. The distribution may be focal or zonal, with the perivenular zone being mainly affected. The cells, which can measure up to 100 µm in maximum dimension, are lightly stained with eosin, have a faintly striated or crinkled cytoplasm and pyknotic, eccentric or centrally located nuclei (Fig. 3.119) . The striations are best demonstrated with the Masson trichrome or a PAS stain (Fig. 3.120 ). Intense acid phosphatase (Fig. 3.121 ) and lysozyme activity are found by histochemical or immunohistochemical methods, respectively. Gaucher cells are also strongly immunoreactive to anti-KP-1 (Fig. 3.122) . They usually contain a small amount of iron that is derived from both ingested erythrocytes and the labile plasma pool. 1675 Other staining reactions of Gaucher cells have been reviewed. 1675, 1676 Gaucher cells in the liver may enlarge to such an extent that they completely block sinusoidal spaces. They also compress hepatocytes with progressive atrophy and disruption of the hepatic plates. There

Niemann-Pick (NP) disease 1687, 1688 refers to a group of storage disorders with characteristic foamy storage cells currently grouped into types A, B and C. Types A and B are the two phenotypic variants caused by mutation in the sphingomyelin phosphodiesterase-1 gene (SMPD1) localized to chromosome 11p15.4. The gene encodes acid sphingomyelinase (ASM), whose deficiency leads to sphingomyelin accumulation in both types, which are extremely different clinically. Mutations in both type A and B have been documented and may bear some correlation with phenotype. 1689 Niemann-Pick disease, type A Type A Niemann-Pick disease (NPA) begins in utero and is detected after birth by massive hepatosplenomegaly; severe disease presents as hydrops fetalis. 1690, 1691 Placental ultrasonographic abnormalities caused by storage cells can be detected in the first two trimesters. 1692 Paucity of the intrahepatic bile ducts has been reported, and giant cell transformation with pruritus has been observed in infants. 1693 Abnormal neurological development may not be detected until 3 months of age; developmental regression occurs by 1 year. Moderate lymphadenopathy may be present. Malnutrition, weakness and hypotonia lead to death between 2 and 5 years of age. Macular cherry-red spots are found in 50% of patients. 1694 

Fatal liver failure has been documented in two children with type B Niemann-Pick disease (NPB), 1695 and cirrhosis with complications of portal hypertension reported in a number of adults. [1696] [1697] [1698] However, the natural history of type B patients is characterized by hepatosplenomegaly with stable liver dysfunction and progressive hypersplenism, worsening atherogenic lipid profile and gradual deterioration in pulmonary function from foam cell infiltration. 1699 The latter has is a variable increase in the number of reticulin and collagen fibres in the space of Disse. Perisinusoidal fibrosis and mechanical blockage of sinusoidal spaces are presumed to be the cause of portal hypertension, but the pathogenesis of tissue injury in Gaucher disease may be complex and could also involve activation of stellate cells. Severe fibrosis with formation of septa and cirrhosis (Fig. 3.123 ) has been reported. 1651, [1677] [1678] [1679] [1680] Coexistent autoimmune hepatitis was reported in one patient. 1681 The autopsy of a 59-year-old woman with Gaucher disease type I who died following sepsis, disseminated intravascular coagulation and multiorgan failure, 5 years after starting ERT, demonstrated a paucity of Gaucher cells in spleen and liver, the latter containing a multinodular cholangiocarcinoma. 1682 Brain and lung remain affected because of poor accessibility of ERT. 1683 The ultrastructural aspects of the Gaucher cell have been described in detail. 5, 1675, 1677, 1684 The cytoplasm is filled with spindle-or rodshaped inclusion bodies bounded by a limiting membrane and measuring 0.6 µm in diameter (Fig. 3.124) . In cross section the inclusions contain numerous small tubules, 13-75 nm in diameter. Acid phosphatase activity has been localized to the inclusions by eEM histochemistry. 1684 Freeze-fracture and x-ray diffraction analysis of the purified deposits have shown that they consist of twisted membranous bilayers 6 µm in thickness. 1685 The iron in the Gaucher cell is dispersed as individual micelles of ferritin. 1686 cholesterol. By this technique, lysosomal cholesterol may not be deemed abnormal in 15% of cases. Challenging fibroblasts with purified human LDL 3 days after culture in lipoprotein-deficient media provides more consistent results. 1716 Actual cholesterol ester measurement can be performed. LDL cholesterol accumulates in lysosomes; transport to other sites is impaired. There is no repression of cholesterol and LDL receptor synthesis. For the prenatal diagnosis, demonstration of abnormal intracellular cholesterol trafficking is a complex procedure, and mutational analysis (NPC1 or NPC2/HE1 gene), whenever feasible, represents a major advance. 1717 Therapeutic trials with low-cholesterol diets, cholestyramine, niacin and lovastatin have been unsuccessful in altering the course of NPC. 1718 At present, no specific therapy has emerged for the treatment of NPA and NPB. Miglustat, a substrate reduction therapy, has been shown to stabilize disease progression in children, juveniles and adults with NPC. 1719, 1720 Allogeneic haematopoetic progenitor cell transplantation from a HLA-matched sister has corrected enzyme levels in a 18-month-old NPC patient. 1721 Spontaneous mouse models of NPC 1722 have been used to study cholesterol accumulation and cell death 1723 ; other studies of NPC gene function are performed on fibroblast cell lines. 1704 A sphingomyelinase knockout mouse for NPA/NPB is a model used to evaluate hepatic gene transfer by means of recombinant encoding of sphingomyelinase. 1724 A study of pulmonary macrophages from the same model suggests that macrophage lipid accumulation leads to abnormalities in mannose-6-phosphate receptor trafficking and/or degradation, resulting in reduced enzyme uptake. 1725 Both the liver and the spleen are enlarged in Niemann-Pick disease. The characteristic finding is the presence of large macrophages with a foamy or microvesicular cytoplasm. These are least conspicuous and easily overlooked in type C, particularly in the liver with associated hepatitis, but generally obvious in a bone smear (Fig. 3.125 ). In the liver, Kupffer cells are greatly hypertrophied and have a vacuolated cytoplasm (Fig. 3.126 A) . They are often light tan in colour due to their content of lipofuscin (ceroid). A single, small, eccentric or centrally placed nucleus is generally found in each cell. Hepatocytes also contain sphingomyelin, and their cytoplasm shows progressive loss of eosinophilia with increasing vacuolization, until they become indistinguishable from affected Kupffer cells. The foam cells are autofluorescent but have a nodular pattern, in contrast to the uniform fluorescence of Gaucher cells. 1726 The cells are positively stained with Oil Red O, Luxol fast blue and Baker acid haematin stain in frozen sections; the latter stain becomes negative after pyridine extraction. more clinical relevance than in type A and can result in death. Rupture of the spleen is another cause of death. The multisystemic involvement and clinical variability are highlighted in a broad, prospective, crosssectional survey. 1700 Abnormal linear growth and delayed skeletal maturation are common in children and adolescents. 1701 Macular cherry-red spots are detected in less than 10% of patients. Cerebellar ataxia may be present.

The finding of large, foamy macrophages in bone marrow, liver or spleen may be the initial clue to the diagnosis. The diagnosis of NPA and NPB is confirmed by sphingomyelinase assay in leukocytes, lymphocytes or skin fibroblasts. Antenatal diagnosis is possible by assaying ASM activity in chorionic villi or cultured amniocytes. 1702 Niemann-Pick disease, type C Type C Niemann-Pick disease (NPC) is clinically, biochemically and genetically distinct from types A and B. NPC is caused by a defect in intracellular cholesterol and glycosphingolipid trafficking that leads to the accumulation of unesterified cholesterol and other lipids in endo/lysosomal compartments. 1703 Approximately 95% of patients have mutations in the NPC1 gene (mapped to chromosome 18q11-12) which encode a large endosomal membrane glycoprotein. The remainder have mutations in the NPC2/HE1 gene (mapped at 14q24.3) which encodes a small soluble lysosomal protein with cholesterol-binding properties. 1702, 1704 The identical biochemical patterns observed in NPC1 and NPC2 mutants suggest that the two proteins function in a coordinate manner. Numerous mutations have been identified, 1705 with the recent finding that the Q775P mutation may correlate with a severe infantile neurological form and the C177Y mutation with a late infantile clinical phenotype. 1706 NPC presents clinically at any age between the perinatal period and adulthood. Its manifestations are highly variable, according to findings in a large national UK cohort. 1707 The markedly different presentation of the disease in monozygotic twins suggests the role of epigenetic and postzygotic events. 1708 Patients may have fetal ascites. 1709 Two-thirds of patients present with neonatal hepatitis syndrome. Rarely, an infant presents with chronic-pattern neonatal liver failure (near-normal serum aminotransferases low serum albumin, coagulopathy). Most patients clear their cholestasis but have residual mild hepatosplenomegaly. However, liver failure with cholestasis develops in 10% of cases. 1710 Two reported patients had biliary atresia and meconium ileus. 1711 Severe forms of NPC result in death by age 3-5 years. Other patients present later with mild splenomegaly that regresses with aging. 1710, 1712 All patients develop neurological complications. The most consistent finding is vertical supranuclear gaze palsy. Other manifestations include cerebellar involvement (ataxia, dystonia, dysarthria), cataplexy with or without narcolepsy and learning difficulties. Late changes include mental regression, seizures and neurological pyramidal signs. 1712 A linear clinical progression, independent of age of onset, has been highlighted. 1713 One patient with sea-blue histiocytes developed hepatocellular carcinoma with recurrence in the transplanted liver along with further neurological deterioration. 1714 Speak et al. 1715 recently described defect in the function in NK lymphocytes.

As with NPA and NPB, the finding of large, foamy macrophages in bone marrow, liver or spleen may be the initial clue to the diagnosis of NPC. The foam cells can resemble sea-blue histiocytes in 50% of cases. In infants, rectal biopsy may disclose abnormalities in the ganglion cells consistent with neuronal storage. 1710 The diagnosis is further suspected by normal sphingomyelinase levels. The accumulation of unesterified cholesterol in lysosomes is confirmatory. Specialized laboratories prefer to work with cultured fibroblasts for diagnosis. Filipin staining demonstrates the intense staining of unesterified rhizomelic chondrodysplasia punctata, which is clearly distinct from the other disorders.

• Single peroxisomal (enzyme-) protein deficiencies. There is decreased or absent activity of peroxisomal matrix enzymes or membrane protein involved in fatty acid β-oxidation, glyoxylate metabolism

The cytoplasm is variably PAS positive or negative, depending on the quantity of lipofuscin (Fig. 3.126 B) . Cholesterol-containing sea-blue histiocytes may be present in NPC, as previously mentioned. Intrahepatic cholestasis is found in some infants, and a number of cases with giant cell transformation have been reported in both NPC and NPB disease. 1693, [1727] [1728] [1729] [1730] As in Gaucher disease and other metabolic disorders, there may be varying degrees of atrophy of hepatic plates and parenchymal fibrosis (Fig. 3.127) . A true cirrhosis has been reported in both children and adults. 1698 Fibrosis in NPB may depend on the phenotype. 1697 Ultrastructurally, the foam cells contain dense, mixed lipid inclusions or lipid cytosomes; these are polymorphic and range from less than 1 µm to 5 µm in diameter. 1726 The inclusions consist of concentrically laminated myelin-like figures with a periodicity of approximately 5 nm (Fig. 3.128) . 5, 1731 Typical lipofuscin bodies, lipid droplets and cholesterol clefts may also be observed.

Peroxisomes may form by synthesis of their membranes, followed by importation of enzymes synthesized elsewhere in the cell, or by budding from pre-existing peroxisomes. They perform numerous functions, including catabolism of glyoxylate, α-oxidation of phytanic acid, biosynthesis of bile acids, biosynthesis of ether phospholipids (plasmalogens), biosynthesis of docosahexaenoic acid and β-oxidation of fatty acids; peroxisomes are essential for β-oxidation of very-longchain (C:24 or C:26) fatty acids. The peroxisomal disorders are usually subdivided into the following two subgroups 1732 : very-long-chain fatty acids, pipecolic acid and phytanic acid and measurement of red blood cell (RBC) plasmalogens. [1746] [1747] [1748] Bile acid synthesis is abnormal because of disturbances to peroxisomal enzymes involved in side-chain modification of nascent bile acids. Liver biopsy with EM establishes the absence of peroxisomes. 1749, 1750 Peroxisomal enzymes and structure can be studied in cultured fibroblasts. 1751 The incidence of Zellweger syndrome is estimated at 1 in 25,000 to 100,000 births. 1752 Inheritance is autosomal recessive. Prenatal diagnosis in affected families is possible using techniques to assess adequate peroxisomal function. Referral to a qualified centre is essential. Therapy is supportive.

Whereas much progress has been made in biochemistry and genetics of peroxisomal disorders, determination of the pathophysiology and therapy has been slow. 1734 The increasing availability of mouse models for these disorders, however, is a major step forward. 1753, 1754 Autopsy findings in Zellweger syndrome include cerebral anomalies (abnormal convolutional pattern, heterotopic cortex, olivary dysplasia), renal glomerular microcysts, cardiovascular defects (patent ductus, patent foramen ovale), thymic anomalies and pancreatic islet cell hyperplasia. 1755 The hepatic histopathological findings are not consistent. Some cases have shown no or only minimal, nonspecific alterations. Portal inflammation, periportal fibrosis, focal necrosis with progression to parenchymal fibrosis, cholestasis and haemosiderosis have been recorded. [1755] [1756] [1757] [1758] [1759] [1760] In a survey of the literature, Gilchrist et al. 1757 found a reduction of 'cholangioles' in 23% of cases. Patients with severe fibrosis and disruption of the parenchyma [1759] [1760] [1761] [1762] [1763] and even cirrhosis 1750, 1764, 1765 have been described.

The absence of peroxisomes in liver cells, first described by Goldfischer et al., 1766 has been a consistent finding in subsequent ultrastructural studies. 5, 1749, 1759, 1760 In some cases, however, small bodies resembling incompletely developed peroxisomes could be found. 5 A variant of the disease with detectable hepatic peroxisomes has also been reported. 1767 Another ultrastructural feature is the occurrence within macrophages of large, angulate lysosomes filled with fine, double lamellae. 1759 Mitochondria show derangement and twisting of their cristae and have a dense matrix. 5, 1759, 1768 The absence of catalase, a peroxisomal enzyme, was demonstrated at the ultrastructural level in a liver biopsy specimen from a patient with Zellweger syndrome. A diffuse rather than granular pattern of staining using anticalase antibodies on formalin-fixed paraffin-embedded (FFPE) tissue is observed in patients with Zellweger syndrome. 1769 Several other peroxisomal enzymes can also be demonstrated by immunogold labelling. 1770 

Less severe variants of classic Zellweger syndrome include neonatal adrenoleucodystrophy and infantile Refsum disease. 1745 The dysmorphic features are less striking than those of classic Zellweger syndrome, and the peroxisomes in the liver are not as markedly diminished. 1771 Because these diseases are generally milder, with some hope for neurological development, controlled clinical trials of therapies to bypass the deficient peroxisomal enzymes have been initiated. 1772 A single case of neonatal liver failure associated with X-linked adrenoleucodystrophy has been described. 1773 In adrenoleucodystrophy, there is variable fibrosis and irregular nodularity of the hepatic parenchyma. 1774, 1775 Cirrhosis was reported in one patient. 1776 PASpositive macrophages and Kupffer cells were identified in another. 1777 Ultrastructurally, hepatic peroxisomes are either absent or greatly reduced in number and size 1771, 1776 and may contain electron-dense cores. 1778 Lamellar cytoplasmic inclusions are found in Kupffer cells and hepatocytes. 1777, 1778 Mitochondria with crystalline inclusions and/or abnormal cristae have also been noted. 1778 (primary hyperoxaluria type 1), ether phospholipid biosynthesis, bile acid synthesis and hydrogen peroxide (H 2 O 2 ) metabolism.

The disorders described in this section include X-linked adrenoleucodystrophy, di-and trihydroxycholestanoic acidaemia, mevalonate kinase deficiency and adult Refsum disease. Some of the other disorders are discussed in the relevant disease sections. 1734 At least 21 genetic disorders have now been found that are linked to peroxisomal dysfunction. 1735 Only the peroxisomal disorders that result in liver disease-Zellweger syndrome, di-and trihydroxycholestanoic acidaemia and mevalonate kinase deficiency-are discussed.

Diseases of the Zellweger spectrum represent a continuum of clinical disorders with Zellweger syndrome having the most severe phenotype and neonatal adrenoleukodystrophy, infantile Refsum disease and Heimler syndrome having progressively milder phenotypes. The Zellweger syndrome spectrum is caused by defects in any of at least 12 peroxin (PEX) genes required for normal organelle assembly. Most common are mutations in PEX1, which encodes a 143-kD ATPases Associated with diverse cellular Activities (AAA) ATPase protein needed for peroxisome biogenesis, followed by PEX26, PEX6, PEX12, PEX10 and PEX2. 1736 The PEX1 mutations identified to date comprise insertions, deletions, nonsense, missense and splice site mutations. Mutations that produce premature truncation codons (PTCs) are distributed throughout the PEX1 gene, whereas the majority of missense mutations segregate with the two essential AAA domains of the PEX1 protein. Severity at the two ends of the Zellweger spectrum correlates broadly with mutation type and impact (i.e. the severe syndrome correlates with PTCs on both alleles, and the milder phenotypes correlate with missense mutations), but exceptions to these general correlations exist. 1737 Chromosomes 12, 8, 7 and 6 contain loci associated with Zellweger disease spectrum. [1738] [1739] [1740] [1741] [1742] [1743] [1744] Zellweger syndrome Patients present at birth with a characteristic facial dysmorphia, severe hypotonia, hepatomegaly, renal cysts, optic atrophy, seizures and severe neurological impairment. 1745 Diagnosis is made through a combination of studies that include plasma quantitation of cervical region. Serum IgD levels (>100 U/mL) remain elevated during the attack, most often associated with raised IgA levels. 1789 The diagnosis is confirmed by MVK gene screening, in particular the V377I mutation, which has been identified exclusively in HIDS patients. 1794, 1795 Hepatomegaly is common, and cholestatic liver disease has been recorded, 1793 but detailed histological changes in these disorders are not available. Mild portal fibrosis with a mainly lymphocytic inflammatory cell infiltrate is mentioned in a case report of a child with MVK deficiency. 1796 

Mitochondrial cytopathies comprise a broad array of diseases affecting multiple organ systems. [1797] [1798] [1799] [1800] A mitochondriopathy, defined as a disorder of mitochondrial function or structure, may result in combinations of many diverse symptoms, including hepatic failure, or cholestasis with preserved liver function, cardiomyopathy, pigmentary retinopathy, myoclonic seizures, hypotonia, proximal tubular disorder, endocrinopathies or pancytopenia, pancreatic deficiency or gut dismotility. Disease severity is highly variable, as are the time of presentation and rate of disease progression. Many of these disorders affect the neuromuscular system with no known hepatic involvement. This section focuses on mitochondrial disorders in which liver disease is a prominent clinical feature. Most of these are genetic disorders. Acquired hepatic mitochondrial disorders, for example, associated with toxicity of nucleoside analogue retroviral drugs or with chronic viral hepatitis, are discussed in other chapters. Inherited hepatic mitochondriopathies tend to present clinically in infancy or childhood; late hepatic involvement is less common.

Classification of the mitochondriopathies is also challenging, especially as the number of known mitochondrial cytopathies continues to expand. Diseases can be classified by the genetic defect (autosomal or mitochondrial) or by the affected enzymatic system (oxidative phosphorylation or fatty acid oxidation). A comprehensive classification of mitochondrial disease has been proposed, 1801 as well as one focusing on liver involvement. 1802 Table 3 .6 provides a classification of hepatic mitochondriopathies.

Mitochondria produce ATP within cells and, coincidentally, activated oxygen species; in hepatocytes, mitochondria play an important role in β-oxidation. Mitochondria are unique among cell organelles in having their own complement of DNA, which encodes some of the proteins in the respiratory chain responsible for oxidative phosphorylation, as well as specific RNAs critical to protein synthesis in mitochondria. Inheritance of mitochondrial DNA (mtDNA) is along maternal lines. Mitochondria are derived almost exclusively from the ovum, since sperm contain very few mitochondria. Mitochondria have their own DNA polymerase, polymerase γ (POLG, or POLγ), for production of mtDNA. Proofreading and DNA repair capacities are extremely limited in mitochondria. Tissue expression of mtDNA abnormalities is complex, depending on the population of mitochondria in each cell. Gene localization and determination of specific genetic defects are available for some of the mitochondriopathies. Lack of simple one-to-one correspondence of a certain mtDNA mutation to a clinical disease pattern, along with the feature of heteroplasmy, has made genotype-phenotype correlations especially difficult.

Mitochondrial disorders are rare, but their exact incidence is undetermined, mainly because accurate diagnosis previously was difficult. Clinically, the mitochondrial cytopathies with liver disease present principally in two ways. 1803 First, severe liver disease may be evident during the first week of life; mitochondrial disorders constitute An accentuated lobular architecture, with fibrous bands linking portal areas together, has been observed in Refsum disease. 1779 A micronodular cirrhosis was found in a patient who died at age 12 years. 1779 A deficiency of hepatic peroxisomes has been detected ultrastructurally and cytochemically. [1780] [1781] [1782] Phillips et al. 5 believes that while some hepatocytes totally lack peroxisomes, others contain very small, underdeveloped peroxisomes that sometimes have a very dense matrix. Numerous angulate lysosomes have also been noted in Kupffer cells in this disorder.

Patients with this rare disease present with severe cholestasis and obstructive jaundice. Trihydroxycoprostanic acid coenzyme A (THCA-CoA), a bile acid ester, is converted to δ 4 -THCA initiated by a specific THCA-CoA oxidase. Similarly, acid is also processed in the peroxisomes. In di-and trihydroxycholestanoic acidaemia ('alligator bile syndrome'), serum levels of these precursors are high because either transport of the CoA ester into the peroxisome or subsequent processing is deficient. [1783] [1784] [1785] An isolated case of THCA-CoA has been subsequently reallocated to a peroxisomal biogenesis disorder on the basis of mutations in the PEX12 gene, although all peroxisomal functions in cultured skin fibroblasts were normal, leading the author to question the existence of THCA-CoA as an entity. 1786 

The gene encoding mevalonate kinase (MVK) was mapped by FISH to chromosome 14q24. 1787 Gene mutations lead to two groups of disorders: (1) mevalonate aciduria, the first recognized defect in the biosynthesis of cholesterol and isoprenoids, resulting from severe deficiency in MVK, 1788 and (2) hyperimmunoglobulinaemia D (hyper-IgD) syndrome/periodic fever, seemingly associated with mild deficiency. 1789 MVK deficiency is included in the monogenic autoinflammatory syndromes, a group of disorders manifesting with inflammatory symptoms of variable degree of severity, duration and frequency due to dysregulation of the innate immune system. 1790, 1791 The clinical spectrum of mevalonate aciduria shows varying degrees of severity despite a uniformly absent MVK activity in all. Severely affected patients have profound developmental delay, dysmorphic facies, cataracts, hepatosplenomegaly, lymphadenopathy and anaemia, as well as diarrhoea and malabsorption, and die in infancy. Less severely affected patients have psychomotor retardation, hypotonia, myopathy and ataxia. All patients will have recurrent crises, with fever, lymphadenopathy, increased size of liver and spleen, arthralgia, oedema and morbilliform rash. 1788, 1792 Haematological anomalies, in particular anaemia, petechiae, cutaneous extramedullary haematopoiesis, hepatosplenomegaly, leukocytosis, recurrent febrile episodes and facial rashes, in patients without significant neurologic abnormalities raise the differential diagnosis of congenital infections, myelodysplastic syndromes or chronic leukaemia. 1793 Mevalonic acid concentrations are grossly elevated in body fluids in all patients because of disordered biosynthesis of cholesterol. Mevalonic acid can be detected clinically by urinary organic acid analysis. Prenatal diagnosis is possible by measurement of mevalonic acid in amniotic fluid. 1788 Hyper-IgD syndrome (HIDS)/periodic fever is characterized by recurrent attacks of spiking fever with early onset before 1 year of age, associated with abdominal pains (72%), vomiting (56%), diarrhoea (82%), polyarthralgia (80%) and nondestructive arthritis (68%); 82% of patients report skin lesions, with vasculitis histologically. Swollen, tender lymph nodes are noted most often in the demanding technically and generally relies on molecular techniques. Meticulous evaluation for a hepatic mitochondriopathy is mandatory for assessing the infant with neonatal liver failure of any type, and whenever liver transplantation (LT) might be a treatment option. 1806 Accumulating evidence indicates that many infants with mitochondrial disorders exhibit abnormalities before birth. 1808 Prenatal diagnosis depends on identification and cloning of mutant genes or direct measurement of mitochondrial metabolism in cultured chorionic villus cells or amniocytes. 1809 If the gene involved in the mitochondriopathy of a previously affected sibling has been identified, the family can benefit from prenatal diagnosis. If a family with a known mitochondrial disorder desires prenatal diagnosis, a centre specializing in these disorders should be contacted to determine the status of prenatal diagnosis of the particular disease.

Therapy for the mitochondrial disorders vary with the disease. Intensive supportive care is required for the neonate with hepatic failure, especially to permit accurate diagnosis and comprehensive evaluation of extrahepatic involvement. Patients with the more delayed form of liver disease may need supportive treatment, including nutritional and metabolic strategies; neurological features may require antiepileptic medication, which must be specifically selected and monitored to avoid exacerbating hepatic disease. In some cases, use of a 'mitochondrial cocktail' has been said to improve a patient's clinical condition, 1810 but benefits may be uncertain unless a specific deficiency can be supplemented. 1811 Treatment for fatty acid oxidation disorders is customized to the actual defect. 1812, 1813 LT is controversial. In general, the outcome has been poor. Nevertheless several authors an important etiology for neonatal liver failure. Such patients die suddenly or appear to be septic. Typical patients have transient hypoglycaemia, severe neurological involvement (hypotonia, myoclonic seizures, developmental delay) and hepatic failure with a rapidly fatal clinical course. [1803] [1804] [1805] In some patients the neonatal liver failure dominates the clinical picture, and extrahepatic involvement is either not present or difficult to discern. Alternatively, the onset of symptoms is delayed such that clinical presentation occurs between 2 and 18 months of age. Liver disease is less severe initially (although hepatic failure occurs progressively), neurological involvement is variable, and some patients survive for an extended period. This second group includes 'Alpers progressive infantile poliodystrophy', now known as Alpers syndrome. A third possible clinical presentation is chronic liver disease with liver enlargement and possibly hepatic steatosis or cirrhosis; if sought, hypoglycaemia or lactic acidosis may be found.

Screening for a mitochondrial disorder includes a careful medical history and physical examination to uncover any subtle supporting signs and symptoms. 1806 Lactic acidosis is an important finding. Hypoglycaemia may be the only sign of a mitochondrial disorder. 1807 Laboratory findings that support a diagnosis of mitochondrial respiratory chain defect include elevated plasma lactate, arterial plasma lactate/pyruvate ratio and arterial α-hydroxybutyrate/acetoacetate ratio. These abnormalities may be exaggerated after a meal or oral glucose load. Urine organic acids, serum carnitine levels or renal tubular function may also be abnormal in disorders of fatty acid oxidation. Confirming the diagnosis of a mitochondriopathy can be Long-chain acyl-CoA dehydrogenase presentation is acute liver failure without a seizure disorder. Childhood myocerebrohepatopathy spectrum (MCHS) represents another group of infantile disorders with POLG mutations in which liver failure may occur, along with developmental delay, failure to thrive, lactic acidosis and myopathy. 1844 Mitochondrial cytopathies, particularly Alpers syndrome, are a risk factor for valproate-induced fulminant liver failure, which may obscure the underlying diagnosis. [1845] [1846] [1847] [1848] [1849] Pearson syndrome consists of refractory sideroblastic anaemia, with vacuolization of marrow precursors, and exocrine pancreatic dysfunction. 1850 Patients have large deletions or rearrangements of the mitochondrial genome. 1851 One patient had predominantly hepatic manifestations, such as microvesicular steatosis, massive haemosiderosis and rapidly developing cirrhosis. 1852 This patient had a 7436-bp deletion of the mitochondrial genome in all tissues investigated, compatible with Pearson syndrome. He died within 3 months of birth from liver failure. Haemosiderosis in this patient may have been caused by compound heterozygosity (C282Y and H63D) for mutations of the hereditary haemochromatosis gene HFE, but other infants with Pearson syndrome also have had hepatic haemosiderosis, one of whom was heterozygous for the C282Y mutation. 1853, 1854 Navajo neurohepatopathy (NNH) is an autosomal recessive disorder resulting in sensorimotor neuropathy in full-blooded Navajo Indian children (of the southwestern United States) first described by Appenzeller et al. 1855 in 1976 and further characterized by Singleton et al. 1856 Holve et al. 1857 in 1999 . The latter authors suggested changing the name from 'neuropathy' to 'neurohepatopathy' because liver involvement is an important component of the disease. They described three clinical phenotypes, based on age at presentation and course: an infantile type presenting before 6 months of age with jaundice and failure to thrive; a childhood type presenting between 1 and 5 years of age with liver dysfunction that progressed to liver failure and death within 6 months; and a classic type with variable onset of liver disease but progressive neurological deterioration. Liver histopathological findings in NNH are characterized by multinucleated giant cells, mixed macro-and microvesicular steatosis, pseudoacini, cholestasis, inflammation, bridging fibrosis and cirrhosis in some cases. Ultrastructural findings in four patients have included abnormalities of mitochondria (ringed cristae, swelling and loss of cristae, pleomorphic contour), effacement of canalicular microvilli and accumulation of intracellular bile pigments and fat-containing vesicles. 1857 The pathogenesis of NNH remains poorly understood; however, the genetic defect is mutations in MPV17, which encodes a protein MPV17, in the inner mitochondrial membrane essential for maintaining mDNA. 1858, 1859 Although the infantile form has some similarities to intrahepatic cholestasis disorders, the childhood form suggests a mitochondrial disorder, 1857 and in fact it appears to be in the spectrum of mtDNA depletion disorders. Extrahepatic features may be severe. Hepatocellular carcinoma has been reported in a child with NNH. 1859

These disorders involve mutations in transfer or elongation factors. Typically they present clinically as neonatal liver failure. Transfer factors of note are the ubiquinol cytochrome-c reductase required for assembly of complex II in the OX-PHOS chain, encoded by BCSIL, and Sco1, which is required for assembly of complex IV; these have been described in connection with respiratory chain disorders. Relevant nuclear transfer factors include TRMU, EFG1, EFTs and EFTu, all of which are involved in production of complexes I, III and IV. Mutations in TRMU have been associated with neonatal liver failure 1860 and liver failure in a 2-year-old, who subsequently recovered. 1861 Neonatal hepatitis syndrome (possibly neonatal liver failure) was reported with mutated have reported successful resolution of liver disease with LT. However, in patients with Alpers syndrome or other mitochondriopathies with neurological involvement, LT does not slow the progression of the neurological disease. Careful patient selection is crucial: LT is not indicated for patients with clinically evident extrahepatic disease. 1814, 1815 Genetic mitochondrial disorders Defects originating from mutations in nuclear DNA are inherited as autosomal traits, whereas defects in mtDNA are inherited maternally. Genetic mitochondrial disorders can be classified on the basis of whether the mutation affects a single protein in the mitochondrion or production of mtDNA.

Mutations affecting single proteins in the respiratory chain responsible for oxidative phosphorylation (OX-PHOS) have been described in detail. The usual clinical features are either neonatal liver failure or else severe neonatal hepatitis syndrome. 1803, [1816] [1817] [1818] [1819] [1820] [1821] [1822] Children with mitochondrial respiratory chain defects may be at increased risk of developing hepatocellular carcinoma. 1823 A cytochrome-c oxidase deficiency found in Quebec kindreds may be associated with fatty liver. 1824 Abnormalities in proteins vital to assembly of respiratory chain proteins can also cause liver disease; an important example is neonatal liver failure associated with mutations in SCO1, a protein vital to assembly of complex IV (cytochrome-c oxidase) in the mitochondrial OX-PHOS chain. 1825 GRACILE syndrome is a severe multisystem autosomal recessive disorder with features including cholestasis and hepatic iron overload and lactic acidosis; the mutation is in the gene for the protein BCS1L, which is required for assembly of complex III. 1826 Liver failure caused by BCS1L mutations has also been described. 1827 Disorders of mitochondrial DNA production Another important group of mitochondrial disorders display mtDNA depletion, 1828 which may result in respiratory chain dysfunction. Infantile villous atrophy presenting as intractable diarrhoea with mitochondrial abnormalities in muscle or liver may be an example of such a disease process. 1829, 1830 Various specific gene defects are known to be associated with mtDNA depletion; of these, mutations in deoxyguanosine kinase (dGK or DGOUK) is the abnormality frequently associated with liver disease. [1831] [1832] [1833] [1834] [1835] It may present as a chronic-pattern neonatal liver failure with features similar to perinatal haemochromatosis; it may also present as liver failure later in the first year of life. 1836 Other genes whose mutations may lead to mtDNA depletion include MPV17, SUCLG1, and PEO1/C10orf2, which enclosed the Twinkle DNA helicase. Any of these disorders may present as neonatal liver failure. MPV17 mutations can also present with the chronic liver disease picture of Navajo neurohepatopathy (NNH).

Alpers syndrome (or Alpers-Huttenlocher syndrome) typically follows a relatively more chronic course and is associated with mutations in DNA polymerase γ. [1837] [1838] [1839] [1840] Mutations in POLG can lead to a diverse spectrum of clinical disease, which may account for some of the heterogeneity of Alpers syndrome. 1841 Patients typically present with a clinical triad of refractory seizures, psychomotor regression and hepatopathy. 1828 They have diffuse cerebral degeneration and progressive neuromuscular deterioration, including ataxia, which leads to death, often in the first 2 years of life. 1842, 1843 The initial presentation is usually neurological, with myoclonic seizures and developmental delay; hepatic involvement is variable but can progress to liver failure over months, and thus frequently heralds death. Rarely, the clinical mitochondrial translation elongation factor G1, encoded by GFM1. 1862 Neonatal liver failure occurred with mutations in the gene TSFM which encodes the elongation factor EFTs. 1863 In the rare case with mutated EFTu, neurological disease dominated the clinical picture, although there was hepatomegaly. 1864

Fatty acid oxidation disorders represent a broad spectrum of defects in β-oxidation. 1865 Hepatocellular fatty acid metabolism involves complex processes that take place in both the cytoplasm and mitochondria. Long-chain acyl-CoA esters are transported into mitochondria by a carnitine-dependent mechanism; these esters are then metabolized by β-oxidation within the mitochondria. Some of these processes occur at the inner mitochondrial membrane, and others occur within the mitochondrial matrix. Defects in fatty acid oxidation compromise energy production and interfere with formation of ketone bodies; production of dicarboxylic acids becomes a dominant alternate pathway. Hepatic clinical presentation often mimics Reye syndrome. 1812 Disorders likely to cause liver disease include defects in carnitine handling, especially carnitine uptake (OCTN2) and carnitine palmitoyl transferase (CPT1, CPT2) defects, medium-chain acyl-CoA dehydrogenase (MCAD) deficiency and long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, in that fatty liver of pregnancy occurs in a heterozygote mother carrying a homozygote-affected fetus, and because affected individuals may develop neonatal liver failure or have a delayed hepatic presentation with cholestatic liver disease or cirrhosis. 1866 Diagnosis and treatment of these disorders are difficult. 1812, 1865 Carnitine supplementation may be effective in some disorders and indeed lifesaving in carnitine uptake deficiency (OCTN2 defects). Avoiding prolonged fasting is critically important for all these patients.

Histopathological study of liver and muscle, including examination of ultrastructural features with electron microscopy, may reveal characteristic abnormalities.

Steatosis is typically in the form of fine, cytoplasmic vacuolation around a centrally placed nucleus. Macrovesicular steatosis, defined as a single large droplet displacing the hepatocyte nucleus, often coexists ( Fig. 3.129 in small liver biopsy specimens, overlapping therefore with the histological changes of other metabolic disorders. In such cases the clinical context is critical. Criteria for diagnosing hepatic involvement in Alpers syndrome have been proposed and include microvesicular steatosis and oncocytic change, but these criteria are otherwise not particularly distinctive. 1867 Histochemical examination of cytochrome-c oxidase in liver and muscle may be highly informative. 1868 Some respiratory chain subunits can be detected by immunohistochemistry. Molecular biological techniques permit quantification of mtDNA as well as detection of some deletions and mutations in either nuclear or mitochondrial DNA. Whole-exome sequencing revealed homozygous mutations in MPV17 and SERAC1 in two patients with liver failure. 1869, 1870 Some centres have developed polarographic or enzymatic methods of measuring respiratory chain activity; these and newer diagnostic modalities have been reviewed. [1871] [1872] [1873] If fresh tissue is required for these studies, patients may need to go to centres specializing in mitochondrial disorders. Assays of fatty acid oxidation can be performed in skin fibroblasts, either enzymatically or functionally. 1797 Liver biopsy tissue may be informative regarding respiratory chain defects even in the absence of obvious liver disease. 1874 Histopathological changes in defects of mitochondrial OX-PHOS have been described by numerous investigators.* All have been characterized by microvesicular steatosis (see Fig. 3 .129), variable cholestasis and ductular reaction, variable and sometimes progressive fibrosis and in some cases by cirrhosis (Figs 3.130 and 3.131) . The most detailed descriptions, including ultrastructural studies, were reported in a series of 10 patients by Bioulac-Sage et al. 1875 and in another series of five patients by Morris et al. 1877 Additional histopathological features have included haemosiderosis and an oncocytic appearance of liver cells (from increased number of mitochondria) (Fig. 3.131) . 1878 Changes at the ultrastructural level include pleomorphic mitochondria with few or no cristae and a fluffy, granular matrix 1819, 1875 (Fig. 3.132 ). Morphological findings in Alpers syndrome are similar to those of other mitochondrial cytopathies (Figs 3.133 and 3.134) . Correlation of hepatic changes with those in other organ systems may be useful. 1880 In a recent study of 17 patients with mtDNA maintenance disorders due to MPV17 mutations, steatosis (microvesicular or mixed micro-and macrovesicular) was the most frequent change. 1881 Other changes included fibrosis of variable degree, cholestasis and siderosis. Similar findings were reported by Al-Hussaini et al. 1836 in 11 patients with mitochondriopathies caused by MPV17 (seven patients) or DGUOK (four patients) mutations. In a series of eight patients affected by a defect in mitochondrial synthesis caused by a mutation in the gene encoding for tRNA 5-methylaminomethyl-2-thiouridylatemethyltransferase (TRMU), liver biopsy in a 4-year-old child showed cholestasis, microvesicular steatosis and siderosis. 1882 Cholestasis, fibrosis and small-and large-droplet steatosis were described in an infant with encephalopathy and chronic liver failure caused by a mutation in the gene encoding for the mitochondrial translation elongation factor G1 (GFM1). 1883 In nine patients with fatty acid oxidation disorders, including MCAD and LCHAD deficiency, the histopathological findings were mainly those of microvesicular steatosis. 1884 Amirkhan et al. 1876 reported severe ballooning degeneration of liver cells, mild cholestasis and marked bridging fibrosis. Ultrastructurally, large, oval, membranebound vesicles containing a loose, flocculent material and irregular internal membrane profiles were noted. Large-and small-droplet steatosis was identified in the liver of two infants affected by shortchain enoyl-CoA hydratase (SCEH) deficiency. 1885 

Wilson disease is an autosomal recessive disease, with an average incidence of 1 in 30,000 individuals worldwide. The implicated gene, localized to chromosome 13q-14.3, encodes a P-type ATPase which transports copper. Over 500 mutations in this gene have been identified. The symptoms and signs of Wilson disease are the result of copper overload in various organs. The disease is rarely symptomatic before 3 years of age and usually is manifested by signs of liver disease in adolescence. 1886 The diagnosis is occasionally made in patients older than 50. The diagnosis should be considered in any child or adult with hepatocellular disease of undetermined cause, including elevated serum aminotransferases or fatty liver.

Wilson disease may present as a noninfectious recurrent hepatitis or mimic autoimmune hepatitis with findings that include arthropathy, elevated γ-globulin levels and positive antinuclear or anti-smooth muscle antibodies. 1886, 1887 Severe Coombs-negative intravascular haemolysis is usually seen when the presentation is that of acute liver failure (which occurs more often in females); typically such patients have an extremely low serum alkaline phosphatase (ALP) level, comparatively low serum alanine (ALT) and aspartate (AST) aminotransferases and a low serum uric acid level before renal failure. Simple composite indices of laboratory tests have been proposed to facilitate the diagnosis of Wilsonian fulminant hepatic failure. The ratio of serum ALP (in IU/L) to serum bilirubin (in mg/dL) is typically <2 in Wilsonian liver failure. 1888 More recently, in children with Wilsonian hepatic failure, this ratio was <2 IU/µmol; it distinguished paediatric Wilson disease patients from those with acute liver failure from other causes. 1889 A further refinement for adults consists of ALP/total bilirubin (TB) ratio of <4 and AST/ALT ratio of <2.2; together, these ratios can be effective for making the diagnosis Correlation of phenotype with specific mutations (genotype) is difficult in Wilson disease because the vast majority of affected individuals are compound heterozygotes, possessing one copy each of two different mutations. In general, mutations which abrogate production of an intact functional Wilson ATPase protein cause more severe disease, with an earlier and typically hepatic presentation. [1903] [1904] [1905] [1906] Differences in clinical features of various mutations between siblings and even identical twins suggests that other genes or environmental factors are important. 1887, [1907] [1908] [1909] [1910] The only modifying gene thus far identified is apolipoprotein E. 1911 COMMD1 does not appear to act as a gene modifier of ATP7B, 1912, 1913 although there is some suggestion that COMMD1 polymorphism influences age of onset. 1914 The diagnosis is not necessarily simple even when the disease is actively being considered. 1915 In a patient in the age-range 5-50 years who has hepatic disease or typical neurological symptoms, finding serum caeruloplasmin below 5 mg/dL is highly consistent with Wilson disease; finding also a Kayser-Fleischer (KF) ring confirms the diagnosis. Serum caeruloplasmin can be within normal range in as many as one-third of patients. Using receiver-operator curve analysis in patients proven to have Wilson disease by genotyping, Mak et al. 1916 suggest that with the immunoassay, a serum caeruloplasmin below 14 mg/ dL may be informative. (The labour-intensive copper oxidase method is more reliable than immunoassay, which measures apocaeruloplasmin as well as holocaeruloplasmin; its use is generally restricted to research laboratories, but automated techniques are being developed. 1917, 1918 ) Serum caeruloplasmin by itself is not a sufficient diagnostic test for Wilson disease. KF rings are diagnostic, except in patients who have chronic cholestasis of other aetiology. Absence of KF rings occurs in approximately 50% of adult patients with liver disease and thus does not rule out Wilson disease. KF rings may not be present even when there is neurological involvement. 1919 In Wilson disease, the 24-hour urine copper excretion is usually >100 µg (1.6 µmol) and almost always exceeds 40 µg (0.6 µmol). This lower cutoff has proved highly informative in children. 1920 of Wilsonian liver failure, in contrast to serum caeruloplasmin. 1890 Fulminant hepatic failure in Wilson disease may sometimes be precipitated by viral hepatitis. 1891 Neuropsychiatric signs are the predominant presentation in adults but also may be present in up to 50% of teenagers. Tremors, dysarthria, drooling and gait disturbances are frequently observed. Psychiatric manifestations include personality changes and irritability, frank psychosis and depression; some patients may present with only psychiatric symptoms. 1892 Intermittent bouts of jaundice caused by low-grade haemolysis occur in some patients. Bilirubinate gallstones may develop. Ocular findings include the Kayser-Fleischer ring, due to copper accumulation in Desçemet's membrane, and sunflower cataracts, due to copper accumulation in the lens. Both these signs require slit-lamp examination for reliable detection. Relatively common complications include gynaecomastia in males and amenorrhoea in females. Although pregnancy is still possible, repeated spontaneous abortion may occur in women with Wilson disease before diagnosis and treatment. Cardiac complications include ECG abnormalities in 33% of patients. 1893 Ventricular fibrillation is rare, with or without cardiomyopathy. Orthostatic hypotension occurs in 19% of patients, with one-third having an abnormal vascular response. 1893 Urolithiasis is a rare initial presentation. 1894 Renal tubular disease is common and may be either proximal or distal dysfunction. Less well-known complications include hypoparathyroidism, 1895 pancreatic insufficiency from pancreatitis 1896 and rhabdomyolysis.

Although rare in Wilson disease compared to other liver diseases (<20 cases reported), hepatocellular carcinoma occurs in patients of all ages, as young as 9 and 12 years old 1897, 1898 up to the 70s. [1899] [1900] [1901] HCC is a common complication in the Long-Evans Cinnamon rat, the animal model of the disease, but this rat also has hepatic iron overload and abnormalities in p53 function. Cholangiocarcinoma may also occur in Wilson disease. It has been suggested that liver and gastrointestinal malignancies may be more common than often appreciated. 1902 investigated by nuclear magnetic resonance (NMR). 1938, 1939 More than 500 gene alterations in ATP7B have been reported. These are listed comprehensively in various databases, including the HUGO Wilson Disease Database maintained at the University of Alberta (see www.medicalgenetics.med.ualberta.ca/wilson/index.php). The overall pattern of ATP7B mutations (mainly missense) in Wilson disease differs from the ATP7A mutational spectrum found in Menkes disease (large deletions).

Copper disposition in hepatocytes is highly regulated. Available copper in the plasma compartment is bound to albumin or histidine and undergoes reduction to the cuprous form before being transported into hepatocytes by the transmembrane transport hCTR1, encoded by the gene SLC31A1, which appears to span the hepatocellular plasma membrane as a trimer to form a channel. Near the amino terminus, hCTR1 has a copper-binding domain which contains a methionine cluster (MXXXM). 1940, 1941 A second copper transporter, hCTR2, is involved in low-affinity copper uptake by hepatocytes. The action of hCTR1 does not regulate hepatocellular copper homeostasis; however, when copper concentrations are elevated, hCTR1 is degraded. Inside the hepatocyte, little if any copper exists as free copper, apparently because it is a pro-oxidant. Cellular copper toxicity can be prevented by binding to metallothionein and glutathione. Small proteins called 'metallochaperones' mediate delivery of copper to specific sites within the cell. 1942, 1943 CCS1 directs copper to SOD1 in the cytoplasm. Cox17 supplies copper to cytochrome-c oxidase in mitochondria. Sco1 and Sco2 mediate the transfer of copper to subunit II of cytochrome-c oxidase, and other metallochaperones might be involved. ATOX1 transports copper to the Wilson ATPase. ATOX1 has a single CXXC copper-binding motif; it interacts directly with the Wilson ATPase to transfer copper. 1944, 1945 The Wilson ATPase has dual functions: incorporating copper into nascent caeruloplasmin and facilitating biliary excretion of copper. Studies using various model systems have shown that the intracellular location of the Wilson ATPase changes with increased intracellular copper concentration. When intracellular copper concentration is elevated, the Wilson ATPase redistributes to the vicinity of the bile canalicular membrane. 1946 Details of the cellular mechanism of biliary excretion of copper remain unknown. Direct exocytosis into bile of copper from cytoplasmic vesicles in the endosome-lysosome spectrum is an important mechanism. Lysosomal function relating biliary excretion in the Long-Evans Cinnamon (Wilsonian) rat is normal. 1947 Other mechanisms for biliary excretion include a paracellular pathway 1948 and direct transfer of copper bound to glutathione via a bile canalicular transporter. 1949 COMMD1 ('MURR1' renamed, once it became evident that it was part of a family of proteins) is a ubiquitously expressed protein encoded by COMMD1, the gene which may be abnormal in Bedlington terrier hereditary copper toxicosis. The role of COMMD1 in hepatocytes is unclear, but it likely plays a role in the biliary excretion of copper. COMMD1 appears to interact with the Wilson ATPase. 1950 Based on clinical experience, the therapeutic strategy of choice remains chelating agents, particularly D-penicillamine. 1951 In the Long-Evans Cinnamon rat, the drug dissolves copper-rich granules in hepatic lysosomes and prevents the development of fulminant hepatitis. 9 Serious adverse effects may occur with D-penicillamine. Alternatives to D-penicillamine include trientine 1952-1954 and zinc. 1955,1956 Trientine is a chelator with an entirely different structure from that of penicillamine, whereas the mechanism of action of zinc involves competition for copper uptake. It entails induction of enterocyte metallothioneins which have greater affinity for copper than for zinc; consequently, copper taken up by enterocytes is bound and excreted with normal enterocyte turnover. In addition to blocking uptake, this leads to total body depletion of copper by interfering with reabsorption of copper recycled though bile and other fluids

Accumulating data indicate that, if taken as the cutoff for adults, it would improve detection rates for Wilson disease. When penicillamine 500 mg is administered by mouth at the beginning and 12 h later during a 24-hour urine collection, copper excretion >25 µmoles (1587 µg) per 24 h is taken as diagnostic. 1921 This test has been validated only in children, and its sensitivity is not as great as originally thought. Thus its application has become somewhat limited. With compatible pathological changes, a liver copper concentration over 250 µg/g dry weight is diagnostic; however, lower values may be found if the sample is too small or there is variable distribution of parenchymal copper. A lower diagnostic threshold for Wilson disease, based on measurements in a large number of well-characterized patients, has been suggested: 70 µg/g dry weight. 1922 A recent study has shown that when two liver biopsy cores are obtained and one is entirely used for copper estimation, provided that this core weighs more than 1 mg dry weight, a cutoff value of 209 µg/g dry weight has a specificity and sensitivity of 99.4% and 96.1%, respectively. 1923 If the liver copper is in the range of 70-250 µg/g dry weight, further investigations, mainly genetic, are required to exclude or confirm the diagnosis. In the patient who has numerous definite clinical features of Wilson disease, therapeutic intervention should not be withheld until the liver copper concentration is reported. Liver copper <55 µg/g dry weight is within normal range. 1924 Screening the proband's first-degree relatives should include serum AST, ALT, copper and caeruloplasmin determinations, slit-lamp examination for KF rings and basal 24-hour urinary copper determination. Liver biopsy is appropriate for patients with abnormal findings. If the proband's genotype is known, genetic analysis is the more efficient way to screen first-degree relatives.

Mutational analysis can be difficult for several reasons: patients are usually compound heterozygotes; some mutations may be in the promoter region; and mutations must be shown to lead to a nonfunctional Wilson ATPase, a criterion not met currently by all proposed mutations. The role of mutational analysis is critically important in identifying affected first-degree relatives if the genotype of the proband is known. It can also be useful in ethnicities known to have a limited spectrum of ATP7B mutations, for example, in Iceland, Sardinia, the Canary Islands and possibly in northern Europe. However, high-throughput detection methods for analysing DNA are improving rapidly. These include denaturing high-performance liquid chromatography (DHPLC), 1925 automated single-strand conformation polymorphism (SSCP) analysis 1926 and direct sequencing. 1927 A recent study from the United Kingdom of 181 patients with Wilson disease showed that direct sequencing analysis of the entire ATP7B coding region considerably increases the mutation detection rate. 1928 New methods involving microarray techniques have also been reported. 1929 Dietary copper is taken up by the intestinal cell, transported to copper-containing cellular proteins, including metallothionein, or exported from the cell across the basolateral membrane by a process involving the Menkes ATPase (ATP7A). The protein normally resides in the trans-Golgi network and in cell culture moves to the plasma membrane under conditions of high cellular copper concentrations. 1930, 1931 The ATP7A gene is expressed in most tissues except the liver. An X-linked copper deficiency disorder, Menkes disease, results from mutations in this gene. 1932, 1933 The gene abnormal in Wilson disease (ATP7B) shows 56% homology to ATP7A and has 21 exons. [1934] [1935] [1936] It is expressed mainly in the liver. Its product, the Wilson ATPase, has an N-terminus tail comprising six copperbinding sites, each with a cysteine-rich CXXC amino acid motif. Like the Menkes ATPase, this copper-transporting ATPase is also located in the trans-Golgi network. The structure of the Wilson ATPase has been determined by homology mapping using Serca1, the sarcoplasmic Ca 2+ P-type ATPase, as model 1937 ; it has also been draining into the intestinal tract. Zinc treatment may also cause hepatic copper to be stabilized by induction of hepatocellular metallothioneins, and it may have other effects on hepatocellular metabolism. Zinc action is independent of which salt is administered; dosage is calculated as elemental zinc. Compliance remains a major issue because dosage is thrice daily away from food, but effectiveness can be monitored by a decrease in non-caeruloplasmin-bound copper, regression of Kayser-Fleischer rings, improving liver tests and 24-hour urinary excretion of copper. On chelator treatment, this is expected to run in the 3-8 µmol/day range, but on zinc it should diminish toward normal (<1.2 µmol/day as target), as a reflection of decreased total body copper load. Antioxidants (mainly vitamin E) may be used as adjunctive therapy. Dietary therapy includes avoidance of liver, shellfish, mushrooms, chocolate and nuts, but dietary treatment alone will not control the disease.

Liver transplantation is reserved for patients unresponsive to medical therapy or with fulminant hepatic failure. One-year survival is excellent, about 85-90%. 1957, 1958 A recent study from France showed a similar survival rate at 5, 10 and 15 years. 1959 Living-donor transplantation from an individual obliged to be a heterozygote with one ATP7B mutation (e.g. a first-degree relative) is physiologically acceptable. 1960, 1961 LT for neurological complications is highly controversial and generally cannot be recommended. [1962] [1963] [1964] Ammonium tetrathiomolybdate is an experimental therapy mainly used in patients with CNS involvement. 1965 There has been some success with combination therapy with zinc and trientine administered individually in a temporally dispersed pattern every 5-6 h through the day (for clinically severe disease, usually decompensated cirrhosis). 1966 This intensive drug regimen is best reserved for induction therapy: those who improve can usually be switched to a single-drug regimen after several months. Introduction of ATB7B into the Long-Evans Cinnamon rat by recombinant adenovirus-mediated gene delivery restores normal hepatic copper secretion into the serum and bile. [1967] [1968] [1969] The pathological effects of Wilson disease are considered to be directly related to the accumulation of copper in the brain, cornea, liver and kidneys, but pathogenetic mechanisms are unknown. Oxidative stress appears to play an important role because copper is a redox-active pro-oxidant. In severe liver disease requiring LT, extensive functional abnormalities in hepatic mitochondria have been detected. 1970 Detailed studies in a mouse model of Wilson disease indicate that mitochondrial dysfunction is limited to complex IV of the OX-PHOS chain. 1971 The findings may also provide additional rationale for the use of antioxidants in Wilson disease. Recent observations show that copper interferes with nuclear receptor function, principally with RXR, not only in Wilson disease but in severe cholestasis with hepatocellular retention of copper. 1972 When Wilsonian fulminant hepatic failure occurs, evidence of massive hepatocellular apoptosis can be found. 1973 Patients presenting with acute hepatitis are rarely biopsied. According to Scheinberg and Sternlieb, 1887 the livers of these patients show ballooning of hepatocytes, apoptotic bodies, cholestasis and a sparse lymphocytic infiltrate. Typically, the biopsy in the precirrhotic stage is characterized by variable portal inflammation, moderate anisonucleosis, focal necrosis, scattered sinusoidal apoptotic bodies and moderate to marked steatosis 1974 (Figs 3.135 and 3.136 ). Lipofuscin accumulates in periportal areas, and some of the granules are large, irregular in shape and vacuolated. 1974 Kupffer cells may be slightly enlarged and laden with haemosiderin, presumably as a result of the acute haemolytic crises that may complicate the disease. There is a progressive increase in periportal bile ductular reaction and fibrosis. Variable numbers of inflammatory cells, chiefly lymphocytes and plasma cells, are seen in the connective tissue of portal areas. Changes indistinguishable from those of chronic hepatitis due to other aetiologies, in particular autoimmune hepatitis, may be seen [1975] [1976] [1977] (Figs 3.137 and 3.138) . In our experience, helpful differential clues in the diagnosis of Wilson disease (in addition to portal inflammation and interface hepatitis) include steatosis, periportal glycogenated nuclei, moderate to marked copper storage (Fig. 3.139) and Mallory-Denk bodies in periportal liver cells.

Cytochemically demonstrable copper is usually confined to periportal hepatocytes in the precirrhotic stage of Wilson disease. With the use of special stains (Timm stain) and electron probe microanalysis, Goldfischer and Sternlieb 1978 showed that in young, asymptomatic patients, copper is diffusely distributed in the cytoplasm of hepatocytes. In slightly older patients who exhibit early symptoms or signs of the disease, the metal is both diffusely distributed and intralysosomal, whereas in patients with advanced disease, all the copper is confined to lysosomes (Fig. 3.139) . The various staining methods for the demonstration of copper in tissue sections have been reviewed by Lindquist 1979 and Irons et al. 1980 In our experience and that of others, 1980 the p-dimethylamino benzylidene rhodanine method gives the most reproducible results (Fig. 3.139) ; both it and the rubeanic acid method are specific for copper. There is a linear relationship between microscopic evaluation of the stain and actual tissue copper levels. 1980 Copper-binding protein can be stained by of Wilson disease. Early in the disease, copper is mainly in the cytosol and is highly soluble, particularly in poorly buffered formalin; lysosomal copper-binding protein may also be absent. Failure to detect hepatocellular copper histochemically is particularly common in children presenting with Wilson disease. Of note, children with primary sclerosing cholangitis may have periportal deposits of copper and copper-binding protein on liver biopsy specimens, and marked hepatic copper overload mimicking Wilson disease has been described in children with MDR3 deficiency. 679 Both caeruloplasmin and metallothionein have been demonstrated immunohistochemically in the liver in patients with Wilson disease. Graul et al. 1984 found no difference in the pattern of staining of caeruloplasmin in the livers of patients with Wilson disease and normal adults or neonates. Studying the distribution of metallothionein in Wilson disease, Nartey et al. 1985 found that in sections with minimal tissue damage, there was intense cytoplasmic staining for metallothionein in liver cells, whereas in sections with extensive necrosis and fibrosis, there was both nuclear and cytoplasmic staining.

The Wilson ATPase has been examined in the human liver by immunoblotting, IHC and double-label confocal scanning laser microscopy. 1986 It is present predominantly in trans-Golgi vesicles in the pericanalicular area, but relatively small amounts of the protein appear to localize near the canalicular membrane, consistent with a dual function of the protein in holocaeruloplasmin synthesis and biliary copper excretion. Defective trafficking within hepatocytes is a functional characteristic of some mutations.

The cirrhosis of Wilson disease is usually macronodular but can be mixed or even micronodular in type. 1974 Microscopically, it is characterized by varying-sized nodules separated by fibrous septa that may be wide or very thin, with minimal ductular reaction and variable inflammation (Fig. 3.140 ). All changes in the precirrhotic stage are also seen in the cirrhotic liver. In addition, Mallory-Denk bodies can be identified frequently at the periphery of the cirrhotic nodules ( Fig. 3.141 ). Variable numbers of apoptotic bodies may be present. Clusters of large hepatocytes with a granular eosinophilic cytoplasm (oncocytic or oxyphil cells), resulting from an increased number of mitochondria, are often seen. The distribution of copper is quite variable, with some of the cirrhotic nodules containing a lot and others containing little or none. 1974 Copper is rarely demonstrable in Kupffer cells or portal macrophages in the cirrhotic stage, but it is frequently encountered in cases of submassive or massive orcein in Wilson disease and other conditions (e.g. chronic cholestatic disorders), [1980] [1981] [1982] [1983] as well as by aldehyde fuchsin and Victoria blue. The granules also stain with a variety of stains for lipofuscin that is aggregated in the same lysosomes. 1974 Negative staining for both copper and copper-associated protein does not exclude the diagnosis Mallory-Denk bodies appear as masses of randomly oriented and densely packed fibrils (each ~15 µm in diameter), which are partially rimmed by bundles of finer filaments but are not limited by membranes. 1991, 1992 Lipolysosomes, which constitute 1-2% of the lipid droplets in hepatocytes in Wilson disease, may represent a nonspecific alternate route for the mobilization of excess lipid from hepatocytes. 1993 Importantly, ultrastructural mitochondrial changes in Wilson disease cannot be considered pathognomonic; although exceedingly rare with cholestatic liver disease, such changes are found with mtDNA depletion disorders. 1994 However, the presence of abnormal mitochondrial morphology in young children with Wilson disease, in whom copper studies are not clearly diagnostic, may help to confirm the diagnosis. One ultrastructural study of liver tissue from a family of nine siblings suggested that mitochondrial changes may not be sufficient for detecting a presymptomatic affected person. 1995 In our experience with genetically confirmed Wilson disease, mitochondrial changes occur early and can be informative.

The long-term effects of D-penicillamine therapy on the structure and function of the liver in patients with Wilson disease were reported by Sternlieb and Feldmann. 1996 Liver biopsy specimens from seven patients, obtained before and after 3-5 years of therapy, were studied Davies et al. 1987 also noted the presence of copper in hepatic parenchymal and mononuclear phagocytic cells in 11 patients with Wilson disease who, although presenting with fulminant hepatic failure, were cirrhotic. Another case has been described in detail. 1988 Ultrastructural findings in the precirrhotic stage of Wilson disease have been described in detail. 5, 1887, 1989 Of these, the mitochondrial changes are the most distinctive and pathogenetically significant and include heterogeneity of size and shape, increased matrix density, separation of inner from outer membranes, enlarged intercristal spaces and various types of inclusions (Fig. 3.144 ). Sternlieb 1990 also described three distinct patterns of structural abnormalities of the mitochondria in hepatocytes of 40 of 42 asymptomatic and 8 of 32 symptomatic patients with Wilson disease before therapy. There was no correlation between the type of abnormality and the patient's age, hepatic copper concentration, degree of hepatic steatosis or the serum aminotransferase levels. There was, however, a high degree of fraternal concordance, suggesting that the structural changes are genetically determined. Alterations in Wilson disease, other than those affecting mitochondria, include an increase in the number of peroxisomes (which may appear heterogeneous and denser and larger than normal), lipofuscin granules and multivesicular bodies. by EM and stereology. The characteristic mitochondrial abnormalities encountered in the hepatocytes of untreated patients were less pronounced or disappeared after treatment in five of the seven patients. Simultaneously, relative mitochondrial volume, surface density of the external mitochondrial membranes and number of these profiles per unit area increased, whereas abnormal elevations of serum aminotransferases returned to normal.

This hepatic copper toxicosis has been most prevalent in the Indian subcontinent. 1997 Indian childhood cirrhosis (ICC), or a liver disorder strongly resembling it, has been reported from numerous countries, including cases from the United States. 710, 1998 ICC should not be confused with North American Indian cirrhosis (or cholestasis), which is caused by mutations in the cirhin gene. 710, 711, 713 In India, ICC was a significant cause of morbidity and mortality among children younger than 5 years. 1999 The incidence in India has declined sharply after recognition of the role of copper overload in its pathogenesis. 2000, 2001 Epidemiological and clinical aspects of ICC are well reviewed. 1999, 2002 The age range is from 6 months to 5 years, with a peak around 2 years. In 30-50% of patients with ICC, there is a history of sibling disease and death, but Mendelian inheritance is not apparent. Evidence against a genetic background for the disease is its apparent absence in South Asian expatriates in the United Kingdom, Africa and North America. 2003 Three clinical stages of ICC have been recognized 2002 : (1) an early stage with an insidious onset characterized by disturbances of appetite and bowel movement, slight enlargement of the liver and occasional jaundice; (2) an intermediate stage characterized by irritability, minimal jaundice, marked hepatomegaly, splenomegaly and occasionally, subcutaneous oedema, ascites and susceptibility to infection; and (3) a late stage with increasing jaundice, hepatosplenomegaly and progression to hepatic failure and death.

Hepatic histopathology in ICC 2004 has been described in detail. 1999, 2002, 2004 The earliest changes are ballooning degeneration and focal necrosis, followed by formation of Mallory-Denk bodies, 1992 sometimes with neutrophilic satellitosis. Steatosis is conspicuously absent (Fig. 3.145) . The mesenchymal reaction is characterized by inflammatory cell infiltration (lymphocytes, histiocytes, neutrophils and a few plasma cells), variable periportal ductular reaction, progressive fibrosis and eventually development of a micronodular cirrhosis (Fig. 3.146) . Regenerative activity appears absent. 2004 ICC is associated with marked hepatic copper overload (Fig. 3.147) . The copper storage has been demonstrated histochemically (by staining tissue sections with orcein for copper-binding protein and using the rhodanine method for copper) and by quantitative techniques such as atomic absorption spectrophotometry. 2000, 2001, 2005, 2006 It is now generally accepted that the copper storage is directly responsible for the histopathological lesions in ICC. The copper accumulates first in periportal hepatocytes and then extends toward the terminal hepatic venules. Orcein stain may also have diagnostic utility. 2007 In 1983 , Tanner et al. 2008 proposed that increased dietary copper (from copper-contaminated milk stored in brass and copper containers) could be of aetiological significance in ICC. Subsequently, O'Neill and Tanner 2009 demonstrated experimentally that copper (but not zinc) is avidly taken up from brass and bound to casein, from which copper is completely removable by picolinate chelation. They concluded that milk is an effective carrier of copper from a brass utensil to the infant enterocyte. Several studies of clinical recovery, improved long-term survival and even reversal of the hepatic histological lesions by penicillamine therapy in infants with ICC provide evidence for a direct cytopathic effect of copper. [2010] [2011] [2012] Cases of an ICC-like disease caused by chronic ingestion of water with

Primary immunodeficiencies are a group of rare inherited disorders characterized by one or more abnormalities of the immune system. Many of these disorders are X-linked, and males are more likely to be affected. They manifest clinically with infections and/or malignancy, and dysregulated immunity in the form of autoimmunity, autoinflammation and/or allergy. Infections of the upper and/or lower respiratory tract or gastrointestinal (GI) symptoms such as diarrhoea are common clinical presentations. 2020 Recurrent infections affecting multiple sites, of prolonged duration and unusual intensity, and by unusual organisms should raise suspicion of a primary immunodeficiency (PI). Susceptibility to specific organisms is a characteristic of some PIs. Acquired disorders or other conditions such as drug-related immunosuppression, human immunodeficiency virus (HIV) infection or cystic fibrosis need to be excluded in the first instance. Liver involvement in patients can occur for various reasons: directly as a result of the PI, or as a consequence of medical therapy or in connection with haematopoietic cell transplantation. The most common manifestation is sclerosing cholangitis, often related to Cryptosporidium infection. Liver abscesses, granulomatous inflammation, autoimmune hepatitis and nodular regenerative hyperplasia have also been described. The most recent classification 2021 divides the PI disorders into nine categories (Table 3 .7). The reader is referred to this classification; a more detailed description of these disorders is beyond the scope of this chapter. Only the main conditions associated with liver involvement are discussed here.

Chronic granulomatous disease (CGD) is characterized by recurrent purulent infections caused by bacteria (usually catalase-positive) or fungi. The onset is generally before 1 year of age, although milder forms may present in adulthood. Marked lymphadenopathy, hepatomegaly and splenomegaly are common findings. 2022 Liver abscess occurred in approximately one-third of 268 patients with CGD, 2023 and Staphylococcus aureus was the most frequently isolated organism. In CGD, antimicrobial activity of phagocytes is impaired due to the lack of reactive oxygen species, or oxidative burst, normally produced by NADPH oxidase. The most common X-linked form of CGD represents 70% of all cases. 2024 Autosomal recessive forms are considerably rarer. CGD is caused by mutations in the cytochrome-b β-subunit (CYBB) gene, which maps to chromosome Xp21, 2025 cloned in 1986, 2025 and encoding the gp91-phox (phagocyte oxidase) protein, a necessary component in the NADPH oxidase pathway. 2026, 2027 It is currently classified in the category of defects in intrinsic and innate immunity. 2021 Mutations in the CYBB gene responsible for CGD have been described, permitting prenatal diagnosis. 2028 Assessment of defective granulocyte function by flow cytometry can be used in neonates. 2029 Patients are screened for CGD by the nitroblue tetrazolium dye reduction assay. 2030 Although some CGD patients respond to interferon-γ therapy, this has not been a useful long-term treatment. 2031 Radical surgery is recommended for liver abscess. 2032 BMT was helpful in one case. 2033 Granulocyte transfusions from healthy donors given G-CSF subcutaneously and dexamethasone orally 12 hours before collection have helped to eradicate occurrence of invasive aspergillosis. 2034 Recently, stem cell transplantation with a reduced-intensity conditioning protocol has been followed by full donor chimerism and normalization of superoxide production. 2035 Gene therapy, including ex vivo protocols, are promising 2036 and the subject of intense investigation in murine models. [2037] [2038] [2039] The characteristic pathological features of CGD are the granulomatous response to infection and the widespread accumulation of lipofuscin pigment in reticuloendothelial cells [2040] [2041] [2042] [2043] (Fig. 3.148 A) . high levels of copper ('hepatic copper toxicosis') are discussed in Chapter 12. The decline in the incidence of ICC since feeding practices have been changed to avoid the use of copper vessels for infants and young children, and the continued remission of affected children after discontinuing penicillamine once sufficient hepatic copper has been removed, suggest that environmental factors are important in the development of ICC. Developmental and genetic factors cannot be entirely excluded. 2013 Studies indicate that COMMD1, the gene abnormal in Bedlington terrier hereditary copper toxicosis, does not play a role in either ICC or Tyrolean infantile cirrhosis. 2014 A disorder resembling ICC has been described in Indian children 5-15 years old. 2015 The disorder differs from classic ICC because of its late clinical presentation and relatively slow progression of liver damage. It differs from Wilson disease in that serum caeruloplasmin is in normal range or elevated and 24-hour basal urinary copper excretion is only moderately increased (0.8-2.5 µmol/24 h). Liver biopsy shows no steatosis; micronodular cirrhosis may be present. It is not clear whether this is a different disorder or a milder presentation of ICC. Its genetic basis is not known.

Clinically and pathologically indistinguishable from ICC, endemic Tyrolean infantile cirrhosis was reported from a circumscribed rural area of Western Austria between 1900 and 1974. 2016 Some 138 infants and young children died from the disease. The frequency of the disease peaked between 1930 and 1960; it has disappeared from that area since 1974. The inheritance was apparently autosomal recessive. Cow's milk, contaminated with copper from untinned copper or brass vessels, may have contributed to the development of copper toxicosis. Replacement of untinned copper cooking utensils by modern industrial vessels eradicated the disease. Tyrolean infantile cirrhosis is believed to be an ecogenetic disorder requiring the involvement of both genetic and environmental factors for its manifestation. 2016, 2017 It is not an allelic variant of Wilson disease. 2018 Histopathological changes include micronodular cirrhosis with copper overload in the most severely affected children. 2019

Common variable immunodeficiency (CVID) is characterized by impaired B-cell function with hypogammaglobulinaemia, although T-cell function may also be deficient. CVID is currently classified in the category of 'predominantly antibody deficiencies' with the understanding that this term includes several clinical phenotypes caused by various genetic and environmental factors. 2021 Recurrent upper and lower respiratory tract infections are a common manifestation, and autoimmune and lymphoproliferative disorders are common complications. Immunoglobulin replacement therapy is the mainstay of treatment. Nodular regenerative hyperplasia has been described in 5% of 261 patients with CVID, with some patients developing portal hypertension. [2049] [2050] [2051] Daniels et al. 2052 described a mild chronic hepatitis picture in a cohort of 10 CVID patients. A granulomatous component is also common. 2050, 2052 Murakawa et al. 2053 described two patients with a severe enteropathy and hepatitis leading to liver failure and LT. Hepatosplenic T-cell lymphoma mimicked juvenile SLE in a CVID patient. 2054

The largest study with the rare, X-linked hyper-IgM syndrome (XHIM), as reported by the Registry of Primary Immunodeficiencies of the European Society for Immune Deficiency, included the clinical and immunological features and outcome of 56 patients. The defect is caused by mutations in the gene encoding for CD40 ligand, located on chromosome Xq 26.3-27. It is currently classified in the category of 'immunodeficiencies affecting cellular and humoral immunity' . 2021 XHIM is a cellular immunodeficiency characterized by disruption of multiple cellular interactions (e.g. T cells-B cells, T cellsmacrophages). Patients are unable to mount IgG, IgA and IgE responses to T-cell-dependent antigens and lack germinal centres, but their ability to produce IgM is preserved. Infections are the most prominent clinical manifestations of XHIM. Upper and lower respiratory tract infections (the latter frequently caused by Pneumocystis carinii), chronic diarrhoea and liver involvement (both caused by Cryptosporidium infections) are common. 2055 Many patients have chronic neutropenia associated with oral and rectal ulcers. An example of cryptosporidiosis in a 15-year-old male with XHIM (diagnosed Small granulomas consist of rings of mononuclear cells which surround an area of homogeneous eosinophilic material and are associated with many plasma cells and a few giant cells. 2044 Confluent granulomas may show larger areas of necrosis and suppuration. Palisading granulomas with central necrosis and associated giant cells were noted in four of seven cases reported by Nakhleh et al. 2045 Special stains for microorganisms are usually negative, unless the granulomas are caused by fungi. 2046 The pigmented histiocytes have a light-tan colour and are PAS positive, argentophilic, sudanophilic (in frozen sections) and autofluorescent (Fig. 3.148 B) . The accumulation of the pigment is thought to be a secondary phenomenon. 2047 In the liver, most of the lipofuscin is found in clusters of greatly hypertrophied portal macrophages or Kupffer cells. Portal areas are infiltrated by plasma cells and lymphocytes, and there may be minimal to moderate fibrosis. A hepar lobatum-like cirrhotic process was described in one patient. 2048 Varying numbers of granulomas and microabscesses may be scattered within the parenchyma, and there may be slight to moderate portal inflammation and fatty change (Fig. 3.149) . haemopoietic stem cells from HLA-matched related or unrelated donors is feasible and curative if performed before significant infections and organ damage occur. 2060 Successful sequential liver and BMT has been reported. 2056, 2059 Histiocytic and haemophagocytic syndromes

Familial haemophagocytic lymphohistiocytosis (FLH), a fatal inherited form of haemophagocytic lymphohistiocytosis (HLH) syndrome, is a defect in cell-mediated cytotoxicity characterized by the overwhelming activation of T lymphocytes and macrophages. It is currently classified as a disease of 'immune dysregulation' . 2021 FLH is a heterogeneous autosomal recessive disorder; one causative gene (PFR1, localized to chromosome 10q21-22) encoding for perforin, a cytotoxic effector protein, has been identified in a subset of patients. 2061, 2062 at age 18 months) is illustrated in (Fig. 3.150) ; ERCP revealed sclerosing cholangitis. In the series of Levy et al., 2055 19.6% of patients had sclerosing cholangitis and 55% of those patients had concomitant cryptosporidiosis. In another series of 20 children from 16 families, 45% had sclerosing cholangitis. 2056 Liver tests are persistently abnormal, with a median AST of 117 IU/L and a γ-glutamyltransferase (GGT) of 182 IU/L in one series. 2056 Patients with XHIM have developed carcinomas of the liver (hepatocellular carcinoma or bile duct carcinoma), pancreas or gallbladder, and also of neuroectodermal endocrine cells. 2055, 2057, 2058 The tumours were fatal in eight of nine cases in one series 2057 and in most instances were preceded by a chronic cholangiopathy and/ or cirrhosis.

Survival in XHIM is poor, 20% at 26 years in the series of Levy et al. 2055 The treatment of choice is intravenous immune globulin (IVIG). 2055 LT has been associated with a high rate of recurrence of cryptosporidiosis, although long-term survivors have been reported. 2055, 2059 Stem cell transplantation is curative, but its success is hampered by conditioning-related liver complications (e.g. veno-occlusive disease, graft-versus-host disease). 2056 Allogeneic Genes implicated are important for the exocytosis of cytotoxic granules which contain perforin and granzymes and induce apoptosis on entering the target cell and therefore are important for the downregulation of the immune response. 2063 The disease is characterized by fever, anorexia, irritability and pallor in infancy and early childhood, although onset in adolescents and adults up to the fifth decade has been reported. 2064 FLH can usually be distinguished from other infantile causes of histiocytosis by the absence of skin lesions and the high incidence of CNS involvement. Hepatosplenomegaly is typically prominent early, and jaundice may develop later. 2065 Extremely abnormal coagulation studies reflect low fibrinogen levels and thrombocytopenia, but other coagulation factors are normal. Neurological symptoms may develop from histiocytic involvement of the brain. Although clinical manifestations may remit temporarily, the disease is eventually fatal. The diagnosis is based on identifying erythrophagocytosis by histiocytes in bone marrow biopsy material or occasionally on liver biopsy. Perforin expression by peripheral lymphocytes, assessment of 2B4 lymphocyte receptor, and natural killer (NK) cell activity have been proposed as rapid tests to assist differentiating FLH from HLH subtypes, therefore highlighting patients with a poor prognosis who may benefit from BMT. 2061 In an autopsy series, haemophagocytosis was most often observed in the spleen, lymph nodes and bone marrow. 2066 Hepatic involvement is characterized by hypertrophy of Kupffer cells and portal macrophages, which manifest striking erythrophagocytosis (Fig. 3.151 ), but this may be inconspicuous or even absent. 2067 In 19 patients, hepatic histology showed portal and sinusoidal infiltrates of CD3, CD8, granzyme B+ lymphocytes admixed with CD68, CD1a−ve histiocytes, with haemophagocytosis in all specimens. 2068 Portal areas may show lymphohistiocytic infiltrates with a predominance of T lymphocytes, in a pattern reminiscent of chronic hepatitis (Fig. 3.151 ). In some cases there is striking enlargement of endothelial cell nuclei and perivenous erythropoiesis resembling graft rejection. 2067 Other changes include mild hepatocellular damage in the vicinity of the lymphohistiocytic infiltrates, variable cholestasis and epithelioid granulomas. 2067

In haemophagocytic lymphohistiocytosis (HLH), also known as infection-associated (reactive) haemophagocytic syndrome, there is proliferation of morphologically nonmalignant histiocytes showing phagocytosis of haemopoietic cells, with associated fever and pancytopenia. Clinical severity ranges from the incidental observation during infection or findings at autopsy that macrophages throughout the body are large and activated to the full-blown haemophagocytic syndrome (HLH), which includes fever, hepatosplenomegaly, coagulopathy and various cytopenias. 2069 HLH can manifest as acute liver failure. 2070, 2071 It can also present as neonatal liver failure; since FLH often shows very high serum ferritin levels, distinction from so-called neonatal haemochromatosis can be difficult. 2072, 2073 Tissue specimens are critical in distinguishing these two diseases because LT is contraindicated in FHL, whereas it might be lifesaving in neonatal haemochromatosis. 2073 Epstein-Barr virus infection (virus-associated haemophagocytic syndrome) remains the most frequent association with HLH, but since the first report in 1979, many other viruses 2074, 2075 and other infectious agents have been incriminated. 2076, 2077 There are a few reports of simultaneous development of HLH and SLE. 2078 Patients with rheumatic disorders, especially juvenile chronic arthritis, appear particularly at risk; the condition is often referred to as macrophage activation syndrome in this setting. 2079, 2080 Haemophagocytic features are often seen in livers of patients with acquired immunodeficiency syndrome (AIDS) (Fig. 3.152 ). The haemophagocytic syndrome may also develop in diseases other than infections, such as lymphoma and disseminated carcinoma. 2081, 2082 In about one-fifth of patients, according to a large recent series of 103 cases, there was no association with an underlying specific disorder. 2083 Reactive (secondary) HLH and macrophage activation syndrome manifest as a massive cytokine and chemokine release, mostly TNFα, IFN-γ, soluble interleukin-2 (IL-2) receptor, IL-6 and other cytokines whose levels in the blood may have a prognostic value. 2084 This cytokine profile distinguishes HLH from the primary familial conditions in which an underlying genetic defect is identified. In contrast, NK-cell function is preserved in the reactive form but defective in the inherited syndromes. 2069 Histologically, there is infiltration of the portal tracts with normalappearing histiocytes, lymphocytes and plasma cells. Sinusoidal changes are prominent and include sinusoidal congestion and increase in size and number of Kupffer cells, which display prominent haemophagocytosis. In a series of 30 patients with haemophagocytic syndrome, haemophagocytosis was seen in all patients. 2085 In 16 patients, erythrophagocytosis was associated with intracytoplasmic B A accumulation of haemosiderin or bile. Haemophagocytosis was not seen in portal tracts. The Kupffer cells are only weakly stained with PAS, a feature helpful in distinguishing this change from a response to necroinflammatory conditions, in which the Kupffer cells are often strongly PAS positive. 2086 Additionally, Kupffer cells frequently show siderosis, possibly related to the erythrophagocytosis itself or to blood transfusions. 2086 Correlation is lacking between the degree of peripheral cytopenia and the degree of hepatic haemophagocytosis. 2086 Immunohistochemical findings on liver tissues have provided direct evidence for the involvement of activated CD8+ lymphocytes through the production of IFN-γ, and of macrophages through the haemophagocytosis and production of both IL-6 and TNFα, irrespective of the associated condition. 2087 Prendki et al. 2088 have proposed a reduced perforin-positive/CD3-positive lymphocyte ratio as an indicator of haemophagocytosis.

This rare disorder (previously termed 'histiocytosis X') is characterized by infiltration of various tissues and organs by Langerhans cell histiocytes. Langerhans cell histiocytosis (LCH) primarily affects bone, but lung, skin and lymph node involvement may be seen. Hepatic involvement is also well recognized, especially in children, with sclerosing cholangitis occurring in 10-15% of those with multisystemic involvement, 2069, 2089 whereas LCH confined to the liver appears to be very unusual. 2090, 2091 Kaplan et al. 2092 reported nine cases of hepatobiliary LCH and found another 85 acceptable cases in the literature. Ages ranged from 7 days to 62 years (median, 18 months), with a 2:1 female preponderance. Hepatosplenomegaly, jaundice, liver dysfunction and ascites were the most common clinical presentations.

Gross findings vary with the stage of disease and type of hepatic involvement. Large aggregates of Langerhans cells, eosinophils and other inflammatory cells may form tumour-like masses. Infiltration of large ducts may lead to grossly visible cystic dilation and rupture. Other cases show irregularly distributed biliary fibrosis, while a biliary cirrhosis is already present in a few cases. 2092 The diagnostic feature in all cases is the presence of Langerhans cells. 2093 They typically have an abundant pink cytoplasm; lobulated, coffee-bean-shaped or contorted nuclei with a fine chromatin pattern; and no discernible nucleoli (Figs 3.153 and 3.154 ). In the vast majority of cases the Langerhans cells are accompanied by varying numbers of eosinophils (Fig. 3.155) , lymphocytes, neutrophils, plasma cells, non-Langerhans histiocytes and occasional multinucleated giant cells. Immunostains were useful in confirming the nature of the Langerhans cells by using antibodies to S-100 protein, CD1a 2094,2095 (Fig. 3.156 ) and CD31. 2096 CD1a is important as activated Kupffer cells may acquire S-100 positivity. 2097 Langerin is coexpressed with CD1a in LCH, 2098 but it should be assessed in isolation only with caution because langerin-positive CD1-negative cells are present in normal liver. 2098, 2099 The lectin receptor CD207/langerin is useful, but it seems to mark dermal cells unrelated to Langerhans cells. 2100 Typical Birbeck granules may be found ultrastructurally in Langerhans cells.

Many patients with disseminated disease have aggregates of Langerhans cells that range from granulomatous foci to large nodules in the liver, with abundant eosinophils in these lesions 2092, 2101 (Figs  3.157 and 3.158) . The majority of cases show some degree of active bile duct infiltration, injury and destruction by Langerhans cells (Figs 3.159 and 3.160) ; this is the most characteristic feature of hepatic involvement. Small and medium-size bile ducts are often infiltrated by the Langerhans cells, with displacement of the epithelial cells. Some ducts may be entirely replaced by masses of Langerhans cells within the pre-existing basement membrane. Injury to large bile ducts by the Langerhans cells may produce cystic dilation and rupture with a xanthogranulomatous inflammatory response.

Concentric periductal fibrosis is a prominent feature in the majority of cases. When the ductal infiltration by Langerhans cells in all cases clinically or morphologically diagnosed as sclerosing cholangitis in children; however, extrahepatic manifestations of LCH will generally help in reaching the correct diagnosis.

The aetiology and pathogenesis of LCH remain undetermined. Evidence suggests an immune dysregulation with uncontrolled clonal proliferation of dendritic cells exhibiting Langerhans cell characteristic 2103 and of bone marrow rather than epidermal origin. 2104 A low susceptibility to apoptosis 2105 and high level of diverse cytokines production by Langerhans cells, 2106 with sustained stimulation of T cells, lead to the unique pathological picture, which combines features of a neoplasm and chronic inflammation. 2107 The demonstrated clonality of LCH does not prove the neoplastic nature of the lesion. The frequent detection of BRAF V600E or MAP2K1 mutations, in addition to clonality, 2108, 2109 suggests that LCH is a neoplasm. 2104 Viral proteins and DNA sequences of human cytomegalovirus, 2110 Epstein-Barr virus 2111 and human herpesvirus 6 2112 have been detected by immunohistochemistry (IHC), in situ hybridization (ISH) and PCR in LCH tissue, but whether these represent causal agents or opportunistic infections secondary to immune dysregulation remains uncertain. is pronounced, there is often marked surrounding fibrosis with demonstrable Langerhans cells in the fibrous tissue. Ducts at a distance from the Langerhans cell lesions may also show epithelial injury and periductal fibrosis, consistent with a secondary sclerosing cholangitis.

Changes caused by the bile duct lesions include periportal ductular reaction, ductopenia (Fig. 3.161) , chronic cholestatic features with periportal cholate stasis ('pseudoxanthomatous change') and deposition of copper and copper-binding protein. Some degree of periportal or bridging fibrosis is common and progresses to a biliary cirrhosis (Fig. 3.162 ). It must be noted that needle biopsy specimens may show changes caused by a distal cholangiopathy only, without demonstration of Langerhans cells, despite direct LCH infiltration of the major bile ducts. 2102 The differential diagnosis of LCH in childhood includes other forms of sclerosing cholangitis: primary sclerosing cholangitis, with or without chronic inflammatory bowel disease, as well as sclerosing cholangitis associated with immunodeficiency (see Chapter 9). In view of the morphological overlap with LCH, it is recommended that immunostains for S-100 and CD1a and langerin be performed

This disorder was first reported by Rosai and Dorfman 2126 and subsequently reviewed by Foucar et al. 2127 It usually affects patients between ages 10 and 20 years. In addition to massive enlargement of cervical and other lymph nodes, there is fever, leukocytosis, elevated ESR and hyperglobulinaemia. The course is protracted, lasting 3-9 months, but the prognosis is usually excellent. The disease can involve extranodal sites, including soft tissues, the oral cavity, lower respiratory tract, genitourinary system and the liver. Involvement of the last three organs is associated with a poor prognosis. 2127 Liver involvement is uncommon. 2128 Lauwers et al. 2129 studied 11 patients in whom the disease involved the intestinal tract (five patients), liver (five) and pancreas (one). Most patients also had evidence of disease in other extranodal sites, as well as in one or more lymph node groups.

In the review of Foucar et al., 2127 hepatomegaly was noted in 27 of 157 cases. Four patients had histopathological evidence of hepatic involvement. In most instances, gross evidence of disease was lacking, except for one case in which a 1.5-cm, well-circumscribed white nodule was found in the right lobe of the liver. 2127 The hallmark of Rosai-Dorfman disease is the proliferation of histiocytes, which have an abundant cytoplasm and normal-appearing nuclei ( Fig. 3.163 A and B) . The cells are seen in portal areas and in hepatic sinusoids. They display avid leucophagocytosis, but can also phagocytose RBCs. According to Eisen et al., 2130 Although patients with LCH have a good overall prognosis, 2113 approximately 20% of patients with multisystem involvement will show a progressive disease course despite treatment. 2114, 2115 In particular, patients with hepatic involvement have a worse prognosis with survival at 3 years of 96.7% for those without, but only 51.8% for those with liver involvement. 2116 In patients with cirrhosis and end-stage liver failure due to LCH sclerosing cholangitis, orthotopic liver transplantation (OLT) has been proven a successful therapeutic option, 2102, 2117, 2118 with 67% of patients living long-term after surgery (median follow-up, 5.8 years; range, 2.1-7.5 years). A significant number of LCH patients have developed post-transplant lymphoproliferative disorders, apparently related to a higher incidence of refractory rejection. 2119 Disease recurrence in the liver allograft occurs in about 30% of patients and seems easily managed. 2119, 2120 Chemotherapy protocols are chosen on the basis of disease distribution and extent. 2104 Juvenile xanthogranuloma, a histiocytic disorder, is primarily but not exclusively seen throughout the first two decades of life and principally as a solitary cutaneous lesion. It can manifest with multiple small systemic lesions (xanthoma disseminatum), in which case the liver can occasionally be involved. The infiltrating cells are factor XIIIa, fascin and CD68 and CD163 positive among various markers, 2121 but S-100, langerin and CD1a negative. 2098, 2122 Touton cells are rarely seen in extracutaneous sites. There appears to be an overlap with LCH because skin lesions with characteristics of juvenile xanthogranuloma may be found in children with LCH. 2069 Erdheim-Chester disease is a rare, non-Langerhans type of histiocytosis with xanthogranulomas. It appears to be neoplastic. 2123 Liver involvement is uncommon; biliary tract obstruction has been reported. 2124, 2125 named SBDS, which encodes a ribosomal protein involved in ribosomal and other cellular processes. 2149, 2150 Disease-causing SBDS mutations are found in approximately 90% of patients.

SDS was differentiated from cystic fibrosis by Shwachman et al. 2151 in 1964 . The syndrome may begin in utero; the average birth weight is 25% of normal. By age 6 months, patients are below the fifth percentile. The apparent causes of the poor growth, pancreatic insufficiency and fat malabsorption may improve with age. [2152] [2153] [2154] Haematological abnormalities occur in 100% of patients: neutropenia in up to 95%, thrombocytopenia in up to 70% and anaemia in over 50%. 2153, [2155] [2156] [2157] The neutropenia can be intermittent, and abnormal chemotaxis may be present temporarily. SDS is currently listed in the congenital defects of phagocyte number, phagocyte function or both in the most recent classification of primary immunodeficiencies (see Table 3 .7). 2021 Bone marrow biopsy may reveal hypoplasia with fat replacement and myeloid maturation arrest. 2158 EM examination of cartilage reveals material retained in the rough endoplasmic reticulum. 2159 At least half the patients have metaphyseal dysostosis. 2159 Hepatomegaly is present in 15% of patients, and AST and ALT are elevated in up to 60% of patients; the liver tends to improve with age. 2160, 2161 Adults with SDS were found to have hepatic microcysts on MRI. 2161 Veropalumbo et al. 2162 reported SDS as mimicking autoimmune hepatitis and coeliac disease in two children.

The pancreas in SDS shows replacement of exocrine tissue by fat with preservation of the endocrine islets. 534, 2151 According to Burke et al., 2163 the degeneration of pancreatic exocrine tissue is progressive. Cardiomegaly and testicular fibrosis were reported in one case. 2164 The liver shows variable steatosis. 534, 2151 Some of the patients in the series of Bodian et al. 534 also had portal fibrosis or 'cirrhosis', but detailed histological descriptions of the hepatic changes were not reported.

Some SDS patients have responded to treatment with G-CSF. 2165 There is an increased risk of haematological malignancies similar to those that occur with Fanconi anaemia. 2166 Nineteen patients with myelodysplastic syndrome and leukaemia have been reported. 2167 BMT has been attempted; only two of eight patients are disease free, including one who has required LT for veno-occlusive disease. 2168, 2169 Familial and genetic nonalcoholic steatohepatitis and cirrhosis Differentiation is required between familial occurrence of diseases in the nonalcoholic fatty liver disease (NAFLD) spectrum where an acquired defect of insulin disposition is the primary abnormality, possibly enhanced by genetic predisposition, and genetic disorders that involve disordered insulin disposition, thus producing a NAFLDlike hepatic disease (see Chapter 5) . Familial occurrence of nonalcoholic steatohepatitis (NASH) with or without cirrhosis, or with cryptogenic cirrhosis, was reported by Struben et al. 2170 in 18 members of eight kindreds. Fifteen (83%) of the 18 were obese, and 11 (31%) had type 2 diabetes mellitus. The occurrence of these disorders within kindreds suggested a common pathogenesis and possible genetic risk. Other cases of familial cirrhosis 2171, 2172 or cryptogenic cirrhosis with a family history of unexplained liver disease (19% of patients in series of Caldwell et al. 2173 ) have been reported. Susceptibility to NAFLD has been shown to be associated with polymorphism in the patatin-like phospholipase domain-containing 3 (PNPLA3) gene, encoding adiponutrin. [2174] [2175] [2176] Glucose regulatory protein (GCKR) has been associated with fatty liver in obese children, 2177 and transmembrane 6 superfamily member 2 (TM6SF2) polymorphisms may also be important in children. 2178 Various other genes have been implicated. 2179 Various genetic disorders produce a NAFLD-or NASH-like liver disorder. Steatohepatitis 2180 and cirrhosis 2181 have been reported in associated with lysosomal activity (lysozyme, α1-antitrypsin, α1antichymotrypsin); antigens associated with early inflammation (Mac-387, 27E10); antigens commonly found on monocytes, but not tissue macrophages (OKM5, Leu-M1); and activation antigens (Ki-1, receptors for transferrin and IL-2). They are negative for CD1a and langerin. 2098 The cells thus appear to be true, functionally activated macrophages derived recently from circulating monocytes. 2130 

Neonatal lupus erythematosus (NLE) 2131-2136 may cause neonatal hepatitis syndrome. Hepatic involvement may occur with NLE, which is caused by passage of maternal anti-Ro/SSA and anti-La/SSA antibodies, or occasionally U1-ribonucleoprotein, across the placenta. Fetal tissues expressing Ro and La antigenic determinants may be damaged. The heart, skin and liver are most likely to be involved, rarely with thrombocytopenia and leukopenia. 2133, 2137 Congenital heart block is the most important cardiac manifestation. Most infants develop a rash, which typically resembles the rash of subacute cutaneous lupus erythematosus but may have other features, in the newborn period or some weeks later. In approximately 10% to 25% of patients, hepatic disease occurs, usually typical neonatal hepatitis syndrome resembling idiopathic neonatal hepatitis. 2134, 2138, 2139 Occasionally, liver involvement is severe enough to suggest extrahepatic biliary tract obstruction, with acholic stools and nondraining hepatobiliary scan. 2140, 2141 Increased iron accumulation in the liver was found on liver biopsy in the first infant recognized as having NLE with liver involvement, 2138 and subsequently an infant was reported with severe liver disease showing features of perinatal haemochromatosis. 2142 Transient elevation of serum aminotransferases only, or unexplained isolated conjugated hyperbilirubinaemia in the perinatal period and later presentation at 2-3 months of age with transient serum aminotransferase increase, is recognized. 2143 In most infants the liver disease resolves completely between 6 and 12 months of age, as the maternal antibodies are degraded. Mild fibrosis was found in one child with NLE on repeat liver biopsy.

The diagnosis of NLE is difficult in the absence of congenital heart block or typical skin rash. Some infants have only transient jaundice and myocarditis with abnormal ECG. The diagnosis should be suspected if the mother is known to have SLE or Sjögren syndrome. Frequently, however, the mother is asymptomatic with respect to rheumatological disease. Routine methods may fail to detect anti-Ro and anti-La in the infant; these studies should be performed at as young an age as possible. Very high titres of antinuclear antigen (ANA) in the infant may be caused by NLE. Deposits of associated antibodies (anti-Ro and/or anti-La) may be found in affected liver tissue by immunofluorescence. 2144 Most infants with unexplained neonatal hepatitis syndrome do not have NLE. 2145 One infant was reported with neonatal hepatitis syndrome and transplacental transfer of antimitochondrial antibodies. 2146 The disease mechanism is similar to that of gestational alloimmune liver disease (GALD) in that transplacental passage of antibodies causes neonatal liver disease with iron accumulation; however, NLE is milder and tends to be self-limited.

Shwachman-Diamond syndrome (SDS) is an autosomal recessive disorder 2147 characterized by pancreatic exocrine insufficiency, bone marrow dysfunction and skeletal abnormalities. 2148 The Shwachman locus has been mapped to chromosome 7q11.21. Disease-associated mutations have been identified in the gene associated with SDS, by Ruchelli et al. 2204 Arai et al. 2210 have suggested that megakaryocytederived TGFβ1 is one of the candidates in the activation of hepatic stellate cells leading to the hepatic fibrosis. High levels of N-terminal peptide of procollagen III, type IV collagen and hyaluronic acid were found in the serum of a lethal case at 5 days of life. 2212 The liver disease generally accompanies a haematological disorder unique to Down syndrome called transient abnormal myelopoiesis, transient myeloproliferative disorder or transient leukaemia. 2213, 2214 The condition consists of a clonal proliferation of blast cells exhibiting megakaryocytic features and historically associated with a high rate of spontaneous remission. Its true incidence remains to be determined. A number of cases may occur as an incidental finding of abnormal cell counts and blast cells in the peripheral blood in an otherwise well child, but in approximately 20% of cases the disease is manifest as hydrops fetalis and liver or multiorgan failure resulting in death. Of those children who enter a spontaneous remission, 13-33% have been found to develop acute megakaryoblastic leukaemia (AMKL), usually within the first 3 years of life, which if left untreated is fatal. In trisomy 21, fetal haemopoietic progenitors acquire N-terminal truncating mutations in the key megakaryocyte-erythroid transcription factor GATA1. Mutations are found in blast cells of both transient myeloproliferative disorder and megakaryoblastic leukaemia, 2215 suggesting that additional as yet unidentified (epi)genetic mutations are required for progression to AMKL. 2216 A recent multicentre survey suggests a good response of leukaemic patients to early therapy with standard-dose intensive chemotherapy, including cytarabine and anthracyclines. 2217 Neonatal hepatitis syndrome can occur in children with Down syndrome in the absence of transient abnormal myelopoiesis or leukaemia. Generally, these children also have congenital heart disease or GI abnormalities. 2218 This population study suggests that the incidence of neonatal hepatitis syndrome in children with Down syndrome is unexpectedly high (3.9%) and that conjugated hyperbilirubinaemia is more severe in those with transient abnormal myelopoiesis.

The syndrome of fatty liver and encephalopathy, first described in 1963 by Reye et al., 2219 based on postmortem findings in 17 children from Australia, was soon recognized to have a worldwide distribution. 2220 The observation of an association between aspirin and Reye syndrome, 2221 subsequent advice from the Surgeon General of the United States that the use of salicylates be avoided in children suffering from influenza or varicella, and confirmatory prospective studies 2222, 2223 have been followed by a steady decline in the incidence of 'classic' or 'idiopathic' Reye syndrome worldwide. 2224, 2225 At present, all patients presenting with a 'Reye-like syndrome' are presumed to have an inherited metabolic disorder unless there is clear evidence of the classic combination of a flu-like illness and salicylate therapy. In addition, metabolic disorders were subsequently diagnosed in many patients who had survived an acute disease attributed to Reye syndrome. 2226 Consequently, the following account may be in part historical because it is largely based on data collected when knowledge of metabolic disorders and their diagnostic tools were limited. Nevertheless, it seems likely that Reye syndrome as such exists and may reflect a pharmacogenetic or immunogenetic susceptibility in those who do not have a demonstrable metabolic disorder. Which drugs or environmental toxins and which viruses may contribute to development of classic Reye syndrome remain a conundrum.

With few exceptions, 2227, 2228 idiopathic Reye syndrome occurs almost exclusively in children, has no sex predilection, and is usually preceded by a resolving viral illness, particularly influenza B or varicella. Initial symptoms include vomiting (usually repetitive), lethargy patients with partial lipodystrophy. NASH is also reported in children with Bardet-Biedl syndrome and in both children and adults with Alström syndrome, [2182] [2183] [2184] in whom cirrhosis may occur. Steatohepatitis (sclerosing hyaline necrosis) was also described in a patient with Bloom syndrome. 2185 This autosomal recessive disorder is characterized by a normally proportioned but strikingly small body size, characteristic facies, photosensitive skin lesions, immunodeficiency and marked predisposition to a variety of cancers and some evidence of disordered insulin action. Likewise, there are multiple reports of marked hepatic steatosis (but no steatohepatitis or cirrhosis) in patients with Dorfman-Chanarin syndrome, an autosomal recessive disorder characterized by marked hepatic steatosis, ichthyosis and variable CNS and muscle involvement. 2186, 2187 Other rare disorders with NAFLD-like liver disease include mulibrey nanism 2188 and Cohen syndrome. 2189 Hepatotoxicity and other known genetic/metabolic diseases that can cause fatty liver, such as Wilson disease and cystic fibrosis, must be excluded because treatment is radically different. 2190 Although these diseases clearly can manifest a 'nonalcoholic' steatosis, they are neither NAFLD nor NAFLD-like.

Congenital total lipodystrophy is characterized by near-absence of adipose tissue, severe insulin-resistant diabetes hyperlipidaemia, hepatomegaly, muscular hypertrophy, hypertrichosis and acanthosis nigricans. 2191 Inheritance is believed to be autosomal recessive. A disease locus has been identified on chromosome 11q13, 2192 with some families having linkage to 9q34. 2193 An association with peripheral pulmonary artery stenosis was reported in three children by Uzun et al. 2194 Four subtypes are now described, associated with mutation in the AGPAT2, BSCL2, CAV1 and PTRF genes. 2195 The liver is enlarged and grossly yellow or light yellow-brown in colour. Light microscopic changes, described in a number of case reports, [2196] [2197] [2198] [2199] [2200] [2201] [2202] [2203] include steatosis and periportal fibrosis, with portalto-portal bridging. Ductular reaction was noted in several patients with congenital total lipodystrophy. 2200 Cirrhosis was present in some patients. [2196] [2197] [2198] 2201 Hepatocytes in one patient were described as 'plant-like' with prominent cell walls, a pale vacuolated cytoplasm and pale, centrally placed nuclei; the presence of fat and glycogen was demonstrated in the cytoplasm of liver cells by special stains.

Ultrastructural abnormalities have been described in several reports. 5, 2198, 2199, 2201 In addition to numerous lipid droplets, there are many lysosomes containing variable quantities of lipofuscin and lipolysosomes. 5 Peroxisomes are said to be increased 2198, 2200 or reduced in number, 5 and they contain dense matrix granules. Mitochondria are abnormally shaped and contain distinctive, elongated, crystal-like matrical inclusions that adopt various geometric configurations. 5 They possibly represent cholesterol or other lipid material. Partial lysis of swollen and irregular mitochondria was described in one patient with congenital total lipodystrophy. 2196

Severe liver disease can occur in Down syndrome, or trisomy 21 mosaicism. [2204] [2205] [2206] Stillbirth, hydrops fetalis or neonatal liver failure at or within a few weeks of birth are recognized presentations. [2207] [2208] [2209] [2210] [2211] Morphologically, there is diffuse fibrosis surrounding reactive bile ductules and residual hepatocytes. 2204 Extensive hepatic necrosis has also been observed. In most livers a large number of megakaryocytes or megakaryoblasts, staining positively for factor VIII-related antigen and binding to Ulex europaeus 1, as well as other haematopoietic elements, are present in the sinusoids. 2204, 2207 Parenchymal iron deposition of variable degree was noted in most of the cases studied and changes in mental status. Hepatic dysfunction can be overlooked since the liver is minimally enlarged, and there is no jaundice or splenomegaly. Subsequent symptoms and signs are predominantly neurological and terminate in coma. Seizures sometimes occur, particularly in younger children with hypoglycaemia. Most patients have received multiple medications, including aspirin, for the symptoms of the viral illness. Initial laboratory screening tests disclose elevated serum aminotransferase levels, hyperammonaemia and coagulopathy. Although the liver disease is benign and transient, the encephalopathy (secondary to a hypoxic/metabolic insult resulting in cerebral oedema) can be life threatening and can result in permanent neurological disability. 2220 Early diagnosis based on clinical findings and liver biopsy, along with meticulous supportive care, results in decreased mortality and morbidity.

Grossly, liver biopsy or autopsy specimens from patients with Reye syndrome are yellow. The major histopathological finding is diffuse microvesicular steatosis. 2229 In the typical case the hepatocytes are swollen and packed with multiple small vacuoles (Fig. 3.164) ; neutral lipid can be demonstrated in frozen sections stained with Oil Red O or Sudan Black B (Fig. 3.165 A) . The lipid droplets are consistently smaller in the perivenular zone than in other areas. 2229 Vacuolization may not be evident in biopsy material obtained less than 24 hours after the onset of encephalopathy, even though appropriately stained frozen sections will reveal an abundance of fat. Nuclei of the liver cells are enlarged and centrally located. Mitotic activity of variable degree may be seen. Hepatocellular necrosis is generally absent or is mild and spotty. Periportal necrosis is occasionally found, 2230 preceded by ballooning degeneration of periportal hepatocytes. Variation in the severity of glycogen depletion of liver cells in early biopsies correlates with other histological measures of severity, and with the occurrence of hypoglycaemia, severity of encephalopathy at admission and the mortality rate. Portal inflammation is either minimal or absent. Cholestasis is rarely observed; in some instances it may be related to an associated pancreatitis. 2231 Reduction of succinic dehydrogenase and cytochrome oxidase activities (and other mitochondrial enzymes) has been demonstrated by enzymatic stains and is most helpful in confirming the diagnosis 5 ( Fig. 3.165 B) .

At the ultrastructural level, the most dramatic changes are seen in hepatocellular mitochondria, 5, 2232 which are enlarged and misshapen. The degree of enlargement correlates to some extent with the stage of encephalopathy. 2232 The severity of Reye syndrome may also be correlated with lucency of the mitochondrial matrix and loss of matrical dense bodies (Fig. 3.166 ). Other mitochondrial changes in initial hepatic biopsy specimens from patients who die or have severe neurological sequelae include a decrease in size and number of cristae. There may be an increase in the amount of smooth endoplasmic reticulum with varying degrees of dilation, and 50% of hepatic biopsy specimens reveal flocculent peroxisomes. 2233 Microvesicular steatosis has been reported in several inherited metabolic disorders and in drug-and toxin-induced liver injury, such as with tetracycline, nucleoside analogues, aflatoxin, pyrrolizidine alkaloids, margosa oil, hypoglycin A, pentanoic acid and valproic acid (see Chapter 12) . Aspirin toxicity may mimic Reye syndrome. 2233 At the light microscopic level, the liver findings in children with fatal salicylate intoxication resemble those of Reye syndrome, 2234 but the ultrastructural changes appear to be different. 2232 Animal models of Reye syndrome with encephalomyocarditis virus 2235 or influenza B 2236 infection, and the spontaneous 'Reye-like syndrome' in BALB/cByJ mice usually associated with coronavirus infection, have been described. 2237 In another murine model, treatment with 4-pentenoic acid produced a Reye-like syndrome. 2238 

First described as acute febrile mucocutaneous lymph node syndrome in 1967, 2239 Kawasaki disease usually affects children, more rarely adults up to the sixth decade of life. 2240 It is an acute vasculitis of unknown aetiology. It can result in the formation of coronary artery perhaps aspirin has proved beneficial, the former seemingly reducing the frequency of coronary artery abnormalities. 2245, 2246 Corticosteroids have a role in Japanese children at high risk of resistance to IVIG treatment. 2247, 2248 Male gender, abnormal liver enzymes, low albumin and platelets and the percentage of leukocytes/lymphocytes have been found as risk factors for treatment nonresponse. 2249 Patients less than 1 year old or more than 9 years old at diagnosis may have poorer outcomes. 2250 Atypical cases not fulfilling the conventional diagnostic criteria have a much higher mortality rate, perhaps because of the lack of therapy. 2251 The hepatobiliary complications of Kawasaki disease have been underestimated. Biochemical abnormalities of liver involvement are frequently encountered. 2252 The most common problem results from a hydrops of the gallbladder, which is detectable by ultrasonography, with an incidence ranging from 2.5% to 13.7%, and may be a risk factor for the development of coronary aneurysm. 2253, 2254 Prolonged pain has been attributed to poor emptying of the gallbladder. 2255 The patients have right upper quadrant pain sometimes associated with vomiting. A majority have hepatomegaly and at times a palpable gallbladder. Resolution usually occurs in 4 weeks. Perforation is a rare complication. Cholangitis with bile duct injury and ductular reaction has been observed on liver biopsy in three cases. 2256 Pathological findings at laparotomy include inflammation of the gallbladder, with or without evidence of vasculitis, and occasionally cystic duct obstruction due to inflammatory oedema or lymph node compression. Portal vein blood flow may be impaired. 2257 In addition to vasculitis, inflammation has been noted in autopsy cases in the oral cavity (including ductal structures), small bowel and the pancreas (including the ducts) 2258 ; acute cholangitis or bile duct damage has also been observed. [2258] [2259] [2260] Mild bile ductular reaction has been noted, but to date, ductopenia has not been a feature. Cholangitis may be associated with sinusoidal neutrophilic infiltrates (Figs 3.167 and 3.168) , and proliferation and swelling of Kupffer cells are frequently seen.

Similarities between Kawasaki disease and leptospirosis have been raised; although the Weil-Felix reaction may be positive, direct tests for leptospirosis are negative. 2261 The close resemblance of fatal cases to infantile periarteritis nodosa has also been emphasized in several studies. 2258, 2262 Affected vessels include the larger coronary arteries and splenic, renal, pulmonary, pancreatic, spermatic, periadrenal, hepatic and mesenteric vessels. Microscopically, the vessels show periarterial inflammation, necrosis and destruction of the media and intimal inflammation. Lesions of varying stages can be observed aneurysms in approximately one-quarter of patients who do not receive IVIG within 10 days of illness. 2241 The diagnostic criteria, formulated by an international panel for a complete diagnosis of Kawasaki disease, include the presence of unexplained fever more than 5 days and four of five main clinical features: (1) changes in extremities such as acute erythema of palms and soles, oedema of hands or feet and subacute periungual peeling of fingers and toes in weeks 2-3; (2) polymorphous exanthema; (3) bilateral bulbal conjunctival injection without exudate; (4) changes in lips and oral cavity: erythema, lips cracking, strawberry tongue, diffuse injection of oral and pharyngeal mucosae; and (5) cervical lymphadenopathy >1.5 cm, usually unilateral. 2242 'Incomplete' Kawasaki disease is defined by two or three of the previous five criteria plus coronary artery disease. GI signs and symptoms include abdominal tenderness, vomiting, diarrhoea, bloody stools and mild jaundice. Hepatobiliary complications comprise hepatosplenomegaly, mild ascites and hydrops of the gallbladder. Jaundice is a rare presentation. 2243 The laboratory data include abnormal ECGs, neutrophil leucocytosis with a shift to the left, thrombocytosis and an increased ESR. Mortality in boys during the first 2 months of the illness is twice the average rate for the disease generally. 2244 Coronary aneurysms and myocarditis occur in 10-20% of patients, with a higher incidence in boys. 2245 Thus Kawasaki disease is a major cause of acquired heart disease in children. Early therapy with high-dose IV γ-globulin and reviewed. 2283 The liver has been reported to be histologically normal in some patients 2286, 2287 or to show nonspecific changes such as an increased glycogen content, 2286,2288 mild fatty change 2288 or haemosiderosis. 2289 Haemosiderosis, both hepatocellular and reticuloendothelial, was also present in the cases reported by Donohue and Uchida 2281 and Ordway and Stout 2290 in combination with other changes. Both these reports described multiple small nodules in the liver that were composed of large, pale, foamy hepatocytes containing much glycogen and a little fat, with occasional fusion of cells and formation of syncytial masses. Ordway and Stout 2290 interpreted these foci as regenerative nodules (Figs 3.169 and 3.170) . Intrahepatic cholestasis has been reported in several cases 2283 and bile ductular reaction in one case. 2290 in different vessels in the same patient and in different areas of the same type of vessel (e.g. coronary arteries), suggesting that the inflammatory process continues over the course of the disease. Aneurysmal dilation of coronary and other vessels (brachial, iliac, renal and pulmonary) may occur. 2258, 2263 Marks et al. 2264 reported the case of a 4-year-old boy with a hepatic artery aneurysm that caused obstructive jaundice.

Other than leptospirosis, Propionobacterium acnes, 2265 toxin-secreting Staphylococcus aureus, 2266 HIV, 2267 Epstein-Barr virus, 2268 parvovirus B19, 2269 Yersinia infection 2270 and an unusual response in a susceptible individual to an infectious agent such as the measles virus 2271 have all been proposed as causes of Kawasaki disease but are not supported by hard data. Activated T lymphocytes play a key role in the disease mechanism, and genetic susceptibility loci have recently been identified. [2272] [2273] [2274] [2275] 

The salient features of Aarskog-Scott syndrome include short stature and facial, digital and genital malformations. 2276 The disease is X-linked 2277 and has been ascribed to mutations in the FGD1 gene, implicated in skeletal and neuronal development. 2276, 2278, 2279 One reported patient had a slightly elevated total serum bilirubin, and needle biopsy of the liver revealed haemosiderosis and a micronodular cirrhosis. 2280

A rare disorder, leprechaunism (also called Donohue syndrome) is characterized by a grotesque elfin facies with a flat nasal bridge and flaring nostrils, thick lips and large low-set ears. Patients have hirsutism, enlargement of the breasts and external genitalia, motor and mental retardation, failure to thrive and progressive marasmus. Death occurs before 2 years of age. 1030, [2281] [2282] [2283] The disease is autosomal recessive. Patients have mutations in the high-affinity insulin receptor. Two novel mutations have been identified recently. 2284 Rabson-Mendenhall syndrome is a milder form of the disease. Most patients, however, die by adolescence from intractable ketoacidosis. 2285 A consistent pathological feature of the syndrome in females is follicular maturation of the ovaries with cyst formation. Some patients have hyperplasia of the islets of Langerhans and severe malformations of the brain and heart. Other associated findings have been 

Of the several known forms of oculocutaneous albinism, only two involve the liver: Chediak-Higashi syndrome and Hermansky-Pudlak syndrome. Both are listed in the 'diseases of immune dysregulation' category of the latest classification of primary immunodeficiencies (see Table 3 .7). 2021

Patients with this syndrome are distinctive, with a light-cream to slate-grey skin and hair that has a metallic, frosted-grey sheen. Other findings include photophobia, squint, nystagmus and decreased pigment in the retina. Patients have recurrent infections, most often by gram-positive organisms. A progressive neuropathy, usually noted at about 5 years of age, involves cranial and peripheral nerves. Rarely, adults with a less severe form of the disease have findings consistent with either spinocerebellar degeneration or Parkinsonian disease. Hepatosplenomegaly is common, particularly in the accelerated phase of the disease, 2291 which is heralded by fever, lymphadenopathy, hepatosplenomegaly, pancytopenia, hyperlipidaemia and coagulopathy. Tissue infiltrates consist of benign-appearing histiocytes showing haemophagocytosis, plus lymphocytes and plasma cells which, in the liver, are found in portal areas and sinusoids. 2292 Diagnosis is based on the presence of characteristic giant, eosinophilic, peroxidase-positive inclusions in leukocytes that do not degranulate. The disease is autosomal recessive and is caused by a defect in the lysosomal trafficking gene LYST, which is essential for the function of NK cells. 2293 Treatment has included chemotherapeutic agents, particularly during the accelerated phase, but the only cure has been BMT. 2292 

Hermansky-Pudlak syndrome is characterized by oculocutaneous albinism, a mild bleeding diathesis caused by a storage pool platelet defect, and widespread deposition of ceroid pigment in cells of the reticuloendothelial system. 2294, 2295 Complications include pulmonary fibrosis, renal failure, cardiomyopathy and a granulomatous colitis. 2294 The disease is autosomal recessive and genetically heterogeneous, 2296, 2297 resulting from defects in genes affecting the function of multiple cytoplasmic organelles. 2298 Involvement of the liver in Hermansky-Pudlak syndrome is limited to the presence of a light-tan, granular pigment in hypertrophied Kupffer cells and portal macrophages (Fig. 3.171) . The pigment has all the characteristics of ceroid or lipofuscin, being PAS positive and diastase resistant, sudanophilic and argentophilic, and it reveals bright-yellow autofluorescence when viewed by ultraviolet microscopy (Fig. 3.172) . Ultrastructurally, the pigment is granular, intermingled with lipid and bounded by a single membrane. Occasionally, it shows a fingerprint pattern of concentric light and dark bands with a periodicity of approximately 20 nm. 2299 

Gross abnormalities and congenital anomalies of the biliary system are discussed here; congenital anomalies of the vascular structures of the liver are discussed in Chapter 11. Vascular abnormalities in the placenta may lead to neonatal liver disease. Fetal thrombotic vasculopathy has been associated with severe neonatal liver disorders, typically with some degree of neonatal liver failure; although one had a neonatal Budd-Chiari lesion, most infants show only neonatal hepatitis syndrome. 2300 

Absence of the liver is incompatible with life. It has been reported in stillborn fetuses, usually in association with other severe anomalies. 2301 The association with omphalocele has been interpreted as the result of defective development of the septum transversum. 2302 are relatively frequent findings, particularly on the inferior surface of the liver. In one patient an accessory lobe adherent to the left liver lobe had its own gallbladder. 2326 They are connected to the liver by hepatic tissue or by a mesentery containing branches of the portal vein, hepatic vein and hepatic artery, and a bile duct. 2327 Intrathoracic accessory lobes, with their vascular supply perforating the diaphragm, have been reported. 2328 Accessory lobes may rarely require surgical intervention because of their large size, torsion of a pedicle or the presence of other associated defects. 2329 Pedunculated HCC may arise in accessory lobes. Focal nodular hyperplasia has also been described. 2330 Ectopic hepatic tissue Ectopic hepatic tissue may be found in the suspensory ligaments of the liver, lung, wall of the gallbladder, splenic capsule, retroperitoneal space, adrenal gland and greater omentum. [2331] [2332] [2333] [2334] [2335] [2336] [2337] A unique case of ectopic liver in the placenta was reported by Willis. 2338 In most patients, the hepatic tissue in these ectopic sites is microscopically normal, but when the liver is abnormal (fatty change, chronic hepatitis, cirrhosis), the ectopic liver tissue reflects the same changes. 2339, 2340 Infantile haemangioendothelioma arising in an ectopic intrathoracic liver has been reported. 2332 Twenty-three cases of HCC, mostly from Japan, have arisen in ectopic livers. 2340, 2341 Heterotopias Most of the so-called adrenal heterotopias are actually examples of adrenal-hepatic fusion. Dolan and Janovski 2342 made a distinction between 'adhesion' and 'fusion' on the basis of presence or absence of a capsule interposed between the two organs. In both types, there was a marked diminution or complete absence of medullary tissue. The fusion is unilateral and is not associated with clinical evidence of adrenal impairment. It was found in 9.9% of unselected autopsy cases in one study. 2343 The incidence was much higher in older age-groups, suggesting that the condition may be an aging phenomenon. There is a single description of hepatolienal fusion. 2344 Adrenal neoplasms may arise in these adrenal rests (see Chapter 13) .

Pancreatic heterotopia in the liver is rare (Fig. 3.173 ). In the case reported by Ballinger, 2345 an islet cell carcinoma arose in the aberrant pancreatic tissue. Retention cyst has been recorded in an obstructed duct within the heterotopic pancreatic tissue. 2346 Foci of exocrine pancreas in the liver of a 41-year-old patient with cirrhosis were

Absence of the left lobe of the liver has been described, 2303 in one case associated with floating gallbladder. 2304 Radin et al. 2305 collected 19 cases of absence of the right lobe from the literature. The anomaly was associated with biliary tract disease in 12 patients, portal hypertension in seven patients, other congenital anomalies in four patients, but it was an incidental finding in five patients. Inoue et al. 2306 reported a case of hypogenesis of the right hepatic lobe associated with portal hypertension and reviewed 31 other cases of agenesis or hypogenesis in the Japanese literature. Injury to bile ducts occurred at cholecystectomy in a case of right lobe agenesis. 2307

This rare anomaly has been associated with suprahepatic 2308 or retrohepatic 2309 gallbladder, the latter complicated by hepatolithiasis and liver abscess.

Complete atrophy of the left lobe has been found in children 2310 when there is concomitant thrombosis of the left branch of the portal vein and left hepatic vein; clinically evident portal hypertension in such a condition is rare. 2311 A similar process affecting the right lobe is rarer. In adults, atrophy of the left lobe is also more common than atrophy of the right lobe, and it is associated with portal vein thrombosis; thrombosis of the corresponding hepatic vein may not be present or not detected. 2312 Although a bile duct lesion may be present, the portal vein obstruction seems to be dominant. Segmental or lobar atrophy is frequently observed in primary sclerosing cholangitis.

In situs inversus totalis or abdominalis, the liver is found in the left hypochondrium, with the falciform ligament coursing from the left anterior margin toward the umbilicus. Hepatolithiasis has been reported in a patient with situs inversus. 2313 Hepatocellular carcinoma (HCC) is rare. 2314 Adenocarcinoma of the distal common bile duct was reported in a 68-year-old woman with total situs inversus. 2315 A liver in a left or transverse position is one of the anomalies which may be associated with biliary atresia. 53 Varying amounts of hepatic tissue may be displaced into congenital diaphragmatic hernias or omphalocoeles. Hepatic-pulmonary fusion has been described in association with diaphragmatic hernia. 2316 Hepatic tissue was present in 3 of 19 omphalocoeles studied by Soper and Green. 2317 The liver tissue may be the seat of nonparasitic cysts 2318 and may be detached from the rest of the liver. 2319 Several cases of hepatic herniation through defects in the diaphragm have been reported. [2320] [2321] [2322] A unique case of a supradiaphragmatic right liver lobe and gallbladder has been reported. 2323 Partial eventration of the right hemidiaphragm is a congenital lesion caused by aplasia or hypoplasia of part of the musculature of the diaphragm, with resultant bulging of the affected portion from intra-abdominal pressure. 2324 The underlying portion of the liver prolapses into the diaphragmatic pouch, where it may become strangulated.

Riedel lobe is a tongue-like caudal projection from the right lobe of the liver, which may be palpated in the right upper quadrant. In the 31 cases of Reitemeier et al., 2325 all the patients except one were women, their ages ranging from 31 to 77 years. Supernumerary lobes 

Several patients with absence of the common hepatic duct have been described. [2355] [2356] [2357] They presented with obstructive jaundice in very early infancy and at operation were found to have no proximal biliary tree. There were no ductal structures in the hepatic hilum. Palliative surgery appears ineffective and LT is preferred.

Rare infants present with conjugated hyperbilirubinaemia and findings consistent with biliary atresia; however, imaging or direct inspection of the biliary system reveals perfectly formed ducts resembling a miniature version of normal architecture. These infants have extrahepatic biliary hypoplasia. 2358 Kasai portoenterostomy should not be performed. Typically, jaundice clears, but biliary cirrhosis develops and LT may be required.

Nomura et al. 2359 reported a patient with this rare anomaly. Cholangiography before laparoscopic cholecystectomy demonstrated insertion of the right hepatic duct into the cystic duct.

Anomalous ducts are found in about 15% of individuals when the bile ducts are dissected. 2360 Anomalous hepatic ducts that pass beyond the porta hepatis almost invariably arise from the right lobe and frequently from a dorsal segment. The mode of termination is variable; final entry may be into the gallbladder, cystic duct, right or common hepatic duct, junction of the cystic and common hepatic ducts or attributed to a metaplastic process. 2346 Pancreatic acini were found intermingled with peribiliary glandular acini in 4% of autopsy livers, probably representing an intrinsic component of these glands. 2347 Peribiliary glands were shown to be stem cell niches with the ability to differentiate into hepatobiliary and pancreatic cells. Similarities between peribiliary and pancreatic tissue have been proposed to explain shared pathological processes. 2348 Splenic heterotopia presenting as a mass lesion was reported by Lacerda et al. 2349 With one exception, 2350 the rare cases recently reported are examples of splenosis or subcapsular splenic implants following trauma or surgical splenectomy 2351 (see Chapter 15) . Thyroid heterotopia has been occasionally encountered (Fig. 3.174 ) and has been reported in a fetus with trisomy 18 syndrome. 2352

Congenital abnormalities of the biliary tract are best demonstrated and studied by radiographic methods. In a series of 3845 operative cholangiograms, Puente and Bannura 2353 demonstrated 'anatomical variations' (defined as those having no pathological significance) in 24% and 'congenital abnormalities' (defined as pathologically significant deviations from the normal pattern) in 18.4%. The latter included left-sided cystic duct (9.5%), aberrant hepatic ducts (4.6%) and accessory hepatic ducts (1.7%). The common channel is described in the earlier section on ductal plate malformation.

In the very rare absence of the common bile duct, the common hepatic duct empties directly into the gallbladder while the latter drains by a long cystic duct into the second part of the duodenum. 2354 even the common bile duct. 2361 Cullingford et al. 2362 reported a rare case of an anomalous right posterior segmental hepatic duct associated with a stricture and hepatolithiases. Abnormal sectional distribution of the right hepatic duct was found in 36% of 139 patients evaluated as potential donors for living-donor liver transplantation, and a classification was proposed to recognize risk areas when performing right-graft live-donor LT and tumour resections involving the right lobe. 2363 Cholecystohepatic ducts are rare and occur when there is persistence of the fetal connections between the gallbladder and liver parenchyma, with failure of recanalization of the right and left hepatic ducts. 2364 Two cases were reported in association with oesophageal atresia. 2365 Failure to recognize the presence of cholecystohepatic ducts at cholecystectomy may lead to a persistent biliary fistula, bile peritonitis, stricture or death. 2366 Cholangiography is mandatory whenever there is any doubt about the anatomy of the biliary tree, to avoid the increased morbidity and mortality of reoperation. 2366 Anomalous bile ducts may occur in association with biliary cystadenoma of the liver. 2367 Two examples of a long accessory hepatic duct have been found among 23 cases of congenital dilation of the common bile duct. 2368 Atresia of the common hepatic duct with an accessory duct has been reported. 2355 Accessory hepatic ducts may occasionally contain calculi. 2369 

One duct may empty into the pylorus, or both ducts may drain into the duodenum. A choledochal cyst was associated with one case of duplicate bile ducts. 2370 Patients are usually free of symptoms until obstruction by stone or infection occurs. A case of congenital duplication involved the cystic duct and the common hepatic duct, both of which were lined by gastric mucosa. 2371 

Several cases of bronchobiliary and tracheobiliary fistula have been reported. 2372 One patient had a bronchobiliary fistula, as well as a tracheo-oesophageal fistula and oesophageal atresia. 2373 Bronchobiliary fistula has been reported with biliary atresia. 2374, 2375 The bronchobiliary fistula typically arises from the proximal part of the right main stem bronchus, a short distance below the carina, and generally joins the biliary system at the level of the left hepatic duct. The proximal part of the fistula resembles a bronchus, whereas the distal part is lined by columnar and/or squamous epithelium. Patients present in early infancy with aspiration pneumonia and atelectasis. In a recent case, clinical presentation was in adolescence. 2376 Ciliated hepatic foregut cyst More than 100 cases of ciliated hepatic foregut cyst have been reported in the literature. 2377 The cyst is generally found incidentally at laparotomy or by imaging studies. It occurs more frequently in men and is most often in the medial segment of the left hepatic lobe. In one case the cyst appeared closely associated with the left hepatic vein. 2378 In most instances the cyst is unilocular (Fig. 3.175) . The mean cyst diameter is approximately 3 cm. One large cyst was associated with an elevated serum CA19-9 level. 2379 There have been a few isolated reports of squamous cell carcinoma arising in a ciliated foregut cyst (see Chapter 13) . 2380, 2381 Histologically, the cyst wall consists of four layers: pseudostratified ciliated columnar epithelium with mucous cells, subepithelial connective tissue, bundles of smooth muscle and an outermost fibrous capsule [2382] [2383] [2384] [2385] (Fig. 3.176 ). Endocrine cells are present in the cyst B A epithelium. 2385 Gastric metaplasia has also been described. 2377 In all seven cases of Chatelain et al., 2385 immunoreactivity of some cells for CD10 suggested the presence of Clara cells. The cysts are believed to arise from the embryonic foregut and to differentiate toward bronchial structures in the liver.

In the first few months of life, spontaneous bile peritonitis may occur from leakage of bile at the junction of the cystic and common bile ducts. In patients without other bile duct structural lesions, the aetiology is unknown, although congenital weakness of the bile duct walls, mucous plugs and gallstones have been suggested. 142, 143, 2386 The clinical presentation consists of conjugated hyperbilirubinaemia, ascites, failure to thrive and signs of peritoneal irritation. Sepsis can complicate the clinical picture. 2387 The diagnosis can be suspected by finding bile on abdominal paracentesis and confirmed by hepatobiliary scanning with a technetium-99m-labelled iminodiacetic acid derivative. 2386 Treatment is surgical and the prognosis excellent. Pathological descriptions of the liver are usually consistent with obstruction: ductular reaction and oedematous portal tracts.

Neonatal syncytial giant cell hepatitis with paramyxoviral-like inclusions

Neonatal hepatitis: a follow-up study

Liver dysfunction and histologic abnormalities in neonatal hypopituitarism

Neonatal cholestasis, hypoglycemia, and congenital hypopituitarism

Neonatal iron overload and tissue siderosis due to gestational alloimmune liver disease

Severe giant cell hepatitis with autoimmune hemolytic anemia in early childhood

Coombs-positive giant cell hepatitis of infancy: effect of steroids and azathioprine therapy

Recurrent and de novo giant cell hepatitis after orthotopic liver transplantation

Liver transplant for giant cell hepatitis with autoimmune haemolytic anaemia

Cholestasis in newborn infants with perinatal asphyxia

Transient neonatal cholestasis: origin and outcome

Transient cholestasis in newborn infants with perinatal asphyxia

Fate of infants with neonatal hepatitis: pediatric surgeons' dilemma

Hereditary cholestasis with lymphoedema (Aagenaes syndrome, cholestasis-lymphoedema syndrome)

Evidence for genetic heterogeneity in lymphedema-cholestasis syndrome

Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency

Infantile cholestatic jaundice associated with adult-onset type II citrullinemia

Infantile citrullinemia caused by citrin deficiency with increased dibasic amino acids

Clinical heterogeneity of neonatal intrahepatic cholestasis caused by citrin deficiency: case reports from 16 patients

Clinical pictures of 75 patients with neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD)

A reduced segment II/III graft for neonatal liver failure with absence of detectable hepatocytes. A case report and literature review

Neonatal cholestasis associated with fetal arrhythmia

Neonatal hepatocellular giant cell transformation: a review

Neonatal hepatitis and biliary atresia. Washington DC: US Government Printing Office

Combined hepatic and renal transplantation in primary hyperoxaluria type I: clinical report of nine cases

Fulminant Wilson's disease requiring liver transplantation in one monozygotic twin despite identical genetic mutation

Hepatic morphology in the inherited metabolic diseases

Metabolic diseases: foundations of clinical management, genetics, and pathology

The liver: an atlas and text of ultrastructural pathology

Electron microscopy: a method for the diagnosis of inherited metabolic storage diseases. Electron microscopy in diagnosis

Ultrastructural aspects of the liver and its disorders

Late referral for biliary atresia-missed opportunities for effective surgery

Dissolution of copper-rich granules in hepatic lysosomes by D-penicillamine prevents the development of fulminant hepatitis in Long-Evans cinnamon rats

Congenital biliary atresia: liver injury begins at birth

Mutations in TJP2 cause progressive cholestatic liver disease

Metabolic liver disease in childhood

A Role of liver histology in the management of acute liver failure in children

Le foie vide: a unique case of neonatal liver failure

Experimental giant-cell transformation in the liver induced by E. coli endotoxin

Hepatitis syndrome in infancy-an epidemiological survey with 10 year follow up

Intrauterine growth retardation, duodenal and extrahepatic biliary atresia, hypoplastic pancreas and other intestinal anomalies: further evidence of the Martinez-Frias syndrome

Familial extrahepatic biliary atresia

Familial biliary atresia in three siblings including twins

Mother-to-daughter occurrence of biliary atresia: a case report

Lethal autosomal recessive syndrome with intrauterine growth retardation, intra-and extrahepatic biliary atresia, and esophageal and duodenal atresia

Incidence of hepatotropic viruses in biliary atresia

Pathogenesis of biliary atresia: defining biology to understand clinical phenotypes

Biliary atresia, cytomegalovirus, and age at referral

Polymerase chain reaction to detect human cytomegalovirus in livers of infants with neonatal hepatitis

Neonatal hepatitis and extrahepatic biliary atresia associated with cytomegalovirus infection in twins

Relationship between prognosis of biliary atresia and infection of cytomegalovirus

Cytomegalovirus-specific T-cell reactivity in biliary atresia at the time of diagnosis is associated with deficits in regulatory T cells

Biliary atresia and reovirus type 3 infection

Extrahepatic biliary atresia in a rhesus monkey (Macaca mulatta)

Role of reovirus type 3 in persistent infantile cholestasis

Detection of reovirus type 3 in the porta hepatis of an infant with extrahepatic biliary atresia: ultrastructural and immunocytochemical study

Lack of correlation between infection with reovirus 3 and extrahepatic biliary atresia or neonatal hepatitis

Reovirus 3 not detected by reverse transcriptase-mediated polymerase chain reaction analysis of preserved tissue from infants with cholestatic liver disease

Detection of reovirus RNA in hepatobiliary tissues from patients with extrahepatic biliary atresia and choledochal cysts

Detection of group C rotavirus in infants with extrahepatic biliary atresia

Lack of evidence for rotavirus by polymerase chain reaction/enzyme immunoassay of hepatobiliary samples from children with biliary atresia

Presence of human papillomavirus in extrahepatic biliary atresia

Genetics, immunology, and biliary atresia: an opening or a diversion?

possible mechanisms of formation

Morphologic and cytochemical study on neonatal liver "giant" cell transformation

Form of hepatitis in neonatal period simulating biliary atresia

Syncytial giant-cell hepatitis. Sporadic hepatitis with distinctive pathological features, a severe clinical course, and paramyxoviral features

Epidemiology of biliary atresia in France: a national study 1986-96

The frequency and outcome of biliary atresia in the UK and Ireland

Biliary atresia: the Canadian experience

Universal screening for biliary atresia using an infant stool color card in Taiwan

Epidemiology of biliary atresia: a population-based study

Studies in the etiology of extrahepatic biliary atresia: time-space clustering

Extrahepatic biliary atresia and associated anomalies: etiologic heterogeneity suggested by distinctive patterns of associations

Italian cancer figures, report 2013: Multiple tumours

Congenital structural abnormalities in biliary atresia: evidence for etiopathogenic heterogeneity and therapeutic implications

Discordance for biliary atresia in two sets of monozygotic twins

Biliary atresia and other structural anomalies in the congenital polysplenia syndrome

Biliary atresia splenic malformation syndrome: an etiologic and prognostic subgroup

Biliary atresia with associated structural malformations in Canadian infants

Does "cystic" biliary atresia represent a distinct clinical and etiological subgroup? A series of three cases

Biliary atresia with choledochal cyst: implications for classification

Cystic biliary atresia: an etiologic and prognostic subgroup

Neonatal hepatitis and biliary atresia associated with trisomy 17-18 syndrome

Biliary atresia and the Dandy-Walker anomaly in a neonate with 45,X Turner's syndrome

Congenital bile duct anomalies (biliary atresia) and chromosome 22 aneuploidy

Biliary atresia and Kabuki syndrome: another case with long-term follow-up

Zimmermann-Laband syndrome in a child previously described with brachydactyly, extrahepatic biliary atresia, patent ductus arteriosus and seizures

Macrophages are targeted by rotavirus in experimental biliary atresia and induce neutrophil chemotaxis by Mip2/Cxcl2

Loss of interleukin-12 modifies the pro-inflammatory response but does not prevent duct obstruction in experimental biliary atresia

Progressive biliary destruction is independent of a functional tumor necrosis factoralpha pathway in a rhesus rotavirus-induced murine model of biliary atresia

Interleukin 17, produced by γδ T cells, contributes to hepatic inflammation in a mouse model of biliary atresia and is increased in livers of patients

Effector role of neonatal hepatic CD8+ lymphocytes in epithelial injury and autoimmunity in experimental biliary atresia

Cellular and humoral autoimmunity directed at bile duct epithelia in murine biliary atresia

Serial circulating markers of inflammation in biliary atresia: evolution of the post-operative inflammatory process

Considerations of the pathogenesis of neonatal hepatitis, biliary atresia and choledochal cyst: the concept of infantile obstructive cholangiopathy

Maternal microchimerism in underlying pathogenesis of biliary atresia: quantification and phenotypes of maternal cells in the liver

Experimental study of the pathogenesis of infantile obstructive cholangiopathy and its clinical evaluation

Congenital diseases of intrahepatic bile ducts: variations on the theme "ductal plate malformation

Ductal plate malformationlike arrays in early explants after a Kasai procedure are independent of splenic malformation complex (heterotaxy)

Cholangiopathies: past, present, and future

Abnormalities of intrahepatic bile ducts in extrahepatic biliary atresia

Abnormal cilia in a child with the polysplenia syndrome and extrahepatic biliary atresia

Immotile cilia syndrome including polysplenia, situs inversus, and extrahepatic biliary atresia

Mutation of the mouse hepatocyte nuclear factor/forkhead homologue 4 gene results in an absence of cilia and random left-right asymmetry

Human laterality disorders

Inversin, a novel gene in the vertebrate left-right axis pathway, is partially deleted in the inv mouse

Anomalous development of the hepatobiliary system in the Inv mouse

CFC1 gene involvement in biliary atresia with polysplenia syndrome

The pathogenesis of biliary atresia: evidence for a virusinduced autoimmune disease

Biliary atresia: will blocking inflammation tame the disease?

Biliary atresia: cellular dynamics and immune dysregulation

Alpha-enolase autoantibodies cross-reactive to viral proteins in a mouse model of biliary atresia

Immunohistochemistry of the liver and biliary tree in extrahepatic biliary atresia

Biliary atresia is associated with CD4+ Th1 cell-mediated portal tract inflammation

Oligoclonal expansions of CD4+ and CD8+ T-cells in the target organ of patients with biliary atresia

Genetic induction of proinflammatory immunity in children with biliary atresia

Expression of osteopontin correlates with portal biliary proliferation and fibrosis in biliary atresia

Altered expression of genes involved in hepatic morphogenesis and fibrogenesis are identified by cDNA microarray analysis in biliary atresia

Coordinate expression of regulatory genes differentiates embryonic and perinatal forms of biliary atresia

Genomic alterations in biliary atresia suggest region of potential disease susceptibility in 2q37.3

Evidence from human and zebrafish that GPC1 is a biliary atresia susceptibility gene

Common genetic variants regulating ADD3 gene expression alter biliary atresia risk

Genome-wide association study identifies a susceptibility locus for biliary atresia on 10q24.2

Replication of a GWAS signal in a Caucasian population implicates ADD3 in susceptibility to biliary atresia

The Role of ARF6 in Biliary Atresia

Association of X-prolyl aminopeptidase 1 rs17095355 polymorphism with biliary atresia in Thai children

Association between HLA and extrahepatic biliary atresia

HLA and cytokine gene polymorphisms in biliary atresia

Human leukocyte antigens in Japanese patients with biliary atresia: retrospective analysis of patients who underwent living donor liver transplantation

HLA in Egyptian children with biliary atresia

Diverse morphology of biliary atresia in an animal model

Progress in developing animal models for biliary atresia

Obstruction of extrahepatic bile ducts by lymphocytes is regulated by IFN-γ in experimental biliary atresia

Long-term follow-up after surgery for patients with biliary atresia

Long-term results with the Kasai operation for biliary atresia

Conventional treatment of biliary atresia: long-term results

Impact of age at Kasai operation on its results in late childhood and adolescence: a rational basis for biliary atresia screening

The anatomic pattern of biliary atresia identified at time of Kasai hepatoportoenterostomy and early postoperative clearance of jaundice are significant predictors of transplant-free survival

The outcome of the older (≥100 days) infant with biliary atresia

Extrahepatic bile duct atresia: how efficient is the hepatoporto-enterostomy?

Prognostic value of computerized quantification of liver fibrosis in children with biliary atresia

Biliary atresia: should all patients undergo a portoenterostomy?

The extent of biliary proliferation in liver biopsies from patients with biliary atresia at portoenterostomy is associated with the postoperative prognosis

Ductal remnants in extrahepatic biliary atresia: a histopathologic study with clinical correlation

Studies on the pathogenesis of biliary atresia

Histologic study of biliary fibrous remnants in 48 cases of extrahepatic biliary atresia: correlation with postoperative bile flow restoration

In biliary atresia duct histology correlates with bile flow

Does the morphology of the extrahepatic biliary remnants in biliary atresia influence survival? A review of 205 cases

A multivariable risk factor analysis of the portoenterostomy (Kasai) procedure for biliary atresia: twenty-five years of experience from two centers

Long-term results and clinical problems after portoenterostomy in patients with biliary atresia

Biliary atresia: surgical management and treatment options as they relate to outcome

Biliary atresia and survival into adulthood without transplantation: a collaborative multicentre clinic review

Problems during and after pregnancy in female patients with biliary atresia

Sequential treatment of biliary atresia with Kasai portoenterostomy and liver transplantation: a review

British paediatric surveillance unit study of biliary atresia: outcome at 13 years

Health status ten years after pediatric liver transplantation: looking beyond the graft

Intrahepatic biliary cysts in congenital biliary atresia

Identification and functional analysis of ZIC3 mutations in heterotaxy and related congenital heart defects

Abnormalities in villin gene expression and canalicular microvillus structure in progressive cholestatic liver disease of childhood

Patients with biliary atresia have elevated direct/conjugated bilirubin levels shortly after birth

Prognosis of uncorrected biliary atresia: an update

Stool color card screening for biliary atresia

Home-based screening for biliary atresia using infant stool colour cards: a large-scale prospective cohort study and cost-effectiveness analysis

Neonatal hepatitis syndrome

Spontaneous perforation of the common bile duct in children

Spontaneous perforation of the bile duct in infants

Spontaneous perforation of common bile duct in infants

Atypical morphologic presentation of biliary atresia and value of serial liver biopsies

Spontaneous perforation of the extra-hepatic bile ducts in neonates and infants

Outcome of hepatobiliary scanning in neonatal hepatitis syndrome

Delayed excretion of radionuclide in scanning with diisopropyl iminodiacetic acid does not exclude the possibility of primary biliary atresia: case report

Endoscopic retrograde cholangiopancreaticography prior to explorative laparotomy avoids unnecessary surgery in patients suspected for biliary atresia

Selective use of endoscopic retrograde cholangiopancreatography in the diagnosis of biliary atresia in infants younger than 100 days

Diagnostic efficacy of ERCP in cholestatic infants and neonates-a retrospective study on a large series

The prelaparotomy diagnosis of extrahepatic biliary atresia

Histopathological features and accuracy for diagnosing biliary atresia by prelaparotomy liver biopsy in developing countries

Surgical treatment of biliary atresia

Laparoscopic portoenterostomy versus open portoenterostomy for the treatment of biliary atresia: a systematic review and meta-analysis of comparative studies

The experience and technique in laparoscopic portoenterostomy for biliary atresia

A prospective study comparing laparoscopic and conventional Kasai portoenterostomy in children with biliary atresia

Follow-up studies of long term survivors after hepatic portoenterostomy for "noncorrectible" biliary atresia

Prolonged cholestasis with ductopenia after administration of amoxicillin/clavulanic acid

Letter: Intrahepatic bile stasis in 45,X Turner's syndrome

Intrahepatic biliary atresia in Down's syndrome

Association of paucity of interlobular bile ducts with prune belly syndrome

Arteriohepatic dysplasia: familial pulmonary arterial stenosis with neonatal liver disease

Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur

Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases

Syndromic paucity of the intrahepatic bile ducts: diagnostic difficulty; severe morbidity throughout early childhood

Features of Alagille syndrome in 92 patients: frequency and relation to prognosis

Medical management of Alagille syndrome

Mutations in the human Jagged1 gene are responsible for Alagille syndrome

Expression of mutant JAGGED1 alleles in patients with Alagille syndrome

Four generations of arteriohepatic dysplasia

Mutations in JAGGED1 gene are predominantly sporadic in Alagille syndrome

Jagged1 mutations in alagille syndrome

Intrahepatic "cholestasis facies": is it specific for Alagille syndrome?

Facial features in Alagille syndrome: specific or cholestasis facies?

Arteriohepatic dysplasia and cardiovascular malformations

Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome

Ocular abnormalities in Alagille syndrome

Ocular ultrasound in Alagille syndrome: a new sign

Arteriohepatic dysplasia: radiologic features of a new syndrome

Arteriohepatic dysplasia: association of liver disease with pulmonary arterial stenosis as well as facial and skeletal abnormalities

Vertebral anomalies in children with Alagille syndrome: an analysis of 50 consecutive patients

Pathologic lower extremity fractures in children with Alagille syndrome

Portal lymphadenopathy associated with lipofuscin in chronic cholestatic liver disease

Human extrahepatic biliary atresia: portal connective tissue activation related to ductular proliferation

The pathogenesis of biliary atresia: a morphological study of the hepatobiliary system and the hepatic artery

Medial thickening of hepatic artery branches in biliary atresia: a morphometric study

The onecut transcription factor HNF6 is required for normal development of the biliary tract

Hepatic artery malformations associated with a primary defect in intrahepatic bile duct development

Copper kinetics in infantile hepatobiliary disease

Cytomegalovirus-associated biliary atresia: An aetiological and prognostic subgroup

Kasai portoenterostomy: new insights from hepatic morphology

Bile lakes in congenital biliary atresia

Contribution of hepatic parenchymal and nonparenchymal cells to hepatic fibrogenesis in biliary atresia

Expression of collagens type I and IV, osteonectin and transforming growth factor beta-1 (TGFβ1) in biliary atresia and paucity of intrahepatic bile ducts during infancy

Cholestatic syndromes of infancy and childhood

Liver morphology in anicteric patients at long-term follow-up after Kasai operation: a study of 16 cases

Intrahepatic bile duct loss in biliary atresia despite portoenterostomy: a consequence of ongoing obstruction?

Intrahepatic bile ducts in biliary atresia-a possible factor determining the prognosis

Early occurrence of hepatocellular carcinoma in biliary atresia treated by liver transplantation

Hepatocellular carcinoma complicating biliary atresia after Kasai portoenterostomy

Hepatocellular carcinoma in biliary atresia: King's College Hospital experience

Cholangiocarcinoma associated with biliary cirrhosis due to congenital biliary atresia

CT and MR appearance of focal nodular hyperplasia of the liver in children with biliary atresia

Focal nodular hyperplasia in biliary atresia patient after Kasai hepatic portoenterostomy

Macro-regenerative nodules in biliary atresia: CT/MRI findings and their pathological relations

Identification of bile duct paucity in Alagille syndrome: utilizing CK7 and EMA immunohistochemistry as a reliable panel for accurate diagnosis

Hepatocellular carcinoma in Alagille's syndrome: a family study

Hepatocellular carcinoma occurring in Alagille syndrome

Management of large hepatocellular carcinoma in adult patients with Alagille syndrome: a case report and review of literature

Reduced ratio of portal tracts to paucity of intrahepatic bile ducts

Copper overload in paucity of interlobular bile ducts syndrome

Bile duct paucity ("intrahepatic atresia

Possible defect in the bile secretory apparatus in arteriohepatic dysplasia (Alagille's syndrome): a review with observations on the ultrastructure of liver

Syndromatic paucity of interlobular bile ducts: hepatic histopathology of the early and endstage liver

Syndromatic hepatic ductular hypoplasia (arteriohepatic dysplasia): a clinical and hepatic histologic study of three patients

Arteriohepatic dysplasia in infancy and childhood: a longitudinal study of six patients

Paucity of interlobular bile ducts: arteriohepatic dysplasia and nonsyndromic duct paucity

Lack of hepatocellular CD10 along bile canaliculi is physiologic in early childhood and persistent in Alagille syndrome

CD10 immunostaining of bile canaliculi in liver biopsies: change of staining pattern with the development of cirrhosis

Proliferation to paucity: evolution of bile duct abnormalities in a case of Alagille syndrome

Bile canalicular morphometry in arteriohepatic dysplasia

Peripheral bile duct paucity and cholestasis in the liver of a patient with Alagille syndrome: further evidence supporting a lack of postnatal bile duct branching and elongation

Notch signaling in development and cancer

JAGGED1 gene expression during human embryogenesis elucidates the wide phenotypic spectrum of Alagille syndrome

Notch signaling regulates bile duct morphogenesis in mice

The role of Notch receptor expression in bile duct development and disease

The role of notch signaling in the development of intrahepatic bile ducts

Inhibition of Jagged-mediated Notch signaling disrupts zebrafish biliary development and generates multi-organ defects compatible with an Alagille syndrome phenocopy

Fifteen novel mutations in the JAGGED1 gene of patients with Alagille syndrome

The DSL domain in mutant JAG1 ligand is essential for the severity of the liver defect in Alagille syndrome

Renal involvement and the role of Notch signalling in Alagille syndrome

Renal histopathology in Alagille's syndrome

Alagille syndrome and nephroblastoma: unusual coincidence of two rare disorders

Moyamoya syndrome in children with Alagille syndrome: additional evidence of a vasculopathy

Alagille syndrome associated with angiographic moyamoya

Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality

Intracranial hemorrhages in Alagille syndrome

Bleeding tendency in children with Alagille syndrome

Intracranial vascular abnormalities in patients with Alagille syndrome

Multiple abdominal vascular anomalies in a patient with Alagille syndrome

Alagille syndrome: cutaneous manifestations in 38 children

Biliary tract abnormalities in patients with arteriohepatic dysplasia

Arteriohepatic dysplasia. I. Pitfalls in diagnosis and management

Arteriohepatic dysplasia. II. Hepatobiliary morphology

Endoscopic retrograde cholangiopancreatography study in Alagille's syndrome: first report

Long-term complications of arteriohepatic dysplasia

Outcome of liver disease in children with Alagille syndrome: a study of 163 patients

Body composition of children aged 1 to 12 years with biliary atresia or Alagille syndrome

Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome

Liver transplantation for Alagille's syndrome

Effect of Kasai procedure on hepatic outcome in Alagille syndrome

A longitudinal study to identify laboratory predictors of liver disease outcome in Alagille syndrome

Alagille syndrome and liver transplantation

Liver transplantation in children with Alagille syndrome: a study of twelve cases

Does liver transplantation affect growth pattern in Alagille syndrome?

Hepatocellular carcinoma associated with arteriohepatic dysplasia

Congenital dilatation of the bile duct: changes in diagnostic tools over the past 19 years

Choledochal cysts: comparison of findings at MR cholangiopancreatography and endoscopic retrograde cholangiopancreatography in eight patients

Choledochal cyst: a 33-year review

Pancreatitis associated with adult choledochal cysts

Acute pancreatitis in Japanese and Western children: etiologic comparisons

Spontaneous rupture of choledochal cyst: an unusual cause of acute abdomen in children

Choledochal cystic malignancies

Regression of biliary cirrhosis following choledochal cyst drainage

Choledochocele presenting with anaemia

Choledochal cyst: a review of 19 cases

Congenital stenosis of the intrahepatic bile duct associated with choledochal cysts

Surgical treatment of congenital dilatation of bile duct (choledochal cyst) with technical considerations

Choledochal cyst and congenital anomalies of the pancreatico-biliary junction: the clinical findings, radiology and outcome in nine cases

Pancreaticobiliary maljunction

Co-existing biliary anomalies and anatomical variants in choledochal cyst

Choledochal cyst with or without biliary atresia in neonates and young infants: US differentiation

Experimental study of the pathogenesis of choledochal cyst and pancreatitis, with special reference to the role of bile acids and pancreatic enzymes in the anomalous choledocho-pancreatico ductal junction

Type I choledochal cyst in association with familial adenomatous polyposis

Hepaticoenterostomy after excision of choledochal cyst in children: a 30-year experience with 180 cases

Choledochal cysts: age of presentation, symptoms, and late complications related to Todani's classification

Laparoscopic surgery for choledochal cyst in children: a case review of 31 patients

Laparoscopic repair for choledochal cyst: lessons learned from 190 cases

Intrahepatic cholangiocarcinoma arising 10 years after the excision of congenital extrahepatic biliary dilation

Malignant change in the biliary tract after excision of choledochal cyst

Mutation analysis of Jagged1 (JAG1) in Alagille syndrome patients

NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway

NOTCH2 mutations in Alagille syndrome

Notch2 signaling promotes biliary epithelial cell fate specification and tubulogenesis during bile duct development in mice

Notch signaling regulates formation of the three-dimensional architecture of intrahepatic bile ducts in mice

Nonsyndromic paucity of interlobular bile ducts: clinical and laboratory findings of 10 cases

Idiopathic adulthood ductopenia: a cause of chronic cholestatic liver disease and biliary cirrhosis

Idiopathic biliary ductopenia in adults: a report of five cases

Nonsyndromic paucity of intrahepatic bile ducts in infancy and idiopathic ductopenia in adulthood: the same syndrome?

Manifestation late in life of idiopathic adulthood ductopenia

Hepatocellular carcinoma in a long-term survivor of intrahepatic biliary duct hypoplasia

Nonsyndromatic paucity of interlobular bile ducts: light and electron microscopic evaluation of sequential liver biopsies in early childhood

Differential diagnosis of bile duct injury and ductopenia

Congenital dilatation of the bile ducts

Bile duct cysts in adults

Congenital choledochal cysts in adults

Increasing occurrence of choledochal malformations in children: a single-center 37-year experience from Finland

Choledochal cysts: heterogeneity of clinical presentation

Management dilemmas with choledochal cysts

Characteristics of infantile cases of congenital dilatation of the bile duct

Choledochal cyst, a disease for all ages

Antenatal diagnosis of choledochal cyst

Rapid enlargement of a choledochal cyst: antenatal diagnosis and delayed primary excision

Choledochal cyst disease: a changing pattern of presentation

Choledochal cysts: differences in children and adults

Clinicopathological feature and surgical outcome of choledochal cyst in different age groups: the implication of surgical timing

Mutations in SEC63 cause autosomal dominant polycystic liver disease

Polycystic kidney disease: the ciliary connection

Autosomal dominant polycystic kidney disease: molecular genetics and pathophysiology

Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat

Coordinate expression of the autosomal dominant polycystic kidney disease proteins, polycystin-2 and polycystin-1, in normal and cystic tissue

Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease

Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid

Polycystic kidney rat is a novel animal model of Caroli's disease associated with congenital hepatic fibrosis

Role of the hepatocyte nuclear factor-1β (HNF-1β) C-terminal domain in Pkhd1 (ARPKD) gene transcription and renal cystogenesis

A transcriptional network in polycystic kidney disease

Germline and somatic loss of function of the mouse cpk gene causes biliary ductal pathology that is genetically modulated

A mouse model for cystic biliary dysgenesis in autosomal recessive polycystic kidney disease (ARPKD)

Identification and characterization of Pkhd1, the mouse orthologue of the human ARPKD gene

Molecular pathogenesis of autosomal dominant polycystic kidney disease

Inherited polycystic kidney disease in children

Mapping of the gene for autosomal recessive polycystic kidney disease (ARPKD) to chromosome 6p21-cen

Refining the map and defining flanking markers of the gene for autosomal recessive polycystic kidney disease on chromosome 6p21.1-p12

The severe perinatal form of autosomal recessive polycystic kidney disease maps to chromosome 6p21.1-p12: implications for genetic counseling

A 1-Mb BAC/PAC-based physical map of the autosomal recessive polycystic kidney disease gene (PKHD1) region on chromosome 6

The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein

PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcriptionfactor domains and parallel beta-helix 1 repeats

Significance of intestinal metaplasia for the evolution of cancer in the biliary tract

Relation of patient age to premalignant alterations in choledochal cyst epithelium: histochemical and immunohistochemical studies

Choledochal cyst. Its possible autonomic involvement in the bile duct

Congenital dilatation of the intrahepatic bile ducts with cholangiocarcinoma

Carcinoma arising in a congenitally dilated biliary tract

Carcinoma in choledochal cysts. Age-related incidence

A case of choledochal cyst associated with adenocarcinoma exhibiting sarcomatous features

Choledochal cysts: a clinicopathologic study of 36 cases with emphasis on the morphologic and the immunohistochemical features of premalignant and malignant alterations

Cancer arising in a choledochal cyst in a 12-year-old girl

An 11-year-old male patient demonstrating cholangiocarcinoma associated with congenital biliary dilatation

Increased secondary bile acids in a choledochal cyst: possible role in biliary metaplasia and carcinoma

Proliferative activity of bile from congenital choledochal cyst patients

Recent advances in pancreaticobiliary maljunction

What is congenital hepatic fibrosis?

Ludwig symposium on biliary disorders. Part 1. Pathogenesis of ductal plate abnormalities

Biliary tract malformations

Liver disease in children. Philadelphia: Williams & Wilkins

Molecular advances in autosomal dominant polycystic kidney disease

To beat or not to beat: roles of cilia in development and disease

Polycystins, calcium signaling, and human diseases

Inhibition of Pkhd1 impairs tubulomorphogenesis of cultured IMCD cells

Molecular pathogenesis of ADPKD: the polycystin complex gets complex

The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are colocalized in renal cilia

The autosomal recessive polycystic kidney disease protein is localized to primary cilia, with 404

Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy

Nephrocystin-conserved domains involved in targeting to epithelial cell-cell junctions, interaction with filamins, and establishing cell polarity

Study of the malformation of ductal plate of the liver in Meckel syndrome and review of other syndromes presenting with this anomaly

Identification of a gene for renal-hepatic-pancreatic dysplasia by microarray-based homozygosity mapping

Renal-hepatic-pancreatic dysplasia: an autosomal recessive malformation

Chondroectodermal dysplasia (Ellis-van Creveld syndrome) with dysplasia of renal medulla and bile ducts

Sensenbrenner syndrome: a new member of the hepatorenal fibrocystic family

Jeune syndrome and liver disease: report of three cases treated with ursodeoxycholic acid

New diagnosis and treatment of congenital hepatic fibrosis

Joubert syndrome with congenital hepatic fibrosis: an entity in the spectrum of oculoencephalo-hepato-renal disorders

MKS3/TMEM67 mutations are a major cause of COACH syndrome, a Joubert syndrome related disorder with liver involvement

Mutations in 3 genes (MKS3, CC2D2A and RPGRIP1L) cause COACH syndrome (Joubert syndrome with congenital hepatic fibrosis)

Diseases of the intrahepatic biliary tree

Partial hepatectomy in the treatment of Caroli's disease: report of a case and review of the literature

A 32-year-old man with recurrent cholangitis

Caroli's disease

Successful treatment of Caroli's disease by hepatic resection: report of six patients

Caroli's syndrome: a heterogeneous entity

Caroli disease: high-frequency US and pathologic findings

The role of computed tomography in the evaluation of Caroli's disease

Caroli disease: central dot sign in CT

Caroli's disease: a magnetic resonance cholangiopancreatography diagnosis

Spontaneous rupture of a bile duct and its endoscopic management in a patient with Caroli's syndrome

Polycystic disease of kidney and liver presenting in childhood

Hepatology: a textbook of liver disease. Philadelphia: Saunders

Autosomal recessive polycystic kidney disease: radiologic-pathologic correlation

Morphometric analysis of liver lesions in cystic diseases of childhood

Infantile polycystic disease of the liver and kidneys

Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease

Comments upon the classification of infantile polycystic diseases of the liver and kidney, based upon three-dimensional reconstruction of the liver

The ductal plate malformation

Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD)

Caroli's disease in congenital hepatic fibrosis and infantile polycystic disease

Hepatobiliary fibropolycystic diseases. A clinical and histological review of 51 patients

MR cholangiography in children with autosomal recessive polycystic kidney disease

Congenital hepatic fibrosis: asymptomatic adults without renal anomaly

Intercontinental Medical Book

Course of autosomal recessive polycystic kidney disease (ARPKD) in siblings: a clinical comparison of 20 sibships

Congenital hepatic fibrosis

Congenital hepatic fibrosis: report of two new cases and review of the literature

Congenital hepatic fibrosis and nephronophthisis: a family study

Congenital hepatic fibrosis in autosomal-dominant polycystic kidney disease

Autosomal recessive polycystic kidney disease: long-term outcome of neonatal survivors

Congenital hepatic fibrosis in children

Bile duct carcinoma: a late complication of congenital hepatic fibrosis-case report and review of literature

Adenocarcinoma of the liver: association with congenital hepatic fibrosis and Caroli's disease

Congenital hepatic fibrosis

Liver and kidney disease in ciliopathies

Massive hepatomegaly in adult polycystic liver disease

Percutaneous sclerosis of hepatic cysts to treat obstructive jaundice in a patient with polycystic liver disease

Alcohol sclerosis for polycystic liver disease and obstructive jaundice: use of a nasobiliary catheter

Highly symptomatic adult polycystic disease of the liver: a report of fifteen cases

Hepatic venous outflow obstruction in autosomal dominant polycystic kidney disease

Hepatic venous outflow obstruction in patients with polycystic liver disease: pathogenesis and treatment

Hepatic cystic disease in an adult polycystic kidney disease transplant population

Liver resection and cyst fenestration in the treatment of severe polycystic liver disease

Congenital hepatic fibrosis and portal hypertension in autosomal dominant polycystic kidney disease

Management of polycystic liver disease

Autosomal dominant polycystic kidney disease: more than a renal disease

Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease

Hepatic cyst infection in autosomal dominant polycystic kidney disease

Infection of Hepatic Cysts with Pseudomonas aeruginosa in polycystic liver disease

Cyst infections in patients with autosomal dominant polycystic kidney disease

Extrarenal manifestations of autosomal dominant polycystic kidney disease

Polycystic kidney disease in the first year of life

Autosomal dominant polycystic kidney disease with liver and pancreatic involvement in early childhood

Molecular diagnostics in autosomal dominant polycystic kidney disease: utility and limitations

Congenital biliary dilatation in autosomal dominant adult polycystic disease of the liver and kidneys

Polycystic liver disease: a study of cyst fluid constituents

Calcified hepatic and renal cysts in adult dominant polycystic kidney disease

Polycystic liver; analysis of seventy cases

The liver in autosomal dominant polycystic kidney disease: implications for pathogenesis

Localized Caroli's disease associated with mucosecreting papillary adenocarcinoma: value of hepatic resection

Caroli's disease

Transhepatic decompression of the biliary tree in Caroli's disease

Monolobar Caroli's disease in an adult. Case report

Management of intrahepatic calculi in Caroli's disease by extracorporeal shock wave lithotripsy

Caroli's disease and outcomes after liver transplantation

Epithelial dysplasia in Caroli's disease

Caroli's disease associated with infantile polycystic kidney disease: prenatal sonographic appearance

Caroli's disease and adult polycystic kidney disease: a rarely recognized association

Biliary tract manifestations of the Marfan syndrome

The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium

The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains

Identification and localization of polycystin, the PKD1 gene product

Cellular localization and tissue distribution of polycystin-1

PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein

Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells

Evidence for a third genetic locus for autosomal dominant polycystic kidney disease

Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group

Risk of intracranial aneurysm bleeding in autosomal-dominant polycystic kidney disease

Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype

Autosomal dominant polycystic kidney disease

Extrarenal manifestations of ADPKD

Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease

Frequency of hepatic cysts in adult polycystic kidney disease

Characteristics of very early onset autosomal dominant polycystic kidney disease

Benign tumors of the liver. III. Solitary cysts

Carcinoid tumor arising in the wall of a congenital bile duct cyst

Congenital liver cyst presenting as congenital diaphragmatic hernia

Hepatic cyst associated with Pe u t z

Management of bile duct cysts in adults

Treatment of symptomatic non-parasitic liver cysts-surgical treatment versus alcohol injection therapy

Sclerosant therapy as first-line treatment for solitary liver cysts

Laparoscopic fenestration of symptomatic non-parasitic cysts of the liver

Laparoscopic treatment of simple hepatic cysts and polycystic liver disease

Cystic fibrosis of the pancreas and its relationship to celiac disease: a clinical and pathologic study

Identification of the cystic fibrosis gene: genetic analysis

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

Identification of the cystic fibrosis gene: chromosome walking and jumping

Cystic fibrosis

The cystic fibrosis transmembrane conductance regulator is a dual ATP and chloride channel

CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP

The cystic fibrosis transmembrane conductance regulator is regulated by a direct interaction with the protein phosphatase 2A

Submucosal glands are the predominant site of CFTR expression in the human bronchus

Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells

Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis

What is cystic fibrosis?

The molecular basis for disease variability in cystic fibrosis

The spectrum of cystic fibrosis mutations

Genotype analysis for delta F508, G551D and R553X mutations in children and young adults with cystic fibrosis with and without chronic liver disease

Cystic fibrosis-associated liver disease

Cystic fibrosis related liver disease: another black box in hepatology

Cystic dilatation of peribiliary glands in livers with adult polycystic disease and livers with solitary nonparasitic cysts: an autopsy study

The hepatic von Meyenburg complex: prevalence and association with hepatic and renal cysts among 2843 autopsies

Bile duct carcinoma associated with multiple von Meyenburg complexes in the liver

Cholangiocarcinoma in association with multiple biliary microhamartomas

Carcinomas arising in cystic conditions of the bile ducts: a clinical and pathologic study

Biliary cystadenocarcinoma arising in a liver with fibropolycystic disease

Intraductal papillary-mucinous neoplasm of the pancreas associated with polycystic liver and kidney disease

Isolated polycystic liver disease as a distinct genetic disease, unlinked to polycystic kidney disease 1 and polycystic kidney disease 2

Isolated polycystic liver disease not linked to polycystic kidney disease 1 and 2

Clinical profile of autosomal dominant polycystic liver disease

Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease

Molecular characterization of hepatocystin, the protein that is defective in autosomal dominant polycystic liver disease

Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease

Disrupted cell adhesion but not proliferation mediates cyst formation in polycystic liver disease

Whole-exome sequencing reveals LRP5 mutations and canonical Wnt signaling associated with hepatic cystogenesis

Solitary nonparasitic cysts of the liver: the Boston Children's Hospital experience

Solitary nonparasitic cyst of the liver; review of the literature and report of two patients

Congenital solitary nonparasitic cyst of the liver: a rare cause of rapidly enlarging abdominal mass in infancy

Nonparasitic solitary giant hepatic cyst causing obstructive jaundice was successfully treated with monoethanolamine oleate

Spontaneous rupture of nonparasitic cyst of the liver

Surgical diseases of the falciform ligament

Adenocarcinoma and infection in a solitary hepatic cyst: a case report

Primary squamous cell carcinoma originating in congenital cysts of the liver: report of a case and review of the literature

Biliary carcinosarcoma arising in nonparasitic simple cyst of the liver

Gene modifiers in pediatrics: application to cystic fibrosis

The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosis

The major histocompatibility complex influences the development of chronic liver disease in male children and young adults with cystic fibrosis

Genetic modifiers of liver disease in cystic fibrosis

A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis

Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C→T mutation

Intermediate-range sweat chloride concentration and Pseudomonas bronchitis: a cystic fibrosis variant with preservation of exocrine pancreatic function

Increased nasal potential difference and amiloride sensitivity in neonates with cystic fibrosis

Clinical application of transepithelial potential difference measurements in cystic fibrosis

Extensive sequencing of the CFTR gene: lessons learned from the first 157 patient samples

Prediction of liver fibrosis according to serum collagen VI level in children with cystic fibrosis

Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe

Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis

Liver and biliary problems in cystic fibrosis

Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis

Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease

A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease

Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis

Gallbladder disease in cystic fibrosis

Gallstones in cystic fibrosis: a critical reappraisal

Decompression of portal hypertension in a child with cystic fibrosis after transjugular intrahepatic portosystemic shunt placement

Outcome of cystic fibrosisassociated liver cirrhosis: management of portal hypertension

Liver transplantation for cholestasis associated with cystic fibrosis in the pediatric population

Cirrhosis and other liver disease in cystic fibrosis

Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome

Incidence of liver disease in patients with cystic fibrosis and meconium ileus

Hepatic complications of cystic fibrosis

Epidemiology of liver disease in cystic fibrosis: a longitudinal study

Congenital hypoplasia of the exocrine pancreas

Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas: clinical significance and relationship to the disease

Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts

Neonatal hepatitis syndrome with paucity of interlobular bile ducts in cystic fibrosis

Intrapancreatic compression of the common bile duct in cystic fibrosis

Inspissated bile in a neonate with cystic fibrosis

Cystic fibrosis: gastrointestinal and hepatic complications and their management

Analysis of risk factors for the development of liver disease associated with cystic fibrosis

Hepatobiliary disease in cystic fibrosis patients with pancreatic sufficiency

Cystic fibrosisassociated colitis and fibrosing colonopathy

Sclerosing cholangitis with hepatic microvesicular steatosis in cystic fibrosis and chronic pancreatitis

The pathological changes in the liver in cystic fibrosis of the pancreas

Cystic fibrosis with extensive fat replacement of the liver

Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis

The changing epidemiology of cystic fibrosis

Neonatal cholestasis as the presenting feature in cystic fibrosis

Correlation between genotype and phenotype in patients with cystic fibrosis. The Cystic Fibrosis Genotype-Phenotype Consortium

Liver expression in cystic fibrosis could be modulated by genetic factors different from the cystic fibrosis transmembrane regulator genotype

Prevalence of liver disease in cystic fibrosis

Genotype-phenotype correlation in cystic fibrosis: the role of modifier genes

Differential interaction of bile acids from patients with inborn errors of bile acid synthesis with hepatocellular bile acid transporters

Homozygosity mapping identifies a bile acid biosynthetic defect in an adult with cirrhosis of unknown etiology

Bile acid synthetic defects and liver disease

Molecular cloning and sequence analysis of cDNA encoding Δ 4 -3-ketosteroid 5β-reductase of rat liver

Δ 4 -3-Oxosteroid 5 betareductase. Structure and function

Resolution of liver biopsy alterations in three siblings with bile acid treatment of an inborn error of bile acid metabolism (Δ 4 -3-oxosteroid 5β-reductase deficiency)

Cloning and expression of cDNA of human Δ 4 -3-oxosteroid 5β-reductase and substrate specificity of the expressed enzyme

Δ 4 -3-oxosteroid 5β-reductase deficiency described in identical twins with neonatal hepatitis: a new inborn error in bile acid synthesis

Gene analysis in Δ 4 -3-oxosteroid 5β-reductase deficiency

Bile acid biosynthesis

Δ 4 -3-oxosteroid 5β-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid

Mutations in SRD5B1 (AKR1D1), the gene encoding Δ 4 -3-oxosteroid 5β-reductase, in hepatitis and liver failure in infancy

Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7α-hydroxylase gene causes severe neonatal liver disease

Neonatal cholestatic liver disease in an Asian patient with a homozygous mutation in the oxysterol 7α-hydroxylase gene

Successful heterozygous living donor liver transplantation for an oxysterol 7α-hydroxylase deficiency in a Japanese patient

Liver disease in infancy caused by oxysterol 7α-hydroxylase deficiency: successful treatment with chenodeoxycholic acid

Neonatal cholestasis with increased 3β-monohydroxy-Δ 5 bile acids in serum and urine: not necessarily primary oxysterol 7α-hydroxylase deficiency

A 25-hydroxylation pathway of cholic acid biosynthesis in man and rat

Familial giant cell hepatitis with low bile acid concentrations and increased urinary excretion of specific bile alcohols: a new inborn error of bile acid synthesis?

Genetic defects in bile acid conjugation cause fat-soluble vitamin deficiency

Bile acid-CoA ligase deficiency: a new inborn error of bile acid metabolism

Role of the 26-hydroxylase in the biosynthesis of bile acids in the normal state

Cystic fibrosis liver disease and transplantation

Simultaneous liver and pancreas transplantation in patients with cystic fibrosis

Liver and intestinal transplantation in a child with cystic fibrosis: a case report

Combined heart-lungliver, double lung-liver, and isolated liver transplantation for cystic fibrosis in children

Fibrocystic disease of the pancreas: a congenital disorder of mucus production-mucosis. London: William Heinemann Medical Books

Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis

Ultrastructural changes of the pancreas and liver in cystic fibrosis

Pathology of cystic fibrosis review of the literature and comparison with 146 autopsied cases

Cystic fibrosis: its influence on the liver, biliary tree, and bile salt metabolism

A distinctive type of biliary cirrhosis of the liver associated with cystic fibrosis of the pancreas; recognition through signs of portal hypertension

Pancreatic function and disease in early life: pathologic changes associated with pancreatic insufficiency in early life

Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy

Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-associated liver disease

Ultrastructure of liver biopsies in cystic fibrosis

Hepatic parenchymal cells in cystic fibrosis: ultrastructural evidence for abnormal intracellular transport

Bile-duct destruction and collagen deposition: a prominent ultrastructural feature of the liver in cystic fibrosis

Morphological findings in the liver of children with cystic fibrosis: a light and electron microscopical study

The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease

Disorders of bile acid synthesis

Differential diagnosis in patients with suspected bile acid synthesis defects

Familial giant cell hepatitis associated with synthesis of 3β, 7α-dihydroxy-and 3β,7α, 12α-trihydroxy-5-cholenoic acids

Lack of 3β-hydroxy-Δ 5 -C 27 -steroid dehydrogenase/isomerase in fibroblasts from a child with urinary excretion of 3β-hydroxy-δ5-bile acids: a new inborn error of metabolism

Treatment of chronic liver disease caused by 3β-hydroxy-Δ 5 -C 27 -steroid dehydrogenase deficiency with chenodeoxycholic acid

A new cause of progressive intrahepatic cholestasis: 3β-hydroxy-C 27 -steroid dehydrogenase/isomerase deficiency

A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis

A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis

Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis

Characterization of mutations in ATP8B1 associated with hereditary cholestasis

Differences in presentation and progression between severe FIC1 and BSEP deficiencies

Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): evidence for heterogeneity

Byler's disease: fatal intrahepatic cholestasis

Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport

ATP8B1 is essential for maintaining normal hearing

Complementary functions of the flippase ATP8B1 and the floppase ABCB4 in maintaining canalicular membrane integrity

Fatal familial cholestatic syndrome in Greenland Eskimo children

A missense mutation in FIC1 is associated with Greenland familial cholestasis

Fatal familial cholestatic syndrome in Greenland Eskimo children: a histomorphological analysis of 16 cases

Familial intrahepatic cholestatic jaundice in infancy

Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: evidence for improvement of cholestasis with 4-phenylbutyrate

The human bile salt export pump: characterization of substrate specificity and identification of inhibitors

Functional expression of the canalicular bile salt export pump of human liver

Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families

Morphologic findings in progressive familial intrahepatic cholestasis 2 (PFIC2): correlation with genetic and immunohistochemical studies

Progressive familial intrahepatic cholestasis: a personal perspective

Progressive familial intrahepatic cholestasis among the Arab population in Israel

Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11

A novel mutation within a transmembrane helix of the bile salt export pump (BSEP, ABCB11) cerebrotendinous xanthomatosis: an in vivo study

Cerebrotendinous xanthomatosis: a defect in mitochondrial 26-hydroxylation required for normal biosynthesis of cholic acid

Demonstration of 26-hydroxylation of C27-steroids in human skin fibroblasts, and a deficiency of this activity in cerebrotendinous xanthomatosis

Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis

Fine-mapping, mutation analyses, and structural mapping of cerebrotendinous xanthomatosis in U.S. pedigrees

Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis

Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds

Mutation in the sterol 27-hydroxylase gene associated with fatal cholestasis in infancy

Juvenile cataract associated with chronic diarrhea in pediatric cerebrotendinous xanthomatosis

Cerebrotendinous xanthomatosis

Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid

Coronary heart disease in a patient with cerebrotendinous xanthomatosis

A biochemical abnormality in cerebrotendinous xanthomatosis: impairment of bile acid biosynthesis associated with incomplete degradation of the cholesterol side chain

Detection of carriers of cerebrotendinous xanthomatosis

Intrahepatic pigment and crystal forms in patients with cerebrotendinous xanthomatosis (CTX)

Liver in cerebrotendinous xanthomatosis (CTX)-a histochemical and EM study of four cases

Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy

Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use

Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis

Mechanisms of disease: inborn errors of bile acid synthesis

Normal serum gammaglutamyl-transpeptidase activity identifies groups of infants with idiopathic cholestasis with poor prognosis

Familial intrahepatic cholestatic syndromes

Aspects of liver pathology in adult patients with MDR3/ABCB4 gene mutations

Heterozygous nonsense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy

Progressive familial intrahepatic cholestasis

Genotype-phenotype relationships in the low-phospholipid-associated cholelithiasis syndrome: a study of 156 consecutive patients

The syndrome of benign recurrent cholestasis

Benign recurrent intrahepatic cholestasis

Polymorphisms in ABCB11 and ATP8B1 associated with development of severe intrahepatic cholestasis in Hodgkin's lymphoma

Recurrent familial intrahepatic cholestasis in the Faeroe Islands: phenotypic heterogeneity but genetic homogeneity

FIC1 disease: a spectrum of intrahepatic cholestatic disorders

Benign recurrent intrahepatic cholestasis progressing to progressive familial intrahepatic cholestasis: low GGT cholestasis is a clinical continuum

Benign recurrent intrahepatic cholestasis: a report of 26 cases

Defect of multidrugresistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis

Evidence for defective primary bile acid secretion in children with progressive familial intrahepatic cholestasis (Byler disease)

Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene

Treatment of progressive familial intrahepatic cholestasis: liver transplantation or partial external biliary diversion

Ileal exclusion for Byler's disease: an alternative surgical approach with promising early results for pruritus

Progressive familial intrahepatic cholestasis: partial biliary diversion normalizes serum lipids and improves growth in noncirrhotic patients

Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis

ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history

Preoperative observations and short-term outcome after partial external biliary diversion in 13 patients with progressive familial intrahepatic cholestasis

Orthotopic liver transplantation for Byler disease

Progressive familial intrahepatic cholestasis type 1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of with delayed development of cirrhosis

Hepatoma in familial cholestatic cirrhosis of childhood: its occurrence in twin brothers

Hepatoma in siblings with progressive familial cholestatic cirrhosis of childhood

Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency

Paediatric hepatocellular carcinoma due to somatic CTNNB1 and NFE2L2 mutations in the setting of inherited bi-allelic ABCB11 mutations

Mutations in bile salt export pump (ABCB11) in two children with progressive familial intrahepatic cholestasis and cholangiocarcinoma

Retargeting of bile salt export pump and favorable outcome in children with progressive familial intrahepatic cholestasis type 2

Recurrence of bile salt export pump deficiency after liver transplantation

De novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: a novel mechanism of cholestasis

Relapsing features of bile salt export pump deficiency after liver transplantation in two patients with progressive familial intrahepatic cholestasis type 2

Recurrent low gammaglutamyl transpeptidase cholestasis following liver transplantation for bile salt export pump (BSEP) disease (posttransplant recurrent BSEP disease)

A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3

Hepatic canalicular membrane 1: The role of mdr2 P-glycoprotein in hepatobiliary lipid transport

Progressive familial intrahepatic cholestasis type 3: overlapping presentation with Wilson disease

Functional analysis of ABCB4 mutations relates clinical outcomes of progressive familial intrahepatic cholestasis type 3 to the degree of MDR3 floppase activity

ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression

A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults

Heterozygous ABCB4 mutations in children with cholestatic liver disease

The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood

A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis

Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene

Clinical and molecular genetic features of ARC syndrome

Arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome: from molecular genetics to clinical features

Liver biopsy complicated by hemorrhage in a patient with ARC syndrome

Familial benign chronic intrahepatic cholestasis

Demonstration of McCune-Albright mutations in the liver of children with high γGT progressive cholestasis

Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome-a European Collaborative Study

Infant cholestasis in McCune-Albright syndrome

Hepatobiliary and pancreatic neoplasms in patients with McCune-Albright syndrome

Parent-child transmission of infantile cholestasis with lymphoedema (Aagenaes syndrome)

Prognosis, with evaluation of general biochemistry, of liver disease in lymphoedema cholestasis syndrome 1 (LCS1/Aagenaes syndrome)

Advanced hepatocellular carcinoma in adolescence associated with congenital cholestasis: a case description

Hereditary lymphedema, characteristics, and variations in 17 adult patients with lymphedema cholestasis syndrome 1/Aagenaes syndrome

MYO5B and bile salt export pump contribute to cholestatic liver disorder in microvillous inclusion disease

Inherited disorders of bilirubin metabolism

Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences

Congenital familial nonhemolytic jaundice with kernicterus

Congenital non-haemolytic jaundice

New developments in glucuronidation research: report of a workshop on "glucuronidation, its role in health and disease

Effective phototherapy in congenital nonobstructive, nonhemolytic jaundice

Crigler-Najjar syndrome type I: treatment by home phototherapy followed by orthotopic hepatic transplantation

Orthotopic liver transplantation for Crigler-Najjar type I disease in six children

Crigler-Najjar syndrome type I: management with phototherapy crib mattress

Current therapy for Crigler-Najjar syndrome type 1: report of a world registry

Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation

Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host liver steatosis after liver transplantation

Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantation

Severe familial cholestasis in North American Indian children: a clinical model of microfilament dysfunction?

North American Indian cirrhosis in children: a review of 30 cases

Localization of a recessive gene for North American Indian childhood cirrhosis to chromosome region 16q22-and identification of a shared haplotype

A missense mutation (R565W) in cirhin (FLJ14728) in North American Indian childhood cirrhosis

Nucleolar localization of cirhin, the protein mutated in North American Indian childhood cirrhosis

The C-terminus of Utp4, mutated in childhood cirrhosis, is essential for ribosome biogenesis

Cirhin up-regulates a canonical NF-kappaB element through strong interaction with Cirip/HIVEP1

p53-mediated biliary defects caused by knockdown of cirh1a, the zebrafish homolog of the gene responsible for North American Indian childhood cirrhosis

NOL11, implicated in the pathogenesis of North American Indian childhood cirrhosis, is required for pre-rRNA transcription and processing

Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT

Time course of acylcarnitine elevation in neonatal intrahepatic cholestasis caused by citrin deficiency

Sclerosing cholangitis with neonatal onset

Neonatal sclerosing cholangitis in two siblings: a category of progressive intrahepatic cholestasis

Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: a tight junction disease

Confirmation of the origin of NISCH syndrome

Neonatal ichthyosis and sclerosing cholangitis syndrome: extremely variable liver disease severity from claudin-1 deficiency

Claudin-1 involved in neonatal ichthyosis sclerosing cholangitis syndrome regulates hepatic paracellular permeability

Zebrafish vps33b, an ortholog of the gene responsible for human arthrogryposis-renal dysfunction-cholestasis syndrome, regulates biliary development downstream of the onecut transcription factor hnf6

Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome

Arthrogryposis, renal dysfunction, and cholestasis syndrome caused by VIPAR mutation

Chronic idiopathic jaundice: a review of fifty cases

Dubin-Johnson syndrome in Israel. I. Clinical, laboratory, and genetic aspects of 101 cases

Neonatal Dubin-Johnson syndrome with severe cholestasis: effective phenobarbital therapy

Dubin-Johnson syndrome in a neonate

Inheritance of the Dubin-Johnson syndrome

Assignment of the canalicular multispecific organic anion transporter gene (CMOAT) to human chromosome 10q24 and mouse chromosome 19D2 by fluorescent in situ hybridization

Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome

Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome

A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome

Absence of R1066X mutation in six Japanese patients with Dubin-Johnson syndrome

Hepatic pigmentation with photosensitivity: a syndrome in Corriedale sheep resembling Dubin-Johnson syndrome in man

Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene

Pigmentary liver disease in howler monkeys

Pigments in the Dubin-Johnson syndrome

Hepatic ultrastructure in chronic idiopathic jaundice

On the natural and excretion of the hepatic pigment in the Dubin-Johnson syndrome

Familial nonhemolytic jaundice with direct van den Bergh reaction

Hereditary nonhemolytic conjugated hyperbilirubinemia without abnormal liver cell pigmentation: a family study

Rotor-type hyperbilirubinaemia has no defect in the canalicular bilirubin export pump

Cholescintigraphy in the diagnosis of Rotor syndrome

Porphyrias: a 2015 update

High risk of primary liver cancer in a cohort of 179 patients with acute hepatic porphyria

Bone marrow transplant for X-linked protoporphyria with severe hepatic fibrosis

X-chromosomal inactivation directly influences the phenotypic manifestation of X-linked protoporphyria

Molecular mechanisms of dominant expression in porphyria

thymus permits long-term gene therapy in Gunn rats

Crigler-Najjar syndrome in four of five siblings with postmortem findings in one

Orthotopic liver transplantation for type I Crigler-Najjar syndrome

Clinical conference. Crigler-Najjar syndrome (type I) in an adult male

Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency: clinical, biochemical, pharmacologic and genetic evidence for heterogeneity

Crigler-Najjar syndrome type II: new observation of possible autosomal recessive inheritance

Inheritance of type 2 Crigler-Najjar hyperbilirubinaemia

Crigler-Najjar type II disease inheritance: a family study

Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase

The reciprocal relation between caloric intake and the degree of hyperbilirubinemia in Gilbert's syndrome

Gilbert syndrome accelerates development of neonatal jaundice

Constitutional hepatic dysfunction (Gilbert's syndrome). A new definition based on kinetic studies with unconjugated radiobilirubin

Defects in hepatic transport of bilirubin in congenital hyperbilirubinaemia: an analysis of plasma bilirubin disappearance curves

Idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome): a study of 42 families

Nonhemolytic unconjugated hyperbilirubinemia with hepatic glucuronyl transferase deficiency: a genetic study in four generations

The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome

Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase

A case of anorexia nervosa with hyperbilirubinaemia in a patient homozygous for a mutation in the bilirubin UDP-glucuronosyltransferase gene

A nonhuman primate model of Gilbert's syndrome

Excess lipofuscin accumulation in constitutional hepatic dysfunction (Gilbert's syndrome). Light and electron microscopic observations

Gilbert's syndrome: evidence of morphological heterogeneity

Chronic idiopathic jaundice with unidentified pigment in liver cells: a new clinicopathologic entity with a report of 12 cases

Persistent non-hemolytic hyperbilirubinemia associated with lipochrome-like pigment in liver cells: report of four cases

Iron and uroporphyrin in hepatocytes of inbred mice in experimental porphyria: a biochemical and morphological study

Are there diagnostic histologic features of porphyria cutanea tarda in liver biopsy specimens?

Hepatic pathology in porphyria cutanea tarda

Porphyria cutanea tarda and hepatocellular carcinoma: frequency of occurrence and related factors

Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence

Association of porphyria cutanea tarda and primary liver cancer: report of ten cases

Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors

Occurrence of hepatocellular carcinoma in a case of hereditary coproporphyria

Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria: an epidemiological investigation

Acute hepatic porphyria and hepatocellular carcinoma

Hepatocellular carcinoma in patients with acute intermittent porphyria

Acute intermittent porphyria and primary liver-cell carcinoma

Variegate porphyria associated with hepatocellular carcinoma

Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias

Haematoporphyria congenita with hydroa vacciniforme and hirsuties

Erythropoietic protoporphyria: a new porphyria syndrome with solar urticaria due to protoporphyrinaemia

Hepatobiliary changes in erythropoietic protoporphyria

Hepatic complications of erythropoietic protoporphyria

Erythropoietic protoporphyria and hepatic complications

Liver in disorders of porphyrin metabolism

Heme synthetase deficiency in human protoporphyria: demonstration of the defect in liver and cultured skin fibroblasts

The prognostic value of cord blood analysis in erythropoietic protoporphyria: the 'Duesseldorf Cord Blood Study

Protoporphyrin metabolic balance in human protoporphyria

The hepatic porphyrias: pathogenesis, manifestations, and management

Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation

The porphyrias

Hepatic porphyrias

Porphyria cutanea tarda: when skin meets liver

Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency

Associations among behavior-related susceptibility factors in porphyria cutanea tarda

Porphyria cutanea tarda as rare cutaneous manifestation of hepatic metastases treated with interferon

Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda

Porphyria cutanea tarda: the etiological importance of mutations in the HFE gene and viral infection is population-dependent

Association of porphyria cutanea tarda with hereditary hemochromatosis

Porphyria cutanea tarda, hepatitis C, uroporphyrinogen decarboxylase and mutations of HFE gene: a case-control study

Iron-induced liver injury

Fatal liver failure in protoporphyria: synergism between ethanol excess and the genetic defect

Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association

Hepatitis B virus infection in porphyria cutanea tarda

Hepatitis B serum markers in porphyria cutanea tarda

Severe pruritus after completing pegylated interferon for hepatitis C

Extrahepatic manifestations of hepatitis C among United States male veterans

Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis

Porphyria cutanea tarda as a complication of therapy for chronic hepatitis

Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America

Does chloroquine therapy of porphyria cutanea tarda influence liver pathology?

The pathology of the liver in porphyria cutanea tarda

The difference in liver pathology between sporadic and familial forms of porphyria cutanea tarda: the role of iron

Demonstration of needle-shaped hepatic inclusions in porphyria cutanea tarda using the ferric ferricyanide of the liver in three patients

A light and electron microscopic study of the liver in case of erythrohepatic protoporphyria and in griseofulvin-induced porphyria in mice

An autopsy case of erythropoietic protoporphyria with cholestatic jaundice and hepatic failure, and a review of literature

Early involvement of hepatic parenchymal cells in erythrohepatic protoporphyria? An ultrastructural study of patients with and without overt liver disease and the effect of chenodeoxycholic acid treatment

Liver inclusions in erythropoietic protoporphyria

Erythropoietic protoporphyria: juvenile protoporphyrin hepatopathy cirrhosis and death

Erythropoietic protoporphyria: 10 years experience

Hepatic failure and death from erythropoietic protoporphyria

Erythrohepatic protoporphyria with rapidly progressing liver cirrhosis

Changes in protoporphyrin distribution dynamics during liver failure and recovery in a patient with protoporphyria and Epstein-Barr viral hepatitis

Structure-function relationships of protoporphyrin-induced liver injury

Erythropoietic' protoporphyria and cirrhosis in sisters

X-linked dominant protoporphyria: a new porphyria

Molecular expression and characterization of erythroid-specific 5-aminolevulinate synthase gain-of-function mutations causing X-linked protoporphyria

Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and X-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria

Hepato-nephro-megale glykogenica (Glykogenspeicherkrankheit der Leber und Nieren)

Identification of mutations in the gene for glucose-6-phosphatase, the enzyme deficient in glycogen storage disease type 1a

The gene for glycogenstorage disease type 1b maps to chromosome 11q23

Mutations in the glucose-6-phosphatasealpha (G6PC) gene that cause type Ia glycogen storage disease

Neutropenia in type Ib glycogen storage disease

Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes

Historical highlights and unsolved problems in glycogen storage disease type 1

Glucose-6-phosphatase of the liver in glycogen storage disease

Recessive inheritance of erythropoietic protoporphyria with liver failure

A point mutation affecting an SP1 binding site in the promoter of the ferrochelatase gene impairs gene transcription and causes erythropoietic protoporphyria

Recessive inheritance of erythropoietic protoporphyria with liver failure

A novel mutation in the ferrochelatase gene associated with erythropoietic protoporphyria

Structure of the human ferrochelatase gene: exon/intron gene organization and location of the gene to chromosome 18

Molecular studies of liver disease in erythropoietic protoporphyria

Effect of hematin administration to patients with protoporphyria and liver disease

Hematin therapy in children with protoporphyric liver disease

Follow-up after liver transplantation for protoporphyric liver disease

Long-term follow-up after liver transplantation for erythropoietic protoporphyria

Recurrent hepatic allograft injury in erythropoietic protoporphyria

Treatment of recurrent allograft dysfunction with intravenous hematin after liver transplantation for erythropoietic protoporphyria

Bone-marrow transplantation for congenital erythropoietic porphyria

Ferrochelatase structural mutant (Fechm1Pas) in the house mouse

Liver pathology and hepatocarcinogenesis in a long-term mouse model of erythropoietic protoporphyria

Erythropoietic protoporphyria in the house mouse: a recessive inherited ferrochelatase deficiency with anemia, photosensitivity, and liver disease

Reversion of hepatobiliary alterations by bone marrow transplantation in a murine model of erythropoietic protoporphyria

Bone marrow-derived cells promote liver regeneration in mice with erythropoietic protoporphyria

Evidence that hepatic crystalline deposits in a patient with protoporphyria are composed of protoporphyrin

Birefringence of hepatic pigment deposits in erythropoietic protoporphyria: specificity of polarization microscopy in the identification of hepatic protoporphyrin deposits

Hepatic disease in erythropoietic protoporphyria

Apoptotic neutrophils in the circulation of patients with glycogen storage disease type 1b (GSD1b)

Long-term outcome of liver transplantation in patients with glycogen storage disease type Ia

Liver transplantation for type I glycogen storage disease

Orthotopic liver transplantation for type I glycogenosis unresponsive to medical therapy

Successful pregnancy after combined renal-hepatic transplantation in glycogen storage disease type Ia

Simultaneous liver-kidney transplantation for glycogen storage disease type IA (von Gierke's disease)

Liver cell adenomas. A 12-year surgical experience from a specialist hepato-biliary unit

Management of hepatic adenoma in glycogen storage disease Ia

Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia

Liver transplantation for glycogen storage disease type Ia

Treatment with lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) and orthotopic liver transplantation for glycogen storage disease type Ib

The benefits of liver transplantation in glycogenosis type Ib

Living donor liver transplantation for glycogen storage disease type Ib

Over idiopatische hypertrophie van het hart

Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency

Localization and ordering of acid alpha-glucosidase (GAA) and thymidine kinase (TK1) by fluorescence in situ hybridization

A large Alu-mediated deletion, identified by PCR, as the molecular basis for glycogen storage disease type II (GSDII)

Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II

Phenotypical variation within 22 families with Pompe disease

Hers HG. α-Glucosidase deficiency in generalized glycogen storage disease (Pompe's disease)

Glycogen storage diseases of muscle

Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency

Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk

Muscle computed tomography in adult-onset acid maltase deficiency

Transmembrane topology of glucose-6-phosphatase

Inactivation of the glucose 6-phosphate transporter causes glycogen storage disease type 1b

Defective neutrophil and monocyte functions in glycogen storage disease type Ib: a literature review

Crohn's-like ileo-colitis in patients affected by glycogen storage disease Ib: two years' follow-up of patients with a wide spectrum of gastrointestinal signs

Chronic inflammatory bowel disease in glycogen storage disease type 1B

Glycogen storage disease type Ib: infectious complications and measures for prevention

Glycogen storage disease in adults

The hemostatic defect in glycogen storage disease, type 1

Defect of platelet function associated with chronic hypoglycaemia

DDAVP infusion in five patients with type Ia glycogen storage disease and associated correction of prolonged bleeding times

Renal disease in type I glycogen storage disease

Hyperfiltration and renal disease in glycogen storage disease, type I

Glycogen storage disease I and hepatocellular tumours

Hepatocellular carcinoma in glycogen storage disease type Ia: a case series

Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature

Hepatocellular adenoma and metabolic balance in patients with type Ia glycogen storage disease

Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I

Glycogen storage disease: long-term follow-up of nocturnal intragastric feeding

Regression of hepatic adenomas in type Ia glycogen storage disease with dietary therapy

Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I)

Effect of continuous glucose therapy begun in infancy on the long-term clinical course of patients with type I glycogen storage disease

Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1

Amelioration of neutrophil membrane function underlies granulocyte-colony stimulating factor action in glycogen storage disease 1b

Clinical and laboratory findings in four patients with the non-progressive hepatic form of type IV glycogen storage disease

Juvenile polysaccharidosis with cardioskeletal myopathy

Severe cardiopathy in branching enzyme deficiency

Adult polyglucosan body disease: a postmortem correlation study

Adult polyglucosan body disease: a case report of a manifesting heterozygote

Liver transplantation for glycogen storage disease types I, III, and IV

Failure of liver transplantation to diminish cardiac deposits of amylopectin and leukocyte inclusions in type IV glycogen storage disease

Liver transplantation for type IV glycogen storage disease

Progressive cardiac failure following orthotopic liver transplantation for type IV glycogenosis

Characteristic growth pattern in male X-linked phosphorylase-b kinase deficiency

Mutations in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type VI

Identification of a mutation in liver glycogen phosphorylase in glycogen storage disease type VI

X-linked liver phosphorylase kinase deficiency is associated with mutations in the human liver phosphorylase kinase alpha subunit

The natural history of liver glycogenosis due to phosphorylase kinase deficiency: a longitudinal study of 41 patients

Liver glycogenosis due to phosphorylase kinase deficiency: PHKG2 gene structure and mutations associated with cirrhosis

Phosphorylase b kinase deficiency glycogenosis with cirrhosis of the liver

Autosomal recessive liver phosphorylase kinase deficiency caused by a novel splice-site mutation in the gene encoding the liver gamma subunit (PHKG2)

Variability of biochemical and clinical phenotype in X-linked liver glycogenosis with mutations in the phosphorylase kinase PHKA2 gene

Fanconi-Bickel syndrome: the original patient and his natural history, historical steps leading to the primary defect, and a review of the literature

Glucose transporters: structure, function and consequences of deficiency

Fanconi-Bickel syndrome presenting in neonatal screening for galactosaemia

Liver glycogen synthase deficiency: a rarely diagnosed entity

PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease

Glycogen storage disease, types I to X: criteria for morphologic diagnosis

Pathology of the fetus and the infant

The metabolic and molecular bases of inherited disease

Assignment of the human glycogen debrancher gene to chromosome 1p21

DNA-based subtyping of glycogen storage disease type III: mutation and haplotype analysis of the AGL gene in Chinese

Mutational analysis of the AGL gene: five novel mutations in GSD III patients

The long-term outcome of patients with glycogen storage diseases

Molecular characterization of glycogen storage disease type III

An adult case of glycogen storage disease type IIIa

Type IIIb glycogen storage disease associated with end-stage cirrhosis and hepatocellular carcinoma. The Liver Transplant Group

Case report: rupture of a gastric varix in liver cirrhosis associated with glycogen storage disease type III

Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy

Efficacy of cornstarch therapy in type III glycogen-storage disease

Glycogen storage disease type I and III and pyruvate carboxylase deficiency: results of long-term treatment with uncooked cornstarch

Definitive prenatal diagnosis for type III glycogen storage disease

Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene

The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies

Clinical and genetic heterogeneity of branching enzyme deficiency (glycogenosis type IV)

Glycogen storage disease type IV presenting as hydrops fetalis

Severe neonatal onset of glycogenosis type IV: clinical and laboratory findings leading to diagnosis in two siblings

Neonatal type IV glycogen storage disease associated with "null" mutations in glycogen branching enzyme 1

A congenital variant of glycogenosis type IV

Histochemistry and ultrastructure of atypical myoclonus body (type II)

Lafora's disease: distinct clinico-pathologic form of Unverricht's syndrome

Studies in myoclonus epilepsy (Lafora body form). I. Isolation and preliminary characterization of Lafora bodies in two cases

Progressive familial myoclonic epilepsy with Lafora bodies: electron microscopic and histochemical study of a cerebral biopsy

Myoclonus epilepsy with Lafora bodies: case report with electron microscopic observation

Myoclonus epilepsy with Lafora bodies: an ultrastructural and cytochemical study

Progressive myoclonus epilepsy as an inborn error of metabolism comparable to storage disease

Progressive familial myoclonic epilepsy in three families: its clinical features and pathological basis

Lafora disease: diagnosis by liver biopsy

Pathology of the nervous system

Immunological homogeneity of Lafora body, corpora amylacea, basophilic degeneration in heart, and intracytoplasmic inclusions of liver and heart in type IV glycogenosis

Ground-glass hepatocytes with Lafora body like inclusions: histochemical, immunohistochemical and electronmicroscopic characterization

Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia

Glycogen pseudoground glass change in hepatocytes

Congenital galactosemia, a single enzymatic block in galactose metabolism

Genetic basis of galactosemia

A common mutation associated with the Duarte galactosemia allele

Heterodimer formation and activity in the human enzyme galactose-1-phosphate uridylyltransferase

Molecular characterization of a unique patient with epimerase-deficiency galactosaemia

Further observations in a case of uridine diphosphate galactose-4-epimerase deficiency with a severe clinical presentation

Generalised uridine diphosphate galactose-4-epimerase deficiency

Clinical galactosemia

Sepsis due to Escherichia coli in neonates with galactosemia

Computed tomographic demonstration of cerebral edema in a child with galactosemia

Mutations in the liver glycogen synthase gene in children with hypoglycemia due to glycogen storage disease type 0

Long-term follow-up of a new case of liver glycogen synthase deficiency

Liver transplant pathology in pediatric metabolic disorders

Mallory bodies in a patient with type Ia glycogen storage disease

Type IV glycogen-storage disease: light-microscopic, electron-microscopic, and enzymatic study

Comparative study of the intracytoplasmic inclusions in Lafora disease and type IV glycogenosis by electron microscopy

Type IV glycogenosis: patient with absence of a branching enzyme alpha-1,4-glucan:alph a-1,4-glucan 6-glycosyl transferase

Metabolic errors and liver disease

Hepatocellular adenoma in glycogen storage disorder type I: a clinicopathological and molecular study

Adenomas in glycogen storage disease type 1: two cases with unusual histologic features

Hepatic adenomatosis in glycogen storage disease type Ia: report of a case with unusual histology

Case of glycogen storage disease type VI (phosphorylase deficiency) complicated by focal nodular hyperplasia

Glycogenosis type I (glucose 6-phosphatase deficiency). I. Ultrastructural morphometric analysis of juvenile liver cells

Glycogen storage disease type IB

An electron microscopic and biochemical study of type II glycogenosis

Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus

Hepatocyte glycogen accumulation in patients undergoing dietary management of urea cycle defects mimics storage disease

Mutations in NHLRC1 cause progressive myoclonus epilepsy

Identification of a novel protein interacting with laforin, the EPM2a progressive myoclonus epilepsy gene product

Lafora progressive myoclonus epilepsy mutation database: EPM2A and NHLRC1 (EPM2B) genes

Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy

Late-onset and slowprogressing Lafora disease in four siblings with EPM2B mutation

Myoclonic epilepsy with Lafora bodies: some ultrastructural, histochemical, and biochemical aspects

Progressive myoclonus epilepsy with Lafora inclusion bodies. I. Clinical, genetic, histopathologic, and biochemical aspects

Hereditary fructose intolerance: a clinical study of four cases

High liver glycogen in hereditary fructose intolerance

Metabolic cirrhoses of infancy and early childhood

Ultrastructural hepatocellular alterations induced by in vivo fructose infusion

Dried blood spots allow targeted screening to diagnose mucopolysaccharidosis and mucolipidosis

Disease-specific markers for the mucopolysaccharidoses

The laboratory diagnosis of mucopolysaccharidosis III (Sanfilippo syndrome): a changing landscape

Incidence and prevalence of mucopolysaccharidosis type 1 in the Irish Republic

Detection of the carrier state of Hurler's syndrome by assay of alpha-L-iduronidase in leukocytes

Chromosomal localization of the human alpha-L-iduronidase gene (IDUA) to 4p16.3

Mucopolysaccharidosis type I: identification of 8 novel mutations and determination of the frequency of the two common alpha-L-iduronidase mutations (W402X and Q70X) among European patients

Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature

Allelism, non-allelism, and genetic compounds among the mucopolysaccharidoses

Mixed donor chimerism and low level iduronidase expression may be adequate for neurodevelopmental protection in Hurler syndrome

Follow-up of nine patients with Hurler syndrome after bone marrow transplantation

Pregnancy in a patient with mucopolysaccharidosis type IH homozygous for the W402X mutation

Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation

Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome

Cord-blood transplants from unrelated donors in patients with Hurler's syndrome

Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources

Birth defects: atlas and compendium

Long-term follow-up of galactosaemia

An updated review of the long-term neurological effects of galactosemia

Long-term outcome in 134 patients with galactosaemia

Long-term prognosis in galactosaemia: results of a survey of 350 cases

Galactose metabolism in human ovarian tissue

Outcomes of siblings with classical galactosemia

Galactosaemia today: the enigma and the challenge

Galactose-1-phosphate uridyl transferase activity in chorionic villi: a first trimester prenatal diagnosis of galactosemia

Reversibility of extensive liver damage in galactosemia

Fruits and vegetables are a source of galactose: implications in planning the diets of patients with galactosaemia

Endogenous synthesis of galactose in normal men and patients with hereditary galactosaemia

Cholestasis and regeneration of the liver in congenital galactosemia

Hereditary galactose disease

Galactosaemia and other inherited disorders of galactose metabolism

Hereditary fructose intolerance in early childhood: a major diagnostic challengesurvey of 20 symptomatic cases

Hereditary fructose intolerance in childhood: diagnosis, management, and course in 55 patients

Characterization of the human aldolase B gene

Hereditary fructose intolerance

Six novel alleles identified in Italian hereditary fructose intolerance patients enlarge the mutation spectrum of the aldolase B gene

The spectrum of aldolase B (ALDOB) mutations and the prevalence of hereditary fructose intolerance in Central Europe

Patients with hereditary fructose intolerance have normal erythrocyte aldolase activity

Fructose tolerance

Fructosaemia: observations on seven cases

Subcellular pathology of hereditary fructose intolerance

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase

Mucopolysaccharidosis type VII presenting with isolated neonatal ascites

Mucopolysaccharidosis type VII (Sly syndrome) presenting as neonatal cholestasis with hepatosplenomegaly

Rapid prenatal testing for human beta-glucuronidase deficiency (MPS VII)

Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation

Lysosomes and storage disease

Gargoylism; study of pathologic lesions and clinical review of 12 cases

Hurler's syndrome: a histochemical study-new techniques for localization of very water-soluble acid mugopolysaccharides

Hepatic fibrosis in the mucopolysaccharidoses

A case of gargoylism

The pathology and biochemistry of gargoylism; a report of three cases with a review of the literature

Gargoylism; review of the literature and report of the sixth autopsied case with chemical studies

Hepatic ultrastructure in the Hurler syndrome

Biochemical and ultrastructural studies in Hurler's syndrome

Mitochondrial budding and morphogenesis of cytoplasmic vacuoles in hepatocytes of children with the Hurler syndrome and Sanfilippo disease

Crystalloid structures of hepatic mitochondria in children with heparitin sulphate mucopolysaccharidosis (Sanfilippo type)

Van Hoof F. Mucopolysaccharidoses and mucolipidoses

Mucopolysaccharidosis type V (Scheie syndrome): a postmortem study by multidisciplinary techniques with emphasis on the brain

Noncirrhotic portal hypertension and nodular regenerative hyperplasia of the liver in dogs with mucopolysaccharidosis type I

Activation of glycosylasparaginase: formation of active N-terminal threonine by intramolecular autoproteolysis

Lysosomal aspartylglucosaminidase is processed to the active subunit complex in the endoplasmic reticulum

Chromosomal localization of the human glycoasparaginase gene to 4q32-q33

A novel aspartylglucosaminuria mutation affects translocation of aspartylglucosaminidase

Allogeneic blood SCT for children with Hurler's syndrome: results from the German multicenter approach MPS-HCT

Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children

Enzyme replacement therapy in mucopolysaccharidosis type I

Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)

Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I

Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome

Mortality and cause of death in mucopolysaccharidosis type II: a historical review based on data from the Hunter Outcome Survey (HOS)

Bone marrow transplantation in Hunter syndrome

Long-term follow-up following bone marrow transplantation for Hunter disease

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy

The metabolic and molecular bases of inherited disease

Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome

Localisation of a gene for mucopolysaccharidosis IIIC to the pericentromeric region of chromosome 8

Prenatal diagnosis of Sanfilippo syndrome

Prenatal diagnosis of Sanfilippo A syndrome: experience in 35 pregnancies at risk and the use of a new fluorogenic substrate for the heparin sulphamidase assay

Heterogeneity of Morquio disease

Findings of hepatobiliary scintigraphy and liver biopsy in Maroteaux-Lamy syndrome presenting as neonatal cholestasis

Mucopolysaccharidosis type VI: structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase

Development of an assay for the detection of mucopolysaccharidosis type VI patients using dried blood-spots

Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up

Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a Phase I/II study

Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)

Fucosidosis type 2

Fucosidosis with angiokeratoma: immunohistochemical and electron microscopic study of a new case and literature review

Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation

Hepatic ultrastructure in fucosidosis

I-cell disease and pseudo-Hurler polydystrophy: disorders of lysosomal enzyme phosphorylation and localization

Sialidosis: a review of human neuraminidase deficiency

Disorders of connective tissue

Molecular pathology of NEU1 gene in sialidosis

Infantile sialidosis: a phenocopy of type 1 GM1 gangliosidosis distinguished by genetic complementation and urinary oligosaccharides

A genetic map of chromosome 20q12-q13.1: multiple highly polymorphic microsatellite and RFLP markers linked to the maturity-onset diabetes of the young (MODY) locus

Prenatal diagnosis of congenital sialidosis

Short-term, high dose enzyme replacement therapy in sialidosis mice

A severe infantile mucolipidosis: clinical, biochemical, and pathologic features

I-cell disease and pseudo-Hurler polydystrophy: disorders of lysosomal enzyme phosphorylation and localization

Missense mutations in N-acetylglucosamine-1-phosphotransferase alpha/beta subunit gene in a patient with mucolipidosis III and a mild clinical phenotype

Chromosomal assignment of N-acetylglucosaminylphosphotransferase, the lysosomal hydrolase targeting enzyme deficient in mucolipidosis II and III

Birth defects encyclopedia. Dover MA: Center for Birth Defects Information Services

Disorders of connective tissue

Neonatal mucolipidosis II (I-cell disease): clinical and radiologic features in three cases

Prenatal mucolipidosis type II (I-cell disease) can present as Pacman dysplasia

An autopsy case of I-cell disease: ultrastructural and biochemical analyses

Continued neurocognitive development and prevention of cardiopulmonary complications after successful BMT for I-cell disease: a long-term follow-up report

Large quantities of 2-acetamido-1-(β-L-aspartamido)-1,2-dideoxyglucose in the urine of mentally retarded siblings

Aspartylglucosaminuria: psychomotor retardation masquerading as a mucopolysaccharidosis

Impaired oral health in patients with aspartylglucosaminuria. Oral Surg Oral Med Oral Pathol Oral Radiol Endod

Progressive nature of aspartylglucosaminuria

Aspartylglucosaminuria: radiologic course of the disease with histopathologic correlation

Disorders of glycoprotein degradation and structure a alpha-mannosidosis, beta-mannosidoses, fucosidosis, sialidosis, aspartylglucosaminuria and CDGS

Convenient and quantitative determination of the frequency of a mutant allele using solid-phase minisequencing: application to aspartylglucosaminuria in Finland

Five-year follow-up of two siblings with aspartylglucosaminuria undergoing allogeneic stem-cell transplantation from unrelated donors

Aspartylglucosaminuria: unique biochemical and ultrastructural characteristics

Biochemical and fine structural studies on brain and liver biopsies in aspartylglucosaminuria

First-trimester diagnosis of an unusual case of alpha-mannosidosis

Two novel mutations in the gene for human alpha-mannosidase that cause alpha-mannosidosis

Identification of 83 novel alpha-mannosidosis-associated sequence variants: functional analysis of MAN2B1 missense mutations

Mannosidosis: clinical, morphologic, immunologic, and biochemical studies

Sisters with alphamannosidosis and systemic lupus erythematosus

Mannosidosis in an adult

T-cell-depleted peripheral blood stem cell transplantation for alpha-mannosidosis

Effective treatment of alpha-mannosidosis by allogeneic hematopoietic stem cell transplantation

Unusual clinical and ultrastructural features in a boy with biochemically typical mannosidosis

Alpha-L-fucosidase in cultured skin fibroblasts from normal subjects and fucosidosis patients

Disorders of glycoprotein degradation and structure: alpha-mannosidosis, beta-mannosidosis, fucosidosis, sialidosis, aspartylglucosaminuria, and carbohydrate-deficient glycoprotein syndrome

Fucosidosis with angiokeratoma: electron microscopic changes in the skin

Thyroid function tests and characterization of thyroxine-binding globulin in the carbohydrate-deficient glycoprotein syndrome type I

Sialic acid-deficient serum and cerebrospinal fluid transferrin in a newly recognized genetic syndrome

A modified method for the assay of carbohydrate-deficient transferrin (CDT) in serum

Carbohydrate deficient glycoprotein syndrome-like transferrin isoelectric focusing pattern in untreated fructosaemia

Carbohydrate-deficient glycoprotein syndrome type II

Inhibition of phosphomannose isomerase by fructose 1-phosphate: an explanation for defective N-glycosylation in hereditary fructose intolerance

Micro anion exchange chromatography of carbohydrate-deficient transferrin in serum in relation to alcohol consumption (Swedish Patent 8400587-5)

Search for rare liver diseases: the case of glycosylation defects mimicking Wilson disease

Fine mapping of the gene for carbohydrate-deficient glycoprotein syndrome, type I (CDG1): linkage disequilibrium and founder effect in Scandinavian families

CDGS-1: a recently discovered hereditary metabolic disease. Multiple organ manifestations

Linkage of a locus for carbohydrate-deficient glycoprotein syndrome type I (CDG1) to chromosome 16p, and linkage disequilibrium to microsatellite marker D16S406

Carbohydrate-deficient glycoprotein syndrome: normal glycosylation in the fetus

Prenatal diagnosis in CDG1 families: beware of heterogeneity

Diagnosis of the carbohydrate-deficient glycoprotein syndrome by analysis of transferrin in filter paper blood spots

Carbohydrate-deficient glycoprotein syndrome type Ib: phosphomannose isomerase deficiency and mannose therapy

Hyperinsulinemic hypoglycemia as a presenting sign in phosphomannose isomerase deficiency: a new manifestation of carbohydrate-deficient glycoprotein syndrome treatable with mannose

Liver pathology in the carbohydrate-deficient glycoprotein syndrome

Phosphomannose isomerase deficiency: a carbohydrate-deficient glycoprotein syndrome with hepatic-intestinal presentation

Postmortem findings in two patients with the carbohydrate-deficient glycoprotein syndrome

Fibrinogen inclusions in liver cells: a new type of ground-glass hepatocyte-immune light and electron microscopic characterization

Hepatic ultrastructure and histochemistry in mucolipidosis II (I-cell disease)

Clinical, biochemical, and ultrastructural studies in a case of chondrodystrophy presenting the I-cell phenotype in tissue culture

Mucolipidosis IV: morphology and histochemistry of an autopsy case

Transfer of a mitochondrial DNA fragment to MCOLN1 causes an inherited case of mucolipidosis IV

Mapping of the mucolipidosis type IV gene to chromosome 19p and definition of founder haplotypes

Mucolipidosis type IV: clinical spectrum and natural history

Mucolipidosis IV: ocular, systemic, and ultrastructural findings

Mucolipidosis IV, a sialolipidosis due to ganglioside sialidase deficiency

Prenatal diagnosis of mucolipidosis IV by electron microscopy

Early prenatal diagnosis of mucolipidosis IV

Congenital corneal clouding with abnormal systemic storage bodies: a new variant of mucolipidosis

Birth defects encyclopedia. Dover MA: Center for Birth Defects Information Services

Understanding human glycosylation disorders: biochemistry leads the charge

Congenital disorders of glycosylation: new defects and still counting

Congenital disorders of glycosylation caused by defects in mannose addition during N-linked oligosaccharide assembly

Early manifestations of the carbohydrate-deficient glycoprotein syndrome

Carbohydrate-deficient glycoprotein syndrome

Carbohydrate-deficient glycoprotein syndrome: clinical expression in adults with a new metabolic disease

Intestinal, pancreatic and hepatic involvement in carbohydrate-deficient glycoprotein syndrome type I

Glycoproteins in liver disease

The endoplasmic reticulum-Golgi membrane system

Hemostatic studies in patients with carbohydrate-deficient glycoprotein syndrome

Decreased blood coagulation activities in carbohydrate-deficient glycoprotein syndrome

A unique pattern of coagulation abnormalities in carbohydrate-deficient glycoprotein syndrome

Endocrinology of the carbohydrate-deficient glycoprotein syndrome type 1 from birth through adolescence

Mortality in individuals with severe deficiency of α1-antitrypsin: findings from the National Heart, Lung, and Blood Institute Registry

Risk of cirrhosis and primary liver cancer in alpha-1-antitrypsin deficiency

Alpha-1-antitrypsin deficiency (second of two parts)

Heterozygous MZ alpha-1-antitrypsin deficiency in adults with chronic liver disease

Chronic 'cryptogenic' liver disease and malignant hepatoma in intermediate alpha-1-antitrypsin deficiency identified by a Pi Z-specific monoclonal antibody

Heterozygous MZ alpha-1-antitrypsin deficiency in adults with chronic active hepatitis and cryptogenic cirrhosis

Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control study

Prevalence of hepatocellular carcinoma in alpha-1-antitrypsin deficiency

Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease

Liver carcinoma in PiZ alpha-1-antitrypsin deficiency

Heterozygosity for the α1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma

Rare alpha-1-antitrypsin variants: are they really so rare?

Serum levels and genotype distribution of α1-antitrypsin in the general population

Challenging identification of a novel PiISF and the rare PiM malton Z α1-antitrypsin deficiency variants in two patients

Alpha-1-antitrypsin deficiency associated with the Mattawa variant

Clinical heterogeneity and potential high pathogenicity of the M malton alpha 1 antitrypsin allele at the homozygous, compound heterozygous and heterozygous states

Heterozygous M3M malton α1-antitrypsin deficiency associated with end-stage liver disease: case report and review

Practical genetics: alpha-1-antitrypsin deficiency and the serpinopathies

Differential detection of PAS-positive inclusions formed by the Z, S iiyama , and M malton variants of α1-antitrypsin

The ultrastructure of hepatocytes in alpha-1-antitrypsin deficiency with the genotype Pi

Alpha 1-antitrypsin Null(isola di procida): an alpha 1-antitrypsin deficiency allele caused by deletion of all alpha 1-antitrypsin coding exons

Alpha-1-antitrypsin Pi S phenotype and liver cell inclusion bodies in alcoholic hepatitis

C1 inhibitor: molecular and clinical aspects

Chromosomal elements regulate gene activity and chromatin structure of the human serpin gene cluster at 14q32.1

Serpins 2005-fun between the beta-sheets. Meeting report based upon presentations made at the 4th International Symposium on Serpin Structure, Function and Biology

Structure and variation of human alpha 1-antitrypsin

Human alpha-1-proteinase inhibitor mechanism of action: evidence for activation by limited proteolysis

Metabolic basis of inherited disease

Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder

The electrophoretic α1-globulin pattern of serum in α1-antitrypsin deficiency

Liver disease in alpha-1-antitrypsin deficiency: prognostic indicators

Liver disease associated with α1-antitrypsin deficiency in childhood

Liver disease in α1-antitrypsin deficiency detected by screening of 200,000 infants

Alpha 1-antitrypsin deficiency

Worldwide racial and ethnic distribution of α1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys

Alpha-1-antitrypsin deficiency

Amino acid substitution Glu leads to Lys α1-antitrypsin PiZ

Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease

A polymorphism of the α1-antitrypsin gene represents a risk factor for liver disease

Molecular pathogenesis of alpha-1-antitrypsin deficiency-associated liver disease: a meeting review

Alpha-1-antitrypsin deficiency

Prospective study of children with alpha-1-antitrypsin deficiency: eight-year-old follow-up

The natural history of liver disease in alpha-1-antitrypsin deficient children

Orthotopic liver transplantation for alpha-1-antitrypsin deficiency: an experience in 29 children and ten adults

Outcome of liver disease associated with alpha-1 antitrypsin deficiency (PiZ): implications for genetic counselling and antenatal diagnosis

Liver involvement in α1-antitrypsin-deficient phenotypes PiSZ and PiMZ

Natural history and life expectancy in severe α1-antitrypsin deficiency, Pi Z

Missense mutations in the human beta fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion

Mutations in the fibrinogen alpha gene account for the majority of cases of congenital afibrinogenemia

Molecular analysis of the fibrinogen gene cluster in 16 patients with congenital afibrinogenemia: novel truncating mutations in the FGA and FGG genes

Congenital afibrinogenemia in 10 offspring of uncle-niece marriages

Pregnancy in congenital afibrinogenaemia: report of a successful case and review of the literature

Coexistence of hypofibrinogenemia and factor V Leiden mutation: is the balance shifted to thrombosis?

Dysfibrinogen Kagoshima with the amino acid substitution γThr-314 to Ile: analyses of molecular abnormalities and thrombophilic nature of this abnormal molecule

Hepatic fibrinogen storage disease: identification of two novel mutations (p.Asp316Asn, fibrinogen Pisa and p.Gly366Ser, fibrinogen Beograd) impacting on the fibrinogen gamma-module

Fibrinogen γ375 arg→trp mutation (fibrinogen aguadilla) causes hereditary hypofibrinogenemia, hepatic endoplasmic reticulum storage disease and cirrhosis

Hereditary hypofibrinogenaemia with hepatic storage of fibrinogen

Hepatocellular fibrinogen storage in familial hypofibrinogenemia

Hereditary hypofibrinogenemia with fibrinogen storage in the liver

Fibrinogen storage disease without hypofibrinogenemia associated with estrogen therapy

Metabolic errors and liver disease

Cytoplasmic inclusion bodies and minimal hepatitis: fibrinogen storage without hypofibrinogenemia

Fibrinogen storage disease without hypofibrinogenaemia associated with acute infection

A case of primary biliary cirrhosis accompanied with fibrinogen storage disease

Endoplasmic storage disease of liver: characterization of intracytoplasmic hyaline inclusions

Liver histology of an afibrinogenemic patient with the Bβ-L353R mutation showing no evidence of hepatic endoplasmic reticulum storage disease (ERSD); comparative study in COS-1 cells of the intracellular processing of the Bβ-L353R fibrinogen vs. the ERSD-associated γ-G284R mutant

Chronic cryptogenic liver disease and hepatocyte endoplasmic reticulum storage of fibrinogen in hereditary hypofibrinogenemia

Intra-and extracellular alpha 1-antitrypsin in liver disease with special reference to Pi phenotype

Alpha-1-antitrypsin globules in the liver and PiM phenotype

Hepatic hyaline globules associated with passive congestion

Alpha 1 antitrypsin liver disease: differential diagnosis of PAS-positive, diastase-resistant globules in liver cells

The fetal liver in PiZZ alpha-1-antitrypsin deficiency: a report of five cases

Alpha 1-antitrypsin deficiency: the spectrum of pathology and pathophysiology

Neonatal giant cell hepatitis: histological and etiological findings

Prognosis of alpha-1-antitrypsin deficiency-related liver disease in the era of paediatric liver transplantation

HFE mutations in alpha-1-antitrypsin deficiency: an examination of cirrhotic explants

Heterozygous α1-antitrypsin Z allele mutation in presumed healthy donor livers used for transplantation

Progression of morphological changes after transplantation of a liver with heterozygous alpha-1 antitrypsin deficiency

Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency

An autophagy-enhancing drug promotes degradation of mutant α1-antitrypsin Z and reduces hepatic fibrosis

Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model

Pathogenesis of alpha 1-antitrypsin deficiency-associated liver disease

Cloning of the human alpha 1 antichymotrypsin gene and genetic analysis of the gene in relation to alpha 1 antitrypsin deficiency

Regional location of alpha 1-antichymotrypsin and alpha 1-antitrypsin genes on human chromosome 14

Familial alpha 1-antichymotrypsin deficiency

Alpha1-antichymotrypsin globules within hepatocytes in patients with chronic hepatitis C and cirrhosis

Role of alpha-1-antichymotrypsin deficiency in promoting cirrhosis in two siblings with heterozygous alpha-1-antitrypsin deficiency phenotype SZ

Alpha-1-antichymotrypsin deficiency in two siblings with end-stage liver disease and phenotype SZ alpha-1-antitrypsin deficiency

Congenital afibrinogenemia

Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15

Hereditary tyrosinemia type I: strong association with haplotype 6 in French Canadians permits simple carrier detection and prenatal diagnosis

Prenatal diagnosis of type I hereditary tyrosinaemia

Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I

Self-induced correction of the genetic defect in tyrosinemia type I

No evidence of maternal cell colonization in reverted liver nodules of tyrosinemia type I patients

Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia

Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione)

Nitisinone in the treatment of hereditary tyrosinaemia type 1

Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec

NTBC treatment in tyrosinaemia type I: long-term outcome in French patients

Nontransplant treatment of tyrosinemia

Tyrosinemia type 1: metastatic hepatoblastoma with a favorable outcome

Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1

Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?

Effect of dietary treatment on the renal tubular function in a patient with hereditary tyrosinemia

Renal tubular function in children with tyrosinaemia type I treated with nitisinone

Coagulation defect of congenital tyrosinaemia

The nephropathy of type I tyrosinemia after liver transplantation

Hereditary tyrosinaemia: clinical, enzymatic, and pathological study of an infant with the acute form of the disease

Hereditary tyrosinemia type I (chronic form): pathologic findings in the liver

Liver cell dysplasia and early liver transplantation in hereditary tyrosinemia

Liver transplantation for tyrosinemia: a review of 10 cases from the University of Pittsburgh

A patient with tyrosinemia and hypermethioninemia

Tyrosinemia associated with hypermethioninemia and islet cell hyperplasia

DNA ploidy abnormalities in the liver of children with hereditary tyrosinemia type

Fibrinogen concentrate: a potential universal hemostatic agent

Antithrombin III: summary of first database update

Thrombosis in antithrombin-III-deficient persons: report of a large kindred and literature review

Antithrombin III deficiency

Antithrombin III deficiency: an etiology of Budd-Chiari syndrome

Budd-Chiari syndrome and antithrombin III deficiency

Mortality in hereditary antithrombin-III deficiency: 1830 to 1989

Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency: an update

Severe antithrombin III deficiency in an infant associated with multiple arterial and venous thromboses

On the enzymic defects in hereditary tyrosinemia

The metabolic and molecular bases of inherited disease

Early liver transplantation is indicated for tyrosinemia type I

Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment

Tyrosinemia: the Quebec experience

Tyrosinaemia type I: an update

Neurologic crises in hereditary tyrosinemia

Liver disease in children

Tyrosinaemia type I and hypertrophic obstructive cardiomyopathy

Cardiomyopathy in fumarylacetoacetase deficiency (hereditary tyrosinaemia): a new feature of the disease

The occurrence of hepatoma in the chronic form of hereditary tyrosinemia

HCC prevalence and histopathological findings in liver explants of patients with hereditary tyrosinemia type 1

Silent" tyrosinemia presenting as hepatocellular carcinoma in a 10-year-old girl

Liver transplantation for hereditary tyrosinemia: the Quebec experience

A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I

Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview

A novel mutation of the ornithine transcarbamylase gene leading to fatal hyperammonemia in a liver transplant recipient

Neonatal hemodialysis: effective therapy for the encephalopathy of inborn errors of metabolism

The role of liver transplantation in urea cycle disorders

Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University

Lysosomal transport disorders. Cystinosis and sialic acid storage disorders

New aspects of the pathogenesis of cystinosis

CTNS mutations in an American-based population of cystinosis patients

A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis

Cystinosis. Washington DC: US Government Printing Office

Hypothyroidism in cystinosis: a clinical, endocrinologic and histologic study involving sixteen patients with cystinosis

Cadaver renal transplantation in children with cystinosis

Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy

Drug-induced lupus and antiphospholipid syndrome associated with cysteamine therapy

Benign cystinosis: the clinical, biochemical and morphologic findings in a family with two affected siblings

Prenatal diagnosis of cystinosis

Prenatal diagnosis of cystinosis utilizing chorionic villus sampling

Lysosomes and storage diseases

Electron microscopy in the diagnosis of cystinosis

Prenatal diagnosis of nephropathic cystinosis: pregnancy at risk ascertained through heterozygote diagnosis of parents

Light and electron microscopy of infants and foetal tissus in cystinosis

Non-invasive diagnosis of cystinosis by infra-red spectroscopy of hair

FISH diagnosis of the common 57-kb deletion in CTNS causing cystinosis

Cystinosis and liposomal free amino acids

Lysosomal site of crystalline deposits in cystinosis as shown by ferritin uptake

Pathology of the kidney in cystinosis

correlation with histopathologic features

Hepatic regenerating nodules in hereditary tyrosinemia

Hereditary tyrosinemia and tyrosyluria: clinical report of four patients

Chromosomal instability in hereditary tyrosinemia type I

Hereditary tyrosinemia with hyperplasia and hypertrophy of juxtaglomerular apparatus

Pathological findings in patients with tyrosinemia

Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I

Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors

Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death

Cross-sectional observational study of 208 patients with non-classical urea cycle disorders

Urea cycle disorders

Urea cycle disorders: clinical presentation outside the newborn period

Natural history of symptomatic partial ornithine transcarbamylase deficiency

Urea cycle disorders: diagnosis, pathophysiology, and therapy

Urea cycle defects: management and outcome

Severe liver fibrosis in argininosuccinic aciduria

Argininosuccinic aciduria: assignment of the argininosuccinate lyase gene to the pter to q22 region of human chromosome 7 by bioautography

Interallelic complementation in an inborn error of metabolism: genetic heterogeneity in argininosuccinate lyase deficiency

Absence of argininosuccinate lyase protein in the liver of two patients with argininosuccinic aciduria

Histopathological findings in livers of patients with urea cycle disorders

Liver fibrosis in arginase deficiency

Ultrastructural study of the liver in argininosuccinase deficiency

Ornithine carbamoyltransferase deficiency in an adult male patient: significance of hepatic ultrastructure in clinical diagnosis

Primary ornithine transcarbamylase deficiency: a case report and electron microscopic study

Novel liver findings in ornithine transcarbamylase deficiency due to Xp11.4-p21.1 microdeletion

Demyelinating central nervous system disease, macular atrophy and acanthocytosis (Bassen-Kornzweig syndrome)

Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia

Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia

Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia

Identification of two novel mutations and long-term follow-up in abetalipoproteinemia: a report of four cases

and vitamin E replacement in abetalipoproteinemia

Abetalipoproteinemia: report of two cases and review of therapy

Persistence of the intestinal defect in abetalipoproteinaemia after liver transplantation

Intestinal and hepatic apolipoprotein B gene expression in abetalipoproteinemia

Morphologic features of the liver in abetalipoproteinemia

Liver ultrastructure in abetalipoproteinemia: evolution of micronodular cirrhosis

Hepatic peroxisomal abnormalities in abetalipoproteinemia

Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins

Familial hypobetalipoproteinemia

Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B

Hypobetalipoproteinemia with an apparently recessive inheritance due to a "de novo" mutation of apolipoprotein B

Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia

Characterization of three kindreds with familial combined hypolipidemia caused by lossof-function mutations of ANGPTL3

Liver fibrosis in a patient with familial homozygous hypobetalipoproteinaemia: possible role of vitamin supplementation

Dual mechanisms for the low plasma levels of truncated apolipoprotein B proteins in familial hypobetalipoproteinemia: analysis of a new mouse model with a nonsense mutation in the Apob gene

Asymptomatic elevation of aminotransferase levels and fatty liver secondary to heterozygous hypobetalipoproteinemia

Monographs in human genetics

Ultrastructure of the liver in a case of childhood cystinosis

Hepatic fibrosis associated with hereditary cystinosis: a novel form of noncirrhotic portal hypertension

Veno-occlusive disease of the liver associated with cysteamine treatment of nephropathic cystinosis

Noncirrhotic portal hypertension in association with juvenile nephropathic cystinosis: case presentation and review of the literature

Cystinosis as a cause of noncirrhotic portal hypertension

Cholestatic liver disease in long-term infantile nephropathic cystinosis

The natural history of homocystinuria due to cystathionine beta-synthase deficiency

Coexistence of hereditary homocystinuria and factor V Leiden: effect on thrombosis

Cystathionine synthase in tissue culture derived from human skin: enzyme defect in homocystinuria

Homocystinuria due to cystathionine beta-synthase deficiency in Ireland: 25 years' experience of a newborn screened and treated population with reference to clinical outcome and biochemical control

The gene for cystathionine beta-synthase (CBS) maps to the subtelomeric region on human chromosome 21q and to proximal mouse chromosome 17

Human cystathionine betasynthase: gene organization and expression of different 5' alternative splicing

Evidence for three distinct classes of cystathionine beta-synthase mutants in cultured fibroblasts

Cystathionine beta-synthase mutations in homocystinuria

Subnormal serum folate levels, increased folate clearance and effects of folic acid therapy

Homocystinuria due to cystathionine beta-synthase deficiency: the effects of betaine treatment in pyridoxine-responsive patients

Homocystinuria: clinical and pathological review of ten cases

Pathological findings in homocystinuria

studies of 20 families with 38 affected members

Electron microscopic changes in hepatocytes of patients with homocystinuria

Homocystinuria due to cystathionine synthase deficiency: enzymatic and ultrastructural studies

Cystathionine beta-synthase deficiency promotes oxidative stress, fibrosis, and steatosis in mice liver

Malformation of the erythrocytes in a case of atypical retinitis pigmentosa

double-blind, placebo-controlled trial

Heart-liver transplantation in a patient with familial hypercholesterolaemia

Cellular pathology of homozygous familial hypercholesterolemia

Acid lipase deficiency Wolman disease and cholesterol ester storage disease

New lysosomal acid lipase gene mutants explain the phenotype of Wolman disease and cholesteryl ester storage disease

The transport of lysosomal enzymes

In situ localization of the genetic locus encoding the lysosomal acid lipase/cholesteryl esterase (LIPA) deficient in Wolman disease to chromosome 10q23.2-q23.3

Generalized xanthomatosis with calcified adrenals

Hydrops revisited: literature review of 1,414 cases published in the 1980s

The use of parenteral hyperalimentation and elemental formula feeding in the treatment of Wolman disease

Cholesteryl ester storage disease and Wolman disease: phenotypic variants of lysosomal acid cholesteryl ester hydrolase deficiency

Neutral lipid storage with acid lipase deficiency: a new variant of Wolman's disease with features of the Senior syndrome

Hepatic cholesterol ester storage disease, a familial disorder. I. Clinical aspects

Small intestinal mucosa in cholesterol ester storage disease: a light and electron microscope study

Cholesterol ester storage disease: clinical, biochemical, and pathological studies

A novel variant of lysosomal acid lipase in cholesteryl ester storage disease associated with mild phenotype and improvement on lovastatin

Enzyme deficiency in cholesteryl ester storage idisease

Pulmonary vascular obstruction associated with cholesteryl ester storage disease

Cholesterol ester storage disease and mesenteric lipodystrophy

Subclinical course of cholesteryl ester storage disease in an adult with hypercholesterolemia, accelerated atherosclerosis, and liver cancer

Cholesterol ester storage disease in an adult presenting with sea-blue histiocytosis

Prenatal diagnosis of Wolman disease

Mutations at the lysosomal acid cholesteryl ester hydrolase gene locus in Wolman disease

Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease

Diffuse fatty liver in familial heterozygous hypobetalipoproteinemia

Liver steatosis in hypobetalipoproteinemia: a case report

Fatty liver in a case with heterozygous familial hypobetalipoproteinemia

Fatty liver due to heterozygous hypobetalipoproteinemia

The gene encoding ATPbinding cassette transporter 1 is mutated in Tangier disease

Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency

Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1

Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy

ATP-binding cassette transporter A1: regulation of cholesterol efflux

The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway

Pathology of Tangier disease

Tangier disease (alpha-lipoprotein deficiency)

The pathology of Tangier disease. A light and electron microscopic study

A Non-classical presentation of Tangier disease with three ABCA1 mutations

Tangier disease: a histological and ultrastructural study

Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol

Familial hypercholesterolemia: a review

Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity

The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein

Evidence for a QTL on chromosome 19 influencing LDL cholesterol levels in the general population

Human genes involved in cholesterol metabolism: chromosomal mapping of the loci for the low density lipoprotein receptor and 3-hydroxy-3-methylglutarylcoenzyme A reductase with cDNA probes

Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a 1529

Wolman's disease: three new patients with a recently described lipidosis

Wolman's disease. A rare lipidosis with adrenal calcification

Wolman's disease: report of a case, with multiple studies

Primary familial xanthomatosis with involvement and calcification of the adrenals: report of two more cases in siblings of a previously described infant

Wolman's disease: deficiency of E600-resistant acid esterase activity with storage of lipids in lysosomes

Wolman's disease: an electron microscopic, histochemical, and biochemical study

Distinctive histopathological features that support a diagnosis of cholesterol ester storage disease in liver biopsy specimens

Wolman disease and cholesteryl ester storage disease diagnosed by histological and ultrastructural examination of intestinal and liver biopsy

Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis

Mutations in B4GALNT1 (GM2 synthase) underlie a new disorder of ganglioside biosynthesis

Familial neurovisceral lipidosis: an analysis of eight cases of a syndrome previously reported as "Hurler-variant," "pseudo-Hurler," and "Tay-Sachs disease with visceral involvement

Generalized gangliosidosis

Association of dermal melanocytosis with lysosomal storage disease: clinical features and hypotheses regarding pathogenesis

Infantile G(M1) gangliosidosis: complete morphology and histochemistry of two autopsy cases, with particular reference to delayed central nervous system myelination

Assignment of human beta-galactosidase-A gene to 3p21.33 by fluorescence in situ hybridization

GM1-gangliosidosis: defective recognition site on beta-galactosidase precursor

The liver in GM1 gangliosidosis types 1 and 2: a light and electron microscopical study

Coincidental GM1 gangliosidosis in an infant with alpha-1-antitrypsin deficiency

Ganglioside-storage diseases

Bone marrow transplantation correcting beta-galactosidase activity does not influence neurological outcome in juvenile GM1-gangliosidosis

The liver in lipidosis: an electron miscroscopic and histochemical study

Canine GM1-gangliosidosis: a clinical, morphologic, histochemical, and biochemical comparison of two different models

Lysosomal acid lipase mutations that determine phenotype in Wolman and cholesterol ester storage disease

A splice junction mutation causes deletion of a 72-base exon from the mRNA for lysosomal acid lipase in a patient with cholesteryl ester storage disease

Compound heterozygosity for a Wolman mutation is frequent among patients with cholesteryl ester storage disease

Wolman disease and its treatment

Wolman's disease corrected by displacement bone marrow transplantation with immunoprophylaxis

Wolman's disease: a review of treatment with bone marrow transplantation and considerations for the future

Wolman disease successfully treated by bone marrow transplantation

Cholesteryl ester storage disease: hepatopathology and effects of therapy with lovastatin

Safety and efficacy of treatment of pediatric cholesteryl ester storage disease with lovastatin

Asymptomatic cholesteryl ester storage disease in an adult controlled with simvastatin

Lovastatin therapy for cholesterol ester storage disease in two sisters

Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease

Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease

Orthotopic liver transplantation for cholesteryl ester storage disease

Liver transplantation for cholesteryl ester storage disease

End-stage renal disease in a patient with cholesteryl ester storage disease following successful liver transplantation and cyclosporine immunosuppression

Muscular involvement in lysosomal acid lipase deficiency in rats

Morphological characteristics of lipid accumulation in liver-constituting cells of acid lipase deficiency rats (Wolman's disease model rats)

Cloning of rat lysosomal acid lipase cDNA and identification of the mutation in the rat model of Wolman's disease

Lysosomal acid lipase deficiency: correction of lipid storage by adenovirus-mediated gene transfer in mice

Restoration of a regulatory response to low density lipoprotein in acid lipasedeficient human fibroblasts

Lipid accumulation and acid lipase deficiency in fibroblasts from a family with Wolman's disease, and their apparent correction in vitro

Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy

Significance of screening for Fabry disease among male dialysis patients

Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype

Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry

Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments

Enzyme replacement therapy of Fabry disease

Fabry's disease

Ultrastructural and biochemical liver analyses in Fabry's disease

Light-and electronmicroscopic histochemistry of Fabry's disease

Fabry disease: ultrastructural lectin histochemical analyses of lysosomal deposits

Immunoelectronmicroscopic detection of globotriaosylceramide accumulated in the skin of patients with Fabry disease

Cloning and expression of human arylsulfatase A

Molecular genetics of metachromatic leukodystrophy

Genetic heterogeneity in metachromatic leukodystrophy

Heterogeneity in late-onset metachromatic leukodystrophy: effect of inhibitors of cysteine proteinases

Adult metachromatic leukodystrophy (sulphatide lipidosis) simulating acute schizophrenia: report of a case

Slow progression of juvenile metachromatic leukodystrophy 6 years after bone marrow transplantation

Clinical outcome in four children with metachromatic leukodystrophy treated by bone marrow transplantation

Hematopoietic stem cell transplantation in the leukodystrophies: a systematic review of the literature

Pseudodeficiency of arylsulfatase A: a counseling dilemma

Arylsulfatase A in the urine and metachromatic leukodystrophy

Metachromatic leukodystrophy (sulfatide lipidosis)

Sulfatide lipidosis in childhood: report of a case investigated during life and at autopsy

The visceral lesions of metachromatic leukodystrophy

Papillomatosis of the gallbladder associated with metachromatic leukodystrophy

Beta-galactosidase deficiency: studies of two patients with prolonged survival

Letter: Beta-galactosidase deficiency in young adults

Tay-Sachs disease: screening and prevention

Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene

Juvenile GM2 gangliosidosis (AMB variant): inability to activate hexosaminidase A by activator protein

Deficient hexozaminidase activity in an exceptional case of Tay-Sachs disease with additional storage of kidney globoside in visceral organs

Juvenile Sandhoff disease: some properties of the residual hexosaminidase in cultured fibroblasts

Natural history and inherited disorders of a lysosomal enzyme, beta-hexosaminidase

Franceschetti syndrome in a child with a de novo balanced translocation (5;13) (q11;p11) and significant decrease of hexosaminidase B

Molecular heterogeneity in the infantile and juvenile forms of Sandhoff disease (O-variant GM2 gangliosidosis)

Correction of enzymatic deficiencies by renal transplantation: Fabry's disease

Sandhoff disease (SHD) heterozygote frequencies (HF) in North America (NA) Jewish (J) and non-Jewis (NJ) populations: implications for carrier (C) screening

In utero diagnosis of Sandhoff's disease

Generalized accumulation of neutral glycosphingolipids with GM2 ganglioside accumulation in the brain: Sandhoff's disease (variant of Tay-Sachs disease)

The pathology of Sandhoff's disease

The ratio of alphagalactosidase to beta-glucuronidase activities in dried blood for the identification of female Fabry disease patients

Fabry disease: a review

Enzymatic defect in Fabry's disease: ceramide trihexosidase deficiency

Fabry's disease

Assignment of alphagalactosidase (alpha GAL) to the q22 leads to qter region of the X chromosome in man

Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease

Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy

Fabry disease; alpha-galactosidase deficiency

Shindler disease; alpha-N-acetylgalactosaminidase deficiency

Fabry's disease in a heterozygous woman

Gaucher's disease

Understanding the natural history of Gaucher disease

Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history

Gaucher disease: clinical, laboratory, radiologic, and genetic features of 53 patients

Cutaneous manifestations of Gaucher disease

Gaucher disease: assessment with MR imaging

The Gaucher Registry: demographics and disease characteristics of 1698 patients with Gaucher disease

Severe pulmonary involvement in adult Gaucher's disease: report of three cases and review of the literature

Gaucher's disease and fatal hepatic fibrosis despite prolonged enzyme replacement therapy

Neonatal cholestasis and infantile Gaucher disease: a case report

Long-term follow-up of partial splenectomy in Gaucher's disease

Partial splenectomy in Gaucher's disease

Gaucher disease: abdominal MR imaging findings in 46 patients

Gaucher disease and cancer incidence: a study from the Gaucher Registry

Expanding spectrum of the association between type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple typescorrelation with genotype and phenotype

Hydrops fetalis due to infantile Gaucher's disease

Collodion babies with Gaucher's disease

Clinical heterogeneity among patients with Gaucher's disease

Gaucher disease in the neonate: a distinct Gaucher phenotype is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene

Hydrops fetalis associated with Gaucher disease

Neonatal cholestasis as initial manifestation of type 2 Gaucher disease: a continuum in the spectrum of early onset Gaucher disease

Type 2 Gaucher disease occurs in Ashkenazi Jews but is surprisingly rare

Oculomotor deficits in Gaucher disease

The role of neurogenetics in Gaucher disease

Studies of the pathogenesis of Gaucher's disease: tissue distribution and biliary excretion of [14C] L-glucosylceramide in rats

Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype

Metachromatic leukodystrophy: a cause of cholelithiasis in childhood

Metachromatic leucodystrophic polyposis of the gall bladder

Papillomatosis of the gallbladder in metachromatic leukodystrophy

Papillomatous transformation of the gallbladder in metachromatic leukodystrophy

Villous papilloma of the gallbladder in association with leukodystrophy

Pathology of the gallbladder in a child with metachromatic leukodystrophy

Laboratory methods in histotechnology. Washington DC: American Registry of Pathology

Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase: identification of the first molecular lesion causing Farber disease

The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis, and expression

Molecular analyses of novel ASAH1 mutations causing Farber lipogranulomatosis: analyses of exonic splicing enhancer inactivating mutation

The metabolic and molecular basis of inherited disease

Bone marrow involvement and obstructive jaundice in Farber lipogranulomatosis: clinical and autopsy report of a new case

Farber's disease. Light and electron microscopic study of the eye

The cellular lesions of Farber's disease and their experimental reproduction in tissue culture

Farber's disease: report of a case with observations on its histogenesis and notes on the nature of the stored material

Phenotypic variability in siblings with Farber disease

The 'lipogranulomatosis' syndrome: review with report of patient showing milder involvement

A case of lipogranulomatosis Farber: some clinical and ultrastructural aspects

Farber's disease (disseminated lipogranulomatosis): a pathological, histochemical and ultrastructural study

Other lysosomal storage disorders. InLysosomes and storage diseases

Farber bodies found in murine phagocytes after injection of ceramides and related sphingolipids

Banana bodies" in disseminated lipogranulomatosis (Farber's disease)

Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease

Gaucher's disease: clinical features and natural history

The surface ultrastructure of Gaucher cells

Gaucher's disease, a review

Gaucher's disease

Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features

Enfermedad de Gaucher con cirrosis y gammapetia monoclonal benigna

Cirrosis hepatica en la enfermedad de Gaucher

An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment

Gaucher's disease in a patient with chronic active hepatitis

Autopsy case of Gaucher disease type I in a patient on enzyme replacement therapy: comments on the dynamics of persistent storage process

CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings

A histochemical and electron microscopic study of Gaucher cells

The bilayer nature of deposits occurring in Gaucher's disease

Identification of ferritin within Gaucher cells: an electron microscopic and immunofluorescent study

Ein unbekanntes Krankenheitsbild

Uber die lipoidzellige Splenohepatomegalie Typus Niemann-Pick als Stoffwechselerkrankung

The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations

Niemann-Pick disease: a review of eighteen patients

Niemann-Pick disease associated with nonimmune hydrops fetalis

Placental ultrasonographic biochemical and histochemical studies in human fetuses affected with Niemann-Pick disease type A

Niemann-Pick disease and giant cell transformation of the liver

Niemann-Pick disease types A and B: acid sphingomyelinase deficiencies

Fatal liver failure in two children with Niemann-Pick disease type B

Orthotopic liver transplantation in two adults with Niemann-Pick and Gaucher's diseases: implications for the treatment of inherited metabolic disease

Liver abnormalities in patients with Gaucher's disease

Hepatic calcifications in a patient with Gaucher's disease

Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3

Assignment of the gene coding for human beta-glucocerebrosidase to the region q21-q31 of chromosome 1 using monoclonal antibodies

The human glucocerebrosidase gene and pseudogene: structure and evolution

Gaucher disease: pathological mechanisms and modern management

Gaucher's disease: molecular, genetic and enzymological aspects

ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity

Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease

Activator protein deficient Gaucher's disease: a second patient with the newly identified lipid storage disorder

Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this Gaucher disease variant

Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease

Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1

Gaucher's disease: a paradigm for interventional genetics

Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis

Guidance on the use of miglustat for treating patients with type 1 Gaucher disease

Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project

Management of neuronopathic Gaucher disease: a European consensus

Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease

Orthotopic liver transplantation in the treatment of complications of type 1 Gaucher disease

Chimerism after liver transplantation for type IV glycogen storage disease and type 1

Gaucher's disease

Long-term expression and secretion of human glucocerebrosidase by primary murine and human myoblasts and differentiated myotubes

Surface marker and other characteristics of Gaucher's cells

Correction of enzyme levels with allogeneic hematopoeitic progenitor cell transplantation in Niemann-Pick type B. Pediatr Blood Cancer

Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study

Cholesterol accumulation and liver cell death in mice with Niemann-Pick type C disease

AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick disease

Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: implications for Niemann-Pick disease enzyme replacement therapy

Niemann-Pick disease

Liver findings in Niemann-Pick disease type C

Niemann-Pick type C disease and early cholestasis in three brothers

Progressive neonatal liver failure due to type C Niemann-Pick disease

Niemann-Pick variant lipidosis presenting as "neonatal hepatitis

Lipid histochemistry and electron microscopy in adult Niemann-Pick disease

Human disorders of peroxisome metabolism and biogenesis

Heimler syndrome is caused by hypomorphic mutations in the peroxisome-biogenesis genes PEX1 and PEX6

Peroxisomal disorders I: biochemistry and genetics of peroxisome biogenesis disorders

Clinical approach to inherited peroxisomal disorders

The PEX Gene Screen: molecular diagnosis of peroxisome biogenesis disorders in the Zellweger syndrome spectrum

PEX1 mutations in the Zellweger spectrum of the peroxisome biogenesis disorders

Phenotype-genotype relationships in complementation group 3 of the peroxisome-biogenesis disorders

Mutations in the PTS1 receptor gene, PXR1, define complementation group 2 of the peroxisome biogenesis disorders

Human peroxisome assembly factor-2 (PAF-2): a gene responsible for group C peroxisome biogenesis disorder in humans

Phenotype of patients with peroxisomal disorders subdivided into sixteen complementation groups

Zellweger syndrome and a microdeletion of the proximal long arm of chromosome 7

Heterogeneity of liver disorder in type B Niemann-Pick disease

Cirrhosis and portal hypertension in a patient with adult Niemann-Pick disease

The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal study

A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B

Growth restriction in children with type B Niemann-Pick disease

Niemann-Pick disease type C

Lipid and cholesterol trafficking in NPC

Mannose 6-phosphate receptors, Niemann-Pick C2 protein, and lysosomal cholesterol accumulation

Identification of 58 novel mutations in Niemann-Pick disease type C: correlation with biochemical phenotype and importance of PTC1-like domains in NPC1

Identification of 25 new mutations in 40 unrelated Spanish Niemann-Pick type C patients: genotype-phenotype correlations

Observational cohort study of the natural history of Niemann-Pick disease type C in the UK: a 5-year update from the UK clinical database

Phenotypic heterogeneity of Niemann-Pick disease type C in monozygotic twins

Fetal ascites: an unusual presentation of Niemann-Pick disease type C

Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease

Biliary atresia and meconium ileus associated with Niemann-Pick disease

Phenotypic and genetic heterogeneity in Niemann-Pick disease type C: current knowledge and practical implications

Linear clinical progression, independent of age of onset

Progression of neurovisceral storage disease with supranuclear ophthalmoplegia following orthotopic liver transplantation

Altered distribution and function of natural killer cells in murine and human Niemann-Pick disease type C1

Niemann-Pick disease type C: an update

Prenatal diagnosis of Niemann-Pick diseases types A, B and C

Niemann-Pick disease type C: from bench to bedside

Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series

Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial

Cerebro-hepato-renal syndrome of Zellweger: clinical and autopsy findings and a review of previous cases in Japan

Cerebro-hepato-renal syndrome: a newly recognized hereditary disorder of multiple congenital defects, including sudanophilic leukodystrophy, cirrhosis of the liver, and polycystic kidneys

Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome

Zellweger-like syndrome with detectable hepatic peroxisomes: a variant form of peroxisomal disorder

Liver in the cerebro-hepato-renal syndrome: defective bile acid synthesis and abnormal mitochondria

Peroxisomal disorders in children: immunohistochemistry and neuropathology

Immunocytochemical localization of peroxisomal enzymes in human liver biopsies

Multiple peroxisomal enzymatic deficiency disorders: a comparative biochemical and morphologic study of Zellweger cerebrohepatorenal syndrome and neonatal adrenoleukodystrophy

Peroxisomal disorders: post-and prenatal diagnosis based on a new classification with flow charts

X-linked adrenoleukodystrophy presenting with severe cholestasis and liver disease in a neonate

Neonatal adrenoleukodystrophy: clinical, pathologic, and biochemical delineation of a syndrome affecting both males and females

Adrenoleukodystrophy and Zellweger syndrome in fatty acid oxidation: clinical, biochemical and molecular aspects

Liver pathology in neonatal adrenoleukodystrophy

Neonatal-onset adrenoleukodystrophy in a girl

Pathology of hepatic peroxisomes and mitochondria in patients with peroxisomal disorders

Infantile Refsum's disease: a generalized peroxisomal disorder-case report with postmortem examination

Dysmorphic syndrome with phytanic acid oxidase deficiency, abnormal very long chain fatty acids, and pipecolic acidemia: studies in four children

Hepatic peroxisomes are deficient in infantile Refsum disease: a cytochemical study of 4 cases

Infantile phytanic acid storage disease, a possible variant of Refsum's disease: three cases, including ultrastructural studies of the liver

Trihydroxycoprostanic acid in the duodenal fluid of two children with intrahepatic bile duct anomalies

The metabolism of 3alpha, 7alpha, 12alpha-trihydorxy-5beta-cholestan-26-oic acid in two siblings with cholestasis due to intrahepatic bile duct anomalies: an apparent inborn error of cholic acid synthesis

Mutations in PEX1 are the most common cause of peroxisome biogenesis disorders

A human gene responsible for Zellweger syndrome that affects peroxisome assembly

The metabolic and molecular bases of inherited disease

Biochemical markers predicting survival in peroxisome biogenesis disorders

The cerebrohepatorenal (Zellweger) syndrome: increased levels and impaired degradation of very-long-chain fatty acids and their use in prenatal diagnosis

Hyperpipecolic acidaemia: a diagnostic tool for peroxisomal disorders

Human peroxisomal disorders

A metabolic disorder similar to Zellweger syndrome with hepatic acatalasia and absence of peroxisomes, altered content and redox state of cytochromes, and infantile cirrhosis with hemosiderosis

Peroxisomal organization in normal and cerebrohepatorenal (Zellweger) syndrome fibroblasts

Absence of peroxisomes in mouse hepatocytes causes mitochondrial and ER abnormalities

Peroxisome biogenesis disorders: the role of peroxisomes and metabolic dysfunction in developing brain

Cerebro-hepato-renal syndrome of Zellweger: two patients with islet cell hyperplasia, hypoglycemia, and thymic anomalies, and comments on iron metabolism

Cerebro-hepato-renal syndrome of Zellweger. A report of eight cases with comments upon the incidence, the liver lesion, and a fault in pipecolic acid metabolism

Studies of malformation syndromes of man XIB: the cerebro-hepato-renal syndrome of Zellweger-comparative pathology

Cerebro-hepato-renal syndrome of Zellweger

Ultrastructure of the liver in th cerebrohepatorenal syndrome of Zellweger

Light and electron microscopic liver changes in the cerebro-hepato-renal syndrome of Zellweger

Peroxisomal diseases

Fetal cerebrohepatorenal (Zellweger) syndrome: dysmorphic, radiologic, biochemical, and pathologic findings in four affected fetuses

A syndrome of multiple developmental defects including polycystic kidneys and intrahepatic biliary dysgenesis in 2 siblings

Mitochondrial DNA depletion syndrome is expressed in amniotic fluid cell cultures

Therapy of mitochondrial disorders

CoQ(10) deficiencies and MNGIE: two treatable mitochondrial disorders

Recognition and management of fatty acid oxidation defects: a series of 107 patients

Disorders of mitochondrial datty acid oxidation and ketone body metabolism

Liver transplantation in mitochondrial respiratory chain disorders

End-stage liver disease as the only consequence of a mitochondrial respiratory chain deficiency: no contra-indication for liver transplantation

Mitochondrial cytochrome deficiency presenting as a myopathy with hypotonia, external ophthalmoplegia, and lactic acidosis in an infant and as fatal hepatopathy in a second cousin

Mitochondrial myopathy with lactic acidaemia, Fanconi-De Toni-Debre syndrome and a disturbed succinate: cytochrome c oxidoreductase activity

Fatal neonatal hepatocellular deficiency with lactic acidosis: a defect of the respiratory chain

Fatal neonatal liver failure and mitochondrial cytopathy: an observation with antenatal ascites

Liver cytochrome c oxidase deficiency in a case of neonatal-onset hepatic failure

Mitochondrial respiratory chain defect: a new etiology for neonatal cholestasis and early liver insufficiency

Severe complex I deficiency in a case of neonatal-onset lactic acidosis and fatal liver failure

Risk of hepatocellular carcinoma in liver mitochondrial respiratory chain disorders

A biochemically distinct form of cytochrome oxidase (COX) deficiency in the Saguenay-Lac-Saint-Jean region of Quebec

Mutations of the SCO1 gene in mitochondrial cytochrome c oxidase deficiency with neonatalonset hepatic failure and encephalopathy

The GRACILE syndrome, a neonatal lethal metabolic disorder with iron overload

A mutant mitochondrial respiratory chain assembly protein causes complex III deficiency in patients with tubulopathy, encephalopathy and liver failure

The clinical diagnosis of POLG disease and other mitochondrial DNA depletion disorders

Mitochondrial DNA rearrangements with onset as chronic diarrhea with villous atrophy

A clinical experience with familial paucity of intrahepatic bile ducts associated with defective metabolism of trihydroxycoprostanic acid to cholic acid

Reinvestigation of trihydroxycholestanoic acidemia reveals a peroxisome biogenesis disorder

Mevalonate kinase map position 12q24

Clinical and biochemical phenotype in 11 patients with mevalonic aciduria

Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group

Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues

Recommendations for the management of autoinflammatory diseases

Mevalonate kinase deficiency: enlarging the clinical and biochemical spectrum

Hematological abnormalities and cholestatic liver disease in two patients with mevalonate kinase deficiency

MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever

Carrier frequency of the V377I (1129G>A) MVK mutation, associated with hyper-IgD and periodic fever syndrome, in the Netherlands

Significant liver disease in a patient with Y116H mutation in the MVK gene

Mitochondria and childhood liver diseases

Mitochondrial respiratory chain disorders and the liver

Nuclear genes in mitochondrial disorders

Mitochondrial DNA mutations in human disease

Developing a systematic approach to the diagnosis and classification of mitochondrial disease

Mitochondrial hepatopathies: advances in genetics, therapeutic approaches, and outcomes

Neonatal and delayedonset liver involvement in disorders of oxidative phosphorylation

Hepatic failure in disorders of oxidative phosphorylation with neonatal onset

Fatal infantile liver failure associated with mitochondrial DNA depletion

Evaluation of the child with suspected mitochondrial liver disease

Respiratory chain defects may present only with hypoglycemia

Antenatal manifestations of mitochondrial respiratory chain deficiency

Fatal acidosis in a neonate with Pearson syndrome

Pearson syndrome in an infant heterozygous for C282Y allele of HFE gene

Acromutilating, paralyzing neuropathy with corneal ulceration in Navajo children

Neuropathy in Navajo children: clinical and epidemiologic features

Liver disease in Navajo neuropathy

Navajo neurohepatopathy is caused by a mutation in the MPV17 gene

MPV17-associated hepatocerebral mitochondrial DNA depletion syndrome: new patients and novel mutations

Acute infantile liver failure due to mutations in the TRMU gene

Acute liver failure with subsequent cirrhosis as the primary manifestation of TRMU mutations

Toward genotype phenotype correlations in GFM1 mutations

Mutation in the mitochondrial translation elongation factor EFTs results in severe infantile liver failure

Infantile encephalopathy and defective mitochondrial DNA translation in patients with mutations of mitochondrial elongation factors EFG1 and EFTu

Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders

Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical presentation and follow-up of 50 patients

POLG mutations in Alpers syndrome

Mitochondrial mosaics in the liver of 3 infants with mtDNA defects

Individual exome analysis in diagnosis and management of paediatric liver failure of indeterminate aetiology

Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies

Clinical presentations and laboratory investigations in respiratory chain deficiency

Respiratory chain enzyme analysis in muscle and liver

Molecular diagnostics of mitochondrial disorders

The importance of liver biopsy in the investigation of possible mitochondrial respiratory chain disease

Fatal neonatal liver failure and mitochondrial cytopathy (oxidative phosphorylation deficiency): a light and electron microscopic study of the liver

Clinical, biochemical, and morphologic investigations of a case of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency

Liver failure associated with mitochondrial DNA depletion

Mitochondrial cytopathy: an unusual infantile cause of total villous atrophy

Depletion of mitochondrial deoxyribonucleic acid in a family with fatal neonatal liver disease

Mitochondrial DNA depletion and dGK gene mutations

Clinical, biochemical and morphological features of hepatocerebral syndrome with mitochondrial DNA depletion due to deoxyguanosine kinase deficiency

New DGK gene mutations in the hepatocerebral form of mitochondrial DNA depletion syndrome

Deoxyguanosine kinase mutations and combined deficiencies of the mitochondrial respiratory chain in patients with hepatic involvement

Clinical and molecular characteristics of mitochondrial DNA depletion syndrome associated with neonatal cholestasis and liver failure

Mitochondrial DNA polymerase gamma deficiency and mtDNA depletion in a child with Alpers' syndrome

Mitochondrial DNA depletion in Alpers syndrome

POLG mutations and Alpers syndrome

Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-γA

Consequences of mutations in human DNA polymerase γ

Liver involvement in Alpers disease

Progressive neuronal degeneration of childhood (Alpers syndrome) with hepatic cirrhosis

Molecular and clinical genetics of mitochondrial diseases due to POLG mutations

Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity

Valproate-induced liver failure in one of two siblings with Alpers disease

Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure

Inappropriate liver transplantation in a child with Alpers-Huttenlocher syndrome misdiagnosed as valproate-induced acute liver failure

Fatal deterioration of neurological disease after orthotopic liver transplantation for valproic acid-induced liver damage

A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction

Detection and characterization of mitochondrial DNA rearrangements in Pearson and Kearns-Sayre syndromes by long PCR

Microvesicular steatosis, hemosiderosis and rapid development of liver cirrhosis in a patient with Pearson's syndrome

Severe hepatic Wilson's disease in preschool-aged children

Genotype-phenotype correlations for a wide spectrum of mutations in the Wilson disease gene (ATP7B)

Truncating mutations in the Wilson disease gene ATP7B are associated with very low serum ceruloplasmin oxidase activity and an early onset of Wilson disease

Wilson's disease in Israel: a genetic and epidemiological study

Detection of the His1069Gln mutation in Wilson disease by rapid polymerase chain reaction

Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype-phenotype correlation, and functional analyses

Defining Wilson disease phenotypes: from the patient to the bench and back again

The impact of apolipoprotein E genotypes on age at onset of symptoms and phenotypic expression in Wilson's disease

COMMD1 (MURR1) as a candidate in patients with copper storage disease of undefined etiology

Copper toxicosis gene MURR1 is not changed in Wilson disease patients with normal blood ceruloplasmin levels

Analysis of the human homologue of the canine copper toxicosis gene MURR1 in Wilson disease patients

Diagnosis and treatment of Wilson disease: an update

Diagnostic accuracy of serum ceruloplasmin in Wilson disease: determination of sensitivity and specificity by ROC curve analysis among ATP7B-genotyped subjects

Usefulness of ferroxidase activity of ceruloplasmin in the diagnosis of Wilson's disease

Automation of o-dianisidine assay for ceruloplasmin activity analyses: usefulness of investigation in Wilson's disease and in hepatic encephalopathy

Late-onset Wilson's disease with neurological involvement in the absence of Kayser-Fleischer rings

Diagnosis and outcome of Wilson disease in a paediatric cohort

Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease

Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease

Prospective evaluation of the diagnostic accuracy of hepatic copper content, as determined using the entire core of a liver biopsy sample

Reference limits for copper and iron in liver biopsies

Rapid identification of Wilson's disease carriers by denaturing high-performance liquid chromatography

Molecular diagnosis of Wilson disease

Depletion of mitochondrial DNA associated with infantile cholestasis and progressive liver fibrosis

Depletion of mitochondrial DNA in the liver of an infant with neonatal giant cell hepatitis

Morphological correlates of mitochondrial dysfunction in children

Clinical, biochemical, cellular and molecular characterization of mitochondrial DNA depletion syndrome due to novel mutations in the MPV17 gene

Reversible infantile respiratory chain deficiency is a unique, genetically heterogenous mitochondrial disease

Infantile progressive hepatoencephalomyopathy with combined OXPHOS deficiency due to mutations in the mitochondrial translation elongation factor gene GFM1

Biochemical diagnosis of fatty acid oxidation disorders by metabolite analysis of postmortem liver

Clinical and biochemical characterization of four patients with mutations in ECHS1

Wilson's disease. Philadelphia: Saunders

Failure of simple biochemical indexes to reliably differentiate fulminant Wilson's disease from other causes of fulminant liver failure

Fulminant Wilson's disease in children: appraisal of a critical diagnosis

Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests

Fulminant hepatic failure resulting from coexistent Wilson's disease and hepatitis E

Neuropsychological aspects of Wilson's disease

Cardiac Wilson's disease

Wilson's disease presenting as symptomatic urolithiasis: a case report and review of the literature

Hypoparathyroidism in Wilson's disease

Wilson's disease associated with pancreatitis

Beneath the copper-pediatric Wilson's disease cirrhosis and hepatocellular carcinoma: a case report with literature review

Hepatocellular carcinoma in Wilson's disease: a rare association in childhood

Hepatocellular carcinoma in a case of Wilson's disease

Primary hepatocellular carcinoma associated with Wilson's disease in a young woman

Hepatocellular carcinoma in Wilson's disease: case report and review of the literature

Abdominal malignancies in patients with Wilson's disease

The Wilson disease gene: spectrum of mutations and their consequences

The copper toxicosis gene product Murr1 directly interacts with the Wilson disease protein

Wilson's disease; new oral therapy

Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride

Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine)

Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride (trientine) treatment

Zinc acetate for the treatment of Wilson's disease

Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study

Liver transplantation for Wilson's disease: long-term results and quality-of-life assessment

Liver transplantation for children with Wilson disease: comparison of outcomes between children and adults

Long term results of liver transplantation for Wilson's disease: experience in France

Living related liver transplantation from heterozygote genetic carriers to children with Wilson's disease

Long-term outcomes for 32 cases of Wilson's disease after living-donor liver transplantation

Cerebral manifestation of Wilson's disease successfully treated with liver transplantation

Liver transplantation for neuropsychiatric Wilson disease

Different neurological outcome of liver transplantation for Wilson's disease in two homozygotic twins

Treatment of Wilson disease with ammonium tetrathiomolybdate. III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy

Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc

Restoration of holoceruloplasmin synthesis in LEC rat after infusion of recombinant adenovirus bearing WND cDNA

Chances and shortcomings of adenovirus-mediated ATP7B gene transfer in Wilson disease: proof of principle demonstrated in a pilot study with LEC rats

Restoration of copper metabolism and rescue of hepatic abnormalities in LEC rats, an animal model of Wilson disease, by expression of human ATP7B gene

Oxidative-phosphorylation defects in liver of patients with Wilson's disease

Mitochondrial structure and function in the untreated Jackson toxic milk (tx-j) mouse, a model for Wilson disease

Efficient detection of mutations in Wilson disease by manifold sequencing

A genetic study of Wilson's disease in the United Kingdom

Genotyping microarray as a novel approach for the detection of ATP7B gene mutations in patients with Wilson disease

Biochemical characterization and intracellular localization of the Menkes disease protein

Ligand-regulated transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the plasma membrane: a novel mechanism of regulated trafficking

Isolation of a candidate gene for Menkes disease and evidence that it encodes a coppertransporting ATPase

Molecular genetics and pathophysiology of Menkes disease

The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene

Mapping, cloning and genetic characterization of the region containing the Wilson disease gene

The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene

Structural and functional insights of Wilson disease copper-transporting ATPase

Solution structure of the N-domain of Wilson disease protein: distinct nucleotidebinding environment and effects of disease mutations

NMR characterization of copper-binding domains 4-6 of ATP7B

The N-terminus of the human copper transporter 1 (hCTR1) is localized extracellularly, and interacts with itself

Identification of methionine-rich clusters that regulate copper-stimulated endocytosis of the human Ctr1 copper transporter

Function, structure, and mechanism of intracellular copper trafficking proteins

Copper chaperones: personal escorts for metal ions

Structural basis for copper transfer by the metallochaperone for the Menkes/Wilson disease proteins

The N-terminal metal-binding site 2 of the Wilson's disease protein plays a key role in the transfer of copper from Atox1

Trafficking of the copper-ATPases, ATP7A and ATP7B: role in copper homeostasis

Pleiotropic effect of LEC mutation: a rodent model of Wilson's disease

ATP7B copperregulated traffic and association with the tight junctions: copper excretion into the bile

Comparison of the disposition behavior of organic anions in an animal model for Wilson's disease (Long-Evans Cinnamon rats) with that in normal Long-Evans Agouti rats

Hepatic copper overload and features of Indian childhood cirrhosis in an American sibship

Indian childhood cirrhosis

Orcein-positive liver deposits in Indian childhood cirrhosis

Increased hepatic copper concentration in Indian childhood cirrhosis

Indian childhood cirrhosis

Indian childhood cirrhosis

Infantile cirrhosis: an analytic review of the literature and a report of 50 cases

Cytoplasmic copper and its toxic effects: studies in Indian childhood cirrhosis

Hepatic copper in Indian childhood cirrhosis

Diagnostic potential of histochemical demonstration for copper-orcein stain

Early introduction of copper-contaminated animal milk feeds as a possible cause of Indian childhood cirrhosis

Uptake of copper from brass vessels by bovine milk and its relevance to Indian childhood cirrhosis

Clinical trials of penicillamine in Indian childhood cirrhosis

Sequential histopathologic alterations in Indian childhood cirrhosis treated with D-penicillamine

Long term survival in Indian childhood cirrhosis treated with D-penicillamine

Role of copper in Indian childhood cirrhosis

The canine copper toxicosis gene MURR1 does not cause non-Wilsonian hepatic copper toxicosis

Atypical copper cirrhosis in Indian children

Endemic Tyrolean infantile cirrhosis: an ecogenetic disorder

Early childhood cirrhoses (ECC) in Germany between 1982 and 1994 with special consideration of copper etiology

Endemic Tyrolean infantile cirrhosis is not an allelic variant of Wilson's disease

Different pathomorphologic patterns in exogenic infantile copper intoxication of the liver

Diagnosing primary immunodeficiency: a practical approach for the non-immunologist

Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency

The metabolic and molecular basis of inherited disease

Common severe infections in chronic granulomatous disease

Elevated copper impairs hepatic nuclear receptor function in Wilson's disease

Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/ Fas) mediated apoptosis

Histology of the liver in Wilson's disease: a study of 34 cases

Chronic hepatitis as a first manifestation of Wilson's disease

Wilson's disease, presenting as chronic active hepatitis

Wilson's disease with superimposed autoimmune features: report of two cases and review

Changes in the distribution of hepatic copper in relation to the progression of Wilson's disease (hepatolenticular degeneration)

Studies on the pathogenesis of hepatolenticular degeneration. II. Cytochemical methods for the localization of copper

Cytochemical methods for copper: semiquantitative screening procedure for identification of abnormal copper levels in liver

Demonstration of an intracellular copper-binding protein by orcein staining in long-standing cholestatic liver diseases

Histological demonstration of copper and copper-associated protein in chronic liver diseases

Copper-binding protein in liver cells

Immunocytochemical identification of caeruloplasmin in hepatocytes of patients with Wilson's disease

Hepatic copper and metallothionein distribution in Wilson's disease (hepatolenticular degeneration)

Defective cellular localization of mutant ATP7B in Wilson's disease patients and hepatoma cell lines

Hepatic morphology and histochemistry of Wilson's disease presenting as fulminant hepatic failure: a study of 11 cases

Fulminant Wilsonian hepatitis unmasked by disease progression: report of a case and review of the literature

Mitochondrial and fatty changes in hepatocytes of patients with Wilson's disease

Fraternal concordance of types of abnormal hepatocellular mitochondria in Wilson's disease

Evolution of the hepatic lesion in Wilson's disease (hepatolenticular degeneration)

Immunohistochemical analysis of Mallory bodies in Wilsonian and non-Wilsonian hepatic copper toxicosis

Lipolysosomes in human hepatocytes: ultrastructural and cytochemical studies of patients with Wilson's disease

The hepatic mitochondrial DNA depletion syndrome: ultrastructural changes in liver biopsies

Wilson disease: comparative ultrastructure in a sibship of nine

Effects of anticopper therapy on hepatocellular mitochondria in patients with Wilson's disease: an ultrastructural and stereological study

Copper metabolic defects and liver disease: environmental aspects

Chronic granulomatous disease of males

Thirteen boys with progressive septic granulomatosis

Nodular regenerative hyperplasia in common variable immunodeficiency

Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities

Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia

Hepatitis in common variable immunodeficiency

Liver transplantation for severe hepatitis in patients with common variable immunodeficiency

Common variable immunodeficiency associated with hepatosplenic T-cell lymphoma mimicking juvenile systemic lupus erythematosus

Clinical spectrum of X-linked hyper-IgM syndrome

Liver disease in children with hyper IgM syndrome

Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM

X-linked hyper-IGM syndrome associated to sclerosing cholangitis and gallbladder neoplasm: clinical case

Liver disease in primary immunodeficiencies

Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience

Haemophagocytic lymphohistiocytosis: proposal of a diagnostic algorithm based on perforin expression

Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis

Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy

Familial hemophagocytic lymphohistiocytosis may present during adulthood: clinical and genetic features of a small series

Familial hemophagocytic lymphohistiocytosis

Autopsy findings in 27 children with haemophagocytic lymphohistiocytosis

Histopathology of the liver in histiocytosis syndromes

Pathology of the liver in familial hemophagocytic lymphohistiocytosis

Liver involvement in the histiocytic disorders of childhood

Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group

Differential clinical characteristics of acute liver failure caused by hemophagocytic lymphohistiocytosis in children

Use of an X-linked human neutrophil marker to estimate timing of lyonization and size of the dividing stem cell pool

DNA linkage analysis of X chromosome-linked chronic granulomatous disease

Chronic granulomatous disease. Molecular genetics

X-Linked chronic granulomatous disease: mutations in the CYBB gene encoding the gp91-phox component of respiratory-burst oxidase

Prenatal diagnosis in a family with X-linked chronic granulomatous disease with the use of the polymerase chain reaction

Detection of defective granulocyte function with flow cytometry in newborn infants

In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood

Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma

Cut it out: managing hepatic abscesses in patients with chronic granulomatous disease

Successful bone marrow transplantation in a child with X-linked chronic granulomatous disease

Granulocyte transfusions in children with chronic granulomatous disease and invasive aspergillosis

Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients

Progress toward effective gene therapy for chronic granulomatous disease

Gene correction reduces cutaneous inflammation and granuloma formation in murine X-linked chronic granulomatous disease

Long-term high-level reconstitution of NADPH oxidase activity in murine X-linked chronic granulomatous disease using a bicistronic vector expressing gp91phox and a Delta LNGFR cell surface marker

Recent advances in chronic granulomatous disease

Gastrointestinal manifestations of chronic granulomatous disease

Histopathological features of chronic granulomatous disease (CGD) in childhood

Small bowel obstruction in chronic granulomatous disease

Colitis in chronic granulomatous disease

A fatal granulomatous disease of childhood: the clinical, pathological, and laboratory features of a new syndrome

Hepatic pathology of chronic granulomatous disease of childhood

Chronic granulomatous disease: a syndrome of phagocyte oxidase deficiencies

Increased S-100 protein-immunoreactivity of Kupffer cells is associated with lymphohematological malignancy

Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders

Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders

Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin

Nodular Langerhans cell histiocytosis of the liver in an adult with colonic adenocarcinoma

Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell histiocytosis

Langerhans cell histiocytosis: current concepts and treatments

Langerhans cell histiocytosis: a clinicopathologic review and molecular pathogenetic update

Expression of apoptosisregulatory proteins in lesions of pulmonary Langerhans cell histiocytosis

Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis

Langerhans-cell histiocytosis 'insight into DC biology

Langerhans'-cell histiocytosis (histiocytosis X): a clonal proliferative disease

Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis

Human cytomegalovirus infection in foci of Langerhans cell histiocytosis

Expression of Epstein-Barr virus in Langerhans' cell histiocytosis

Langerhans cell histiocytosis: a primary viral infection of bone? Human herpes virus 6 latent protein detected in lymphocytes from tissue of children

Langerhans cell (eosinophilic) granulomatosis: a clinicopathologic study encompassing 50 years

Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome

Predictors of outcome in children with Langerhans cell histiocytosis

A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group

Pediatric liver transplantation for Langerhans' cell histiocytosis

Liver transplantation in an adult with sclerosing cholangitis due to Langerhans cell histiocytosis

Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children

Hemophagocytic syndrome presenting as acute hepatic failure in two infants: clinical overlap with neonatal hemochromatosis

Liver failure with marked hyperferritinemia: 'ironing out' the diagnosis

Occurrence of haemophagocytic lymphohistiocytosis at less than 1 year of age: analysis of 96 patients

Viral infections associated with haemophagocytic syndrome

Reactive histiocytic disorders

Clinical assessment of Mycoplasma pneumoniae-associated hemophagocytic lymphohistiocytosis

Presenting manifestations of hemophagocytic syndrome in a male patient with systemic lupus erythematosus

Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders

Macrophage activation syndrome in juvenile idiopathic arthritis

Reactive hemophagocytic syndrome: a study of 7 fatal cases

Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases: a multicenter study from Turkey

Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients

Hypercytokinemia in hemophagocytic syndrome

Hepatic manifestations of hemophagocytic syndrome: a study of 30 cases

Liver changes in reactive haemophagocytic syndrome

Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-γ-producing lymphocytes and IL-6-and TNF-α-producing macrophages

Prevalence and clinical significance of Kupffer cell hyperplasia with hemophagocytosis in liver biopsies

Langerhans' cell granuloma confined to the bile duct

Langerhans cell histiocytosis: report of a single organ involvement in a child

Liver involvement in Langerhans' cell histiocytosis: a study of nine cases

Macrophage activation and hemophagocytic syndrome in Langerhans cell histiocytosis: report of 30 cases

Immunohistochemical detection of CD1A antigen in formalin-fixed and paraffin-embedded tissue sections with monoclonal antibody 010

Langerhans' cell histiocytosis: definitive diagnosis with the use of monoclonal antibody O10 on routinely paraffin-embedded samples

Sinus histiocytosis with massive lymphadenopathy and Langerhans cell histiocytosis express the 2145

Neonatal liver disease associated with placental transfer of anti-mitochondrial antibodies

Segregation analysis in Shwachman-Diamond syndrome: evidence for recessive inheritance

Clinical and molecular pathophysiology of Shwachman-Diamond syndrome: an update

Mutations in SBDS are associated with Shwachman-Diamond syndrome

Shwachman-Bodian Diamond syndrome is a multi-functional protein implicated in cellular stress responses

The syndrome of pancreatic insufficiency and bone marrow dysfunction

Shwachman's syndrome: pathomorphosis and long-term outcome

Shwachman syndrome: exocrine pancreatic dysfunction and variable phenotypic expression

Serum immunoreactive cationic trypsinogen: a useful indicator of severe exocrine dysfunction in the paediatric patient without cystic fibrosis

Shwachman's syndrome: a review of 21 cases

Shwachman syndrome: phenotypic manifestations of sibling sets and isolated cases in a large patient cohort are similar

Shwachman syndrome associated with de novo reciprocal translocation t(6;12) (q16.2;q21.2)

Pancreatic insufficiency with bone marrow dysfunction (Shwachman-Diamond-Oski-Khaw's syndrome): report of a case

Electron microscopic examination of cartilage in the syndrome of exocrine pancreatic insufficiency, neutropenia, metaphyseal dysostosis and dwarfism

Shwachman-Diamond syndrome presenting as hepatosplenomegaly

The natural history of Shwachman-Diamond syndrome-associated liver disease from childhood to adulthood

Shwachman-Diamond syndrome with autoimmune-like liver disease and enteropathy mimicking celiac disease

Association of pancreatic insufficiency and chronic neutropenia in childhood

Testicular fibrosis and cardiomegaly in Shwachman's syndrome

Human granulocyte colony-stimulating factor (rHuG-CSF) for treatment of neutropenia in Shwachman syndrome

The occurrence of leukemia in patients with the Shwachman syndrome

Haematological abnormalities in Shwachman-Diamond syndrome

Recurrence of Langerhans cell histiocytosis in the graft after pediatric liver transplantation

Solitary (juvenile) xanthogranuloma: a comprehensive immunohistochemical study emphasizing recently developed markers of histiocytic lineage

Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations

Chester-Erdheim disease: a neoplastic disorder

Biliary manifestation of Erdheim-Chester disease mimicking Klatskin's carcinoma

Portal hypertension and ascites secondary to Erdheim Chester disease without intrinsic liver involvement on liver biopsy

Sinus histiocytosis with massive lymphadenopathy: a newly recognized benign clinicopathological entity

Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity

Rosai-Dorfman disease: a case with lymphadenopathy and liver involvement

The digestive system manifestations of Rosai-Dorfman disease (sinus histiocytosis with massive lymphadenopathy): review of 11 cases

Immunophenotypic characterization of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease)

Description of 214 cases of autoimmune congenital heart block: results of the French neonatal lupus syndrome

Congenital lupus with multiorgan involvement: a case report and review of literature

Neonatal lupus erythematosus

Neonatal lupus erythematosus with cholestatic hepatitis

Early cholestasis in neonatal lupus erythematosus

Vitamin D deficiency presenting in an infant with neonatal lupus erythematosus

Non-cardiac manifestations of neonatal lupus erythematosus

Liver disease in neonatal lupus erythematosus

Liver disease in association with neonatal lupus erythematosus

Intrahepatic cholestasis in neonatal lupus erythematosus

Neonatal lupus mimicking extra hepatic biliary atresia

Neonatal hemochromatosis associated with maternal autoantibodies against Ro/SS-A and La/ SS-B ribonucleoproteins

Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry

A case of severe neonatal lupus erythematosus without cardiac or cutaneous involvement

A gene for congenital generalized lipodystrophy maps to human chromosome 9q34

Congenital total lipodystrophy and peripheral pulmonary artery stenosis

Congenital generalized lipodystrophies: new insights into metabolic dysfunction

Congenital generalized lipodystrophy: report on one case, with special reference to postmortem findings

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1-1975

Hepatic ultrastructure in congenital total lipodystrophy with special reference to peroxisomes

Ultrastructural abnormalities of the liver in total lipodystrophy

Sicca syndrome and total lipodystrophy: a case in a fifteen-year-old female patient

Ultrastructural abnormalities of the liver in total lipodystrophy

Lipoatrophic diabetes. II. Metabolic studies concerning the mechanism of lipemia

The syndromes of total lipodystrophy and of partial lipodystrophy

Severe perinatal liver disease and Down syndrome: an apparent relationship

Down syndrome, transient myeloproliferative disorder, and infantile liver fibrosis

Liver disease is frequently observed in Down syndrome patients with transient abnormal myelopoiesis

Perinatal visceral fibrosis accompanying the megakaryoblastic leukemoid reaction of Down syndrome

Transient abnormal myelopoiesis and diffuse hepatic necrosis in Down's syndrome with prominent bleeding diathesis

Megakaryocytosis of the liver in a trisomy 21 stillbirth

Immunohistochemical study on transforming growth factor-beta1 expression in liver fibrosis of Down's syndrome with transient abnormal myelopoiesis

Hydrops fetalis in a neonate with Down syndrome, transient myeloproliferative disorder and hepatic fibrosis

A fetal case of transient abnormal myelopoiesis with severe liver failure in Down syndrome: prognostic value of serum markers

Life-threatening complications of transient abnormal myelopoiesis in neonates with Down syndrome

Transient leukemia in newborns with Down syndrome

Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome

Related donor liver transplant for veno-occlusive disease following T-depleted unrelated donor bone marrow transplantation

Bone marrow transplantation in Shwachman-Diamond syndrome: report of two cases and review of the literature

Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds

Familial cirrhosis: a clinical and pathological study

Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity

Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents

TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children

Genetics of nonalcoholic fatty liver disease

Steatohepatitis associated with limb lipodystrophy

Cirrhosis in partial lipodystrophy

Hepatic dysfunction in two sibs with Alstrom syndrome: case report and review of the literature

Early-onset liver disease complicated with acute liver failure in Alstrom syndrome

Evaluation of insulin resistant diabetes mellitus in Alstrom syndrome: a long-term prospective follow-up of three siblings

Sclerosing hyaline necrosis of the liver in Bloom syndrome

A cause of fatty liver: neutral lipid storage disease with ichthyosis-electron microscopic findings

Dorfman-Chanarin syndrome: a case with prevalent hepatic involvement

Insulin resistance syndrome in subjects with mutated RING finger protein TRIM37

Cohen syndrome with insulin resistance and seizure

Steatohepatitis in children

Acquired and inherited lipodystrophies

Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13

Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young

Acute cholestasis: atypical onset of Kawasaki disease

Mortality among children with Kawasaki disease in Japan

Cardiac sequelae of Kawasaki disease in Japan: statistical analysis

Long-term changes in coronary artery aneurysms in patients with Kawasaki disease: comparison of therapeutic regimens

Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial

Management of Kawasaki disease: corticosteroids revisited

Predicting factors for refractory Kawasaki disease

Kawasaki disease at the extremes of the age spectrum

Atypical Kawasaki disease: analysis of clinical presentation and diagnostic clues

Abnormal liver panel in acute Kawasaki disease

Hepatobiliary risk factors for clinical outcome of Kawasaki disease in children

Hydrops of the gallbladder associated with Kawasaki syndrome

Prolonged postprandial abdominal pain following Kawasaki syndrome with acute gallbladder hydrops: association with impaired gallbladder emptying

Intrahepatic bile duct damage in children with Kawasaki disease

Decreased portal vein flow during Kawasaki disease in a liver transplant patient

General pathology of Kawasaki disease: on the morphological alterations corresponding to the clinical manifestations

Intrahepatic cholangitis associated with mucocutaneous lymph node syndrome

Kawasaki disease manifesting with acute cholangitis: a case report

Mucocutaneous lymph-node syndrome with positive Weil-Felix reaction but negative Leptospira studies

Infantile periarteritis nodosa or mucocutaneous lymph node syndrome: a report on four cases and diagnostic considerations

Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome

Hepatic artery aneurysm associated with the mucocutaneous lymph node syndrome

Variant strain of Propionibacterium acnes: a clue to the aetiology of Kawasaki disease

Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis

Myeloid leukaemia in children with Down syndrome: report of the registry-based French experience between

Population-based study of incidence and clinical outcome of neonatal cholestasis in patients with Down syndrome

Encephalopathy and fatty degeneration of the viscera: a disease entity in childhood

Reye's syndrome

Reye's syndrome and salicylate use

Public Health Service study on Reye's syndrome and medications. Report of the pilot phase

Public Health Service study of Reye's syndrome and medications. Report of the main study

Reye's syndrome in the United States from 1981 through 1997

Reye's syndrome

Whatever happened to Reye's syndrome? Did it ever really exist?

Reye's syndrome in nonpediatric age groups

Reye's syndrome in the adult: case report and review of the literature

The hepatic lesion in Reye's syndrome

Periportal hepatic necrosis in Reye's syndrome: one case in a review of eight patients

Pancreatitis and Reye's syndrome

Mitochondrial ultrastructure in Reye's syndrome (encephalopathy and fatty degeneration of the viscera)

The fine structure of hepatocytes in Reye's syndrome

Hepatic and cerebral pathology findings in children with fatal salicylate intoxication: further evidence for a causal relation between salicylate and Reye's syndrome

Reye's syndrome simulacra in liver of mice after treatment with chemical agents and encephalomyocarditis virus

Experimental influenza B virus toxicity in mice: a possible model for Reye's syndrome

Spontaneous Reye's-like syndrome in BALB/cByJ mice

Microvesicular fatty liver in rats with resembling Reye's syndrome induced by 4-pentenoic acid

Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children

Kawasaki disease in adults: observations in France and literature review

American Heart Association recommendations for treatment of Kawasaki disease

Primary immunodeficiency diseases: a molecular and genetic approach

Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: a possible mechanism for deregulation of T lymphocyte activation

Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies

Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in alpha-granules, platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor

Linkage disequilibrium mapping of the gene for Hermansky-Pudlak syndrome to chromosome 10q23.1-q23.3

Mutation analysis of patients with Hermansky-Pudlak syndrome: a frameshift hot spot in the HPS gene and apparent locus heterogeneity

An autopsy case of Hermansky-Pudlak syndrome: a case report and review of the literature on treatment

Hermansky-Pudlak syndrome: a clinicopathologic study

Familial perinatal liver disease and fetal thrombotic vasculopathy

Hepatic agenesis

Liver agenesis with omphalocele: a report of two human embryos using serial histological sections

Congenital absence of the left lobe of the liver: a radiologic diagnosis

Hypoplasia of the left hepatic lobe associated with floating gallbladder: a case report

Agenesis of the right lobe of the liver

Hypogenesis of right hepatic lobe accompanied by portal hypertension: case report and review of 31 Japanese cases

Biliary injury after laparoscopic cholecystectomy in a patient with right liver agenesis: case report and review of the literature

Suprahepatic gallbladder with hypoplasia of the right lobe of the liver

Hypoplastic right hepatic lobe with retrohepatic gallbladder complicated by hepatolithiasis and liver abscess: a case report

Computer tomography of congenital absence of the left lobe of the liver

Lobar atrophy caused by combined portal and hepatic vein thrombosis in children

Hepatic lobar atrophy: association with ipsilateral portal vein obstruction

Hepatolithiasis with situs inversus: first case report

Situs inversus totalis (SIT) with hepatocellular carcinoma (HCC): a rare case report and review of 12 other cases

Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome

Kawasaki disease associated with HIV infection

Epstein-Barr virus genomepositive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease

Active or recent parvovirus B19 infection in children with Kawasaki disease

Serum anti-Yersinia antibody in Chinese patients with Kawasaki disease

Isolation of measles virus from child with Kawasaki disease

Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease

Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease

A genome-wide association study identifies three new risk loci for Kawasaki disease

Genetics insights into the pathogenesis of Kawasaki disease

A familial syndrome of short stature associated with facial dysplasia and genital anomalies

Autosomal dominant inheritance of the Aarskog syndrome

Phenotypic and molecular characterisation of the Aarskog-Scott syndrome: a survey of the clinical variability in light of FGD1 mutation analysis in 46 patients

Aarskog-Scott syndrome: a novel mutation in the FGD1 gene associated with severe craniofacial dysplasia

Aarskog syndrome: new findings and genetic analysis

Leprechaunism: a euphemism for a rare familial disorder

Leprechaunism: an inherited defect in a high-affinity insulin receptor

A case of leprechaunism with severe hyperinsulinemia

Two novel mutations identified in familial cases with Donohue syndrome

Syndrome of extreme insulin resistance (Rabson-Mendenhall phenotype) with atrial septal defect: clinical presentation and treatment outcomes

Leprechaunism (Donohue's syndrome): a case report

Leprechaunism in a male infant

Donohue's syndrome): a possible case, with emphasis on changes in the adenohypophysis

Intrauterine growth retardation, jaundice, and hypoglycemia in a neonate

Chediak-Higashi syndrome: cytologic and serum lipid observations in a case and family

Hypoglycemia from metastasizing insular carcinoma of aberrant pancreatic tissue in liver

Pathologic observations of intrahepatic peribiliary glands in 1000 consecutive autopsy livers. Heterotopic pancreas in the liver

Alcohol-related injury to peribiliary glands is a cause of peribiliary cysts: based on analysis of clinical and autopsy cases

Intrahepatic spleen presenting as a mass lesion

Intrahepatic splenic tissue without medical history of splenic injury or splenectomy

Intrahepatic splenosis with severe iron deposition presenting with atypical magnetic resonance images

Heterotopic thyroid tissue at the porta hepatis in a fetus with trisomy 18

Radiological anatomy of the biliary tract: variations and congenital abnormalities

Agenesis of the common bile duct

Atresia of the common hepatic duct with shunt via an accessory duct: report of a case

Agenesis of the extrahepatic bile ducts: report of five cases

Biliary duct hypoplasia

Anomalous insertion of the right hepatic duct into the cystic duct: report of a case diagnosed before laparoscopic cholecystectomy

Surgical anatomy of the pancreatobiliary ductal system

Anatomy and function of the extrahepatic biliary system

Hepatolithiasis associated with anomalous biliary anatomy and a vascular compression. Hepatolithiasis and anomalous anatomy

A new systematic classification of peripheral anatomy of the right hepatic duct: experience from adult live liver donor transplantation

Cholecystohepatic ducts: case report

Association of oesophageal atresia and cholecystohepatic duct

Biliary cystadenoma and cystadenocarcinoma: report of 14 cases and review of the literature

Long accessory hepatic duct associated with congenital dilation of the common bile duct

Surgical lesions of the biliary tract

Choledochus cyst with a double common bile duct

Duplication of the cystic and common hepatic ducts, lined with gastric mucosa

Cancer of bile duct with situs inversus

Hepatic pulmonary fusion: two cases with diaphragmatic hernia and one case with pentalogy of Cantrell

Nonparasitic liver cysts in children

Ectopic liver in omphalocele

Identification of uncommon liver lobulations

Hepatic herniation through the Morgangi foramen

Intrathoracic lobe of the liver: case report and review of the literature

Supradiaphragmatic right liver lobe and gallbladder

Partial eventration of the right diaphragm (congenital diaphragmatic herniation of the liver)

Riedel's lobe of the liver

A very original case of a mini accessory liver lobe with its own gallbladder

Accessory lobes of the liver

Intrathoracic accessory lobe of the liver

Focal nodular hyperplasia on accessory lobe of the liver: preoperative diagnosis and management

Supradiaphragmatic liver in the lung

Infantile hemangioendothelioma of heterotopic intrathoracic liver associated with diaphragmatic hernia

Heterotopic liver in an adrenal gland

Ectopic or heterotopic liver (choristoma) associated with the gallbladder

Heterotopic supradiaphragmatic liver formation in association with congenital cardiac anomalies

Heterotopia of gastric mucosa and liver involving the gallbladder

Left-sided gallbladder with accessory liver accompanied by intrahepatic cholangiocarcinoma

Some unusual developmental heterotopias

Cirrhosis in ectopic liver tissue

Propensity of ectopic liver to hepatocarcinogenesis: case reports and a review of the literature

Ectopic liver and hepatocarcinogenesis

Adreno-hepatic union (adrenal dystopia)

Adreno-hepatic fusion: an autopsy study

Hepatolienal fusion: case report of an unusual lesion

Congenital bronchobiliary fistula: MRI appearance

Congenital bronchobiliary fistula associated with esophageal atresia and tracheo-esophageal fistula

Congenital bronchobiliary fistula associated with biliary atresia

Surgical experience in a baby with congenital broncho-biliary fistula

Congenital tracheobiliary fistula in an adolescent patient

Ciliated hepatic foregut cyst: a report of 6 cases and a review of the English literature

Ciliated hepatic foregut cyst of the left hepatic vein

Ciliated hepatic foregut cyst mimicking neoplasm

Squamous cell carcinoma arising in a ciliated hepatic foregut cyst

Squamous cell carcinoma arising in a ciliated hepatic foregut cyst

Ciliated hepatic foregut cyst: a rare but increasingly reported liver cyst

Ciliated hepatic foregut cyst: a study of six cases and review of the literature

Ciliated hepatic foregut cyst: a mucus histochemical, immunohistochemical, and ultrastructural study in three cases in comparison with normal bronchi and intrahepatic bile ducts

The ciliated hepatic foregut cyst, an unusual bronchiolar foregut malformation: a histological, histochemical, and immunohistochemical study of 7 cases

Spontaneous perforation of the bile duct in infancy and childhood: a systematic review

Complex spontaneous bile duct perforation: an alternative approach to standard porta hepatis drainage therapy